<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004332.pub2" GROUP_ID="ADDICTN" ID="603702030110413085" MERGED_FROM="" MODIFIED="2010-12-21 09:34:38 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-12-21 09:43:26 +0100" NOTES_MODIFIED_BY="Laura Amato" REVIEW_NO="50" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2010-12-21 09:43:26 +0100" MODIFIED_BY="Laura Amato">
<TITLE MODIFIED="2009-12-19 12:32:00 +0100" MODIFIED_BY="[Empty name]">Acamprosate for alcohol dependence</TITLE>
<CONTACT>
<PERSON ID="4E40049882E26AA201AFF0120850B0DA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rösner</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>susanne.roesner@med.uni-muenchen.de</EMAIL_1>
<EMAIL_2>susan.roesner@web.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0)89 5160 5387</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-12-21 09:22:50 +0100" MODIFIED_BY="Laura Amato">
<PERSON ID="4E40049882E26AA201AFF0120850B0DA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rösner</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>susanne.roesner@med.uni-muenchen.de</EMAIL_1>
<EMAIL_2>susan.roesner@web.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0)89 5160 5387</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="71686423079288857512091120102118" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrea</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hackl-Herrwerth</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>andrea.m.hackl@gmx.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0) 89 4140 4249</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leucht</LAST_NAME>
<SUFFIX/>
<POSITION>Oberarzt</POSITION>
<EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-89-4140 ext: 4249</PHONE_1>
<PHONE_2/>
<FAX_1>+49-89-4140-4888</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5576" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Philippe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lehert</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>lehert@fucam.ac.be</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Statistics &amp; Computer Sciences Dept</DEPARTMENT>
<ORGANISATION>University of Mons</ORGANISATION>
<ADDRESS_1>FUCAM</ADDRESS_1>
<ADDRESS_2>151 Chaussee de Binche</ADDRESS_2>
<CITY>Mons</CITY>
<ZIP>B-7000</ZIP>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+32 653 23292</PHONE_1>
<PHONE_2/>
<FAX_1>+32 653 15691</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11551" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simona</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vecchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research worker</POSITION>
<EMAIL_1>vecchi@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>39 0683060421</PHONE_1>
<PHONE_2/>
<FAX_1>39 0683060374</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8A992A7082E26AA200D45F892BEB5B30" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Soyka</LAST_NAME>
<SUFFIX/>
<POSITION>Psychiatrist; Clinical Director</POSITION>
<EMAIL_1>Michael.Soyka@privatklinik-meiringen.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+41 339728295</PHONE_1>
<PHONE_2>+41 339728290</PHONE_2>
<FAX_1>+41 339728291</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-11-23 11:01:20 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Minor update: 27/07/04&lt;/p&gt;" NOTES_MODIFIED="2010-11-23 11:01:20 +0100" NOTES_MODIFIED_BY="Laura Amato">
<UP_TO_DATE>
<DATE DAY="30" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-12-21 09:43:26 +0100" MODIFIED_BY="Laura Amato">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-12-21 09:43:26 +0100" MODIFIED_BY="Laura Amato">
<DATE DAY="21" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>Correction of an error in analysis 1.5</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-23 11:25:13 +0100" MODIFIED_BY="Laura Amato">
<DATE DAY="23" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>minimum editorial corrections</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-09 13:22:29 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>comments from authors have been included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-28 09:53:37 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2009-10-28 09:53:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="1" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-06 15:00:12 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-11-06 14:59:31 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-06 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<NAME>Ludwig Maximilian University of Munich</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>provision of infrastructure and related services</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2008-11-06 14:59:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>Technical University of Munich</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>provision of infrastructure and related services</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-11-06 15:00:12 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-06 15:00:12 +0100" MODIFIED_BY="[Empty name]">
<NAME>Federal Ministry of Education and Research</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>financial support / salary</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS MODIFIED="2009-10-28 09:53:37 +0100" MODIFIED_BY="[Empty name]" VERIFIED="NO"/>
<KEYWORDS MODIFIED="2009-10-28 09:53:37 +0100" MODIFIED_BY="[Empty name]"/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<SUMMARY MODIFIED="2010-07-13 11:29:33 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-12-04 14:54:48 +0100" MODIFIED_BY="[Empty name]">Acamprosate for alcohol dependent patients</TITLE>
<SUMMARY_BODY MODIFIED="2010-07-13 11:29:33 +0200" MODIFIED_BY="[Empty name]">
<P>Alcohol dependence is an important health risk factor that can lead to disability and death for people in developed and developing countries. Alcohol consumption is potentially avoidable, which emphasizes the need for effective strategies to help people who are dependent on alcohol to reduce excessive drinking and maintain abstinence following detoxification. Psychosocial programs have limited success in preventing relapse after detoxification programs. The addition of a pharmacological agent could provide support in achieving or maintaining abstinence or to cut down alcohol consumption. The synthetic glutamate antagonist acamprosate and naltrexone, which is an opioid antagonist, are used for this purpose.</P>
<P>This systematic review shows that acamprosate appears to be an effective and safe treatment in alcohol dependent patients for supporting continuous abstinence after detoxification from alcohol. When added to psychosocial treatment strategies, acamprosate reduced the risk of returning to any drinking after detoxification compared with treatment with a placebo (number need to treat (NNT) for one person to benefit was nine). The cumulative abstinence time was also clearly increased. Return to heavy drinking did not change. Even though the size of the treatment effect was moderate, the benefit should be valued because of the relapsing nature of alcoholism and the limited treatment options that are currently available. Diarrhea was the most frequently reported side effect with acamprosate. Overall, side effects did not cause more participants to stop treatment when taking acamprosate compared with placebo.</P>
<P>These conclusions are based on 24 randomised controlled trials with 6915 participants who were treated as outpatients in all but one trial that involved adolescent inpatients. The majority of participants were men, median age 42 years. Most studies were conducted in Europe; two studies were conducted in the United States and one study in each of South Korea,Australia and Brazil. The effects of acamprosate did not differ in industry-sponsored and non-profit funded trials.</P>
<P>Three trials compared acamprosate and naltrexone and did not indicate a superiority of one or the other drug on return to any drinking, return to heavy drinking and cumulative abstinence duration.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-07-10 14:07:43 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-07-10 14:04:24 +0200" MODIFIED_BY="[Empty name]">
<P>Alcohol dependence is among the main leading health risk factors in most developed and developing countries. Therapeutic success of psychosocial programs for relapse prevention is moderate, but could potentially be increased by an adjuvant treatment with the glutamate antagonist acamprosate. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-07-10 12:08:40 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and tolerability of acamprosate in comparison to placebo and other pharmacological agents. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-21 17:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE and CINAHL in January 2009 and inquired manufacturers and researchers for unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-07-10 12:09:07 +0200" MODIFIED_BY="[Empty name]">
<P>All double-blind randomised controlled trials (RCTs) which compare the effects of acamprosate with placebo or active control on drinking-related outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-07-10 12:09:42 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data. Trial quality was assessed by one author and cross-checked by a second author. Individual patient data (IPD) meta-analyses were used to verify the primary effectiveness outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-07-10 14:07:43 +0200" MODIFIED_BY="[Empty name]">
<P>24 RCTs with 6915 participants fulfilled the criteria of inclusion and were included in the review. Compared to placebo, acamprosate was shown to significantly reduce the risk of any drinking RR 0.86 (95% CI 0.81 to 0.91); NNT 9.09 (95% CI 6.66 to 14.28) and to significantly increase the cumulative abstinence duration MD 10.94 (95% CI 5.08 to 16.81), while secondary outcomes (gamma-glutamyltransferase, heavy drinking) did not reach statistical significance. Diarrhea was the only side effect that was more frequently reported under acamprosate than placebo RD 0.11 (95% 0.09 to 0.13); NNTB 9.09 (95% CI 7.69 to 11.11). Effects of industry-sponsored trials RR 0.88 (95% 0.80 to 0.97) did not significantly differ from those of non-profit funded trials RR 0.88 (95% CI 0.81 to 0.96). In addition, the linear regression test did not indicate a significant risk of publication bias (p = 0.861).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-07-10 14:07:32 +0200" MODIFIED_BY="[Empty name]">
<P>Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification in alcohol dependent patients. Even though the sizes of treatment effects appear to be rather moderate in their magnitude, they should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<BACKGROUND MODIFIED="2010-07-13 11:46:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the abbreviations used in the text</P>
<SUBSECTION>
<HEADING LEVEL="2">Description of the condition</HEADING>
<P>Alcohol dependence is among the main leading health risk factors in most developed and developing countries (<LINK REF="REF-Alonso-2004" TYPE="REFERENCE">Alonso 2004</LINK>). The one year prevalence of alcohol-use disorders in people aged between 15 to 64 years is estimated at 5.2% in the American Region, 5.5% in European countries and at over 10% in the Eastern European countries (<LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). According to the World Health Organisation (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>), the misuse of alcohol belongs to the globally leading health risk factors, causing 20&#8211;30% of oesophageal cancer, liver disease, epilepsy, motor vehicle accidents, homicide and other intentional injuries. In the year 2004, 3.8% of all global deaths and 4.6% of global disability-adjusted life-years were attributable to alcohol (<LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). The costs attributable to alcohol consumption are estimated at more than 1% of the gross domestic products in high-income and middle-income countries (<LINK REF="REF-Konnopka-2007" TYPE="REFERENCE">Konnopka 2007</LINK>; <LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). At the same time, alcohol consumption belongs to major potentially avoidable health risk factors, underscoring the need for effective strategies to reduce excessive drinking and to support abstinence in patients who are dependent on alcohol. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Description of the intervention  </HEADING>
<P>Relapse prevention for alcohol dependence was exclusively dominated by psychosocial treatment strategies for many decades. Even though elaborated techniques from different theoretical and therapeutical backgrounds have been developed, treatment effects obtained by an exclusive application of psychosocial treatment are limited: A considerable high proportion of patients does not respond to the interventions at all and of those who respond, only a small portion succeeds in maintaining abstinence in a long-term perspective (<LINK REF="REF-Moos-2006" TYPE="REFERENCE">Moos 2006</LINK>).</P>
<P>With the investigation of the neurobiological mechanism of alcohol dependence, various pharmacological agents have been examined in their potential to support alcohol dependent patients in achieving abstinence or in cutting down their alcohol consumption. Some of these agents showed promising effects in first small size trials, but could not be confirmed by multicenter trials, while two substances were repeatedly shown to be effective: The opioid antagonist naltrexone<I> </I>and the glutamate antagonist acamprosate.</P>
<P>Acamprosate is a synthetic molecule with a chemical structure similar to that of the endogenous amino acid N-acetyl homotaurine (<LINK REF="REF-Zornoza-2003" TYPE="REFERENCE">Zornoza 2003</LINK>), a small, highly flexible molecule with analogy to many amino acids, most notably glutamate, gamma-aminobutyric acid, aspartate, glycine, and taurine (<LINK REF="REF-Spanagel-1997" TYPE="REFERENCE">Spanagel 1997</LINK>; <LINK REF="REF-Mann-2008" TYPE="REFERENCE">Mann 2008</LINK>). In animal models of alcohol dependence, acamprosate was shown to diminish the temporary increase in voluntary alcohol intake observed during a reinstated access to alcohol after a period of deprivation (<LINK REF="REF-Czachowski-2001" TYPE="REFERENCE">Czachowski 2001</LINK>; <LINK REF="REF-Heyser-1998" TYPE="REFERENCE">Heyser 1998</LINK>; <LINK REF="REF-LeMagnen-1987" TYPE="REFERENCE">LeMagnen 1987</LINK>;<LINK REF="REF-Olive-2002" TYPE="REFERENCE">Olive 2002</LINK>; <LINK REF="REF-Spanagel-1996" TYPE="REFERENCE">Spanagel 1996</LINK>) - the so-called "alcohol deprivation effect" (ADE), which serves as model of relapse. Besides its effects demonstrated in the limited access paradigm, acamprosate was shown to attenuate self-administration of alcohol under free-choice conditions (<LINK REF="REF-Spanagel-2003" TYPE="REFERENCE">Spanagel 2003</LINK>) and to inhibit the development of the conditioned place preference in rats (<LINK REF="REF-McGeehan-2003" TYPE="REFERENCE">McGeehan 2003</LINK>). It was also shown to selectively reduce alcohol-seeking behavior elicited by environmental stimuli predictive of alcohol availability (<LINK REF="REF-Bachteler-2005" TYPE="REFERENCE">Bachteler 2005</LINK>).</P>
<P>Until today, various clinical studies have been conducted, with the majority of trials demonstrating superiority of acamprosate compared to placebo. Indicated for the maintenance of abstinence in alcohol dependent patients, acamprosate was first mainly used in European Countries, but was approved by the US Food and Drug Administration (FDA) in 2004. It is meanwhile prescribed in 40 countries worldwide and in clinical use for more than 20 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">How the intervention might work  </HEADING>
<P>Acamprosate's precise mechanism of action is still under investigation. Current evidence suggests a multiple mediation of effects, with modulations of the N-methyl-D-aspartic acid (NMDA) receptor, which was early identified as one central mode of operation (<LINK REF="REF-Zeise-1993" TYPE="REFERENCE">Zeise 1993</LINK>), being still considered as the primary mechanism of action (<LINK REF="REF-Littleton-2003" TYPE="REFERENCE">Littleton 2003</LINK>).<B> </B>Acamprosate acts as a partial co-agonist with enhanced functioning at low levels of endogenous activators, and inhibitation at high levels (<LINK REF="REF-Lipha-2002" TYPE="REFERENCE">Lipha 2002</LINK>; <LINK REF="REF-Naassila-1998" TYPE="REFERENCE">Naassila 1998</LINK>). The increased calcium influx through NMDA glutamate receptors during alcohol withdrawal induces a state of neuronal hyperexcitability associated with physical symptoms of withdrawal and an increased desire to start drink again. By inhibiting the calcium influx, acamprosate is restoring the balance between inhibitory and excitatory neurotransmitters. Besides its effects on acute withdrawal, acamprosate additionally attenuates conditioned reactions ("pseudo-withdrawal") and opponent processes associated with drinking related cues (<LINK REF="REF-Cole-2000" TYPE="REFERENCE">Cole 2000</LINK>; <LINK REF="REF-Littleton-1995" TYPE="REFERENCE">Littleton 1995</LINK>), the latter explaining the potency of the substance to prevent a relapse after physical symptoms of withdrawal have disappeared. Evidence suggests that besides its effects on withdrawal-related processes, acamprosate's reductive effect on drinking is also attributable, at least in part, to its potential to reduce rewarding effects of alcohol (<LINK REF="REF-Cano_x002d_Cebrian-2003" TYPE="REFERENCE">Cano-Cebrian 2003</LINK>; <LINK REF="REF-McGeehan-2003" TYPE="REFERENCE">McGeehan 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this review  </HEADING>
<P>Acamprosate has already been subject to various meta-analyses, which indicate small to moderate, but significant effects of the substance in maintaining abstinence in alcohol dependent patients (<LINK REF="REF-Berglund-2003" TYPE="REFERENCE">Berglund 2003</LINK>; <LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>; <LINK REF="REF-Chick-2003" TYPE="REFERENCE">Chick 2003</LINK>; <LINK REF="REF-Hopkins-2002" TYPE="REFERENCE">Hopkins 2002</LINK>; <LINK REF="REF-Kranzler-2001" TYPE="REFERENCE">Kranzler 2001</LINK>; <LINK REF="REF-Mann-2004" TYPE="REFERENCE">Mann 2004</LINK>; <LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK>; <LINK REF="REF-Schoechlin-2000" TYPE="REFERENCE">Schoechlin 2000</LINK>). Within the last years, the primary database for acamprosate has been extended and some of the newer trials partly differ from the previous research in terms of the study design, the trial setting and the source of financial sponsoring. Thus, an update of the database by integrating newer acamprosate trials is likely to increase the validity of conclusions. Besides the statistical integration of primary effects, a systematic assessment of bias risks allows to discuss the demonstrated effects against the background of methodological considerations.</P>
<P>The present review is the first review on acamprosate undertaken within the framework of the Cochrane Collaboration. Available Cochrane reviews on alcoholism treatment evaluate 12-step programmes for alcohol dependence (<LINK REF="REF-Ferri-2006" TYPE="REFERENCE">Ferri 2006</LINK>), brief interventions for heavy alcohol users admitted to general hospital wards (<LINK REF="REF-McQueen-2009" TYPE="REFERENCE">McQueen 2009</LINK>) and for primary care populations (<LINK REF="REF-Kaner-2007" TYPE="REFERENCE">Kaner 2007</LINK>) as well as opioid antagonists for the treatment of alcohol dependence (<LINK REF="REF-Srisurapanont-2005" TYPE="REFERENCE">Srisurapanont 2005</LINK>).</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-06-21 10:03:56 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and tolerability of acamprosate in comparison to placebo and other pharmacological agents.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-07-13 11:52:14 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-07-12 11:48:01 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-07-10 15:12:36 +0200" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) with a double-blind design, which compare the effects of acamprosate (monotherapy and combined therapy) with placebo or active control (other pharmacological treatments for alcohol dependence) on<I> </I>drinking-related outcomes. Randomization was required to be restricted to procedures which consider the individual patient as the unit of allocation, excluding group or cluster randomisation studies. Cross-over and multi-phase designs were only considered if medication-free periods ensured the washout of previous treatments. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-01-20 10:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>Individuals with alcohol dependence according to the criteria of the <I>Diagnostic and</I> <I>Statistical Manual of Mental Disorders (</I>DSM) or the <I>International Statistical Classification of Diseases</I> (ICD) irrespective of any other characteristics. Patient samples including both, patients with alcohol dependence and alcohol abuse, were only included if patients with alcohol dependence constituted the majority of the sample (&gt;50%).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-07-11 15:57:19 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Experimental intervention: acamprosate</LI>
<LI>Control interventions: placebo; other pharmacological treatments for alcohol dependence.</LI>
</OL>
<P>A minimum treatment duration of four weeks was required to ensure an adequate implementation of the intervention. Any dose, any mode of administration and any combination of therapies was included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-07-12 11:48:01 +0200" MODIFIED_BY="[Empty name]">
<P>The selection of the primary and secondary outcomes of the review was constituted in consideration of the availability of outcomes, their clinical relevance and their theoretical and conceptual foundation (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>).</P>
<P>The study end-points of the primary effectiveness outcomes were considered as constitutive for effectiveness conclusions, while the secondary effectiveness outcomes had only complementary value in the interpretation of results. The primary end-points were evaluated with both, meta-analyses based on literature (MAL) and individual patient database (IPD) analyses, while secondary outcomes were exclusively estimated on the base of MAL. For reasons of clarity and conciseness, post-treatment evaluations were restricted to the primary outcomes of the review. Rates of drop-out and drop-out due to side effects were discussed as potential moderators of effect sizes, but were not included in the evaluation of effectiveness.</P>
<P>
<B>Primary outcomes  </B>
</P>
<OL>
<LI>Return to any drinking</LI>
<LI>Cumulative abstinence duration.</LI>
</OL>
<P>Return to <I>any drinking </I>(complementary event: continuous abstinence) was considered as the primary endpoint for most of the previous RCTs and meta-analyses on acamprosate. It is a binary variable containing the information whether a patient returned to drinking after detoxification, or whether a patient remained fully abstinent. The <I>cumulative abstinence duration (CAD)</I> is the total sum of days a patient remained abstinent in the course of a trial (including continuous as well as interrupted abstinence intervals) related to the entire duration of the study, multiplied with the factor 100. To allow clinically relevant conclusions on treatment stability, post-treatment evaluations (follow-up after treatment termination) had to include at least 12 weeks of observation.</P>
<P>
<B>Secondary outcomes  </B>
</P>
<OL>
<LI>Return to heavy drinking;</LI>
<LI>Gamma-glutamyl transpeptidase (GGT)</LI>
<LI>Side effects.</LI>
</OL>
<P>Heavy drinking was<I> </I>considered as predetermined by the definitions in the clinical trials. <I>Gamma-glutamyl transpeptidase</I> (GGT) levels were uniquely transformed into "units per liter". All side effects<I> </I>presented in the trial publications were extracted, while only those with significant group differences were considered as clinically relevant.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-07-13 11:46:59 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-07-13 11:46:59 +0200" MODIFIED_BY="[Empty name]">
<P>The electronic search was conducted using the following bibliographic databases in descending order:</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> issue 2 2009) which also contains the Cochrane Drugs and Alcohol Group's Trials Register;</LI>
<LI>MEDLINE (from 1966 to January 2009);</LI>
<LI>EMBASE (from 1988 to January 2009);</LI>
<LI>CINAHL (from 1982 to January 2009).</LI>
</UL>
<P>Search strategies were developed and applied by the trial search coordinator (SV) of the Cochrane Drugs and Alcohol Group (CDAG). For the MEDLINE search, the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (sensitivity maximizing version) was applied as outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). No operators and no restrictions in language, date, gender, age or tag terms were used. Search strategies for further databases were invariably based on the strategy developed for MEDLINE but revised for the specific requirements of each database.</P>
<P>Details of the search strategies are provided in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>We searched for ongoing clinical trials and unpublished studies via Internet on the following sites:</P>
<OL>
<LI>http://www.controlled-trials.com;</LI>
<LI>http://clinicaltrials.gov;</LI>
<LI>http://www.clinicalstudyresults.org;</LI>
<LI>http://www.centrewatch.com</LI>
</OL>
<P>For relevant trials with a completion data before 30 April 2009, the principal investigators were contacted and requested to provide reports, manuscripts or unpublished results in advance.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-03-08 15:35:11 +0100" MODIFIED_BY="[Empty name]">
<P>Key informants, experts, public sponsors and the drug manufacturer, Merck Serono (Geneve), were contacted with the request to indicate further studies of potential relevance. For this purpose, reference lists with identified studies and criteria of inclusion and exclusion of the review were provided. Finally, hand searching of reference lists of included studies and current reviews was conducted to complete and to verify the preceding searches.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-07-13 11:52:14 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-07-10 15:20:43 +0200" MODIFIED_BY="[Empty name]">
<P>The eligibility and relevance of trials was assessed on the base of their abstracts retrieved from the electronic searches. For studies that met the criteria of inclusion according to the abstract information, full text versions were retrieved for a closer inspection in a second step of the study selection. On their base, the relevance and eligibility of studies was assessed by one author (SR), in case of uncertainties a author (AH) was consulted. The process of study identification and its results are outlined as a flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) according to the PRISMA statement (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).</P>
<P>After request, the manufacturer Merck Serono (Geneve) provided unconditioned access to a database with individual patient data (IPD) on acamprosate. The set of studies identified with the search strategies described above was compared with the study base of the IPD file. For studies, not included in the IPD file, investigators were contacted and requested to provide access to the raw data bases.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-07-10 15:59:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Aggregated data extraction and management  </B>
</P>
<P>Information considered in the study tables was extracted by one author (SR) and cross-checked by a second author (AH), while outcome statistics were coded from the study reports by two authors (SR &amp; AH) parallel and independently. If necessary, extracted statistics were standardized and converted for the meta-analyses, including a) the application of the intention-to-treat (ITT) principle on binary outcome data in studies which have not considered this principle in their primary analyses; b) the pooling of outcome data provided for patients subgroups or different dosage forms and c) the standardization of units of the measurement. If the alcohol content of standard drink units (SDUs) was not specified in the trial publications, country-specific values as provided by the International Drinking Guidelines (<LINK REF="REF-ICAP-2003" TYPE="REFERENCE">ICAP 2003</LINK>) were applied. All outcome statistics and calculation steps were entered into electronic data templates (Microsoft Excel) and compared value by value. In case of disagreements, the following sequential procedures were undertaken in descending order:</P>
<OL>
<LI>comparison of published and extracted information to identify transcription and comprehension errors;</LI>
<LI>explication of the coding decisions by each reviewer, followed by consensus discussion and arbitration.</LI>
</OL>
<P>Finally, after comparisons and corrections were concluded, data were transformed into Review Manager 5 (<LINK REF="REF-The-Nordic-Cochrane-Centre-2008" TYPE="REFERENCE">The Nordic Cochrane Centre 2008</LINK>).</P>
<P>
<B>Individual patient data (IPD) acquisition and management </B>
</P>
<P>The IPD base on acamprosate, which was used to additionally assess the primary outcomes of the review on the base of non-aggregate data, has been established in the course of a collaborative, multistage research project, started in 2005 and initiated from the Plinius Major Society, a private initiative of European alcoholism investigators. The database is constituted on raw data files, which were obtained from the primary study investigators and data centres in the course of the research project. Computerized data entry files, which were available in various mainframe formats and various devices, were combined in the course of a standardization process. Data checking against the original case report forms (CRFs) was performed, using a so-called "military standard control"-process, based on the assessment of a random sampling of values of the file. In this test, the acceptable quality level (AQL) was fixed to a value of AQL =0.001 for main endpoints. Data transferred from the original data files to the centralized IPD base included study specific dates (e.g. date of publication), patient characteristics (e.g. age, sex, weight, marital status) and various outcome statistics. The harmonization of the raw data files was conducted by a team of researchers, familiar with the clinical guidelines in the respective countries in which the trials have been conducted. The funds for establishing and maintaining the database were coming from non-industry national grants as well as a grant from Merck Serono (Geneve), which provided unconditioned access to the data for the purpose of the review. The database was updated according to the study set identified with the study search for the review (<LINK TAG="SEARCH_METHODS" TYPE="SECTION">Search methods for identification of studies</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-07-10 16:10:28 +0200" MODIFIED_BY="[Empty name]">
<P>The risk of bias was assessed in accordance with the <I>Cochrane Collaboration'</I>s <I>risk of bias assessment tool </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).<I> </I>Besides the bias domains prespecified by the tool,<I> </I>the risk of<I> baseline imbalance </I>and <I>differential medication compliance </I>were considered as further bias risks (item "free of other bias")<I>. </I>
</P>
<P>Risk of bias tables were completed by one author (SR) and cross-checked by a second author (AH). Methods for bias control were only considered as applied, if these were adequately described in the study publication or the informal investigator report. Otherwise the associated bias risk was rated as "uncertain". The following criteria were considered as constitutive for the rating of bias risks:</P>
<P>
<B>Sequence generation (Selection bias)</B>
</P>
<P>Methods used for <I>sequence generation</I> were rated as adequate if based on a random process, which is providing an equal chance for every study participant to be assigned to each of the treatment conditions. In contrast, methods that would permit any prediction of assignment in advance (e.g. sequence generation by day of birth), were considered as inadequate.</P>
<P>
<B>Allocation concealment (Selection bias)</B>
</P>
<P>Strategies applied for <I>allocation concealment</I> were considered as adequate if a) randomisation and drug preparation was undertaken centralized and remote from patient recruitment centres; AND if b) allocation codes were protected against identification by the use of sealed randomisation envelopes.</P>
<P>
<B>Blinding (Detection bias, performance bias)</B>
</P>
<P>
<I>Blinding</I> was rated as adequate, if a) at least patients and research staff were specified as being included in the blinding procedures; AND if b) active medication and placebo were of identical appearance. If different active substances were used within one study, a double-dummy design was required. For studies, which checked and confirmed the integrity of blinding at the end of the treatment, blinding was rated as adequate irrespective of the criteria outlined above.</P>
<P>
<B>Handling of incomplete outcome data (Attrition bias)</B>
</P>
<P>
<I>Handling of incomplete outcome data </I>was considered as adequate if a) all randomised patients or at least those who have received at least one dose of treatment were included in the statistical analyses; AND if b) the methods of handling drop-outs or lost to follow-ups adequately considered the association between attendence to study visits and drinking status, either by generally assigning missing participants to the relapse category (substitution by "worst case") or by analysing the pattern of missingness (e.g. pattern-mixture analyses). The handling of incomplete outcome data<I> </I>was rated separately for binary and continuous outcomes; for reasons of clarity and conciseness, the summary rating of the attrition bias risk was restricted to the primary effectiveness outcomes only.</P>
<P>
<B>Selective reporting (Reporting bias)</B>
</P>
<P>A trial publication was considered as free of <I>selective reporting </I>if all outcomes listed in the protocol or the methods section of the publication were adequately reported in the results section.</P>
<P>
<B>Other bias </B>
</P>
<P>A study was rated as being "free of other bias" if baseline equivalence between groups and equivalence of medication compliance were ensured: </P>
<P>
<B>Baseline equivalence (Selection bias)</B>
</P>
<P>
<I>Baseline equivalence</I> was rated as being equivalent between groups, if treatment groups were compared in potentially effect-determining baseline characteristics (age AND gender AND baseline drinking AND (drinking OR treatment history)). If differences between groups became evident, these had be adequately controlled in the statistical analyses.</P>
<P>
<B>Treatment exposure (Performance bias)</B>
</P>
<P>Treatment groups were considered as <I>equally exposed</I> to interventions, if they were shown not to significantly differ in medication compliance.</P>
<P>
<B>Funding bias </B>
</P>
<P>The risk of funding bias was assessed by comparing the "risk for return to any drinking" between trials that a) were sponsored, organized and conducted by the pharmaceutical industry, b) have received grants and facilities by the manufacturer, who has not been involved in the study management and data analyses and c) were investigator-driven and completely non-profit funded.</P>
<P>
<B>Publication bias </B>
</P>
<P>The risk of publication bias was graphically and statistically examined as outlined in the section <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-07-12 12:20:03 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment effects of acamprosate on dichotomous effectiveness outcomes were measured by risk ratio (RR), relating the risk of any drinking or heavy drinking observed in the intervention group to the corresponding risk in a reference group. Risk differences (RD) between treatment groups were calculated to assess side effects. Treatment effects on continuous outcomes (cumulative abstinence duration, gamma-glutamyl transpeptidase) were measured by mean differences (MD) of standardized units. For all treatment effects, 95% confidence intervals (CI) were provided. For binary outcomes with statistical significance, the numbers needed to treat for an additional beneficial outcome (NNTB) and the numbers needed to treat for an additional harmful outcome (NNTH) were calculated as the inverse of the absolute risk reduction (ARR). A P value of 0.05 and below was chosen to indicate the statistical significance of effects.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-01-20 14:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>Only parallel group designs were considered in the review and from repeated measurements, only one time-point (study endpoint) was included in the evaluation of effectiveness. Thus, the unit of allocation invariably corresponds to the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-06-28 09:22:37 +0200" MODIFIED_BY="[Empty name]">
<P>For the analyses of binary outcome data (return to any drinking, return to heavy drinking), all randomised patients were included in the statistical analyses, with drop-outs or lost to follow ups being assigned to the relapse category.</P>
<P>For the MAL analyses of continuous effectiveness outcomes (cumulative abstinence duration, GGT), means and standard deviations were included as provided by the study publications irrespective of the handling of missing data in the primary analysis. For IPD analyses of cumulative abstinence duration, any time between the last study visit of an early terminating patient and the end of the trial was considered as a non-abstinent interval (irrespective of the reasons for dropping out) and related to the entire study duration.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-01-20 16:58:23 +0100" MODIFIED_BY="[Empty name]">
<P>Inconsistency across studies was quantified with the I<SUP>2</SUP>-statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), using a variability of 50% as the threshold value for substantial heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>) and the Tau<SUP>2</SUP>-statistic for providing an estimate of between-study variance<B> </B>(<LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>) independent of the sample size. </P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-07-13 11:52:14 +0200" MODIFIED_BY="[Empty name]">
<P>The risk of publication bias was graphically illustrated with the funnel plot method (<LINK REF="REF-Light-1984" TYPE="REFERENCE">Light 1984</LINK>) and statistically examined with a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), determining the linear regression coefficient between log odds ratio (OR) and its standard error for "return to any drinking". The linear regression test was performed non-weighted and weighted by precision. The risk of outcome reporting bias (<LINK REF="REF-Pocock-1987" TYPE="REFERENCE">Pocock 1987</LINK>; <LINK REF="REF-Tannock-1996" TYPE="REFERENCE">Tannock 1996</LINK>; <LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>; <LINK REF="REF-Williamson-2005" TYPE="REFERENCE">Williamson 2005</LINK>) was not quantitatively analysed, but considered in the discussion of results.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-07-10 16:17:47 +0200" MODIFIED_BY="[Empty name]">
<P>For synthesizing aggregate outcome measures, a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) was chosen according to the recommendation of <LINK REF="REF-Brockwell-2001" TYPE="REFERENCE">Brockwell 2001</LINK>, with study effects being weighting with the Mantel-Haenzel approach<B> </B>(<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>). For outcomes with low effect heterogeneity (I<SUP>2 </SUP>&lt; 30%), a fixed effect model was additionally applied within the scope of sensitivity analyses.</P>
<P>IPD analyses were carried out using a multi-level one-stage approach (<LINK REF="REF-Riley-2007" TYPE="REFERENCE">Riley 2007</LINK>). For continuous outcome data, a two-level model including study-level and patient-level, with random treatment effects and fixed study effects was applied (<LINK REF="REF-Higgins-2001" TYPE="REFERENCE">Higgins 2001</LINK>). Analyses of binary outcomes were conducted within the multilevel framework as introduced by <LINK REF="REF-Turner-2000" TYPE="REFERENCE">Turner 2000</LINK>. IPD analyses were performed with the "R" statistical package (version 2.6.2).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-06-08 11:59:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Subgroup analyses</B>
</P>
<P>Due to the low availability of subgroup outcomes in the trial publications, subgroup analyses could not be conducted on a meta-analytic level of evidence.</P>
<P>
<B>Investigation of heterogeneity</B>
</P>
<P>As a preliminary exploration of heterogeneity indicated a low statistical power due to the high missing rates for selected design characteristics (e.g. quality of blinding, allocation concealment, handling of missing outcome data), which were foreseen as predictors in the regression model as well as the high sensitivity of the results to the presumptions of the model, the authors of the review decided to obtain the missing information from the investigators and to deliver the meta-regression at a later stage.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-07-10 16:19:27 +0200" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were conducted to determine the influence of the underlying statistical model, by comparing effect sizes for low heterogeneity outcomes (I<SUP>2 </SUP>&lt; 30%) calculated on the base of random effects models versus fixed effect models.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<STUDY_DESCRIPTION MODIFIED="2010-07-12 11:34:19 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-07-10 16:25:21 +0200" MODIFIED_BY="[Empty name]">
<P>The study search for the review yielded 414 potentially relevant references, of which 384 were identified through bibliographic databases and 30 through other sources (personal communication: n = 1, database of ongoing trials: n = 29). 203 of the 414 identified references were identified as duplicates and removed. The remaining 211 records were screened and 163 records were excluded on the base of the information provided in the abstracts. For the remaining 48 records, full-text articles were obtained and on their base, another 24 studies were excluded. Reasons for exclusions was an open study design (n = 12), the missing of a control group (n = 5), a treatment duration below 30 days (n = 4), a non-dependent study sample (n = 1), a cross-over design (n = 1) and a single-blinded design. Finally 24 RCTS were considered as eligible for the review and included in the meta-analyses. The steps of trial identifying and their results are outlined in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> as flow-diagram according to the PRISMA statement (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-07-12 11:34:19 +0200" MODIFIED_BY="[Empty name]">
<P>A total of 24 RCTs with 6894 patients were included in the review. Of those, 3563 patients were treated with acamprosate, 2929 patients with placebo and 402 with naltrexone.</P>
<P>
<B>Comparisons</B>
</P>
<P>In 18 of the 24 RCTs, which met the inclusion criteria of the review, patients were either randomised to acamprosate or to placebo. Four trials included three treatment arms, comparing different dose regimes of acamprosate with each other and with placebo (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>) or comparing acamprosate with placebo and the opioid antagonist naltrexone (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>). Two studies were based on a four-armed design (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>), considering acamprosate monotherapy, naltrexone monotherapy, placebo and a combined treatment with naltrexone and acamprosate.</P>
<P>
<B>Patients</B>
</P>
<P>To participate in a clinical study, patients were required to fulfil the criteria of alcohol dependence (according to DSM-III-R, DSM-IV or ICD-10) and to have a minimum age of 18 years, apart from one study (<LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>), which examined acamprosate`s effectiveness in a sample of adolescent patients. In the remaining studies, the mean age of the sample varied between 40 and 47 years, with a median of 42 years. Two studies included patients with alcohol dependence and alcohol abuse (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>). Samples were mostly of mixed gender, with men constituting the majority, while two trials (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>) exclusively included male patients.</P>
<P>
<B>Funding and design </B>
</P>
<P>11 of the 24 RCTs (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>) were sponsored, organized and conducted by the pharmaceutical industry within the scope of new drug application processes, while six studies have received grants and facilities by the manufacturer, who was not involved in the management, analyses, and interpretation of data (<LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) and seven trials were investigator-driven research (ICDR) with non-proft funding (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>). 18 of the 24 RCTs included in the review used a multicenter design, 6 trials (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>) a single-center design. Sample sizes varied from 10 patients (<LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>) to 1383 patients (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>), with the COMBINE-study (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>) being the largest trial included in the review. Treatment was provided in outpatient settings, with the exception of one trial (<LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>), which provided treatment on an inpatient base. Psychosocial treatment was concurrently applied, but not specified in most trial publications. In multi-centre trials, psychosocial treatment was applied centre-specific (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>). In eight studies (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>) patients were additionally encouraged to participate in Alcoholics Anonymous (AA) groups.</P>
<P>
<B>Countries in which the studies were conducted</B>
</P>
<P>Most studies (n = 19) were conducted in Europe, two studies were conducted in the United States (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>) and one study each in South Korea (<LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>), Australia (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) and Brazil (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>).</P>
<P>
<B>Treatment regimen and duration</B>
</P>
<P>Before treatment, patients were detoxified, whereby a minimum of 3 to 7 days of continuous abstinence was required to enter randomisation with the exception of two studies (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>), which demanded 12 days and 14 days of baseline abstinence and one study (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>), which did not require detoxification at all. In this study, about half of the sample was actively drinking before treatment started.</P>
<P>One trial started with a placebo run-in week (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>) and in the study of <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>, acamprosate was prescribed from the start of the alcohol withdrawal phase. At the beginning of the treatment, patients were randomly assigned to either intervention or control. Treatment was applied in a double-blind fashion and in the course of the study, drinking-related outcomes and side effects were repeatedly measured.</P>
<P>Most studies dosed acamprosate weight dependent, providing a daily dose of 1332 mg to patients with a body weight lower than 60 kg and 1998 mg to those who weighted more than 60 kg (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>). With 1332 mg acamprosate per day, dosing was lowest in the studies of <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK> and <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>, while the highest doses of 3000 mg were applied in the US trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>). <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK> gave one capsule per 10 kg body weight, keeping a minimum dose of 1000 mg and a maximum dose of 2250 mg. In three studies, high dose regimes of 3000 mg per day (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>) or low dose regimes of 1332 mg per day (<LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>) were tested against the standard dose of 1998 mg, respectively 2000 mg.  </P>
<P>Treatment duration varied from eight weeks (<LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>) to one year (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>), with a duration of six months being most common (<LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>).</P>
<P>
<B>Outcomes </B>
</P>
<P>The most frequently considered outcome was &#8220;return to any drinking&#8221; (or its complementary event "continuous abstinence"), available for 24 RCTs, followed by cumulative abstinence duration, available for 19 RCTs. The secondary outcomes of the review, "return to heavy drinking" and GGT values were less frequently provided; anyhow, information on these outcomes was available for six trials (heavy drinking: <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>) and seven trials (GGT: <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>). Most of the outcome information was available from the trial publications with the following exceptions: "Return to any drinking&#8221;-rates were extracted from the manufacturer report for three trials (<LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>) and subsequently provided by the investigator (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>) and the study sponsor (<LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>) for one trial at a time; cumulative abstinence duration was extracted the manufacturer report in the case of three trials (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>) and provided by the sponsor for one trial (<LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>). Post-treatment "return to any drinking", available for 7 RCTS (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) and post-treatment cumulative abstinence duration, available for 9 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>), was exclusively extracted from trial publications.</P>
<P>For the definition of heavy drinking, a cut-off value of five SDUs was chosen in most studies (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>), one trial (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) considered six drinks as critical threshold for heavy drinking. <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK> also assigned patients to the heavy drinking category if drinking occurred on five or more days a week.</P>
<P>
<B>Methods of data assessment</B>
</P>
<P>Assessment of drinking was mostly based on retrospective quantity/ frequency reports (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) or drinking cards (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>), on which patients were to record drinking patterns and drinking amount on a daily basis. Four studies (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>) assessed drinking with the Time Line Follow-Back method (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>), a semi-structured interview that uses calendar format to record the quantity and frequency of drinking.</P>
<P>For 17 of 24 RCTs, patient-reported drinking was validated by objective measures. To verify patients` self reports, GGT values were used in most studies (<LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>). Alternatively, <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK> and <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK> used carbohydrate-deficient transferrin (CDT) as a validity check for self-reported drinking data, <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>, <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK> and <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK> used the mean corpuscular volume (MCV), <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK> and <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK> the breath alcohol concentration, <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK> and <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK> the urine alcohol concentration and <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK> and <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK> used collateral reports.</P>
<P>To systematically assess side effects, checklists (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>), an open ended inquiry (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), a rating scale (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>) and the Systematic Assessment for Treatment Emergent Effects (SAFTEE) developed by <LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK> and <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK> were used (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>).</P>
<P>Compliance was assessed by pill count in most trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>, <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>, <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>, <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>, <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Pelc-1992" TYPE="STUDY">Pelc 1992</LINK>; <LINK REF="STD-Pelc-1997" TYPE="STUDY">Pelc 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>), in one study (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>), acamprosate plasma levels were examined to validate compliance estimates based on pill count. Post-treatment drinking status was assessed at intervals of 3 months (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>), 6 months (<LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>) and 12 months (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) after treatment was discontinued.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-07-10 16:59:19 +0200" MODIFIED_BY="[Empty name]">
<P>24 trials were excluded on the basis of their full-text versions. Reasons for exclusion was the use of an open label study design in 12 studies (<LINK REF="STD-Buri-2007" TYPE="STUDY">Buri 2007</LINK>; <LINK REF="STD-Croissant-2006" TYPE="STUDY">Croissant 2006</LINK>, <LINK REF="STD-de-Sousa-2005" TYPE="STUDY">de Sousa 2005</LINK>, <LINK REF="STD-Florez-2008" TYPE="STUDY">Florez 2008</LINK>, <LINK REF="STD-Fuchs-2002" TYPE="STUDY">Fuchs 2002</LINK>, <LINK REF="STD-Kampman-2009" TYPE="STUDY">Kampman 2009</LINK>, <LINK REF="STD-Kiritze_x002d_Topor-2004" TYPE="STUDY">Kiritze-Topor 2004</LINK>, <LINK REF="STD-Laaksonen-2008" TYPE="STUDY">Laaksonen 2008</LINK>, <LINK REF="STD-Nespor-2006" TYPE="STUDY">Nespor 2006</LINK>, <LINK REF="STD-Pelc-2002" TYPE="STUDY">Pelc 2002;</LINK> <LINK REF="STD-Rychlik-2001" TYPE="STUDY">Rychlik 2001</LINK>; <LINK REF="STD-Soyka-2002" TYPE="STUDY">Soyka 2002</LINK>), the lack of placebo or active control group in five studies (<LINK REF="STD-De-Wildt-2002" TYPE="STUDY">De Wildt 2002</LINK>; <LINK REF="STD-Feeney-2002" TYPE="STUDY">Feeney 2002</LINK>; <LINK REF="STD-Hammarberg-2004" TYPE="STUDY">Hammarberg 2004</LINK>; <LINK REF="STD-Han-2008" TYPE="STUDY">Han 2008</LINK>; <LINK REF="STD-Reid-2005" TYPE="STUDY">Reid 2005</LINK>), a treatment duration below 30 days in four studies (<LINK REF="STD-Boeijinga-2004" TYPE="STUDY">Boeijinga 2004</LINK>; <LINK REF="STD-Johnson-2003" TYPE="STUDY">Johnson 2003</LINK>; <LINK REF="STD-Ooteman-2007" TYPE="STUDY">Ooteman 2007</LINK>; <LINK REF="STD-Staner-2006" TYPE="STUDY">Staner 2006</LINK>), a study sample of non-dependent drinkers (<LINK REF="STD-Mason-2002" TYPE="STUDY">Mason 2002</LINK>), the non-availability of data from the first treatment period in a cross-over design (<LINK REF="STD-Gerra-1992" TYPE="STUDY">Gerra 1992</LINK>) and the use of a single-blind design (<LINK REF="STD-Rubio-2001" TYPE="STUDY">Rubio 2001</LINK>). Results after treatment were excluded because of a post-treatment duration of 4 weeks (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>) and 8 weeks (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>) and the use of a single-blind placebo design (<LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> </P>
<ALLOCATION MODIFIED="2010-07-12 11:36:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Sequence generation </B>
</P>
<P>For 6 of the 24 RCTs included in the review (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>), the methods used for sequence generation were specified in the trial publications. All of the reported strategies were considered as adequate: Five trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) have used computer-generated randomisation lists to create random sequences and in one study (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>), an interactive voice response system was applied. For the remaining 18 RCTs, methods used for sequence generation were not reported and remained unclear.  </P>
<P>
<B>Allocation concealment </B>
</P>
<P>3 of 24 RCTs included in the review (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) met both criteria of adequate allocation concealment (centralized randomisation and drug preparation, sealed envelopes). Randomization was described as centralized and conducted by an independent support unit remote from patient recruitment centres in four trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), while in three of these trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), drug containers were additionally described as being prepared by an independent pharmacy. The second criteria for adequate allocation concealment, the use of sealed envelopes, was reported in six trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-12-30 16:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>From the 24 RCTs included in the review, 7 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>) fulfilled both criteria of adequate blinding (blinding of patients and research stuff, identically matched placebo). 13 trials reported to have used placebo and active medication with identical appearance (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>) and seven of these trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>) have additionally specified patients and research stuff as being included in the double-blinding procedures. Two trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) additionally tested and confirmed the integrity of blinding by inquiries on patients and therapists. In studies with an active control group (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), blinding was ensured with a double-dummy design signifying that an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-07-10 17:10:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Binary outcomes </B>
</P>
<P>The handling of missing binary data was considered as adequate for 19 of the 24 RCTs. In these trials, all randomised patients or at least those who received treatment, were included in the data analysis and assigned to the relapse-category. The problem of incomplete binary outcome data was considered as inadequately addressed in two trials, which either excluded patients who dropped out early (<LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>) or which only considered those who had at least one outcome criteria available (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>). Bias risks were rated as "uncertain" in three trials, which did not provide information on the handling of missing binary outcome data (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>) or which classified drop-outs according to the reason of their drop-out (<LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>). </P>
<P>
<B>Continuous outcomes </B>
</P>
<P>For 13 of the 19 RCTs, which considered cumulative abstinence duration as an outcome, the handling of missing data was considered as adequate. If a patient was absent from a study visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for cumulative abstinence duration calculation in these trials. Bias risks were rated as "unclear" in six trials, which did either not provide any information on how missing abstinence durations were handled (<LINK REF="STD-Borg-2003" TYPE="STUDY">Borg 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>, <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>) or which only rated the drop-out interval as non-abstinent, if the early discontinuation was verified to be unrelated to alcohol use (<LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Besson-1998" TYPE="STUDY">Besson 1998</LINK>).</P>
<P>The handling of missing GGT values was rated as inadequate for one trial (<LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>), which excluded missing participants. For the remaining trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>), the handling of missing end-point GGT remained unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-07-08 13:39:45 +0200" MODIFIED_BY="[Empty name]">
<P>The comparison between prespecified and presented outcomes did not indicate inconsistencies for any of the included studies. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<P>13 of 24 RCTs included in the review (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Gual-2001" TYPE="STUDY">Gual 2001</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>) were considered as "free" of other potential sources of bias, ensuring the equivalence of baseline characteristics (age, gender, baseline drinking, drinking or treatment history) and the equivalence of medication compliance between groups. For the remaining 11 RCTs, the risk of other potential sources of bias remained "unclear".</P>
<SUBSECTION>
<HEADING LEVEL="4">Publication bias</HEADING>
<P>Plotting of log odds ratio for "return to any drinking" and its standard error showed a slight asymmetry with a gap in the bottom corner of the graph <I>see</I> Figure 4 or Analysis 5.1, while the linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) did not indicate a considerable risk of publication bias, neither for the non-weighted regression (R<SUP>2 </SUP>= 0.23; p = 0.342; SE = 1.440; n = 25) nor for the weighted regression (R<SUP>2 </SUP>= 0.46; p = 0.861; SE = 1.412; n = 25), <I>see</I> <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Founding sources</HEADING>
<P>Synthesis of effects "return to any drinking" according to their sponsoring indicated the highest magnitude of effects for partially industry-supported trials RR 0.84 (95% CI 0.78 to 0.89), the lowest magnitude for fully industry-sponsored trials RR 0.88 (95% CI 0.80 to 0.97) and a value in between for non-profit sponsored, investigator-driven trials RR 0.86 (95% CI 0.81 to 0.91), <I>see</I> <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK> or <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato">
<P>
<U>
<B>Comparison 1: Acamprosate versus placebo</B>
</U>
<B> </B>
</P>
<P>
<B>
<I>Primary outcomes</I> </B>
</P>
<P>
<U>Return to any drinking</U>: A statistically significant difference was shown between groups; acamprosate reduced the risk to return to any drinking after detoxification to 86% of the risk in the placebo group, RR 0.86 (95% CI 0.81 to 0.91) <I>see</I> <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> or <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>. The numbers needed to treat for an additional prevention of drinking was estimated at NNTB 9.09 (95% CI 6.66 to 14.28).</P>
<P>
<U>Cumulative abstinence duration</U>: A statistically significant difference was shown between groups; acamprosate on average increased the cumulative abstinence duration by 11% compared to placebo, MD 10.9 (95% CI 5.08 to 16.81) <I>see</I> <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> or <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>.</P>
<P>
<B>
<I>Secondary outcomes</I>
</B>
</P>
<P>
<U>Return to heavy drinking</U>: No statistically significant difference was shown between groups; the risk to return to heavy drinking was 1% lower in the acamprosate group than in the placebo group, RR 0.99 (95% CI 0.94 to 1.04) <I>see </I>
<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
<P>
<U>GGT</U>: No statistically significant difference was shown between groups; acamprosate was associated with a reduction of the GGT by about 12 units per liter compared to placebo, MD -11.91 (95% CI -24.12 to 0.30) <I>see</I> <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
<P>
<U>Side effects</U>: Among 38 side effects, only diarrhoea was more frequently reported under acamprosate than under placebo, RD 0.11 (95% CI 0.10 to 0.13) <I>see</I> <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>. The numbers needed to treat for an additional case of experiencing diarrhoea as a side effect of acamprosate was estimated at NNTH 9.09 (95% CI 7.69 to 11.11). For further adverse events <I>see </I>
<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>.</P>
<P>
<U>Drop-out due to adverse events</U>: A statistically significant difference was shown between groups; the risk to drop-out early from a study due to side effects was 35% higher in the acamprosate group than in the placebo group, RR 1.35 (95% CI 1.01 to 1.80) <I>see</I> <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>.</P>
<P>
<U>Drop-out for any cause</U>: A statistically significant difference was shown between groups; the risk of dropping out irrespective of reasons was 9% lower in the acamprosate group than in the placebo group, RR 0.91 (95% CI 0.83 to 0.99) <I>see</I> <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>.</P>
<P>
<U>Post-treatment outcomes</U>: A statistically significant difference between groups was shown three to twelve months after treatment was discontinued; patients who were in the acamprosate group had a 9% lower risk to return to any drinking than those who were in the placebo group, RR 0.91 (95% CI 0.87 to 0.96) <I>see</I> <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK> and a 9% higher continuous abstinence duration MD 8.92 (95% CI 5.08 to 12.77) <I>see</I> <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>. The numbers needed to treat for an additional prevention of drinking until the post-treatment evaluation was estimated at NNTB 12.50 (95% CI 9.09 to 25.00).</P>
<P>
<B>Sensitivity analyses </B>
</P>
<P>If data synthesis for "return to heavy drinking" (I<SUP>2</SUP> &lt; 30%) was based on a fixed-effect model, with RR 0.97 (95% CI 0.92 to 1.03) <I>see</I> <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>, the magnitude of effects was marginally higher compared than that calculated with the random-effects model RR 0.99 (95% CI 0.94 to 1.04), but the selection of the statistical model did not have an impact on the significance of effects.</P>
<P>
<B>Heterogeneity</B>
</P>
<P>With the exception of the effect variance for "return to heavy drinking", which was exclusively explained by sampling error (I<SUP>2</SUP> 0%, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), with proportions of between-study heterogeneity over 75%, I<SUP>2</SUP> statistics indicated a considerable level of heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). High levels of heterogeneity for the continuous outcomes of the review (cumulative abstinence duration: I<SUP>2 </SUP>94%, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> and GGT: I<SUP>2</SUP> 80%, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) were confirmed by &#964;<SUP>2</SUP>statistics (cumulative abstinence duration: &#964;<SUP>2 </SUP>138.67; GGT: &#964;<SUP>2 </SUP>197.21), while the &#964;<SUP>2</SUP>statistics indicate<SUP> </SUP>moderate heterogeneity<SUP> </SUP>for<SUP> </SUP>the binary outcome<SUP> </SUP>"return to any drinking" (&#964;<SUP>2 </SUP>0.01).</P>
<P>
<U>
<B>Comparison 2: Acamprosate versus naltrexone</B>
</U>
<B> </B>
</P>
<P>
<B>
<I>Primary outcomes </I>
</B>
</P>
<P>
<U>Return to any drinking</U>: No statistically significant difference was shown between groups; the risk to return to any drinking was 3% higher in the acamprosate group than in the naltrexone group, RR 1.03 (95% CI 0.96 to 1.10), <I>see</I> <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> or <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>. If effects are compared on an individual study base, effects on return to any drinking demonstrated in the studies of <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK> and <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK> favoured naltrexone, while those found in the study of <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK> indicated a superiority of acamprosate.</P>
<P>
<U>Cumulative abstinence duration</U>: No statistically significant difference was shown between groups; acamprosate on average increased the cumulative abstinence duration by 3% compared to naltrexone MD 2.98 (95% CI -7.45 to 13.42) <I>see</I> <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>. If effects are considered on an individual study base, effects on cumulative abstinence duration in the study of <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK> favoured naltrexone, while those found in the study of <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK> indicated a superiority of acamprosate.</P>
<P>
<B>
<I>Secondary outcomes</I>
</B>
</P>
<P>
<U>Return to heavy drinking</U>: No statistically significant difference was shown between groups; the risk to return to heavy drinking was 4% higher in the acamprosate group than in the naltrexone group, RR 1.04 (95% CI 0.95 to 1.15) <I>see</I> <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
<P>
<U>GGT</U>: A statistically significant difference was shown between groups; acamprosate was associated with a 9.7 units higher GGT compared to naltrexone, MD 9.7 (95% CI 5.18 - 14.22) <I>see</I> <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; the effect is based on one trial only (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>).</P>
<P>
<U>Side effects</U>: Acamprosate was associated with a higher risk of diarrhoea than naltrexone RD 0.27 (95% CI 0.21 to 0.33) <I>see</I> <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>, while naltrexone caused more often nausea RD -0.08 (95% CI -0.13 to -0.03) <I>see</I> <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>, fatigue RD -0.13 (95% CI -0.26 to -0.10), somnolence RD -0.07 (95% CI -0.13 to -0.01) and vomiting RD -0.06 (95% CI -0.11 to 0.01) <I>see</I> <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>.</P>
<P>
<U>Drop-out due to adverse events</U>: No statistically significant difference was shown between groups; acamprosate was associated with a 24% lower risk of terminating a study early because of adverse events than naltrexone, RR 0.76 (95% CI 0.37 to 1.58) <I>see</I> <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>.</P>
<P>
<U>Drop-out for any cause</U>: No statistically significant difference was shown between groups; acamprosate was associated with a 9% higher risk of terminating the study early irrespective of reasons than naltrexone, RR 1.09 (95% CI 0.91 to 1.3) <I>see</I> <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>.</P>
<P>
<U>
<B>Comparison 3: Acamprosate + naltrexone versus placebo </B>
</U>
</P>
<P>
<B>
<I>Primary outcomes</I>
</B>
</P>
<P>
<U>Return to any drinking</U>: No statistically significant difference was shown between groups; the risk to return to any drinking was 30% lower under combined treatment with acamprosate and naltrexone than under placebo, RR 0.70 (95% CI 0.35 to 1.39) <I>see</I> <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> or <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>.</P>
<P>
<U>Cumulative abstinence duration</U>: No statistically significant difference was shown between groups; the combined treatment with acamprosate and naltrexone on average increased the cumulative abstinence duration by 2% compared to placebo, MD 2.20 (95% CI -1.90 to 6.30) <I>see</I> <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> or <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>
</P>
<P>
<B>
<I>Secondary outcomes</I>
</B>
</P>
<P>
<U>Return to heavy drinking</U>: No statistically significant difference was shown between groups; the risk to return to heavy drinking was 29% lower under combined treatment with acamprosate and naltrexone than under placebo, RR 0.71 (95% CI 0.38 to 1.35) <I>see</I> <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>
</P>
<P>
<U>GGT:</U> No statistically significant difference was shown between groups; the combined treatment with acamprosate and naltrexone was associated with a 8.7 units lower GGT compared to placebo, MD -8.70 (95% CI -24.86 to 7.46) <I>see</I> <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>
</P>
<P>
<U>Side effects</U>: The combined therapy with acamprosate and naltrexone caused significantly more often diarrhoea RD 0.20 (95% CI 0.13 to 0.27) <I>see</I> <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>, with decreased appetite RD 0.11, (95% CI 0.05 to 0.17), nausea RD 0.20 (95% CI 0.14 to 0.26) and vomiting RD 0.09 (95% CI 0.03 to 0.14) <I>see</I> <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>.</P>
<P>
<U>Drop-out due to adverse events</U>: A statistically significant difference was shown between groups; the combined therapy with acamprosate and naltrexone was associated with an almost four times higher risk of terminating a study early because of adverse events than placebo, RR 3.75 (95% CI 1.33 to 10.55) <I>see</I> <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>.</P>
<P>
<U>Drop-out for any cause</U>: No statistically significant difference was shown between groups; the combined therapy with acamprosate and naltrexone was associated with a 17% lower risk of terminating a study irrespective of reasons than placebo, RR 0.83 (95% CI 0.28 to 2.49) <I>see</I> <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>.</P>
<P>
<U>
<B>Comparison 4: Acamprosate + naltrexone versus acamprosate </B>
</U>
</P>
<P>
<B>
<I>Primary outcomes</I>
</B>
</P>
<P>
<U>Return to any drinking</U>: No statistically significant difference was shown between groups; the risk to return to any drinking was 20% lower under combined treatment with acamprosate and naltrexone than under acamprosate alone, RR 0.80 (95% CI 0.49 to 1.30) <I>see</I> <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> or <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<U>Cumulative abstinence duration</U>: No statistically significant difference was shown between groups; the combined treatment with acamprosate and naltrexone on average increased the cumulative abstinence duration by 2% compared to acamprosate alone, MD 2.10 (95% CI -2.03 to 6.23) <I>see</I> <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> or <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>.</P>
<P>
<B>
<I>Secondary outcomes</I>
</B>
</P>
<P>
<U>Return to heavy drinking</U>: No statistically significant difference was shown between groups; the risk to return to heavy drinking was 19% lower under combined treatment with acamprosate and naltrexone than under acamprosate alone, RR 0.81 (95% CI 0.50 to 1.34) <I>see</I> <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.</P>
<P>
<U>GGT</U>: No statistically significant difference was shown between groups; the combined treatment with acamprosate and naltrexone was associated with a 1 units lower GGT compared to acamprosate alone, MD 1.00 (95% CI - 8.65 to 10.65) <I>see</I> <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>.</P>
<P>
<U>Side effects</U>: The combined therapy with acamprosate and naltrexone caused significantly more often nausea, RD 0.18 (95% CI 0.11 to 0.24) and vomiting, RD 0.08 (95% CI 0.03 to 0.13) than acamprosate alone <I>see</I> <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>.</P>
<P>
<U>Drop-outs due to adverse events</U>: No statistically significant difference was shown between groups; the combined therapy with acamprosate and naltrexone was associated with a 41% higher risk of terminating a study early because of adverse events than acamprosate alone, RR 1.41 (95% CI 0.68 to 2.90) <I>see</I> <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>.</P>
<P>
<U>Drop-out for any cause</U>: No statistically significant difference was shown between groups; the combined therapy with acamprosate and naltrexone was associated with a 16% lower risk of terminating a study irrespective of reasons than acamprosate alone, RR 0.84 (95% CI 0.49 to 1.44) <I>see</I> <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-07-13 11:52:52 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-07-13 11:52:52 +0200" MODIFIED_BY="[Empty name]">
<P>A total of 24 RCTs with 6915 participants were included in the review. Effects on both primary effectiveness outcomes clearly support the abstinence-promoting effects of acamprosate when compared to placebo: Added to psychosocial treatment strategies, the glutamate antagonist was shown to reduce the risk to return to any drinking after detoxification to 86% of the risk in the placebo group RR 0.86 (95% CI 0.80 to 0.91), NNTB 9.09 (95% CI 6.66 to 14.28) and to increase abstinence duration by about 11%, MD 10.94 (95% CI 5.08 to 16.81). Treatment effects estimated on the base of individual patient data (IPD) confirmed the statistical significance of the primary effectiveness outcomes based on literature, indicating a marginally higher magnitude of effects for return to any drinking RR 0.83 (95%CI 0.79 to 0.87); NNTB 7.14 (95% CI 5.15 to 11.76) and a slightly lower magnitude for the cumulative abstinence duration MD 9.82 (95% CI 8.05 to 11.35). Post-treatment evaluations, available from a subset of ten RCTs, showed that effect sizes were lower after treatment with acamprosate was discontinued; nevertheless, 3 to 12 months after the end of the treatment period, effects still reached statistical significance (return to any drinking RR 0.91 (95% CI 0.87 to 0.96); NNTB 12.50 (95% CI 9.09 to 25.00); cumulative abstinence duration MD 8.92 (95% CI 5.08 to 12.77)).</P>
<P>At the same time, acamprosate was shown to be safe to use. The only side-effect, which was more frequently reported in the acamprosate group, was diarrhoea RD 0.11 (95% CI 0.09 to 0.13); NNTH 9.09 (95% CI 7.69 to 11.11). Side effects did not more often lead to an early termination of the treatment under acamprosate than under placebo RR 1.35 (95% CI 1.01 to 1.80), indicating that most patients accept the experienced adverse events as a tolerable part of alcoholism treatment.</P>
<P>Nevertheless, primary and secondary outcomes of the review did not provide a completely consistent picture: While the effectiveness of acamprosate was confirmed by the primary outcomes of the review, the secondary outcomes, gamma-glutamyltransferase (GGT) MD -11.91 (95% CI -24.12 to 0.30) and "return to heavy drinking" RR 0.99 (95% CI 0.94 to 1.04), did not reach statistical significance. Thereby the non-significance of the summary GGT was mainly caused by one outlier value, whereas non-superiority of acamprosate to avoid heavy drinking was attributable to the majority of primary studies. It should also be considered in this context that acamprosate is mainly indicated for supporting continuous abstinence, rather than to avoid a relapse to heavy drinking.</P>
<P>The meta-analytic integrations based on head-to-head comparisons between acamprosate and naltrexone did not indicate a superiority of one or the other drug (return to any drinking RR 1.03 (95% CI 0.96 to 1.10); cumulative abstinence duration MD 2.98 (95% CI -7.45 to 13.42); return to heavy drinking RR 1.04 (95% CI 0.95 to 1.15)), but the corresponding study base of three RCTs is too sparse to draw final conclusions. The same applies to the effects of combined treatments with acamprosate and naltrexone, based on two RCTs, which are promising, but need to be confirmed by further effectiveness and safety studies (heavy drinking RR 0.71 (95% CI 0.38 to 1.35); any drinking RR 0.70 (95% CI 0.35 to 1.39); drinking days MD -2.20 (95% CI -6.30 to 1.90).</P>
<P>The high heterogeneity of effects (I<SUP>2 </SUP>&gt; 75%) is emphasizing the diverse nature of evidence in terms of treatment characteristics, patient characteristics and features of the study designs, supporting the need to develop theoretically well-considered models to further explore the variability of effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-07-11 17:36:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Completeness of the database</B>
</P>
<P>The evaluation of primary outcomes of the review refers to almost complete databases: meta-analysis based on literature (MAL) for "return to any drinking" includes data from all 24 RCTs and cumulative abstinence duration analysis includes all but five trials (<LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>), for which no aggregate data were available. IPD analyses on both outcomes consider all RCTs apart from one small sample size trial (<LINK REF="STD-Niederhofer-2002" TYPE="STUDY">Niederhofer 2002</LINK>) with 26 patients. In contrast, databases of secondary outcomes as well as post-treatment outcomes, reported by a limited subset of trials, are rather incomplete: Outcome data on GGT were based on seven RCTs (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Lhuintre-1985" TYPE="STUDY">Lhuintre 1985</LINK>; <LINK REF="STD-Lhuintre-1990" TYPE="STUDY">Lhuintre 1990</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Rousseaux-1996" TYPE="STUDY">Rousseaux 1996</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>), heavy drinking rates on six RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Namkoong-2003" TYPE="STUDY">Namkoong 2003</LINK>), and post-treatment primary effectiveness outcomes on a total of 11 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Baltieri-2003" TYPE="STUDY">Baltieri 2003</LINK>; <LINK REF="STD-Barrias-1997" TYPE="STUDY">Barrias 1997</LINK>; <LINK REF="STD-Geerlings-1997" TYPE="STUDY">Geerlings 1997</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Ladewig-1993" TYPE="STUDY">Ladewig 1993</LINK>; <LINK REF="STD-Paille-1995" TYPE="STUDY">Paille 1995</LINK>; <LINK REF="STD-Poldrugo-1997" TYPE="STUDY">Poldrugo 1997</LINK>; <LINK REF="STD-Sass-1996" TYPE="STUDY">Sass 1996</LINK>; <LINK REF="STD-Tempesta-2000" TYPE="STUDY">Tempesta 2000</LINK>; <LINK REF="STD-Whitworth-1996" TYPE="STUDY">Whitworth 1996</LINK>).</P>
<P>
<B>Applicability of the results</B>
</P>
<P>With the acamprosate trials included in the review, treatment durations, types of psychosocial interventions and intensity of co-treatments are represented with high variability. Additionally, inclusion criteria were defined in a non-restrictive way and thus samples can be assumed to reflect a mix of different characteristics of the population of interest. Limitations in the generalizability might arise from the proceeding to screen out patients with concurrent psychiatric illnesses from acamprosate trials. In contrast, some features of the study design, including the pretreatment of patients, the dosing of acamprosate as well as the settings of treatment, did not considerably vary between studies: With few exceptions, patients were detoxified before treatment, dosing was between 4 and 6 tables (à 333 mg) and treatment was realized in outpatient programs. Thus, the generalizability of the demonstrated results might not be provided, if the frame conditions in clinical practice differ from those applied in research.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-07-11 17:59:33 +0200" MODIFIED_BY="[Empty name]">
<P>Within the acamprosate trials included in the review, various features of the study design have been adequately implemented to ensure a high level of validity: Patients were randomly assigned to treatment groups to prevent selection bias. Active medication and placebo with identical appearance were used to mask treatment allocation and to reduce the general susceptibility of outcomes to bias effects; objective measures of drinking were considered (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), either to validate patient-reported outcomes or as a discrete outcome criteria in the majority of studies.</P>
<P>Treatment groups did not differ in relevant baseline characteristics and if so, group differences were controlled in statistical analyses of treatment effects. Group differences in medication compliance were indeed demonstrated in some selected trials, but all in all, appear more likely to be generated by chance than by systematic influences. The risk of attrition bias, associated with the appearance of high and differential drop-out rates, has adequately been encountered in the majority of trials: Data analyses were conducted in accordance with the original ITT principle (<LINK REF="REF-Newell-1992" TYPE="REFERENCE">Newell 1992</LINK>) or a modified version (treatment received analysis), which takes into account the high initial drop-out in addiction treatment by including all patients who received treatment (<LINK REF="REF-Lehert-1993" TYPE="REFERENCE">Lehert 1993</LINK>). To replace missing end-point data, these were substituted by "worst-case" scenarios - a proceeding which has been well established in addiction research. Because of its good tolerability, the risk that specific side effects unmask blinding - a methodological limitation that was also discussed for antidepressant therapy (<LINK REF="REF-Moncrieff-2004" TYPE="REFERENCE">Moncrieff 2004</LINK>) - appears to be low for acamprosate. Furthermore, quantitative analyses of bias risks did neither suggest a difference between industry sponsored trials and investigator-driven research (sponsoring bias) nor indicate that non-significant trials have been omitted from publication (publication bias).</P>
<P>Nevertheless, some uncertainties still persist. As some features of the study designs were omitted from trial reports, it remains unclear whether these have not been implemented or whether they were implemented, but not reported. The poor reporting of the study design mainly concerns the methods used for generating random sequences, the specification of person groups included in the blinding process and the methods applied for allocation concealment. Particularly the latter,<B> </B>unclear concealment, has repeatedly been shown to be associated with bias effects in various fields of clinical research (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Huwiler_x002d_Muntener-2002" TYPE="REFERENCE">Huwiler-Muntener 2002</LINK>; <LINK REF="REF-Pildal-2007" TYPE="REFERENCE">Pildal 2007</LINK>). The fact that a considerable portion of included trials has been initiated before 1996, when the Good Clinical Practice (GCP) guidelines were published by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (<LINK REF="REF-ICH-1996" TYPE="REFERENCE">ICH 1996</LINK>), might at least explain the poor reporting in earlier trials.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-07-11 18:36:21 +0200" MODIFIED_BY="[Empty name]">
<P>To lower the risk of bias in the review process, all outcome statistics were extracted by two authors independently (SR &amp; AH). To prevent confirmation bias (<LINK REF="REF-Nickerson-1998" TYPE="REFERENCE">Nickerson 1998</LINK>)<B>, </B>at least one author has participated in each review step, who has not been involved in addiction treatment or research before. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-07-12 13:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Small to moderate, but significant effects have already been demonstrated for acamprosate by former meta-analyses (<LINK REF="REF-Schoechlin-2000" TYPE="REFERENCE">Schoechlin 2000</LINK>; <LINK REF="REF-Kranzler-2001" TYPE="REFERENCE">Kranzler 2001</LINK>; <LINK REF="REF-Hopkins-2002" TYPE="REFERENCE">Hopkins 2002</LINK>; <LINK REF="REF-Berglund-2003" TYPE="REFERENCE">Berglund 2003</LINK>; <LINK REF="REF-Chick-2003" TYPE="REFERENCE">Chick 2003</LINK>; <LINK REF="REF-Slattery-2003" TYPE="REFERENCE">Slattery 2003</LINK>; <LINK REF="REF-Mann-2004" TYPE="REFERENCE">Mann 2004</LINK>; <LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>; <LINK REF="REF-Verheul-2005" TYPE="REFERENCE">Verheul 2005</LINK>; <LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK>). In contrast to most available meta-analyses on the glutamate antagonist, which considered continuous abstinence as the primary dichotomous effectiveness outcome, with "return to any drinking", the complementary of continous abstinence was chosen in the review at hand. The defintion of the outcome follows the recommendation of the Cochrane Collaboration (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>) to consider the onset of a disease as the event of interest, if participants are "well" at the beginning of the study (in the majority of included trials, a successful detoxification of study participants was required to enter the treatment phase). The selection of the primary dichotomous effectiveness outcome also goes in line with the outcome definition in the Cochrane review on opioid antagonists for alcohol dependence (<LINK REF="REF-Srisurapanont-2005" TYPE="REFERENCE">Srisurapanont 2005</LINK>).</P>
<P>Nevertheless, in contrast to the relative risk (RR), the numbers needed to treat for an additional beneficial outcome (NNTB) was related to continuous abstinence. With NNTB 9.09 (95% CI 6.55 to 14.28), the magnitude of absolute effects varies within the range of values estimated by previous analyses. Based on 17 RCTs and 4087 patients, the meta-analysis by <LINK REF="REF-Mann-2004" TYPE="REFERENCE">Mann 2004</LINK> found a NNTB value of 7.8 (95% CI 6.0 to 12.2) after 6 months of treatment and of 7.5 (95% CI 5.3 to 12.8) after 12 months. A former meta-analysis conducted by the authors of the review (<LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK>), based on a total of 21 RCTs with 5280 patients, identified a RR for "return to any drinking" of 0.84 (95% CI 0.78 to 0.91) and a corresponding NNTB of 7.7 (95% CI 5.6 to 13.0), while the meta-analysis of the Spanish Agency for Health Technology Assessment (<LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>) with 11 RCTs and 3324 patients, estimated a NNTB of 10 (95% CI 7.0 to 14.0). The marginally lower magnitude of treatment effects estimated by the meta-analysis at hand compared to <LINK REF="REF-Mann-2004" TYPE="REFERENCE">Mann 2004</LINK> and <LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK> can be explained by the inclusion of newer studies with negative results (e.g. <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Mason-2006" TYPE="STUDY">Mason 2006</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-07-12 14:31:11 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-07-12 14:18:11 +0200" MODIFIED_BY="[Empty name]">
<P>Based on comprehensive evidence from 24 RCTs with 6915 participants, the review confirms the effectiveness of acamprosate in alcoholism treatment. Acamprosate was shown to reduce the risk of any drinking after detoxification to 86% of the risk a patient would have under placebo and to increase the number of abstinent days by about three additional days a month. In a population of alcohol dependent patients, acamprosate is expected to prevent drinking after detoxification in one out of nine patients (NNTB = 9), who would otherwise have relapsed. </P>
<P>However, when translating research into clinical practice, it needs to be taken into consideration that the low levels of medication compliance and the high rates of patients dropping-out early from treatment in addiction treatment additionally impede the demonstration of therapeutic effects in clinical trials. For patients, who take acamprosate regularly, therapeutic benefits are likely to exceed those demonstrated in the review. Secondly, it should be kept in mind that acamprosate was applied as an adjunctive therapy to psychosocial and psychotherapeutic interventions. Thus, strictly speaking, effect sizes rather reflect the additional benefit of adding acamprosate to psychosocial treatments than its benefit compared to placebo - a fact which often remained unconsidered in the interpretation of treatment effects. Nevertheless, despite these obstacles and restrictions, demonstrated treatment effects for acamprosate are comparable in their magnitude with those obtained in other areas of psychiatric research (see <LINK REF="REF-Adams-2007" TYPE="REFERENCE">Adams 2007</LINK>; <LINK REF="REF-Arroll-2009" TYPE="REFERENCE">Arroll 2009</LINK>; <LINK REF="REF-Citrome-2008" TYPE="REFERENCE">Citrome 2008</LINK>).</P>
<P>All in all, acamprosate does not appear to be magic bullet in the treatment of alcohol dependence and - considering the complexity of processes involved in the development and maintenance of addiction - there will probably never be a single strategy that can "cure" alcohol dependence. But, after summarizing and appraising the availbale evidence, the glutamate antagonist appears to be an helpful and effective mean to support abstinence in alcohol dependent patients. Nevertheless, the principle that therapeutic decisions should be shared decisions between physicians and patients applies to pharmacological relapse prevention in a particular way; this is not only to respect a patient's` free choice of treatment, but also to ensure commitment and compliance. Patients' doubts and reservations against a therapeutic strategy which uses a substance to treat dependency from another one, should be taken seriously when informing patients about their treatment options and the associated risks and benefits. At the same time, therapeutic strategies which have been shown to work in well-controlled trials, should not kept back from patients, particularly if these concern the treatment of a disease that is known to have a high impact on health and quality and duration of life and for which alternative therapeutic options are of limited effectiveness. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-07-12 14:31:11 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment of alcohol dependence is a complex therapeutic process and research on its effectiveness meets with particular difficulties. One of the main methodological challenges in addiction research results from the high magnitude of drop-out rates. The inclusion of all randomized patients in the data analyses according to the intention-to-treat (ITT) principle and a handling of missing data, which accounts for the close linkage between treatment attendance and consumption in patients with substance use disorders, appear to be essential means for preventing attrition bias in addiction research. Nevertheless, as even the most elaborated methods for substituting incomplete patient data are associated with error, persistent efforts should be made to validly assess the drinking status of drop-outs and to ensure the validity of self-reports by objective measures. For those patients who were lost to follow-up, substitution by &#8220;worst case&#8221; appears as one the most appropriate method to handle missing data in addiction research.</P>
<P>Because of the good tolerability of acamprosate, the risk that specific side effects unmask blinding was considered as comparatively low in the trials included in the review. Nevertheless, the use of side effects imitating placebo could help to ensure the integrity of blinding; if not realizable, the assessment of blinding quality by inquiries on patients, treatment providers and investigators should be used to identify threats to blinding quality.</P>
<P>The reporting of clinical trials with acamprosate was clear and comprehensible in most study publications; nevertheless some deficits became apparent. A stricter adherence to methodological standards of reporting as outlined in the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would help to remove remaining doubts and uncertainties.</P>
<P>Finally, the review at hand refers to gaps in knowledge, that need to be addressed by future research. Further head-to-head comparisons between acamprosate and naltrexone are needed to determine the relative effectiveness of both substances and their specific profile of effectiveness. Thereby a conceptual distinction between different achievements in drinking control such as a patient's ability to maintain continuously abstinent or his/her ability to stop drinking once started (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>) will help to specify differential efficacy profiles. The identification of patient characteristics which determine a patient's responsiveness to the availbale psychosocial and pharmacological interventions is indispensable for the deduction of elaborated techniques of combining therapeutic strategies and their tailoring to the individual treatment goals and therapeutic needs of patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-07-12 14:32:12 +0200" MODIFIED_BY="[Empty name]">
<P>We thank the team of the Cochrane Drugs and Alcohol Group (CDAG, Rome, Italy) for their support in the preparation and conduction of this review. We also thank Anton RF (Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, USA), Baltieri D (Psychiatric Institute, University of Sao Paulo, Sao Paulo, Brazil), Barrias JA (Regional Alcohol Studies Center, Porto, Portugal), Gual A (Unitat d&#8217; Alcohologia de la Generalitat, Barcelona, Spain), Morley KC (Central Clincial School of Medicine, University of Sydney, Sydney, Australia), Namkoong K (Yongdong Severance Hospital, Seoul, South Korea) and Merck Serono (Geneva, Switzerland) for the disposal of unreported data and information*. Our gratitude also goes to V Hesslbrock V (Alcohol Research Center, University of Connecticut Health Center, Farmington, USA) for the reference to ongoing studies and to P Thomson (CSR Incorporated, Arlington, USA), for providing advice for analyses of the COMBINE data set.</P>
<P>
<SUB>* authors of primary studies not mentioned in this section were either not requested as all relevant data and information were available from the trial publication or were unable to provide the requested data or information. </SUB>
</P>
<P>This work was financially supported by the Federal Ministry<SUP> </SUP>of Education and Research (BMBF) under the grant number 01KG0724. All responsibilities for the contents of this publications remain with the authors.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-06-23 17:11:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Rösner, S: </B>No conflict of interest known</P>
<P>
<B>Hackl-Herrwerth, A: </B>No conflict of interest known</P>
<P>
<B>Leucht, S: </B>Received speaker/consultancy/advisory board honoraria from Sanofi-Aventis, BMS, EliLilly, Janssen/Johnson and Johnson, Lundbeck and Pfizer</P>
<P>
<B>Vecchi, S: </B>No conflict of interest known</P>
<P>
<B>Lehert, P: </B>Received speaker/consultancy/advisory board honoraria from Lundbeck, SanofiAventis, Merck,</P>
<P>
<B>Soyka, M: </B>Reveived speaker/consultancy/advisory board honoraria from Lipha Pharmaceuticals, Forest Laboratories, Sanofi-Aventis, Essex Pharma, Eli Lilly, Prempharm and AstraZeneca</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-29 19:04:07 +0100" MODIFIED_BY="[Empty name]">
<P>SUSANNE RÖSNER: </P>
<UL>
<LI>protocol elaboration</LI>
<LI>study selection</LI>
<LI>data extraction</LI>
<LI>data management</LI>
<LI>analysis of data (MAL)</LI>
<LI>interpretation and discussion of results</LI>
<LI>writing the review</LI>
<LI>securing funding</LI>
</UL>
<P>ANDREA HACKL-HERRWERTH:</P>
<UL>
<LI>study selection</LI>
<LI>data extraction</LI>
</UL>
<P>STEFAN LEUCHT:</P>
<UL>
<LI>protocol elaboration</LI>
<LI>interpretation and discussion of results</LI>
</UL>
<P>SIMONA VECCHI:</P>
<UL>
<LI>development of search strategies</LI>
<LI>study search</LI>
</UL>
<P>PHILIPPE LEHERT: </P>
<UL>
<LI>Analysis of data (IPD)</LI>
</UL>
<P>MICHAEL SOYKA: </P>
<UL>
<LI>protocol elaboration</LI>
<LI>interpretation and discussion of results (clinical perspective)</LI>
<LI>securing funding</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-07-12 14:33:20 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Authors</B>
</P>
<P>Andrea Hackl-Herrwerth, Simona Vecchi and Philippe Lehert have not been considered as authors in the protocol as their contribution was not known at the protocol stage. </P>
<P>
<B>Selection of outcomes </B>
</P>
<P>The selection of the primary and secondary outcomes in the protocol was mainly based on theoretical considerations concerning different compounds of drinking control (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>) and their clinical relevance. In the process of data extraction, limitations in the availability of outcomes became evident, which required changes in the outcome selection. Accordingly, heavy drinking rates, available from six trials only, were removed from the primary outcome list of the protocol and considered as a secondary outcome in the review. Cumulative abstinence duration was in contrast included as a primary outcome, as it was more frequently reported in the trial publications (n = 19). Drop-out rates were considered as potential moderators of effectiveness in the review, but were not included in the evaluation of effectiveness as originally outlined in the protocol. The decision is based on the fact that various indicators of drinking behavior are available, which were assumed to be more closely related to therapeutic success than drop-out rates.</P>
<P>
<B>IPD analyses</B>
</P>
<P>The IPD analyses were not foreseen in the protocol, as the authors did not have access to the IPD data set at the time, the protocol was elaborated.</P>
<P>
<B>Assessment of heterogeneity</B>
</P>
<P>The inclusion of &#964;<SUP>2</SUP>-statistic in the assessment of heterogeneity, which was additionally applied to I<SUP>2</SUP>-statistic in the review to provide a measure of variability independent of the sample size, is based on considerations outlined by <LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>, which were not known to the authors at the time the protocol was elaborated.</P>
<P>
<B>Publication bias</B>
</P>
<P>Besides the graphical illustration with the funnel plot method (<LINK REF="REF-Light-1984" TYPE="REFERENCE">Light 1984</LINK>), the risk of publication bias was additionally quantified with a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) in the review. The authors did not consider this option when writing the protocol.</P>
<P>
<B>Sensitivity analyses</B>
</P>
<P>The investigation of <I>within-study selective outcome reporting bias </I>by sensitivity analyses was not conducted as outlined in the protocol due to the low availability of unreported outcomes. Instead, a sensitivity analysis was conducted to examine the influence of the funding source on the study outcomes.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-10-28 09:53:37 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-07-08 13:56:17 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-07-08 13:56:17 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-07-08 13:56:17 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2006" MODIFIED="2010-06-24 12:14:32 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:14:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al</AU>
<TI>Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomised controlled trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>2003-17</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Baltieri-2003" MODIFIED="2010-06-24 12:14:40 +0200" MODIFIED_BY="[Empty name]" NAME="Baltieri 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-24 12:14:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baltieri D A, De Andrade A G</AU>
<TI>Acamprosate in alcohol dependence: a randomised controlled efficacy study in a standard clinical setting</TI>
<SO>Journal of studies on alcohol</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>136-9</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-28 19:38:50 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Barrias-1997" MODIFIED="2010-06-24 12:14:50 +0200" MODIFIED_BY="[Empty name]" NAME="Barrias 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-24 12:14:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter AS, Teixeira de Sousa E</AU>
<TI>Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study</TI>
<SO>Psiquiatria Clinica</SO>
<YR>1997</YR>
<VL>18</VL>
<PG>149-60</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Besson-1998" MODIFIED="2010-07-08 13:56:03 +0200" MODIFIED_BY="[Empty name]" NAME="Besson 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-08 13:56:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Besson J, Aeby F, Kasas A, Lehert P, Potgieter A</AU>
<TI>Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1998</YR>
<VL>22</VL>
<PG>573-9</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Borg-2003" MODIFIED="2010-01-21 09:50:10 +0100" MODIFIED_BY="[Empty name]" NAME="Borg 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-21 09:50:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Borg S</AU>
<TI>Randomized controlled trial of acamprosate versus placebo in Swedish alcoholics</TI>
<SO>Unpublished trial</SO>
<YR>2003</YR>
<PB>Data on file Lipha SA, Lyon</PB>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chick-2000" MODIFIED="2010-06-24 12:15:48 +0200" MODIFIED_BY="[Empty name]" NAME="Chick 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-24 12:15:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chick J, Howlett H, Morgan M Y, Ritson B</AU>
<TI>United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>176-87</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geerlings-1997" MODIFIED="2010-06-24 12:15:54 +0200" MODIFIED_BY="[Empty name]" NAME="Geerlings 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-24 12:15:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geerlings PJ, Ansoms C, van den Brink W</AU>
<TI>Acamprosate and prevention of relapse in alcoholics. Results of a randomised, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg</TI>
<SO>European Addiction Research</SO>
<YR>1997</YR>
<VL>3</VL>
<PG>129-37</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gual-2001" MODIFIED="2009-11-23 16:00:01 +0100" MODIFIED_BY="[Empty name]" NAME="Gual 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-23 16:00:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gual A, Lehert P</AU>
<TI>Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>413-8</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiefer-2003" MODIFIED="2009-11-21 15:44:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kiefer 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-18 18:18:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al</AU>
<TI>Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>92-9</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladewig-1993" MODIFIED="2010-07-08 13:56:17 +0200" MODIFIED_BY="[Empty name]" NAME="Ladewig 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-07-08 13:56:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladewig D, Knecht T, Leher P, Fendl A</AU>
<TI>Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients</TI>
<SO>Therapeutische Umschau</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>182-8</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lhuintre-1985" MODIFIED="2010-06-24 12:16:19 +0200" MODIFIED_BY="[Empty name]" NAME="Lhuintre 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-24 12:16:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lhuintre J P, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, et al</AU>
<TI>Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>1014-6</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lhuintre-1990" MODIFIED="2010-06-24 12:16:26 +0200" MODIFIED_BY="[Empty name]" NAME="Lhuintre 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-24 12:16:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, et al</AU>
<TI>Acamprosate appears to decrease alcohol intake in weaned alcoholics</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1990</YR>
<VL>25</VL>
<PG>613-22</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mason-2006" MODIFIED="2010-06-24 12:16:32 +0200" MODIFIED_BY="[Empty name]" NAME="Mason 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:16:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Goodman AM, Chabac S, Lehert P</AU>
<TI>Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2006</YR>
<VL>40</VL>
<PG>383-93</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morley-2006" MODIFIED="2010-06-24 12:16:37 +0200" MODIFIED_BY="[Empty name]" NAME="Morley 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:16:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, et al</AU>
<TI>Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomised, double-blind, placebo-controlled trial</TI>
<SO>Addiction</SO>
<YR>2006</YR>
<VL>101</VL>
<PG>1451-62</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Namkoong-2003" MODIFIED="2010-06-24 12:16:42 +0200" MODIFIED_BY="[Empty name]" NAME="Namkoong 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-24 12:16:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E</AU>
<TI>Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomised, double-blind, placebo-controlled study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>135-41</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niederhofer-2002" MODIFIED="2010-06-24 12:16:48 +0200" MODIFIED_BY="[Empty name]" NAME="Niederhofer 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-24 12:16:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niederhofer H, Staffen W</AU>
<TI>Acamprosate and its efficacy in treating alcohol dependent adolescents</TI>
<SO>European Child &amp; Adolescent Psychiatry</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>144-8</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Paille-1995" MODIFIED="2010-06-24 12:16:55 +0200" MODIFIED_BY="[Empty name]" NAME="Paille 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-24 12:16:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P</AU>
<TI>Double-blind randomised multi centre trial of acamprosate in maintaining abstinence from alcohol</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>239-47</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pelc-1992" MODIFIED="2010-06-24 12:17:06 +0200" MODIFIED_BY="[Empty name]" NAME="Pelc 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-24 12:17:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Pelc I Le Bon O Lehert P Verbanck P</AU>
<TI>Acamprosate in the treatment of alcohol dependence: A six month post detoxification study</TI>
<SO>Novel pharmacological interventions for alcoholism</SO>
<YR>1992</YR>
<PG>348-52</PG>
<ED>Naranjo C, Sellers E</ED>
<PB>Springer</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pelc-1997" MODIFIED="2010-06-24 12:17:12 +0200" MODIFIED_BY="[Empty name]" NAME="Pelc 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-24 12:17:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P</AU>
<TI>Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>73-7</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Poldrugo-1997" MODIFIED="2010-06-24 12:17:18 +0200" MODIFIED_BY="[Empty name]" NAME="Poldrugo 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-24 12:17:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poldrugo F</AU>
<TI>Acamprosate treatment in a long-term community-based alcohol rehabilitation programme</TI>
<SO>Addiction</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>1537-46</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rousseaux-1996" MODIFIED="2010-06-24 12:17:24 +0200" MODIFIED_BY="[Empty name]" NAME="Rousseaux 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-24 12:17:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roussaux JP, Hers D, Ferauge M</AU>
<TI>Does acamprosate diminish the appetite for alcohol in weaned alcoholics?</TI>
<SO>Journal de Pharmacie de Belgique</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>65-8</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sass-1996" MODIFIED="2010-06-24 12:17:29 +0200" MODIFIED_BY="[Empty name]" NAME="Sass 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-24 12:17:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sass H, Soyka M, Mann K, Zieglgansberger W</AU>
<TI>Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>673-80</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tempesta-2000" MODIFIED="2010-06-24 12:17:40 +0200" MODIFIED_BY="[Empty name]" NAME="Tempesta 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-24 12:17:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A</AU>
<TI>Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>202-9</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Whitworth-1996" MODIFIED="2010-06-24 12:17:46 +0200" MODIFIED_BY="[Empty name]" NAME="Whitworth 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-06-24 12:17:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al</AU>
<TI>Comparison of acamprosate and placebo in long-term treatment of alcohol dependence</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>1438-42</PG>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-06-24 12:20:49 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boeijinga-2004" MODIFIED="2010-06-24 12:17:55 +0200" MODIFIED_BY="[Empty name]" NAME="Boeijinga 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-24 12:17:55 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:17:55 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boeijinga PH, Parot P, Soufflet L, Landron F, Danel T, Gendre I, et al</AU>
<TI>Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence</TI>
<SO>Neuropsychobiology</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>1</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buri-2007" MODIFIED="2010-06-24 12:18:01 +0200" MODIFIED_BY="[Empty name]" NAME="Buri 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-24 12:18:01 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buri C, Moggi F, Giovanoli A, Strik W</AU>
<TI>Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>4</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croissant-2006" MODIFIED="2010-06-24 12:18:09 +0200" MODIFIED_BY="[Empty name]" NAME="Croissant 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:18:09 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croissant B, Diehl A, Klein O, Zambrano S, Nakovics H, Heinz A, et al</AU>
<TI>A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>4</NO>
<PG>630-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Sousa-2005" MODIFIED="2010-06-24 12:18:16 +0200" MODIFIED_BY="[Empty name]" NAME="de Sousa 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-24 12:18:16 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:16 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Sousa A</AU>
<TI>An open randomised study comparing disulfiram and acamprosate in the treatment of alcohol dependence</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>6</NO>
<PG>545-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Wildt-2002" MODIFIED="2010-06-24 12:18:23 +0200" MODIFIED_BY="[Empty name]" NAME="De Wildt 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-24 12:18:23 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:23 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Wildt WA, Schippers GM, Van Den Brink W, Potgieter A S, Deckers F, Bets D</AU>
<TI>Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>4</NO>
<PG>375-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feeney-2002" MODIFIED="2010-06-24 12:18:29 +0200" MODIFIED_BY="[Empty name]" NAME="Feeney 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-24 12:18:29 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feeney GF, Young RM, Connor JP, Tucker J, McPherson A</AU>
<TI>Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>5</NO>
<PG>622-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Florez-2008" MODIFIED="2010-06-24 12:18:38 +0200" MODIFIED_BY="[Empty name]" NAME="Florez 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-24 12:18:38 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:18:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Florez G, Garcia-Portilla P, Alvarez S, Saiz P A, Nogueiras L, Bobes J</AU>
<TI>Using topiramate or naltrexone for the treatment of alcohol-dependent patients</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1251-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuchs-2002" MODIFIED="2010-06-24 12:18:47 +0200" MODIFIED_BY="[Empty name]" NAME="Fuchs 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-24 12:18:47 +0200" MODIFIED_BY="[Empty name]" NOTES="ger" NOTES_MODIFIED="2010-06-24 12:18:47 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs WJ, Riebenfeld D</AU>
<TI>Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland</TI>
<SO>Praxis (Bern 1994)</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>17</NO>
<PG>735-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerra-1992" MODIFIED="2010-06-24 12:18:56 +0200" MODIFIED_BY="[Empty name]" NAME="Gerra 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-24 12:18:56 +0200" MODIFIED_BY="[Empty name]" NOTES="Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial" NOTES_MODIFIED="2010-06-24 12:18:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerra G, Caccavari R, Delsignore R</AU>
<TI>Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial</TI>
<SO>Current Therapeutic Research</SO>
<YR>1992</YR>
<VL>52</VL>
<PG>291-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammarberg-2004" MODIFIED="2010-06-24 12:19:04 +0200" MODIFIED_BY="[Empty name]" NAME="Hammarberg 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-24 12:19:04 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:19:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammarberg A, Wennberg P, Beck O, Franck J</AU>
<TI>A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>3</NO>
<PG>251-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2008" MODIFIED="2010-06-24 12:19:15 +0200" MODIFIED_BY="[Empty name]" NAME="Han 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-24 12:19:15 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:19:15 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han DH, Lyool I K, Sung YH, Lee SH, Renshaw PF</AU>
<TI>The effect of acamprosate on alcohol and food craving in patients with alcohol dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>3</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2003" MODIFIED="2010-06-24 12:19:27 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-24 12:19:27 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:19:27 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, O'Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, et al</AU>
<TI>Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects</TI>
<SO>Journal of Clinical Psychopharmacoly</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>281-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kampman-2009" MODIFIED="2010-06-24 12:20:01 +0200" MODIFIED_BY="[Empty name]" NAME="Kampman 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-24 12:20:01 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin D W, et al</AU>
<TI>Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence</TI>
<SO>Addictive Behaviors</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>6-7</NO>
<PG>581-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiritze_x002d_Topor-2004" MODIFIED="2010-06-24 12:20:06 +0200" MODIFIED_BY="[Empty name]" NAME="Kiritze-Topor 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-24 12:20:06 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:06 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiritze-Topor P, Huas D, Rosenzweig C, Comte S, Paille F, Lehert P</AU>
<TI>A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>6</NO>
<PG>520-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laaksonen-2008" MODIFIED="2010-06-10 11:56:01 +0200" MODIFIED_BY="[Empty name]" NAME="Laaksonen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-10 11:56:01 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-10 11:56:01 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H</AU>
<TI>A randomised, multi centre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>1</NO>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mason-2002" MODIFIED="2010-01-21 10:08:48 +0100" MODIFIED_BY="[Empty name]" NAME="Mason 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-21 10:08:48 +0100" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-01-21 10:08:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, et al</AU>
<TI>A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>596-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nespor-2006" MODIFIED="2010-06-24 12:20:17 +0200" MODIFIED_BY="[Empty name]" NAME="Nespor 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:20:17 +0200" MODIFIED_BY="[Empty name]" NOTES="cze" NOTES_MODIFIED="2010-06-24 12:20:17 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nespor K, Csemy L</AU>
<TI>Treatment and prevention of alcohol-related problems and evidence based medicine</TI>
<SO>Casopis Lekaru Ceskych</SO>
<YR>2006</YR>
<VL>145</VL>
<NO>12</NO>
<PG>964-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ooteman-2007" MODIFIED="2010-06-24 12:20:21 +0200" MODIFIED_BY="[Empty name]" NAME="Ooteman 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-24 12:20:21 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W</AU>
<TI>The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics</TI>
<SO>European Neuropsychopharmacoly</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>8</NO>
<PG>558-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelc-2002" MODIFIED="2010-06-24 12:20:27 +0200" MODIFIED_BY="[Empty name]" NAME="Pelc 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-24 12:20:27 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:27 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelc I, Ansoms C, Lehert P, Fischer F, Fuchs W J, Landron F, et al</AU>
<TI>The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction</TI>
<SO>Alcoholism Clinical and Experimental Research</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1529-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-2005" MODIFIED="2010-06-24 12:20:32 +0200" MODIFIED_BY="[Empty name]" NAME="Reid 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-24 12:20:32 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid SC, Teesson M, Sannibale C, Matsuda M, Haber PS</AU>
<TI>The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomised controlled trial</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>6</NO>
<PG>833-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-2001" MODIFIED="2010-06-24 12:20:36 +0200" MODIFIED_BY="[Empty name]" NAME="Rubio 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-24 12:20:36 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T</AU>
<TI>Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>5</NO>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rychlik-2001" MODIFIED="2010-06-10 11:57:12 +0200" MODIFIED_BY="[Empty name]" NAME="Rychlik 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-10 11:57:12 +0200" MODIFIED_BY="[Empty name]" NOTES="ger" NOTES_MODIFIED="2010-06-10 11:57:12 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rychlik R, Paschen B, Kirchhoff D, Daniel D, Pfeil T, Kilburg A</AU>
<TI>Adjuvant drug treatment of alcoholism with acamprosate: between sectorial budgets and disease management</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>2001</YR>
<VL>126</VL>
<NO>33</NO>
<PG>899-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soyka-2002" MODIFIED="2010-01-21 10:13:14 +0100" MODIFIED_BY="[Empty name]" NAME="Soyka 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-21 10:13:14 +0100" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-01-21 10:13:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soyka M, Preuss U, Schuetz C</AU>
<TI>Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study</TI>
<SO>Drugs in Road Traffic</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staner-2006" MODIFIED="2010-06-24 12:20:49 +0200" MODIFIED_BY="[Empty name]" NAME="Staner 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-24 12:20:49 +0200" MODIFIED_BY="[Empty name]" NOTES="eng" NOTES_MODIFIED="2010-06-24 12:20:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staner L, Boeijinga P, Danel T, Gendre I, Muzet M, Landron F, et al</AU>
<TI>Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>9</NO>
<PG>1492-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-12-08 11:56:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gaebel" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel" YEAR="2006">
<IDENTIFIERS MODIFIED="2008-12-05 18:52:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-05 13:39:15 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00159107"/>
<IDENTIFIER MODIFIED="2008-12-05 18:52:01 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="01EB0133"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbutt" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Garbutt" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-05 18:56:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-05 13:47:39 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00381043"/>
<IDENTIFIER MODIFIED="2008-12-05 18:56:33 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CMP-MD-06"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Haber" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Haber" YEAR="">
<IDENTIFIERS MODIFIED="2008-12-05 20:04:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-05 20:04:35 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00120601."/>
<IDENTIFIER MODIFIED="2008-12-05 20:04:47 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="X99-0277"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mann" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Mann" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-05 20:12:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-05 20:12:17 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00317031"/>
<IDENTIFIER MODIFIED="2008-12-05 20:12:23 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PREDICT"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrakis" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Petrakis" YEAR="2010">
<IDENTIFIERS MODIFIED="2008-12-05 19:54:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 12:48:03 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00463346 "/>
<IDENTIFIER MODIFIED="2008-12-05 19:54:49 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CMP-MD-13"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettinati" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Pettinati" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-05 19:14:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 10:42:54 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00360594"/>
<IDENTIFIER MODIFIED="2008-12-05 19:14:10 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="804481"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonne" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sonne" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-05 19:00:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-05 19:00:14 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00330174"/>
<IDENTIFIER MODIFIED="2008-12-05 19:00:24 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CMP-MD-04"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witte" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Witte" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-05 19:56:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 13:14:59 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00452543"/>
<IDENTIFIER MODIFIED="2008-12-05 19:56:48 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="2006-P-001592/1"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-06-24 13:40:23 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-06-24 13:40:23 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-2007" MODIFIED="2010-06-24 12:35:31 +0200" MODIFIED_BY="[Empty name]" NAME="Adams 2007" TYPE="COCHRANE_REVIEW">
<AU>Adams CE, Awad G, Rathbone J, Thornley B</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-12-08 11:46:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-08 11:46:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alonso-2004" MODIFIED="2010-06-24 12:35:38 +0200" MODIFIED_BY="[Empty name]" NAME="Alonso 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H</AU>
<TI>Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project</TI>
<SO>Acta Psychiatrica Scandinavia Supplement</SO>
<YR>2004</YR>
<VL>420</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arroll-2009" MODIFIED="2010-06-20 18:41:34 +0200" MODIFIED_BY="[Empty name]" NAME="Arroll 2009" TYPE="COCHRANE_REVIEW">
<AU>Arroll B, Elley CR, Fishman T, Goodyear-Smith F A, Kenealy T, Blashki G</AU>
<TI>Antidepressants versus placebo for depression in primary care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-06-20 18:41:34 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-20 18:41:34 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bachteler-2005" MODIFIED="2010-06-24 12:35:49 +0200" MODIFIED_BY="[Empty name]" NAME="Bachteler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R</AU>
<TI>The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berglund-2003" MODIFIED="2009-12-15 10:22:50 +0100" MODIFIED_BY="[Empty name]" NAME="Berglund 2003" TYPE="OTHER">
<AU>Berglund MA, Franck J, Fridell M, Hakanson I, Johansson BA</AU>
<TI>Treatment of alcohol and drug abuse - an evidence-based review</TI>
<SO>Swedish Council on Technology Assessment in Health Care (SBU)</SO>
<YR>2003</YR>
<VL>156</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouza-2004" MODIFIED="2010-06-24 12:35:56 +0200" MODIFIED_BY="[Empty name]" NAME="Bouza 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bouza C, Angeles M, Munoz A, Amate JM</AU>
<TI>Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>7</NO>
<PG>811-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brockwell-2001" MODIFIED="2010-06-24 12:36:00 +0200" MODIFIED_BY="[Empty name]" NAME="Brockwell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brockwell SE, Gordon IR</AU>
<TI>A comparison of statistical methods for meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>6</NO>
<PG>825-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cano_x002d_Cebrian-2003" MODIFIED="2010-06-24 12:36:05 +0200" MODIFIED_BY="[Empty name]" NAME="Cano-Cebrian 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cano-Cebrian MJ, Zornoza-Sabina T, Guerri C, Polache A, Granero L</AU>
<TI>Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus</TI>
<SO>Naunyn Schmiedebergs Archives of Pharmacology</SO>
<YR>2003</YR>
<VL>368</VL>
<NO>4</NO>
<PG>324-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2010-06-24 12:36:10 +0200" MODIFIED_BY="[Empty name]" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomised trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chick-2003" MODIFIED="2010-01-21 12:18:40 +0100" MODIFIED_BY="[Empty name]" NAME="Chick 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chick J, Lehert P, Landron F</AU>
<TI>Does acamprosate improve reduction of drinking as well as aiding abstinence?</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>397-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2008" MODIFIED="2010-06-24 12:36:16 +0200" MODIFIED_BY="[Empty name]" NAME="Citrome 2008" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Compelling or irrelevant? Using number needed to treat can help decide</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>2008</YR>
<VL>117</VL>
<NO>6</NO>
<PG>412-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-2000" MODIFIED="2010-06-24 12:36:20 +0200" MODIFIED_BY="[Empty name]" NAME="Cole 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cole JC, Littleton JM, Little HJ</AU>
<TI>Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2000</YR>
<VL>147</VL>
<NO>4</NO>
<PG>403-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czachowski-2001" MODIFIED="2010-06-24 12:36:24 +0200" MODIFIED_BY="[Empty name]" NAME="Czachowski 2001" TYPE="JOURNAL_ARTICLE">
<AU>Czachowski CL, Legg BH, Samson HH</AU>
<TI>Effects of acamprosate on ethanol-seeking and self-administration in the rat</TI>
<SO>Alcoholism Clinical and Experimental Research</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>3</NO>
<PG>344-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2010-01-21 13:18:51 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>243-293</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Johm Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-06-24 12:36:31 +0200" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-06-24 12:36:36 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferri-2006" MODIFIED="2010-06-24 12:36:46 +0200" MODIFIED_BY="[Empty name]" NAME="Ferri 2006" TYPE="COCHRANE_REVIEW">
<AU>Ferri M, Amato L, Davoli M</AU>
<TI>Alcoholics Anonymous and other 12-step programmes for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-06-20 18:42:23 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-20 18:42:23 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858.CD005032.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heyser-1998" MODIFIED="2010-06-24 12:36:52 +0200" MODIFIED_BY="[Empty name]" NAME="Heyser 1998" TYPE="JOURNAL_ARTICLE">
<AU>Heyser CJ, Schulteis G, Durbin P, Koob GF</AU>
<TI>Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>125-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2001" MODIFIED="2010-06-24 12:36:56 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2001" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG</AU>
<TI>Meta-analysis of continuous outcome data from individual patients</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>15</NO>
<PG>2219-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-06-24 12:37:00 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-12-08 10:11:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>243-296</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Johm Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopkins-2002" MODIFIED="2009-12-09 09:55:54 +0100" MODIFIED_BY="[Empty name]" NAME="Hopkins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS</AU>
<TI>Naltrexone and acamprosate: Meta-analysis of two medical treatments for alcoholism</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>Suppl</NO>
<PG>130A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huwiler_x002d_Muntener-2002" MODIFIED="2010-06-24 12:37:09 +0200" MODIFIED_BY="[Empty name]" NAME="Huwiler-Muntener 2002" TYPE="JOURNAL_ARTICLE">
<AU>Huwiler-Muntener K, Juni P, Junker C, Egger M</AU>
<TI>Quality of reporting of randomised trials as a measure of methodologic quality</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>21</NO>
<PG>2801-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICAP-2003" MODIFIED="2010-01-21 13:20:09 +0100" MODIFIED_BY="[Empty name]" NAME="ICAP 2003" TYPE="OTHER">
<AU>ICAP International Center for Alcohol Policies</AU>
<TI>International Drinking Guidelines</TI>
<TO>(http://www.icap.org/)</TO>
<SO>Report Nr. 14</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH-1996" MODIFIED="2010-01-21 13:20:30 +0100" MODIFIED_BY="[Empty name]" NAME="ICH 1996" TYPE="OTHER">
<AU>International Conference on Harmonisation</AU>
<TI>Guideline for Good ClinicalPractice E6(R1).</TI>
<SO>(http://www.ich.org/LOB/media/MEDIA482.pdf)</SO>
<YR>1996</YR>
<VL>Jun [cited 2009 Jan 20]</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kadden-1992" MODIFIED="2010-01-10 10:04:32 +0100" MODIFIED_BY="[Empty name]" NAME="Kadden 1992" TYPE="BOOK">
<AU>Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R</AU>
<TI>Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide fro Therapists Treating Individuals with Alcohol Abuse and Dependence</TI>
<SO>NIAAA Project MATCH Monograph Series</SO>
<YR>1992</YR>
<VL>3</VL>
<EN>National Institute on Alcoholism and Alcohol Abuse</EN>
<PB>Matson ED</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaner-2007" MODIFIED="2010-06-24 12:37:38 +0200" MODIFIED_BY="[Empty name]" NAME="Kaner 2007" TYPE="COCHRANE_REVIEW">
<AU>Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, Heather N, Saunders J, Burnand B</AU>
<TI>Effectiveness of brief alcohol interventions in primary care populations</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-06-21 09:57:11 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-21 09:57:11 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858.CD004148.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keller-1972" MODIFIED="2010-06-24 12:37:43 +0200" MODIFIED_BY="[Empty name]" NAME="Keller 1972" TYPE="JOURNAL_ARTICLE">
<AU>Keller M</AU>
<TI>On the loss-of-control phenomenon in alcoholism</TI>
<SO>British Journal of Addiction</SO>
<YR>1972</YR>
<VL>67</VL>
<PG>153-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiefer-2004" MODIFIED="2010-06-24 12:37:47 +0200" MODIFIED_BY="[Empty name]" NAME="Kiefer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kiefer F, Andersohn F, Otte C, Wolf K, Jahn H, Wiedemann K</AU>
<TI>Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence</TI>
<SO>Acta Neuropsychiatrica</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konnopka-2007" MODIFIED="2010-06-24 12:37:51 +0200" MODIFIED_BY="[Empty name]" NAME="Konnopka 2007" TYPE="JOURNAL_ARTICLE">
<AU>Konnopka A, König HH</AU>
<TI>Direct and indirect costs attributable to alcohol consumption in Germany</TI>
<SO>Pharmacoeconomics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>7</NO>
<PG>605-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kranzler-2001" MODIFIED="2010-06-24 12:37:56 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Van Kirk J</AU>
<TI>Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-12-06 19:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for Studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>95-150</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Johm Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehert-1993" MODIFIED="2010-06-24 12:38:03 +0200" MODIFIED_BY="[Empty name]" NAME="Lehert 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lehert P</AU>
<TI>Review and discussion of statistical analysis of controlled clinical trials in alcoholism</TI>
<SO>Alcohol and Alcoholism Supplement</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LeMagnen-1987" MODIFIED="2010-06-24 12:38:08 +0200" MODIFIED_BY="[Empty name]" NAME="LeMagnen 1987" TYPE="JOURNAL_ARTICLE">
<AU>LeMagnen J, Tran G, Durlach J</AU>
<TI>Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats</TI>
<SO>Alcohol and Alcohilsm</SO>
<YR>1987</YR>
<VL>4</VL>
<NO>2</NO>
<PG>103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levine-1986" MODIFIED="2010-06-24 12:38:13 +0200" MODIFIED_BY="[Empty name]" NAME="Levine 1986" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Schooler NR</AU>
<TI>SAFTEE: a technique for the systematic assessment of side effects in clinical trials</TI>
<SO>Psychopharmacol Bulletin</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>2</NO>
<PG>343-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Light-1984" MODIFIED="2010-01-21 13:23:57 +0100" MODIFIED_BY="[Empty name]" NAME="Light 1984" TYPE="BOOK">
<AU>Light RJ, Pillemer BD</AU>
<SO>The science of reviewing research</SO>
<YR>1984</YR>
<PB>Harvard University Press</PB>
<CY>Cambridge (MA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipha-2002" MODIFIED="2009-12-09 09:56:38 +0100" MODIFIED_BY="[Empty name]" NAME="Lipha 2002" TYPE="OTHER">
<AU>Lipha Pharmaceuticals Inc</AU>
<TI>Clincial Background Materials for Psychopharmacologic Drugs Advisory Committee Meeting</TI>
<SO>NDA 21-431</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Littleton-1995" MODIFIED="2010-06-24 12:38:26 +0200" MODIFIED_BY="[Empty name]" NAME="Littleton 1995" TYPE="JOURNAL_ARTICLE">
<AU>Littleton J</AU>
<TI>Acamprosate in alcohol dependence: how does it work?</TI>
<SO>Addiction</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>9</NO>
<PG>1179-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Littleton-2003" MODIFIED="2010-01-21 13:24:43 +0100" MODIFIED_BY="[Empty name]" NAME="Littleton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Littleton J, Zieglgansberger W</AU>
<TI>Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence</TI>
<SO>American Journal of Addiction</SO>
<YR>2003</YR>
<VL>12 Supplement 1</VL>
<PG>3-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mann-2004" MODIFIED="2010-01-21 13:24:58 +0100" MODIFIED_BY="[Empty name]" NAME="Mann 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mann K, Lehert P, Morgan M Y</AU>
<TI>The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>1</NO>
<PG>51-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mann-2008" MODIFIED="2010-06-24 12:38:41 +0200" MODIFIED_BY="[Empty name]" NAME="Mann 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mann K, Kiefer F, Spanagel R, Littleton J</AU>
<TI>Acamprosate: recent findings and future research directions</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" MODIFIED="2010-06-24 12:38:47 +0200" MODIFIED_BY="[Empty name]" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective studies of disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<NO>4</NO>
<PG>719-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marlatt-1985" MODIFIED="2010-01-06 15:57:09 +0100" MODIFIED_BY="[Empty name]" NAME="Marlatt 1985" TYPE="BOOK">
<AU>Marlatt GA, Gordon J</AU>
<SO>Relapse prevention</SO>
<YR>1985</YR>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGeehan-2003" MODIFIED="2010-01-21 13:26:17 +0100" MODIFIED_BY="[Empty name]" NAME="McGeehan 2003" TYPE="JOURNAL_ARTICLE">
<AU>McGeehan AJ, Olive MF</AU>
<TI>The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine</TI>
<SO>British Journal of Pharmacology</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>1</NO>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQueen-2009" MODIFIED="2010-06-20 18:45:15 +0200" MODIFIED_BY="[Empty name]" NAME="McQueen 2009" TYPE="COCHRANE_REVIEW">
<AU>McQueen J, Howe TE, Allan L, Mains D</AU>
<TI>Brief interventions for heavy alcohol users admitted to general hospital wards</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2010-06-20 18:45:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-20 18:45:09 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858.CD005191.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MIller-1994" MODIFIED="2010-01-06 14:47:29 +0100" MODIFIED_BY="[Empty name]" NAME="MIller 1994" TYPE="BOOK">
<AU>Miller WR, Zweben A, DiClemente CC, Rychtarik RG</AU>
<SO>Motivational Enhancement Therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence</SO>
<YR>1994</YR>
<PB>National Institute on Alcohol Abuse and Alcoholism</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2010-06-24 13:38:07 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Jones A, Lepage L, CONSORT Group (Consolitdated Standards for Reporting of Trials)</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1992-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2009-12-09 09:57:06 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman D G</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>PLoS Med</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>e1000097</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-2004" MODIFIED="2009-12-09 09:57:10 +0100" MODIFIED_BY="[Empty name]" NAME="Moncrieff 2004" TYPE="COCHRANE_REVIEW">
<AU>Moncrieff J, Wessely S, Hardy R</AU>
<TI>Active placebos versus antidepressants for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-12-08 11:45:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-08 11:45:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moos-2006" MODIFIED="2010-06-20 17:31:48 +0200" MODIFIED_BY="[Empty name]" NAME="Moos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moos RH, Moos BS</AU>
<TI>Rates and predictors of relapse after natural and treated remission from alcohol use disorders</TI>
<SO>Addiction</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>2</NO>
<PG>212-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naassila-1998" MODIFIED="2010-06-24 13:38:25 +0200" MODIFIED_BY="[Empty name]" NAME="Naassila 1998" TYPE="JOURNAL_ARTICLE">
<AU>Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M</AU>
<TI>Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>4</NO>
<PG>802-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-1992" MODIFIED="2010-06-24 13:38:28 +0200" MODIFIED_BY="[Empty name]" NAME="Newell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newell DJ</AU>
<TI>Intention-to-treat analysis: implications for quantitative and qualitative research</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nickerson-1998" MODIFIED="2010-06-24 13:38:33 +0200" MODIFIED_BY="[Empty name]" NAME="Nickerson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nickerson RS</AU>
<TI>Confirmation Bias: A Ubiquitous Phenomenon</TI>
<SO>Review of General Psychology</SO>
<YR>1998</YR>
<VL>2</VL>
<PG>175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowinski-1995" MODIFIED="2010-01-06 14:51:20 +0100" MODIFIED_BY="[Empty name]" NAME="Nowinski 1995" TYPE="BOOK">
<AU>Nowinski J, Baker S, Carroll, K</AU>
<SO>Twelve Step Facilitation Therapy manual. A clinical research guide for therapists treating individuals with alcohol abuse and dependence</SO>
<YR>1995</YR>
<PB>Project MATCH Monograph Series Volume I. U.S. Department of Health and Human Services</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olive-2002" MODIFIED="2010-01-21 14:23:44 +0100" MODIFIED_BY="[Empty name]" NAME="Olive 2002" TYPE="JOURNAL_ARTICLE">
<AU>Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW</AU>
<TI>Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release</TI>
<SO>European Journal of Pharmacology</SO>
<YR>2002</YR>
<VL>437</VL>
<NO>1-2</NO>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pettinati-2004" MODIFIED="2010-01-21 14:24:39 +0100" MODIFIED_BY="[Empty name]" NAME="Pettinati 2004" TYPE="BOOK">
<AU>Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ</AU>
<SO>Medical Management Treatment Manual. A Clinical Research Guide for MedicallyTrained Clinicians Providing Pharmacotherapy as Part of the Treatment for AlcoholDependence</SO>
<YR>2004</YR>
<VL>2</VL>
<EN>Vol 2</EN>
<PB>COMBINE Monograph Series</PB>
<CY>No (NIH) 04-5289</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pildal-2007" MODIFIED="2010-06-24 13:38:46 +0200" MODIFIED_BY="[Empty name]" NAME="Pildal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pildal J, Hrobjartsson A, Jorgensen K J, Hilden J, Altman D G, Gotzsche P C</AU>
<TI>Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>4</NO>
<PG>847-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pocock-1987" MODIFIED="2010-06-24 13:38:49 +0200" MODIFIED_BY="[Empty name]" NAME="Pocock 1987" TYPE="JOURNAL_ARTICLE">
<AU>Pocock S J, Hughes M D, Lee R J</AU>
<TI>Statistical problems in the reporting of clinical trials. A survey of three medical journals</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>7</NO>
<PG>426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Project-Match-Research-Group-1997" MODIFIED="2010-01-06 10:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Project Match Research Group 1997" TYPE="JOURNAL_ARTICLE">
<AU>Project Match Research Group</AU>
<TI>Matching alcoholism treatment to client heterogeneity: Project Match posttreatment drinking outcomes</TI>
<SO>Journal of Studies on Alcoholism</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>7-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabkin-1992" MODIFIED="2010-01-21 14:25:49 +0100" MODIFIED_BY="[Empty name]" NAME="Rabkin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin J G, Markowitz J S, Ocepek-Welikson K, Wager S S</AU>
<TI>General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rehm-2009" MODIFIED="2010-06-24 13:38:58 +0200" MODIFIED_BY="[Empty name]" NAME="Rehm 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J</AU>
<TI>Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<NO>9682</NO>
<PG>2223-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2007" MODIFIED="2010-06-24 13:39:02 +0200" MODIFIED_BY="[Empty name]" NAME="Riley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Simmonds MC, Look MP</AU>
<TI>Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2007</YR>
<VL>60</VL>
<NO>5</NO>
<PG>431-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosner-2008" MODIFIED="2010-01-21 14:26:37 +0100" MODIFIED_BY="[Empty name]" NAME="Rosner 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rösner S, Leucht S, Lehert P, Soyka M</AU>
<TI>Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>11-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rucker-2008" MODIFIED="2010-01-21 14:27:49 +0100" MODIFIED_BY="[Empty name]" NAME="Rucker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter J R, Schumacher M</AU>
<TI>Undue reliance on I(2) in assessing heterogeneity may mislead</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoechlin-2000" MODIFIED="2010-01-21 14:29:06 +0100" MODIFIED_BY="[Empty name]" NAME="Schoechlin 2000" TYPE="BOOK_SECTION">
<AU>Schoechlin C, Engel RR</AU>
<TI>Meta-analysis of pharmacotherapeutic trials</TI>
<SO>Handbook of Alcoholism</SO>
<YR>2000</YR>
<PG>339-351</PG>
<ED>Zernig G, Saria A, Kurz M, O'Malley S</ED>
<PB>Innsbruck University Press</PB>
<CY>Innsbruck</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-06-24 13:39:14 +0200" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF</AU>
<TI>Subverting randomisation in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>18</NO>
<PG>1456-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selzer-1971" MODIFIED="2010-06-24 13:39:19 +0200" MODIFIED_BY="[Empty name]" NAME="Selzer 1971" TYPE="JOURNAL_ARTICLE">
<AU>Selzer ML</AU>
<TI>The Michigan Alcoholism Screening Test (MAST): The quest for a new diagnostic instrument</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>127</VL>
<PG>1653-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skinner-1982" MODIFIED="2010-06-10 12:10:35 +0200" MODIFIED_BY="[Empty name]" NAME="Skinner 1982" TYPE="JOURNAL_ARTICLE">
<AU>Skinner HA, Allen BA</AU>
<TI>Alcohol dependence syndrome: measurement and validation</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>1982</YR>
<VL>91</VL>
<PG>199-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skinner-1984" MODIFIED="2010-01-08 10:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="Skinner 1984" TYPE="BOOK">
<AU>Skinner HA, Horn JL</AU>
<SO>Alcohol Dependence Scale: Users Guide</SO>
<YR>1984</YR>
<PB>Addiction Research Foundation</PB>
<CY>Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slattery-2003" MODIFIED="2009-12-08 11:58:10 +0100" MODIFIED_BY="[Empty name]" NAME="Slattery 2003" TYPE="OTHER">
<AU>Slattery J, Chick J</AU>
<TI>Prevention of Relapse in Alcohol Dependence</TI>
<SO>Health Technology Assesment Report</SO>
<YR>2003</YR>
<VL>3</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobell-1988" MODIFIED="2010-06-24 13:39:28 +0200" MODIFIED_BY="[Empty name]" NAME="Sobell 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sobell LC, Sobell MB, Riley DM, Schuller R, Pavan DS, Cancilla A, et al</AU>
<TI>The reliability of alcohol abusers' self-reports of drinking and life events that occurred in the distant past</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>3</NO>
<PG>225-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobell-1992" MODIFIED="2010-06-24 13:39:32 +0200" MODIFIED_BY="[Empty name]" NAME="Sobell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sobell LC, Toneatto T, Sobell MB, Leo GI, Johnson L</AU>
<TI>Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment</TI>
<SO>Addictive Behaviors</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>5</NO>
<PG>507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spanagel-1996" MODIFIED="2010-01-21 14:31:51 +0100" MODIFIED_BY="[Empty name]" NAME="Spanagel 1996" TYPE="JOURNAL_ARTICLE">
<AU>Spanagel R, Holter S M, Allingham K, Landgraf R, Zieglgansberger W</AU>
<TI>Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1996</YR>
<VL>305</VL>
<NO>1-3</NO>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spanagel-1997" MODIFIED="2010-06-24 13:39:38 +0200" MODIFIED_BY="[Empty name]" NAME="Spanagel 1997" TYPE="JOURNAL_ARTICLE">
<AU>Spanagel R, Zieglgansberger W</AU>
<TI>Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes</TI>
<SO>Trends in Pharmacological Sciences</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>2</NO>
<PG>54-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spanagel-2003" MODIFIED="2010-06-24 13:39:44 +0200" MODIFIED_BY="[Empty name]" NAME="Spanagel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Spanagel R, Mann K</AU>
<TI>Acamprosate--new preclinical research aspects</TI>
<SO>MMW, Fortschritte der Medizin</SO>
<YR>2003</YR>
<VL>145 Supplement</VL>
<NO>3</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2005" MODIFIED="2010-06-24 13:39:51 +0200" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2005" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Jarusuraisin N</AU>
<TI>Opioid antagonists for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-06-10 12:09:30 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-10 12:09:30 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tannock-1996" MODIFIED="2010-06-24 13:39:57 +0200" MODIFIED_BY="[Empty name]" NAME="Tannock 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tannock I F</AU>
<TI>False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>3-4</NO>
<PG>206-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-The-Nordic-Cochrane-Centre-2008" MODIFIED="2010-01-21 14:33:57 +0100" MODIFIED_BY="[Empty name]" NAME="The Nordic Cochrane Centre 2008" NOTES="The Cochrane Collaboration. Review Manager (RevMan). 5.0." NOTES_MODIFIED="2010-01-21 14:33:57 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager (RevMan). 5.0</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2000" MODIFIED="2010-01-21 14:35:07 +0100" MODIFIED_BY="[Empty name]" NAME="Turner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Turner R M, Omar R Z, Yang M, Goldstein H, Thompson S G</AU>
<TI>A multilevel model framework for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>24</NO>
<PG>3417-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verheul-2005" MODIFIED="2010-06-24 13:40:06 +0200" MODIFIED_BY="[Empty name]" NAME="Verheul 2005" TYPE="JOURNAL_ARTICLE">
<AU>Verheul R, Lehert P, Geerlings P J, Koeter MW, van den Brink W</AU>
<TI>Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2005</YR>
<VL>178</VL>
<NO>2-3</NO>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2009-12-09 09:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="OTHER">
<AU>WHO</AU>
<TI>The World Health Report: Reducing risk, promoting healthy life</TI>
<SO>The World Health Report</SO>
<YR>2002</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2005" MODIFIED="2010-06-24 13:40:13 +0200" MODIFIED_BY="[Empty name]" NAME="Williamson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PR, Gamble C, Altman DG, Hutton JL</AU>
<TI>Outcome selection bias in meta-analysis</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>515-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2010-06-24 13:40:17 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zeise-1993" MODIFIED="2010-01-21 14:36:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zeise 1993" TYPE="JOURNAL_ARTICLE">
<AU>Zeise M L, Kasparov S, Capogna M, Zieglgansberger W</AU>
<TI>Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors</TI>
<SO>European Jorunal of Pharmacology</SO>
<YR>1993</YR>
<VL>231</VL>
<NO>1</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zornoza-2003" MODIFIED="2010-06-24 13:40:23 +0200" MODIFIED_BY="[Empty name]" NAME="Zornoza 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zornoza T, Cano M J, Polache A, Granero L</AU>
<TI>Pharmacology of acamprosate: an overview</TI>
<SO>CNS Drug Reviews</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>359-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-07-12 16:07:27 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-07-12 16:07:27 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Missing data rates" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Financial support" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Data assessment methods">
<INCLUDED_CHAR MODIFIED="2010-07-12 14:50:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2006">
<CHAR_METHODS MODIFIED="2010-07-12 14:35:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>principle of analysis:</B> ITT; <B>study duration:</B> 16 weeks (treatment); 12 months (post-treatment); <B>setting:</B> outpatient; <B>study sites: </B>11; <B>Country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 14:37:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence:</B> 4 to 21 days; <B>baseline characteristics: </B>70% male; mean age: 44.0 years; 42% married: 71% employed; <B>pre-baseline drinking: </B>75% days drinking; 12.4 drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 16.8; percentage of individuals abstinent for at least 4 days: 99%</P>
<P>
<B>Exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence; 2. a dependence or abuse from opioids (last 6 months) ro a chronic treatment with any opiate-containing medications (last 30 days) or urine positive for opioids; 3. a concurrent major psychiatric disorder; 4. prior use of study medication in the last 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 11:45:45 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>3000 mg acamprosate + MM (n = 152)</LI>
<LI>3000 mg acamprosate + MM + CBI (n = 154)</LI>
<LI>100 mg naltrexone + MM (n = 153)</LI>
<LI>100 mg naltrexone + MM + CBI (n = 155)</LI>
<LI>3000 mg acamprosate + 100 mg naltrexone + MM (n = 148)</LI>
<LI>3000 mg acamprosate + 100 mg naltrexone + MM + CBI (n = 157)</LI>
<LI>placebo + MM (n = 153)</LI>
<LI>placebo + CBI (n = 156)</LI>
<LI>CBI only (n = 157)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>a) group 1 to 7:<I> </I>medial management (MM); <B>applied manual: </B>
<LINK REF="REF-Pettinati-2004" TYPE="REFERENCE">Pettinati 2004</LINK>; <B>aim:</B> flexible (with recommendation to abstinence); b)<I> </I>group 2, 4, 6, 8 and 9: combined behavioral intervention (CBI); <B>applied manual: </B>integrates aspects of cognitive behavioral therapy (CBT)<B> </B>(<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK>) as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>), motivational enhancement (ME) <LINK REF="REF-MIller-1994" TYPE="REFERENCE">MIller 1994</LINK>, 12-step facilitation (<LINK REF="REF-Nowinski-1995" TYPE="REFERENCE">Nowinski 1995</LINK>), etc.</P>
<P>
<B>Dosing: </B>flexible dosing allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-12 14:37:45 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to heavy drinking*</LI>
<LI>percent days abstinent</LI>
<LI>good clinical outcome (abstinence; moderate drinking**)</LI>
<LI>time to first heavy drinking*</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women); ** moderate drinking: &#8805; 14 (11) SDU for men (women) per week, with no more than two days on &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 14:50:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates:</B> acamprosate: 38.5% (n = 116); naltrexone: 35% (n = 108); naltrexone + acamprosate: 40.7% (n = 124); ; placebo: 28.5% (n = 88); group difference: not reported; <B>lost to follow-up rates</B>: acamprosate: 4.6% (n = 14); naltrexone: 6.1% (n = 19); naltrexone + acamprosate: 6.2% (n = 19); placebo: 5.8% (n = 18); group difference: not significant</P>
<P>
<B>Post-treatment phase / drop-out rates: </B>acamprosate: 49.2 (n = 149); naltrexone: 46.0% (n = 142); naltrexone + acamprosate: 53.1% (n = 162); placebo: 38.2% (n = 118); group difference: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-12 14:38:35 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA); active control substances and placebo were donated by Lipha Pharmaceuticals; Lipha Pharmaceuticals conducted monitoring visits to the clinical sites</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 14:38:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; nine times during 16 weeks of treatment and at week 10, 36, 42 during post-treatment); <B>assessment of side effects:</B> SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes:</B> CDT (week 8, 16) was used as a validity check for self-reported drinking; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:54:57 +0100" MODIFIED_BY="[Empty name]">
<P>The COMBINE study group provided access to the COMBINE data set, which was used for the calculation of "return to any drinking" for the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 14:53:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baltieri-2003">
<CHAR_METHODS MODIFIED="2010-07-12 14:51:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks (treatment); 12 weeks (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> Brazil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 14:51:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (ICD-10); <B>required abstinence:</B> 7 days; <B>baseline characteristics:</B> 100% male; mean age: 44.2 (SD = 8.28) years; <B>pre-baseline drinking:</B> 360.0 (SD = 150.7) grams alcohol per day</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent psychiatric disorder; 2. a previous psychosis; 3. a condition that requires psychiatric medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-18 16:16:16 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 40)</LI>
<LI>placebo (n = 35)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>psychosocial orientation; patients were encouraged to participate in Alcoholics Anonymous (AA) groups; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 11:42:43 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 14:52:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 25.0% (n = 10); placebo: 20% (n = 7); group difference in drop-out rates: not reported; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 17.5% (n = 7); placebo: 11.4% (n = 4); group difference in lost to follow-up rates: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 09:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Investigator-driven trial with non-profit funding</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 14:53:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>retrospective quantity / frequency report (week 1, 2, 3, 4, 6, 8, 12, 16, 20, 24); <B>assessment of side effects:</B> UKU side effect rating scale (Louzã, 2000); <B>assessment of compliance:</B> not reported; <B>validation of patient-reported outcomes:</B> GGT, collateral reports; <B>laboratory assessment of drop-outs:<I> </I>
</B>
<I>not reported </I>
</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-11-15 18:38:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 14:57:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barrias-1997">
<CHAR_METHODS MODIFIED="2010-07-12 14:55:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 months (treatment); 6 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites</B>: 9; <B>country: </B>Portugal</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 14:56:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III); <B>required abstinence:</B> &#8805; 5 days; <B>baseline characteristics:</B> 92% male; mean age: 40.3 years; 73.2% married; <B>pre-baseline drinking:</B> 97.7% (96%) of patients were physically (psychologically) dependent on alcohol; 88.4% consumed alcohol every day; 64.9% consumed more than 10 SDU a day; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 31.9</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent major psychiatric disorder; 2. a concurrent use of psychotropic medications besides stable medication of benzodiazepines and use of oxazepam and tetrazepam for periods &lt; 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 14:56:32 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 150)</LI>
<LI>placebo (n = 152)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>not specified; patients were encouraged to participate in AA groups; <B>aim: </B>abstinence; <B>dosing:</B> 1. weight dependent; 2. flexible: dose reduction in case of side effects</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-29 10:58:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 14:56:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: acamprosate: 42.7% (n = 64); placebo: 45.4% (n = 69); group difference in drop-out rates: not significant; group difference in reasons for drop-out: significantly more patients refused to continue treatment in the placebo group than in the acamprosate group; <B>lost to follow-up rates: </B>acamprosate: 39% (n = 58); placebo: 43% (n = 66); group difference in missing end point data rates: not significant</P>
<P>
<B>Post-treatment phase / drop-out rates</B>: 53% of the entire sample dropped out during the treatment and post-treatment phase; no group specific values provided</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 11:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Merck Lipha within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 14:57:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> retrospective quantity / frequency report (week 4, 12, 24, 36, 48, 60*, 72*); *post-treatment evaluation; <B>assessment of side effects: </B>side effect checklist (44 symptoms); <B>assessment of compliance: </B>not reported; <B>validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>CAD was extracted from the manufacturer report</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:01:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Besson-1998">
<CHAR_METHODS MODIFIED="2010-07-12 14:59:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 months (treatment); 12 months (post-treatment); <B>principle of analysis: </B>ITT modified; <B>setting: </B>outpatient; <B>study sites: </B>3; <B>country:</B> Switzerland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 14:59:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III); <B>required abstinence:</B> &#8805; 5 days; <B>baseline characteristics:</B> 80% male; mean age: 42.5 years; <B>pre-baseline drinking:</B> 60.1% had previous alcohol detoxifications; 50% had previous psychotherapy; 15.0 years of alcohol dependence; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 31.6</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent major psychiatric disorder requiring medication; 2. a concurrent use of psychotropic medications; benzodiazepines administered during detoxification had to be discontinued by the 14th day of the study and were then prohibited until the end of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 14:59:59 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 55)</LI>
<LI>placebo (n = 55)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>not specified; patients were allowed to participate in AA groups; <B>aim: </B>abstinence; <B>dosing: </B>1. weight dependent; 2. flexible: dose reduction in case of side effects; <B>permitted medication:</B> voluntary use of disulfiram</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 11:25:50 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>mean corpuscular volume (MCV) </LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:00:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: acamprosate: 65.5% (n = 36); placebo: 65.5% (n = 36); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not significant; <B>lost to follow-up rates</B>: acamprosate: 16.4% (n = 9); placebo: 14.5% (n = 8); group difference in lost to follow-up rates: not significant</P>
<P>
<B>Post-treatment phase / drop-out rates</B>: acamprosate: 81.8% (n = 45); placebo: 85.5% (n = 47); only 18 patients (10 previously on acamprosate and 8 previously on placebo) completed the post-treatment phase</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 11:27:27 +0100" MODIFIED_BY="[Empty name]">
<P>The study has received grants and facilities by the manufacturer (Lipha Pharmaceuticals), but the manufacturer had no role in the management, analyses and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:01:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>retrospective quantity / frequency report (week 4, 12, 24, 36, 48, 60*, 72*, 84*, 96*); *post-treatment evaluation; <B>assessment of side effects: </B>spontaneous reports; <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes:</B> a GGT equal or above 1.3 times the upper laboratory normal was considered as suggestive of possible relapse drinking; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-20 11:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Because of the small sample (n=18), no outcomes were provided for the follow-up period (day 361 to day 720)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:04:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borg-2003">
<CHAR_METHODS MODIFIED="2010-07-12 15:03:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 3 months; <B>principle of analysis: </B>ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> Sweden</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:03:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence:</B> no information available; <B>baseline characteristics:</B> no information available; <B>pre-baseline drinking:</B> no information available</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>no information available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-24 12:02:40 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 5)</LI>
<LI>placebo (n = 5)</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-12 15:58:34 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Patients who return to any drinking</LI>
<LI>Cumulative abstinence duration (CAD)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:03:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: no information available; <B>lost to follow-up rates</B>: no information available</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-05 08:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Merck Lipha; sponsored, organized and conducted within the scope of new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:04:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking / side effects / compliance: </B>no information available; <B>validation of patient-reported outcomes:</B> no information available; <B>laboratory assessment of drop-outs: </B>no information available</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-20 11:30:28 +0100" MODIFIED_BY="[Empty name]">
<P>Unpublished trial; information subsequently provided by Lipha Pharmaceuticals </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:10:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chick-2000">
<CHAR_METHODS MODIFIED="2010-07-12 15:08:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>6 months (treatment); 4 weeks (post-treatment); <B>principle of analysis:</B> ITT modified (treatment-received analysis); <B>setting: </B>outpatient; <B>study sites:</B> 20; <B>country: </B>United Kingdom</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:09:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III); <B>required abstinence:</B> 5 to 35 days; <B>baseline characteristics:</B> 83.5% male; mean age: 43.3 years; 56% married: 51% employed; <B>pre-baseline drinking:</B> 25.4 units (à 8 grams) per day; SADQ score: 33.5; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 37.5; 38.2% of patients drank alcohol during the wash-out period</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a drug abuse or dependence (last 12 months); 2. a concurrent major psychiatric disorder; 3. a concurrent use of disulfiram or calcium carbimide or other drugs known to induce hepatic enzymes with the exception of tranquillizers on a regular base</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:09:31 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 289)</LI>
<LI>placebo (n = 292)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>centre specific; cognitive&#8211;behavioral group therapy was applied in 13 of 16 centres; patients were encouraged to participate in AA groups; <B>aim: </B>abstinence; <B>dosing: </B>flexible: dose reduction in case of side effects</P>
<P>
<B>Trial started with a</B> <B>placebo run-in week</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 11:32:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase level (GGT)</LI>
<LI>aspartate aminotransferase</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (3) SDU per drinking day for men (women) or a single day &#8805; 8 (6) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:09:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 65.4% (n = 189); placebo: 64.7% (n = 189); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 23% (n = 66); placebo: 25% (n = 73); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 11:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Lipha Pharmaceuticals within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:10:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> diary cards; retrospective quantity / frequency report (week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28*); *post-treatment evaluation; <B>assessment of side effects: </B>spontaneous reports; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes: </B>breathalyzer test; urine alcohol level; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:56:42 +0100" MODIFIED_BY="[Empty name]">
<P>CAD was extracted from the manufacturer report</P>
<P>Subgroups: compliant subgroup analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:14:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geerlings-1997">
<CHAR_METHODS MODIFIED="2010-07-12 15:12:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>6 months (treatment); 6 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting:</B> outpatient; <B>study sites:</B> 22; <B>country:</B> Netherlands, Belgium, Luxembourg</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:13:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III); <B>required abstinence: </B>&#8805; 5 days; <B>baseline characteristics:</B> 76% male; mean age: 41.0 (SD=8.6) years; 50.6% married; <B>pre-baseline drinking:</B> 74% consumed alcohol every day; 66% consumed more than 10 SDU a day; 53% (61%) of patients were physically (psychologically) dependent on alcohol; mean duration of the prior detoxification period: 19.2 (SD = 19) days</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>a<B> </B>concurrent use of psychotropic medication (antidepressants, neuroleptics, benzodiazepines, barbiturates, meprobamate, anti-epileptic drugs, clomethiazole and disulfiram)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-20 11:48:01 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 128)</LI>
<LI>placebo (n = 134)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>centre specific, no further information provided; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:03:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:13:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: acamprosate: 59.4% (n = 76); placebo: 68.5% (n = 92); group difference in drop-out rates: significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates:</B> not reported</P>
<P>
<B>Post-treatment phase / drop-out rates</B>:<B> </B>acamprosate: 76.6% (n = 98); placebo: 82.8% (n = 111)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 11:50:25 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Merck Lipha (Belgium) within the scope of a new drug application processes </P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:14:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>not reported (week 4, 8, 12, 18, 24, 36*, 48*); *post-treatment evaluation; <B>assessment of side effects:</B> not reported; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-20 11:51:20 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:17:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gual-2001">
<CHAR_METHODS MODIFIED="2010-07-12 15:16:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 6 months; <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>11; <B>country: </B>Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:16:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III-R); <B>required abstinence:</B> &#8805; 7 days; <B>baseline characteristics:</B> 79% male; mean age: 41.0 (SD = 9.2) years; 67.7% married; <B>pre-baseline drinking: </B>84% consumed alcohol every day; 66.3%% consumed more than 10 SDU a day; 12.8 (SD = 7.9) years of alcohol dependence; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 27.8 (SD = 8.5)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a drug abuse or (other than alcohol or nicotine) during the preceding 6 months; 2. a concurrent major psychiatric disorder that would require treatment during the trial. 3. a concurrent use of disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:17:10 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 141)</LI>
<LI>placebo (n = 147)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>no information provided; <B>aim: </B>abstinence; <B>permitted medication: </B>Tetrabamate, chlomethiazole, amitriptyline, imipramine, chlordiazepoxide, clorazepate, triazolam, temazepam; <B>dosing: </B>acamprosate was prescribed from the start of alcohol withdrawal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 12:02:41 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cumulative abstinence duration (CAD)</LI>
<LI>stable recovery duration</LI>
<LI>return to any drinking </LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:17:17 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 31.9% (n = 45); placebo: 38.8% (n = 57); group difference in drop-out rates: not reported; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 14.2% (n = 21); placebo: 18.2% (n = 27); group difference in lost to follow-up rates: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 11:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Merck Lipha (Spain) within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:17:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>retrospective quantity / frequency report (week 4, 8, 12, 18, 24); <B>assessment of side effects:</B> not reported; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes:</B> a GGT equal or above 1.3 times the upper laboratory normal was considered as suggestive of possible relapse drinking; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-20 11:58:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:24:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiefer-2003">
<CHAR_METHODS MODIFIED="2010-07-12 15:23:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>Blinding: </B>double-blind; <B>Study duration: </B>12 weeks (treatment); 12 weeks<B> </B>(post-treatment); <B>Principle of analysis:</B> ITT; <B>Setting: </B>outpatient; <B>study sites:</B> 1; <B>country:</B> Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:23:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>12 to 15 days; <B>baseline characteristics:</B> 73.7% male; mean age: 46.2 (SD=9.3) years; 28% married: 61% employed; <B>pre-baseline drinking:</B> 254.9 (SD = 129.4) grams alcohol per day; 2.7 (SD = 4.0) previous detoxifications</P>
<P>
<B>Exclusionary psychiatric conditions: </B>1. a history of opioid or cocaine abuse; 2. a concurrent major psychiatric impairment or disorder requiring psychotropic medication or inpatient treatment or a history of psychosis; 3. a concurrent use of psychotropic medications or disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:57:36 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 40)</LI>
<LI>50 mg naltrexone (n = 40)</LI>
<LI>50 mg naltrexone and 1998 mg acamprosate (n = 40)</LI>
<LI>placebo plus psychosocial treatment (n = 40)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> cognitive behavioral therapy (CBT); <B>applied manual:</B> <LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 12:02:04 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>time to first relapse* (survival curve)</LI>
<LI>days abstinent</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking days per week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-21 16:20:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>acamprosate: 57.5% (n = 23); naltrexone: 45% (n = 18); naltrexone + acamprosate: 35.0% (n = 14); placebo: 75% (n = 30); group difference in drop-out rates: not reported, but appear significant; group difference in reasons for drop-out: not reported<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-09-18 17:25:32 +0200" MODIFIED_BY="[Empty name]">
<P>University of Hamburg </P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:24:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking</B>: drinking diary (weekly); <B>assessment of side effects: </B>adverse effect checklist; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes:</B> breath alcohol concentrations were randomly registered; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-28 11:16:26 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment results were presented in <LINK REF="REF-Kiefer-2004" TYPE="REFERENCE">Kiefer 2004</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:26:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ladewig-1993">
<CHAR_METHODS MODIFIED="2010-07-12 15:25:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 6 months (treatment); 6 months (post-treatment); <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 3; <B>country: </B>Switzerland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:25:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III); <B>required abstinence: </B>&#8805; 5 days; <B>baseline characteristics:</B> 75.8% male; mean age: 46.8 (SD = 10.2) years; <B>pre-baseline drinking:</B> 85.5% had at least one prior alcohol detoxification; 12.3 (SD = 1.8) years of drinking; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 37.9 (SD = 39.1)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>a<B> </B>concurrent major psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:26:00 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 29)</LI>
<LI>placebo (n = 32)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>no information provided; <B>aim: abstinence; dosing: </B>weight dependent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 12:08:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:26:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: acamprosate: 34.5% (n = 10); placebo: 34.4% (n = 11); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 6.9% (n = 2); placebo: 3% (n = 1); group difference in lost to follow-up rates: not significant</P>
<P>
<B>Post-treatment phase / drop-out rates</B>: 34% of the entire sample dropped out during the treatment and post-treatment phase; no group specific values were provided</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 12:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>The study has received grants and facilities by the manufacturer (Lipha Pharmaceuticals), but the manufacturer had no role in the management, analyses and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:26:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> retrospective quantity / frequency report (week 4, 12, 24, 363, 483); *post-treatment evaluation; <B>assessment of side effects:</B> side effect checklist (44 symptoms); <B>assessment of compliance: </B>not reported; <B>validation of patient-reported outcomes: </B>GGT; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:56:31 +0100" MODIFIED_BY="[Empty name]">
<P>CAD was extracted from the manufacturer report</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:30:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lhuintre-1985">
<CHAR_METHODS MODIFIED="2010-07-12 15:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> completer analysis, subsequently transformed into ITT analysis; <B>setting: </B>outpatient; <B>study sites</B>: 1; <B>country: </B>France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:29:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence:</B> &#8805; 5 days; <B>baseline characteristics:</B> 88.6% male; mean age: 41.4 (SD = 7) years; <B>pre-baseline drinking: </B>not reported</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1.<B> </B>a<B> </B>concurrent major psychiatric disorder; 2. more than two failed attempts of alcohol detoxification</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:30:00 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1000 mg - 2250 mg acamprosate (n = 33 + 9*)</LI>
<LI>placebo (n = 37 + 6*)</LI>
</OL>
<P>
<B>* </B>patients subsequently added to the meta-analyses of binary outcomes as treatment failures</P>
<P>
<B>Psychosocial treatment: </B>no information provided; <B>dosing:</B> weight dependent (with 1 capsule per 10 kg body weight per day; minimum:1000 mg; maximum; 2250 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 13:26:14 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:30:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 21.4% (n = 9); placebo: 14.0% (n = 6); group difference in drop-out rates: not reported; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 9.5% (n = 4); placebo: 11.6% (n = 5); group difference in lost to follow-up rates: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-01 10:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored by MERAM, France </P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:30:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> not reported; <B>assessment of side effects:</B> not reported; <B>assessment of compliance:</B> not reported; <B>validation of patient-reported outcomes: </B>GGT, MCV<I>; </I>
<B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-20 13:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>Completer analyses were subsequently transformed into ITT analyses for the meta-analyses </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:33:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lhuintre-1990">
<CHAR_METHODS MODIFIED="2010-07-12 15:32:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> not reported; <B>setting: </B>outpatient; <B>study sites: </B>30; <B>country: </B>France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:32:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence:</B> 5 to 30 days; <B>baseline characteristics:</B> 81.9% male; mean age: 42.5 (SD=9.5) years; 64.5% married: 62% employed; <B>pre-baseline drinking:</B> 194.5 (SD = 115.0) grams alcohol per day</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1.<B> </B>a concurrent use of benzodiazepines (started within the last six months), high dose antidepressants and neuroleptics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:32:32 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg acamprosate (n = 279)</LI>
<LI>placebo (n = 290)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>not reported; <B>permitted medication: </B>benzodiazepines (if use started at least 6 months before the trial), antidepressants and neuroleptics at low doses, meprobamate, non-barbiturate hypnotics, non-benzodiazepine hypnotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 13:30:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:32:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 37.3% (n = 104); placebo: 37.6% (n = 109); group difference in drop-out rates: not significant; group difference in drop-out reasons: not reported; <B>lost to follow-up rates</B>: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 13:31:42 +0100" MODIFIED_BY="[Empty name]">
<P>The study has received grants and facilities by the manufacturer (Merck LIpha, France), but the manufacturer had no role in the management, analyses and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:33:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>no patient-reported drinking outcomes provided<B> </B>(week 4, 8, 12); <B>assessment of side effects: </B>43-item side effect questionnaire; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported drinking outcomes: </B>no patient-reported drinking outcomes provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Rates of any drinking were extracted from the manufacturer report </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:35:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mason-2006">
<CHAR_METHODS MODIFIED="2010-07-12 15:34:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration: </B>6 months (treatment); 8 weeks (post-treatment); <B>principle of analysis:</B> ITT modified (first visit non-attendants excluded); <B>setting: </B>outpatient; <B>study sites: </B>21; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:34:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence: </B>abstinence was not explicitly required for admission to the study; 49.6% of patients were abstinent at baseline; <B>baseline characteristics:</B> 67.9% male; mean age: 44.5 (SD = 10.1) years; 47% married; 57.2% employed full-time; <B>pre-baseline drinking: </B>67.3 % drinking days; 6.2 (SD = 3.8) drinks per day; 12.8 (SD = 9.0) years of heavy drinking</P>
<P>
<B>Exclusionary of psychiatric conditions:</B> 1. a clinically significant psychiatric condition; 2. need for psychoactive medication; 3. use of any investigational drug, disulfiram or naltrexone in the month prior to screening; 4. dependence on illicit drugs or unable to provide a pre-randomization urine sample</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-20 12:00:17 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>2000 mg acamprosate (n = 253 + 5*)</LI>
<LI>3000 mg acamprosate (n = 82 + 1*)</LI>
<LI>placebo (n = 257 + 3*)</LI>
</OL>
<P>
<B>* </B>patients subsequently added to the meta-analyses of binary outcomes as treatment failures</P>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral techniques and motivational enhancement for medication compliance; <B>applied manual:</B> www.alcoholfree.info; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 13:33:45 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cumulative abstinence duration (CAD)</LI>
<LI>drinks per week</LI>
<LI>drinking days per week</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:35:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 56.3% (n = 192); placebo: 44.4% (n = 114); group difference in drop-out rates: significantly higher drop-out in the acamprosate group; <B>lost to follow-up rates</B>: acamprosate: 15.5% (n = 51); placebo: 10.1% (n = 26); group difference in lost to follow-up rates: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-20 13:34:05 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Lipha Pharmaceuticals within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:35:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; diary cards; retrospective quantity / frequency reports; <B>assessment of side effects: </B>open-ended questionnaire; <B>assessment of compliance:</B> pill count; acamprosate plasma levels; <B>validation of patient-reported outcomes: </B>1. breath alcohol concentration; 2. GGT; 3. collateral reports; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-06-24 08:56:40 +0200" MODIFIED_BY="[Empty name]">
<P>Rates of any drinking, rates of heavy drinking and standard deviations (SD) for CAD were extracted from the manufacturer report</P>
<P>No results provided for the post-treatment evaluation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:37:27 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Description of the study design was provided by the investigator&lt;/p&gt;" NOTES_MODIFIED="2010-07-12 15:37:27 +0200" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morley-2006">
<CHAR_METHODS MODIFIED="2010-07-12 15:36:41 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis: </B>ITT; <B>setting:</B> outpatient; <B>study sites:</B> 3; <B>country: </B>Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:37:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; alcohol abuse; <B>required abstinence:</B> 3 to 21 days; <B>baseline characteristics:</B> 70.4% male; mean age: 44.9 (SD = 9.0) years; 35% married: 66% employed; <B>pre-baseline drinking:</B> 14.8 (SD = 7.9) drinks per drinking day; 15.8 (SD = 10.8) years of problematic drinking; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 20.5 (SD = 8.7); mean duration of abstinence: 4.8 (SD = 3.8) days</P>
<P>
<B>Exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence; 2. a concurrent major psychiatric disorder with psychosis and significant suicide risk; 3. a treatment with naltrexone or acamprosate within 3 months before randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-20 12:00:23 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 53)</LI>
<LI>1998 mg acamprosate (n = 55)</LI>
<LI>placebo (n = 61)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>brief intervention;<B> </B>compliance training<B> </B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 13:37:36 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>Return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;6 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:37:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 25.5% (n = 14); naltrexone: 32.1% (n = 17); placebo: 34.4% (n = 21); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 3.3% (n = 2); naltrexone: 3.8% (n = 2); placebo: 1.6% (n = 1); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-09-18 21:05:25 +0200" MODIFIED_BY="[Empty name]">
<P>National Health and Medical Research Council of Australia, University of Sydney Sesqui Fund</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:37:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 1, 2, 6, 12); daily monitoring cards; <B>assessment of side effects:</B> open-ended enquiry; <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes: </B>urine alcohol concentrations were examined in a randomly selected sample of 10% of the study population; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-29 18:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroups: 1. completed and compliant patients. Further publication used for data extraction: Richardson (2008); information on the study design was provided by the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:40:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Levine, J. and Schooler, N. (1986) SAFTEE: a technique for the&lt;br&gt;systematic assessment of side effects in clinical trials. Psychopharmacology&lt;br&gt;Bulletin 22, 343&amp;#8211;381.&lt;/p&gt;" NOTES_MODIFIED="2010-07-12 15:40:04 +0200" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Namkoong-2003">
<CHAR_METHODS MODIFIED="2010-07-12 15:39:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 8 weeks; <B>principle of analysis: :</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>12; <B>Country: </B>South Korea</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:39:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence:</B> not reported; <B>baseline characteristics:</B> 95.8% male; mean age: 44 (SD = 8.3) years; 76.1% married: 59.9% employed; <B>pre-baseline drinking:</B> 52.7 (SD = 32.7) drinking days; 18.0 (SD = 11.7) drinks per drinking occasion; 4.6 (SD = 6.0) previous admissions to alcoholism in-patient programmes; 42% had previous alcohol detoxifications; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 21.5 (SD = 8.4)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent major psychiatric disorder; 3. a concurrent use of psychotropic medications or disulfiram or a previous treatment with acamprosate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:39:40 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 72)</LI>
<LI>placebo (n = 70)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>brief psychotherapy; patients were encouraged to participate in AA groups or cognitive behavioral therapy; <B>dosing: </B>weight dependent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 09:25:23 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking </LI>
<LI>return to heavy drinking*</LI>
<LI>percent days abstinent</LI>
<LI>percent heavy drinking days</LI>
<LI>drinks per drinking occasion</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:39:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 26.4% (n = 19); placebo: 31.4% (n = 22); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 5.6% (n = 4); placebo: 14.3% (n = 10); group difference in lost to follow-up rates: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 09:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored by Whan-In Pharmaceutical (South Korea)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:40:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly for the first 4 weeks, afterwards biweekly); <B>assessment of side effects:</B> SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes:</B> breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-03-09 15:53:51 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:42:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niederhofer-2002">
<CHAR_METHODS MODIFIED="2010-07-12 15:41:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 6 months; <B>principle of analysis:</B> ITT (modified); <B>setting: </B>inpatient; <B>study sites: </B>1; <B>country: </B>Austria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:41:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence:</B> &#8805; 5 days; <B>baseline characteristics:</B> 65.4% male; mean age: 17.1 (SD = 1.1) years; <B>pre-baseline drinking: </B>no details provided</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>concurrent psychiatric disorders that might require specific drug treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-20 12:00:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg acamprosate (n = 13)</LI>
<LI>placebo (n = 13)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 09:37:53 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking </LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:41:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 46.2% (n = 6); placebo: 38.5% (n = 5); group difference in drop-out rates: not significant; group differences in reasons for drop-out: not significant; <B>lost to follow-up rates</B>: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 09:38:27 +0100" MODIFIED_BY="[Empty name]">
<P>Investigator-driven trial with non-profit funding</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:42:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>not reported; <B>assessment of side effects:</B> side effect checklist (44 items); <B>assessment of compliance:</B> self-report; <B>validation of patient-reported outcomes: </B>GGT, MCV (week 1, 2, 3, 4, 6, 8, 10, 12); <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 09:39:23 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatient programme; sample: alcohol dependent adolescents</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:44:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paille-1995">
<CHAR_METHODS MODIFIED="2010-07-12 15:43:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 months (treatment); 6 months (single-blind placebo); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>31; <B>country: </B>France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:44:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III-R); <B>required abstinence: </B>7 to 30 days; <B>baseline characteristics:</B> 80% male; mean age: 43.2 (SD = 8.6) years; 76% living with family; 68.2% employed; <B>pre-baseline drinking:</B> 200 grams alcohol per day; 9.5 (SD = 7.1) years of alcohol dependence; 73% had been drinking more than 10 SDU per day</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a<B> </B>concurrent major psychiatric disorders; 2. more than three attempted detoxifications in the last 2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:44:25 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1300 mg acamprosate (n = 188)</LI>
<LI>2000 mg acamprosate (n = 173)</LI>
<LI>placebo (n = 177)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>supportive psychotherapy; no further information provided; <B>permitted medication: </B>maprotiline, lorazepam and any symptomatic therapy which had been started more than 3 months prior to the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 09:56:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>Return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:44:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 51.5% (n = 186); placebo: 65.0% (n = 115); group difference in drop-out rates: significant; group difference in reasons for drop-out: significant (more patients in the placebo group took medication that was not permitted); <B>lost to follow-up rates</B>: acamprosate: 15.3% (n = 55); placebo: 15.8% (n = 28); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:01:57 +0100" MODIFIED_BY="[Empty name]">
<P>Investigator-driven trial with non-profit funding</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:44:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>retrospective quantity / frequency report (week 4, 8, 12, 16, 20, 24, 32, 40, 48, 56*, 64*, 72*); *post-treatment evaluation; <B>assessment of side effects: </B>not reported; <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes:</B> GGT; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>If a patient stopped taking the treatment for more than 30 days, the<BR/>protocol called for withdrawal from the trial</P>
<P>The post-treatment phase does not fulfil the criteria of inclusion and are thus not included in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:48:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelc-1992">
<CHAR_METHODS MODIFIED="2010-07-12 15:46:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 6 months; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 5; <B>country: </B>Belgium</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:48:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III); <B>required abstinence:</B> &#8804; 23 days; <B>baseline characteristics:</B> 70% male; mean age: 42.6 (SD = 8.4); <B>pre-baseline drinking: </B>no detailed information provided</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent mental psychiatric disorder; 2. a concurrent use of psychotropic medications and disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:48:18 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 55)</LI>
<LI>placebo (n = 47)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>supportive psychotherapy; no further information provided; <B>dosing:</B> weight dependent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:05:59 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>clinical global impression</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:48:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 52.7% (n = 29); placebo: 79% (n = 37); group difference in drop-out rates: significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 56.4% (n = 31); placebo: 78.7% (n = 37); group difference in lost to follow-up rates: significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:08:51 +0100" MODIFIED_BY="[Empty name]">
<P>Investigator-driven trial with non-profit funding</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:48:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> not reported (week 1, 2, 4, 12, 24); <B>assessment of side effects:</B> side effect check-list (45 items); <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:09:48 +0100" MODIFIED_BY="[Empty name]">
<P>In case of relapse &#8804; 3 days, patients were advised to continue treatment; in case of relapse &gt; 3 days, patients were admitted to in-patient detoxification</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:51:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelc-1997">
<CHAR_METHODS MODIFIED="2010-07-12 15:50:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>3 months; <B>principle of analysis: </B>ITT (modified); <B>setting:</B> outpatient; <B>study sites: </B>11; <B>country: </B>Belgium, France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:50:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III-R); <B>required abstinence: </B>14 days; <B>baseline characteristics</B> 85% male; mean age: 41.3 (SD = 25.7); years; 49.5% married; <B>pre-baseline drinking: </B>76.6% consumed more than 10 SDU a day; 100% had previous detoxifications</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent major psychiatric disorder; 2. prior treatment(s) with acamprosate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-21 09:34:26 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg acamprosate (n = 63)</LI>
<LI>1998 mg acamprosate (n = 63)</LI>
<LI>placebo (n = 62)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>supportive counselling and social support when needed; patients were encouraged to participate in AA groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:14:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cumulative abstinence duration (CAD)</LI>
<LI>time to first drink (survival curve)</LI>
<LI>return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:50:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 31.0% (n = 39); placebo: 48.4% (n = 30); group difference in drop-out rates: significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: acamprosate: 9.5% (n = 12); placebo: 24.2% (n =15); group difference in lost to follow-up rates: not reported, but appear significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Merck Lipha (Belgium) within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:51:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>diary cards; retrospective quantity / frequency report (week 1, 2, 4, 6, 8, 10, 12); <B>assessment of side effects:</B> spontaneous reports (week 1, 2, 4, 6, 8, 10, 12); <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes: </B>urine alcohol concentration; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:16:30 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:54:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poldrugo-1997">
<CHAR_METHODS MODIFIED="2010-07-12 15:53:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>6 months (treatment); 6 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites:</B> 5; <B>country:</B> Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:53:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III); <B>required abstinence</B>: &#8805; 5 days; <B>baseline characteristics:</B> 73% male; mean age: 43.9 (SD = 9.7) years; 58% married; <B>pre-baseline drinking: </B>86% consumed alcohol every day; 75% consumed more than 10 SDU per day; 10.9 (SD = 1) years of alcohol dependence; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 27.1 (SD = 7.5)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>concurrent major psychiatric disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:53:47 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 122)</LI>
<LI>placebo (n = 124)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>psychological support, group sessions, family therapy; patients were encouraged to participate in AA groups; <B>aim of therapy: </B>abstinence; <B>prohibited medication:</B> neuroleptics, barbiturates, meprobamate, valproic acid, carbamazepine, clonidine, benzodiazepines); the use of disulfiram was permitted; <B>dosing: </B>weight dependent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:18:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:54:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 46.7% (n = 57); placebo: 62.1% (n = 77); group difference in drop-out rates: significant; group difference in reasons for drop-out: not significant; <B>lost to follow-up rates</B>: acamprosate: 3.3% (n = 4); placebo: 4.0% (n = 5); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:20:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study has received grants and facilities by the manufacturer (Merck Lipha, Belgium), but the manufacturer had no role in the management, analyses, and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:54:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>retrospective quantity / frequency report (week 4, 12, 24, 36*, 48*); *post-treatment evaluation; <B>assessment of side effects: </B>not reported; <B>assessment of compliance: </B>not reported; <B>validation of patient-reported outcomes: </B>GGT (with a GGT of 1.3 times upper limit of laboratory normal as a threshold value for relapse); <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with a severe relapse during the study were admitted to a hospital for withdrawal treatment while continuing their medication and not considered as protocol violators. Only patients who needed inpatient treatment longer than 14 days were withdrawn from the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:56:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rousseaux-1996">
<CHAR_METHODS MODIFIED="2010-07-12 15:55:53 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>duration: </B>12 weeks (treatment); <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>Belgium</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:55:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (65%); alcohol abuse (35%); <B>baseline characteristics:</B> 70.1% male; mean age: 42.2 years; 32.3% married: 64% employed; <B>pre-baseline drinking:</B> not reported</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>a concurrent use of psychotropic medications and disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:56:08 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 63)</LI>
<LI>placebo (n = 64)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>group therapy, individual therapy; <B>dosing: </B>weight dependent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:22:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>drinks per day</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-19 16:47:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>acamprosate: 28.6% (n = 18); placebo: 26.6% (n = 17); group difference in drop-out rates: not reported; group difference in reasons for drop-out: not reported</P>
<P>
<B>Lost to follow-up rates</B>: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsored and organized by Merck Lipha within the scope of a new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:56:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>not reported; <B>assessment of side effects:</B> not reported; <B>assessment of compliance:</B> not reported; <B>validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-07-10 17:16:00 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 15:59:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sass-1996">
<CHAR_METHODS MODIFIED="2010-07-12 15:58:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 months (treatment); 12 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>12; <B>country:</B> Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 15:58:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III-R); <B>required abstinence: </B>14 to 28 days; <B>baseline characteristics:</B> 77.6% male; mean age: 41.2 (SD = 0.7) years; 46% married; <B>pre-baseline drinking: </B>78% consumed more than 10 SDU a day; 73.1% had previous treatments or detoxifications for alcoholism</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>1. a concurrent drug abuse or dependence 2. a concurrent psychiatric impairment that would require treatment during the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 15:58:28 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998* mg acamprosate (n = 136)</LI>
<LI>placebo (n = 136)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>centre specific;<B> </B>mostly supportive or individual therapy; <B>dosing: </B>1. weight dependent; 2. flexible: dose reductions to 1332 mg/day in case of side effects; <B>prohibited medication:</B> antidepressants, neuroleptics, benzodiazepines, barbiturates, disulfiram, clomethiazole for more than three days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:34:25 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>relapse duration</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 15:58:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 41.9% (n = 57); placebo: 59.6% (n = 81); group difference in drop-out rates: significant; group difference in reasons for drop-out: significant (unwillingness to continue treatment; acamprosate: 14.7%; placebo: 33.1%); <B>lost to follow-up rates</B>: acamprosate: 19.1% (n = 26); placebo: 20.6% (n = 28); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-11-05 09:21:21 +0100" MODIFIED_BY="[Empty name]">
<P>Merck Lipha (Germany); sponsored, organized and conducted within the scope of new drug application processes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 15:59:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>diary cards; retrospective quantity / frequency report (week 4, 8, 12, 24, 36, 48, 96*); *post-treatment evaluation; <B>assessment of side effects: </B>not reported; <B>assessment of compliance:</B> pill count; <B>validation of patient-reported outcomes: </B>GGT, collateral information, breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:37:59 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 16:02:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tempesta-2000">
<CHAR_METHODS MODIFIED="2010-07-12 16:01:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>6 months (treatment); 3 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting:</B> outpatient; <B>study sites: </B>18; <B>country: </B>Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 16:01:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III-R); <B>required abstinence: </B>&#8805; 5 days; <B>baseline characteristics:</B> 82.7% male; mean age: 45.9 (SD=11.2) years; 68.2% married; <B>pre-baseline drinking: </B>85.2% consumed alcohol every day; 53.0% consumed more than 10 SDU a day; 11.5 (SD = 16.4) years of alcohol dependence; 90% had previous treatment for alcohol dependence; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 22.7 (SD = 10.6)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>concurrent major psychiatric disorders that would have required treatment during the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-12 11:46:00 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>1998 mg acamprosate (n = 164)</LI>
<LI>placebo ( n= 166)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>individual behavior-oriented supportive counselling; patients were encouraged to participate in AA groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:39:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>relapse severity</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase</LI>
<LI>alanine aminotransferase</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 16:01:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 24.4% (n = 40); placebo: 26.5% (n = 44); group difference in drop-out rates: not significant; group difference in reasons for drop-out: yes (a higher portion of patients in the placebo group (9.6%) refused to continue than in the acamprosate group (5.5%); <B>lost to follow-up rates</B>: acamprosate: 9.8% (n = 16); placebo: 9% (n = 15); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>Study has received grants and facilities by the manufacturer (Merck Lipha, France), but the manufacturer had no role in the management, analyses, and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 16:02:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>drinking diary (week 4, 8, 12, 16, 20, 24, 30*, 36*); *post-treatment evaluation; <B>assessment of side effects:</B> 1. spontaneous reporting; 2. side effect checklist; <B>assessment of compliance: </B>pill count; <B>validation of patient-reported outcomes:</B> collateral reports; urine was sampled for serum levels of carbohydrate-deficient transferrin (CDT), but it is not reported if the measures were used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:52:25 +0100" MODIFIED_BY="[Empty name]">
<P>Rates of any drinking were extracted from the manufacturer report</P>
<P>Patients with a severe relapse during the study were admitted to a hospital for withdrawal treatment while continuing their medication and not considered as protocol violators. Only patients who needed inpatient treatment longer than 14 days were withdrawn from the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-12 16:04:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitworth-1996">
<CHAR_METHODS MODIFIED="2010-07-12 16:03:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 months (treatment); 12 months (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting: </B>outpatient; <B>study sites: </B>5; <B>country: </B>Austria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-12 16:03:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III); <B>required abstinence:</B> &#8805; 5 days; <B>baseline characteristics:</B> 79% male; mean age: 42.0 (SD = 8.5) years; <B>pre-baseline drinking: </B>62.7% consumed more than 10 SDU (or 121 grams alcohol) per day; MAST score (<LINK REF="REF-Selzer-1971" TYPE="REFERENCE">Selzer 1971</LINK>): 32.6 (SD = 8.8)</P>
<P>
<B>Exclusionary of psychiatric conditions: </B>a<B> </B>concurrent major psychiatric disorders that would require treatment during the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-20 12:01:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>1332 mg/ 1998 mg acamprosate (n = 224)</LI>
<LI>placebo (n = 224)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>standardized between centres; not further information provided</P>
<P>
<B>Dosing: </B>weight dependent</P>
<P>
<B>Prohibited medication:</B> drugs that act on the central nervous system were prohibited during the trial with the exception of thioridazine and dibenzepine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-21 10:43:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking </LI>
<LI>patients who remain abstinent between study visits</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-12 16:03:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: acamprosate: 57.6% (n = 129); placebo: 62.1% (n = 139); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not significant; <B>lost to follow-up rates</B>: acamprosate: 14.7% (n = 33); placebo: 16.1% (n = 36); group difference in lost to follow-up rates: not significant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-12-21 10:44:31 +0100" MODIFIED_BY="[Empty name]">
<P>Study has received grants and facilities by the manufacturer (Merck Lipha), but the manufacturer had no role in the management, analyses, and interpretation of data</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-12 16:04:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> diary cards; retrospective quantity / frequency report (week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96); *post-treatment evaluation; <B>assessment of side effects: </B>side effect checklist (44 items); <B>assessment of compliance: </B>not reported; <B>validation of patient-reported outcomes: </B>GGT, MCV; <B>laboratory assessment of drop-outs: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-21 10:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with a severe relapse during the study were admitted to a hospital for withdrawal treatment while continuing their medication and not considered as protocol violators; only patients who needed inpatient treatment longer than 15 days were withdrawn from the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-07-12 11:46:12 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:05:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boeijinga-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 15 days (effects on alcohol withdrawal)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-10 11:25:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buri-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-10 11:25:33 +0200" MODIFIED_BY="[Empty name]">
<P>open trial; non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:06:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Croissant-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:06:42 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:06:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Sousa-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:06:44 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-12 11:46:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Wildt-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-12 11:46:04 +0200" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (acamprosate alone versus acamprosate + minimal intervention versus acamprosate + brief cognitive behavioral therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-12 11:46:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feeney-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-12 11:46:12 +0200" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (acamprosate + cognitive behavioral therapy versus + cognitive behavioral therapy alone)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Florez-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fuchs-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:19:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerra-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:19:31 +0100" MODIFIED_BY="[Empty name]">
<P>cross-over trial, with no data from the first study period available   </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:10:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hammarberg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (acamprosate + minimum intervention versus acamprosate + extended intervention)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:09:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (acamprosate versus no treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:10:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 23 days (pharmacokinetic / pharmacodynamic study) </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kampman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:11:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiritze_x002d_Topor-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:11:37 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:11:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laaksonen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:11:39 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-29 18:13:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mason-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-29 18:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>sample: healthy patients (pharmacokinetic study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:07:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nespor-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:12:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ooteman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 21 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:12:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelc-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:09:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reid-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:09:27 +0100" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group ( acamprosate + medical care + compliance therapy versus acamprosate + medical care)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:12:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubio-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:12:57 +0100" MODIFIED_BY="[Empty name]">
<P>single-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:13:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rychlik-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:13:10 +0100" MODIFIED_BY="[Empty name]">
<P>open trial; non-randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:13:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soyka-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:13:22 +0100" MODIFIED_BY="[Empty name]">
<P>open trial; non-randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 10:13:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 10:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 15 days (laboratory study) </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-12-21 10:46:56 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Principal investigator" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Collaborators" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Sponsors">
<ONGOING_CHAR MODIFIED="2008-12-05 13:42:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaebel">
<CHAR_STUDY_NAME MODIFIED="2008-12-05 13:41:50 +0100" MODIFIED_BY="[Empty name]">
<P>Integrative Therapy in Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-05 13:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:37:26 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:11:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Abstinence</LI>
<LI>Social functioning</LI>
<LI>Cognitive functioning</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 13:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>May 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 13:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 13:12:37 +0100" MODIFIED_BY="[Empty name]">
<P>Wolfgang Gaebel, Professor  Department of Psychiatry and Psychotherapy, University of Düsseldorf      </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 13:42:59 +0100" MODIFIED_BY="[Empty name]">
<P>German Federal Ministry of Education and Research<BR/>German Addiction Research Network<BR/>Merck Santé<BR/>University Hospital, Bonn<BR/>Univeristat Duisburg-Essen<BR/>University of Homburg<BR/>Psychosomatic Clinic of Bergisch Gladbach</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-05 13:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>Heinrich-Heine University, Duesseldorf</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-05 18:55:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garbutt">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 09:56:05 +0100" MODIFIED_BY="[Empty name]">
<P>Study of Acamprosate for Alcohol Dependence in a Family Medicine Clinic</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:37:38 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with abstinence motivation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:00:54 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Percent days abstinent </LI>
<LI>Adherence to medicine</LI>
<LI>Drop-out/loss to follow-up rate</LI>
<LI>Percent days complete abstinent</LI>
<LI>Percent heavy drinking days</LI>
<LI>Clinical Global Impression</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 09:56:35 +0100" MODIFIED_BY="[Empty name]">
<P>August 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-05 18:55:53 +0100" MODIFIED_BY="[Empty name]">
<P>Amy Ford, MA      <A HREF="mailto:aford%40med.unc.edu">aford@med.unc.edu</A>    </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 09:56:35 +0100" MODIFIED_BY="[Empty name]">
<P>JC Garbutt, MD, University of North Carolina, Chapel Hill    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 18:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>--- </P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 09:56:35 +0100" MODIFIED_BY="[Empty name]">
<P>University of North Carolina</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-11-13 09:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate in a family medicine setting </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-12-21 10:46:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haber">
<CHAR_STUDY_NAME MODIFIED="2008-12-05 20:05:10 +0100" MODIFIED_BY="[Empty name]">
<P>Trial for the Treatment of Alcohol Dependence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-05 20:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-05 20:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-05 20:08:56 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate vs. naltrexone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-05 20:08:16 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time (days) to relapse</LI>
<LI>Time (days) to lapse</LI>
<LI>Days abstinence</LI>
<LI>Drinks per drinking day</LI>
<LI>Biochemical measures of liver function </LI>
<LI>Craving</LI>
<LI>Depression</LI>
<LI>Anxiety</LI>
<LI>Stress</LI>
<LI>Global physical health</LI>
<LI>Global mental health</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-05 20:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>March 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-05 20:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2009-12-21 10:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>Paul Haber, Conjoint Associate Professor, University of Sydney </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 20:11:08 +0100" MODIFIED_BY="[Empty name]">
<P>National Health and Medical Research Council, Australia<BR/>Sydney South West Area Health Service<BR/>South Eastern Area Health Service<BR/>Wentworth Area Health Services</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-05 20:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>University of Sydney</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-05 20:14:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mann">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 13:28:30 +0100" MODIFIED_BY="[Empty name]">
<P>Individually Adapted Therapy of Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with abstinent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate, naltrexone, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:37:58 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to relapse to heavy drinking</LI>
<LI>percentage of days without heavy drinking</LI>
<LI>time to first alcohol consumption</LI>
<LI>percentage of days of complete abstinence from alcohol</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 13:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>November 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 13:35:41 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 13:36:44 +0100" MODIFIED_BY="[Empty name]">
<P>Karl F. Mann, MD, Central Institute of Mental Health, Mannheim, Germany    </P>
<P>Michael N. Smolka, MD, Central Insitute of Mental Health, Mannheim, Germany  </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 20:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>BMBF Federal Ministry of Education and Research<BR/>Merck<BR/>Dupont Pharmaceuticals</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-05 20:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Central Institute of Mental Health, Mannheim</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-11-13 13:29:37 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-05 19:54:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrakis">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 11:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:38:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:38:08 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with a diagnosis of schizophrenia, schizoaffective or psychotic disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprsate vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-05 19:53:47 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking</LI>
<LI>Craving</LI>
<LI>Psychotic symptoms</LI>
<LI>Cognitive functioning </LI>
<LI>Psychiatric distress</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 11:16:43 +0100" MODIFIED_BY="[Empty name]">
<P>September 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 11:18:24 +0100" MODIFIED_BY="[Empty name]">
<P>Elizabeth Ralevski, Ph.D. <A HREF="mailto:elizabeth.ralevski%40yale.edu">elizabeth.ralevski@yale.edu</A>   </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 11:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Ismene L Petrakis, MD     Yale University    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 19:54:24 +0100" MODIFIED_BY="[Empty name]">
<P>Forest Laboratories</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 11:18:34 +0100" MODIFIED_BY="[Empty name]">
<P>Yale University</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-12-20 11:46:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 10:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate Initiated During Alcohol Detoxification</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:38:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, crossover assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:38:20 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-20 11:46:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Days abstinent</LI>
<LI>Days heavy drinking</LI>
<LI>Adverse events</LI>
<LI>Treatment discontinuation</LI>
<LI>Total amount of oxazepam</LI>
<LI>Change in CIWA scores</LI>
<LI>Number of adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 11:08:18 +0100" MODIFIED_BY="[Empty name]">
<P>October 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 11:10:23 +0100" MODIFIED_BY="[Empty name]">
<P> ---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 11:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Helen Pettinati, Ph.D.       University of Pennsylvania    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 19:15:04 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 11:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Forest Laboratories</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-05 19:04:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sonne">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 10:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate in Alcoholics With Comorbid Anxiety or Depression</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with a concurrent diagnosis of a mood disorders, a social anxiety or a generalized anxiety disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:01:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total days abstinent from alcohol</LI>
<LI>Psychiatric assessments including MADRS,HAM-A, Liebowitz Social Anxiety Scale, and Hospital Anxiety and Depression Scale</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 10:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>April 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 10:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Susan C Sonne, PharmD, BCPP  sonnesc@musc.edu      </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-05 19:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>Susan C Sonne, PharmD, BCPP, Medical University of South Carolina  </P>
<P>Jennifer S Potter, PhD, Mclean Hospital        </P>
<P>Richard Rosenthal, MD, Columbia University College of Physicians &amp; Surgeons </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 19:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>Mclean Hospital<BR/>Columbia University</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 10:19:50 +0100" MODIFIED_BY="[Empty name]">
<P>Medical University of South Carolina</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-05 19:57:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Witte">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 13:15:17 +0100" MODIFIED_BY="[Empty name]">
<P>Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled study (randomization unclear)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:39:40 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with alcohol abuse or dependence and major depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>Escitalopram plus acamprosate vs. escitalopram plus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:23:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reduction in alcohol use</LI>
<LI>Reduction in depression score</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 13:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>March 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 13:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>Janet M. Witte, MD, MPH <A HREF="mailto:jwitte%40partners.org">jwitte@partners.org</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 13:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>Janet M Witte, MD Massachusetts General Hospital </P>
<P>Nicholas Bolo, PhD Mclean Hospital    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-05 19:57:52 +0100" MODIFIED_BY="[Empty name]">
<P>Mclean Hospital<BR/>National Alliance for Research on Schizophrenia and Depression</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 13:26:12 +0100" MODIFIED_BY="[Empty name]">
<P>Massachusetts General Hospital</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-07-12 16:07:27 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-24 09:00:15 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 09:00:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Participants are randomly assigned to treatment by a stratified random block design controlling for clinical centres; the randomization was implemented via a central telephone based interactive voice response system at a coordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:22:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:23:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>Randomized; no detailed information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 15:29:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>Balanced randomization between placebo and acamprosate, stratified for the voluntary intake of disulfiram; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>Randomized; no detailed information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 16:52:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>Randomization in blocks of eight; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:21:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>Balanced randomisation in groups of 4 + 4; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:40:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:21:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:43:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>Randomized; no detailed information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:44:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>Randomized; no detailed information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:46:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>Randomized; no detailed information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:48:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>Randomized; no detailed information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:22:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:23:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:23:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 19:49:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>Randomized; predetermined lists; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 19:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>Randomized; no further information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 19:53:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>Randomized; no further information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 10:47:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>Randomized; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>Randomized; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 10:49:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>Randomization with balance of blocks was used to obtain equal numbers of treatment groups; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 10:50:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>Randomization with balance of blocks was used to obtain equal numbers of treatment groups; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:16:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-06-10 11:25:16 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 19:28:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Randomization was performed at the coordinating centre; no further information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:37:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:37:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 14:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>No information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:38:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-12 10:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 13:41:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Randomization was centralized; allocation codes were provided in sealed envelopes for each patient at the pharmacy of the university hospital, where formulation and blinding was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:37:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:38:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:22:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>Identical blister-cards of double-blind medication were centrally prepared and labelled by study number; randomisation numbers were centrally prepared for each site in blocks of 7 and used to randomly assign participants to treatment groups; information on randomisation was provided in sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:22:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>The randomisation was conducted by an independent support unit; prior to the start of the trial all medication packages were collated and packaged by a member of staff not involved in the study; each sealed envelope contained the medication had a subject code, which corresponded to the allocation that was kept in a spreadsheet held by a member of staff not involved in the study; the naltrexone and naltrexone placebo were packaged similarly as were the acamprosate and acamprosate placebo (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:23:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>Patients were randomised by the principal investigator; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-02 19:49:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>Allocation codes were provided in sealed envelopes; no further information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:37:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:39:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-12 10:11:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:25:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>Information on randomisation was provided in sealed envelopes; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-10 11:25:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>Sealed envelope randomisation; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-12 10:17:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>Allocation codes were provided in sealed envelopes for each patient; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-07-12 16:04:13 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 14:38:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients, investigators, research staff, evaluators, health care practitioners and therapists; p<B>lacebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day); acamprosate and acamprosate placebo differed in appearance from naltrexone and naltrexone placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 14:53:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 14:57:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:01:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:04:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information available; <B>placebo appearance: </B>no information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:10:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind: no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:14:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:17:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:24:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day)</P>
<P>The integrity of the double-blind procedure was confirmed by obtaining a prediction from each patient at the end of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:27:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no detailed information provided; <B>placebo appearance: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:30:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>not reported; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:33:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:35:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind,<B> </B>including<B> </B>patients and research staff; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:37:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind including<B> </B>patients, researchers, therapists; <B>placebo appearance: </B>an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:40:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and investigators; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:42:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>not reported; <B>placebo appearance: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:45:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:48:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no further information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:51:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no further information provided; <B>placebo appearance</B>: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:54:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no further information provided; <B>placebo appearance:</B> identical appearance and taste to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 15:56:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research staff; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-03 10:49:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no further information provided</P>
<P>
<B>Placebo appearance</B>: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 16:02:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no further information provided; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-12 16:04:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no further information provided; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-07-12 16:07:27 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>continuous outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>binary outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 14:35:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 14:36:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data (CAD): </B>for the calculation of abstinent days, patients lost to follow-up were assumed to have relapsed to heavy drinking on the day after their last contact</P>
<P>
<B>Handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 14:53:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the analyses (= treatment-received analysis); <B>handling of missing data: </B>lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 14:53:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the analyses (= treatment-received analysis); <B>handling of missing data (CAD, GGT): </B>outcomes not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 14:57:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 14:58:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT):</B> outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:01:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 8; no group specific values provided) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> unless for reasons clearly unrelated to study treatment (intercurrent illness and protocol violation unrelated to treatment), all patients who discontinued the treatment before study completion were considered as non-abstinent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:02:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 8; no group specific values provided) were excluded from the primary analysis (=treatment-received analysis); <B>handling of missing data (CAD):</B> unless for reasons clearly unrelated to study treatment (intercurrent illness and protocol violation unrelated to treatment), the complete intervals of missing participants were coded as a non-abstinent periods; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:04:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> no information available; <B>handling of missing data: </B>no information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:04:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> no information available; <B>handling of missing data: </B>no information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:10:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:11:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD): </B>not reported; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:14:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:14:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT):</B> outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:17:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:18:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:24:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:24:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data (CAD, GGT): </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:27:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:27:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit, the complete interval was excluded for the calculation of cumulative abstinence; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:30:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> completer analysis, patients who did not have at least one outcome criteria available (acamprosate: n = 9; placebo: n = 6) were excluded in the primary analysis, but subsequently added to the meta-analyses of binary outcomes as treatment failures; <B>handling of lost to follow-ups: </B>individuals lost to follow-up were ere excluded from the analysis, but were subsequently categorized as relapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:30:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> completer analysis; <B>handling of missing data (CAD):</B> outcome not considered in the study; <B>handling of lost to follow-ups (GGT): </B>individuals lost to follow-up were excluded from the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:33:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:33:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data (CAD):</B> outcome not considered in the study; <B>handling of missing data (GGT):</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 16:07:27 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT - modified; patients who did not have at least one outcome criteria available (acamprosate: n = 6; placebo: n = 3) were excluded, but subsequently considered in the meta-analysis; <B>handling of missing data: </B>lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:35:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT - modified; patients who did not have at least one outcome criteria available (acamprosate: n = 6; placebo: n = 3) were excluded in the primary analysis, but subsequently added to the meta-analyses of binary outcomes as treatment failures; <B>handling of missing data (CAD): </B>if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of <I>drinking</I> <I>days; </I>if the early discontinuation was verified as not associated with alcohol use, the time was excluded (the denominator in such cases was the actual time on study); <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:37:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of lost to follow-up data: </B>patients lost to follow-up<B> </B>were assumed to have relapsed from the last date of contact<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:37:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of lost to follow-up data (CAD): </B>for the calculations of <I>drinking days</I>,<B> </B>individuals<B> </B>lost to follow-up<B> </B>were assumed to have relapsed from the last date of contact (drinking days); <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:40:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:40:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD, GGT): </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:42:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 7) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:42:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 7) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:45:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:45:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD): </B>if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>not reported<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:49:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:49:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT):</B> outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:51:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:52:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT):</B> outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:54:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:55:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT):</B> outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:56:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 15:56:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data (CAD): </B>outcome not considered<B> </B>in the study; <B>handling of missing data (GGT):</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 15:59:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 16:00:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 16:02:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 16:02:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-12 16:04:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 7) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> lost to follow-ups have been categorized as re lapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-12 16:04:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 7) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data (CAD):</B> if a patient was absent from the visit or reported any alcohol use during a given study period, the complete interval was coded as a non-abstinent period for the calculation of cumulative abstinence duration; <B>handling of missing data (GGT): </B>outcome not considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-07-08 13:46:30 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:37:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> a study protocol is available and the primary outcomes listed in the protocol are reported adequately in the study publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:40:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:41:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section were adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:41:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 19:14:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:42:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:42:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:42:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:42:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:43:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:43:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:43:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:43:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:44:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:44:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:44:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:44:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:45:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:45:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:45:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:45:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:45:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> the publication provides all outcomes specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:46:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> the publication provides all outcomes specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 13:46:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> the publication provides all outcomes specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-07-12 16:05:05 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 14:54:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>67 pretreatment characteristics were compared across groups and no evidence for baseline imbalance was found; socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates</B> (% of prescribed medication taken): acamprosate: 84.2%; naltrexone: 85.4%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 14:54:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2003">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rate: </B>not reported; group difference in compliance rates: <I>not reported </I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 14:58:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barrias-1997">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes (with a trend for more participants in the naltrexone group being unemployed than in the placebo group); drinking frequency and intensity: yes<I>;</I> drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rate</B>: acamprosate: 94.4%; placebo: 92.8%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:02:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besson-1998">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes (with a trend for more participants in the naltrexone group being unemployed than in the placebo group); drinking frequency and intensity: yes<I>;</I> drinking history or treatment history: no*</P>
<P>* baseline differences were found for previous psychotherapy, with more patients in the acamprosate having psychotherapy experience than in the placebo group; as no further indicators of treatment history indicated significant group differences, the difference was not considered as being of clinical relevance</P>
<P>
<B>2. Treatment exposure: compliance rate</B>: not reported; group difference in compliance rates: not sognificant, with exception of the last study visit, when compliance in the placebo group was significantly lower than in the acamprosate group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 12:23:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-2003">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:11:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes*</P>
<P>* significant baseline differences between groups (prior drinking, place of detoxification) were considered as covariates in the statistical analyses and were shown not have a significant influence on treatment effects</P>
<P>
<B>2. Treatment exposure: compliance rates</B> (patients who took at least 90% of their medication): acamprosate: 27%; placebo: 28%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:15:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geerlings-1997">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: no*</P>
<P>* patients in the acamprosate group had a significantly longer alcohol-free period after previous detoxifications than in the placebo group</P>
<P>
<B>2. Treatment exposure: compliance rates </B>(% of medication taken): acamprosate: 86%; placebo: 88%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:18:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gual-2001">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates</B> (% of medication taken): acamprosate: 91.5%; placebo: 91.4%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:24:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes (besides gender); drinking frequency: <I>not reported;</I> drinking intensity: <I>no*;</I> drinking history or treatment history: <I>no*</I>
</P>
<P>* baseline differences between groups (amount of alcohol consumed per day, history of drinking problems, GGT) were considered as covariates in the MANCOVA and were shown not have a significant influence on the treatment effects</P>
<P>
<B>2. Treatment exposure: compliance rates </B>(% of prescribed medication taken): 81.1%; no group specific values provided; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:27:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ladewig-1993">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes (besides gender); drinking frequency: <I>not reported;</I> drinking intensity: yes; drinking history or treatment history: <I>no*</I>
</P>
<P>* patients in the acamprosate group had more previous treatments than patients in placebo group; the difference was not reported to be controlled in the statistical analyses of treatment effects</P>
<P>
<B>2. Treatment exposure: compliance rates: </B>acamprosate: 84.8%; placebo: 92.2%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:31:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lhuintre-1985">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates:</B> not reported;group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:33:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lhuintre-1990">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence</B>: socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure</B>:<B> compliance rates: </B>not reported; group difference in compliance rates: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:35:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-2006">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes*</P>
<P>* there was a non-significant trend for the lower dose acamprosate group for higher alcoholism severity than in other groups</P>
<P>
<B>2. Treatment exposure: compliance rates </B>(% 80% of the prescribed medication taken): acamprosate: 88.9%; placebo: 92.6%;group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:38:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes (except age*); drinking frequency and intensity: no*; drinking history or treatment history: yes</P>
<P>* baseline imbalance was found for age and consecutive abstinent days before treatment and considered as covariate in the statistical analyses</P>
<P>
<B>2. Treatment exposure: compliance rates </B>(patients who took at least 80% of the prescribed medication): 79.7% (of study completers); no group specific values provided; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:40:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Namkoong-2003">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rate </B>(% of tablets taken): acamprosate: 80.5%; placebo: 74.3%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:43:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niederhofer-2002">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rate: </B>not reported; group difference in compliance rates: <I>not reported </I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:45:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paille-1995">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: </B>compliance rates (% of pills taken): acamprosate: 50.9%; placebo: 35.6%; group difference in compliance rates: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:49:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1992">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported; </I>drinking history or treatment history:<I> not reported </I>
</P>
<P>
<B>2. Treatment exposure:</B> compliance rates: not reported; group difference in compliance rates: <I>not reported </I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:52:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelc-1997">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>no significant differences between groups were present at baseline; no further information provided</P>
<P>
<B>2. Treatment exposure: compliance rates</B> (% of tablets taken): 95%; no group specific values provided; group difference in compliance rates: <I>not reported </I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:55:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poldrugo-1997">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates: </B>not reported; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 15:57:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rousseaux-1996">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported</I>; drinking history or treatment history: <I>not reported</I>
</P>
<P>
<B>2. Treatment exposure: compliance rate: </B>not reported; group difference in compliance rates: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 16:00:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sass-1996">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rate</B> (patients who took at least 80% of the prescribed medication): acamprosate: 97%; placebo: 94%; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 16:02:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tempesta-2000">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates </B>(regular intake of study medication): 76.9 - 84.5% (no group specific values provided); group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-12 16:05:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitworth-1996">
<DESCRIPTION>
<P>
<B>1. Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>
<B>2. Treatment exposure: compliance rates:</B> not reported; group difference in compliance rates: not significant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-01-30 11:26:27 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-12-21 09:40:07 +0100" MODIFIED_BY="Laura Amato">
<COMPARISON ID="CMP-001" MODIFIED="2010-12-21 09:40:07 +0100" MODIFIED_BY="Laura Amato" NO="1">
<NAME>Acamprosate versus placebo</NAME>
<DICH_OUTCOME CHI2="110.11472712094125" CI_END="0.9123468791755274" CI_START="0.8128121573418008" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8611426334276567" ESTIMABLE="YES" EVENTS_1="2416" EVENTS_2="2447" I2="79.11269400437362" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.03984000918292748" LOG_CI_START="-0.09000980921004197" LOG_EFFECT_SIZE="-0.06492490919648475" METHOD="MH" MODIFIED="2010-11-23 11:22:31 +0100" MODIFIED_BY="Laura Amato" NO="1" P_CHI2="2.405853294362714E-13" P_Q="0.0" P_Z="3.9202062976244516E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012384687889882194" TOTALS="YES" TOTAL_1="3233" TOTAL_2="2939" WEIGHT="99.99999999999997" Z="5.0727921441134045">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.056879765686625" CI_START="0.908067929859167" EFFECT_SIZE="0.9796522959382552" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="254" LOG_CI_END="0.024025583268712094" LOG_CI_START="-0.04188166198607007" LOG_EFFECT_SIZE="-0.008928039358679023" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.03871424210878468" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0014987925420575968" WEIGHT="6.255493706141648"/>
<DICH_DATA CI_END="1.0130208111642" CI_START="0.385604121549171" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.005618367453996923" LOG_CI_START="-0.4138583327658465" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.24640269015229055" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.06071428571428571" WEIGHT="1.188088151984507"/>
<DICH_DATA CI_END="0.945603862138756" CI_START="0.7123227766253974" EFFECT_SIZE="0.8207162534435262" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="121" LOG_CI_END="-0.02429076266615661" LOG_CI_START="-0.14732316880357127" LOG_EFFECT_SIZE="-0.08580696573486392" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.07226984438534992" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" VAR="0.005222930407482694" WEIGHT="4.932411811445138"/>
<DICH_DATA CI_END="0.9317396468520065" CI_START="0.6672159972300499" EFFECT_SIZE="0.7884615384615384" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" LOG_CI_END="-0.030705424267736377" LOG_CI_START="-0.175733549562391" LOG_EFFECT_SIZE="-0.10321948691506368" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.0851902386988785" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="0.007257376769571895" WEIGHT="4.421532357574159"/>
<DICH_DATA CI_END="2.751430751085456" CI_START="0.36344727178959313" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.43955858681829196" LOG_CI_START="-0.4395585868182919" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Borg-2003" TOTAL_1="5" TOTAL_2="5" VAR="0.2666666666666666" WEIGHT="0.31122595552117505"/>
<DICH_DATA CI_END="1.0467844105660349" CI_START="0.9307509935301755" EFFECT_SIZE="0.9870641469257386" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="260" LOG_CI_END="0.01985724620364623" LOG_CI_START="-0.031166491521665157" LOG_EFFECT_SIZE="-0.005654622659009467" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.02997159611142309" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="8.982965734662717E-4" WEIGHT="6.538291503763971"/>
<DICH_DATA CI_END="0.9866432382495657" CI_START="0.8048838666190908" EFFECT_SIZE="0.8911415289256198" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="121" LOG_CI_END="-0.00583985611315904" LOG_CI_START="-0.0942667776755182" LOG_EFFECT_SIZE="-0.050053316894338624" MODIFIED="2010-02-02 12:42:45 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.05194241144605096" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.0026980141068308457" WEIGHT="5.758121089992152"/>
<DICH_DATA CI_END="1.026140351842458" CI_START="0.7545922437568355" EFFECT_SIZE="0.8799531524497365" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="109" LOG_CI_END="0.01120676609936106" LOG_CI_START="-0.12228766310390542" LOG_EFFECT_SIZE="-0.05554044850227217" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.07841528852208064" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="0.006148957474001152" WEIGHT="4.68596559156039"/>
<DICH_DATA CI_END="0.9898281663574834" CI_START="0.6641699976541734" EFFECT_SIZE="0.8108108108108109" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="-0.004440192149851486" LOG_CI_START="-0.1777207465448136" LOG_EFFECT_SIZE="-0.09108046934733253" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.10178585540417863" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.010360360360360359" WEIGHT="3.8183266751440703"/>
<DICH_DATA CI_END="1.0717706234275655" CI_START="0.5253151635046895" EFFECT_SIZE="0.7503448275862069" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.030101849126561553" LOG_CI_START="-0.2795800628721891" LOG_EFFECT_SIZE="-0.12473910687281378" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.18190868805825366" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.033090770791075044" WEIGHT="1.9097778665772436"/>
<DICH_DATA CI_END="1.0239873192349025" CI_START="0.5155439869712267" EFFECT_SIZE="0.7265745007680492" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="31" LOG_CI_END="0.010294578494882533" LOG_CI_START="-0.28773427415564323" LOG_EFFECT_SIZE="-0.13871984783038036" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.17506362331353223" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="42" TOTAL_2="43" VAR="0.030647272207662307" WEIGHT="2.018221439703739"/>
<DICH_DATA CI_END="0.9637887882514153" CI_START="0.8135611523108403" EFFECT_SIZE="0.8854948430985298" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="245" LOG_CI_END="-0.01601813015025378" LOG_CI_START="-0.08960979722866853" LOG_EFFECT_SIZE="-0.05281396368946116" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.043228109526487986" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="291" VAR="0.0018686694532340413" WEIGHT="6.093162640259209"/>
<DICH_DATA CI_END="1.0856011587689278" CI_START="1.000213803463549" EFFECT_SIZE="1.0420332355816226" ESTIMABLE="YES" EVENTS_1="328" EVENTS_2="240" LOG_CI_END="0.035670298217158336" LOG_CI_START="9.284373962823689E-5" LOG_EFFECT_SIZE="0.017881570978393286" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.020898372871341074" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="4.3674198866960456E-4" WEIGHT="6.773661384415707"/>
<DICH_DATA CI_END="1.1649399043442055" CI_START="0.8177039832249937" EFFECT_SIZE="0.976" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="50" LOG_CI_END="0.0663035220273809" LOG_CI_START="-0.08740388669399729" LOG_EFFECT_SIZE="-0.010550182333308195" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.09028849274688178" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.008152011922503723" WEIGHT="4.228918241720662"/>
<DICH_DATA CI_END="1.1576380046280659" CI_START="0.7176304596787051" EFFECT_SIZE="0.9114583333333334" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="48" LOG_CI_END="0.06357277599740507" LOG_CI_START="-0.14409913603191538" LOG_EFFECT_SIZE="-0.04026318001725515" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.12198750911856665" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.014880952380952382" WEIGHT="3.1852552736214093"/>
<DICH_DATA CI_END="1.0254293219736905" CI_START="0.2901425332604818" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.010905731857356866" LOG_CI_START="-0.5373886014065197" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.3220708054599232" STUDY_ID="STD-Niederhofer-2002" TOTAL_1="13" TOTAL_2="13" VAR="0.10372960372960371" WEIGHT="0.7479529285330933"/>
<DICH_DATA CI_END="0.9580422762523515" CI_START="0.8367396782221287" EFFECT_SIZE="0.895339034084066" ESTIMABLE="YES" EVENTS_1="294" EVENTS_2="161" LOG_CI_END="-0.01861532605923689" LOG_CI_START="-0.07740963626785052" LOG_EFFECT_SIZE="-0.04801248116354371" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.03453606885306898" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="0.0011927400518239213" WEIGHT="6.396500488473734"/>
<DICH_DATA CI_END="0.9349406367664539" CI_START="0.6803930260990964" EFFECT_SIZE="0.7975757575757576" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="-0.029215963398299988" LOG_CI_START="-0.1672401464736392" LOG_EFFECT_SIZE="-0.09822805493596957" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.0810760883691795" STUDY_ID="STD-Pelc-1992" TOTAL_1="55" TOTAL_2="47" VAR="0.006573332105247003" WEIGHT="4.5810704115542435"/>
<DICH_DATA CI_END="0.8214845089550527" CI_START="0.5745854321408876" EFFECT_SIZE="0.6870320455226115" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="53" LOG_CI_END="-0.08540062180746154" LOG_CI_START="-0.2406453891707822" LOG_EFFECT_SIZE="-0.16302300548912188" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.09119154482320685" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="0.008315897847242945" WEIGHT="4.195438021136952"/>
<DICH_DATA CI_END="0.8849317865993751" CI_START="0.6007947517130143" EFFECT_SIZE="0.729151817533856" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="92" LOG_CI_END="-0.05309020483351675" LOG_CI_START="-0.2212738697988827" LOG_EFFECT_SIZE="-0.13718203731619974" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.0987919173232243" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="124" VAR="0.009759842928398786" WEIGHT="3.9218724105748235"/>
<DICH_DATA CI_END="1.3403774575260177" CI_START="0.843217963949116" EFFECT_SIZE="1.06312292358804" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.12722711525814343" LOG_CI_START="-0.07406014980601817" LOG_EFFECT_SIZE="0.026583482726062653" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.11823713588672015" STUDY_ID="STD-Rousseaux-1996" TOTAL_1="63" TOTAL_2="64" VAR="0.013980020302694726" WEIGHT="3.2941014869943634"/>
<DICH_DATA CI_END="0.8802794231107174" CI_START="0.6141884329589351" EFFECT_SIZE="0.7352941176470589" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="102" LOG_CI_END="-0.05537944983509481" LOG_CI_START="-0.2116983669053401" LOG_EFFECT_SIZE="-0.13353890837021748" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.09182250567818115" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="0.008431372549019609" WEIGHT="4.172164311121781"/>
<DICH_DATA CI_END="0.9131528738872305" CI_START="0.6421371767109594" EFFECT_SIZE="0.7657476139978792" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="115" LOG_CI_END="-0.039456509729811545" LOG_CI_START="-0.19237218575546028" LOG_EFFECT_SIZE="-0.11591434774263591" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.08982342504227021" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="0.008068247686324335" WEIGHT="4.246237618934899"/>
<DICH_DATA CI_END="0.9453414379842228" CI_START="0.8188169314722302" EFFECT_SIZE="0.8798076923076923" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="208" LOG_CI_END="-0.024411304876400534" LOG_CI_START="-0.08681318558826366" LOG_EFFECT_SIZE="-0.05561224523233209" MODIFIED="2009-12-04 21:15:00 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.03665517362443969" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="0.001343601753437819" WEIGHT="6.326208633250908"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="316.8484812872409" CI_END="16.805665768647785" CI_START="5.0776414746347625" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="MD" EFFECT_SIZE="10.941653621641274" ESTIMABLE="YES" I2="94.31905119858158" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-11-23 11:16:21 +0100" MODIFIED_BY="Laura Amato" NO="2" P_CHI2="-1.1102230246251565E-15" P_Q="1.0" P_Z="2.5509027711738505E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="138.66870643110596" TOTALS="YES" TOTAL_1="2763" TOTAL_2="2461" UNITS="" WEIGHT="100.00000000000001" Z="3.657094578270377">
<NAME>Cumulative abstinence duration</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours acamprosate</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.212156362543567" CI_START="-4.01215636254355" EFFECT_SIZE="0.10000000000000853" ESTIMABLE="YES" MEAN_1="76.9" MEAN_2="76.8" MODIFIED="2009-06-23 10:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="567" SD_1="26.0" SD_2="25.9" SE="2.098077513148059" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" WEIGHT="6.256666893961112"/>
<CONT_DATA CI_END="22.0039665680965" CI_START="3.9960334319034967" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="48.7" MEAN_2="35.7" MODIFIED="2009-04-07 10:31:18 +0200" MODIFIED_BY="[Empty name]" ORDER="568" SD_1="41.9" SD_2="37.8" SE="4.593944908742529" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" WEIGHT="5.602605613245724"/>
<CONT_DATA CI_END="30.626436077727426" CI_START="3.7735639222725705" EFFECT_SIZE="17.2" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="20.8" MODIFIED="2009-04-07 10:31:51 +0200" MODIFIED_BY="[Empty name]" ORDER="569" SD_1="41.0" SD_2="30.0" SE="6.850348365395202" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" WEIGHT="4.82308568230048"/>
<CONT_DATA CI_END="53.751121597964385" CI_START="-36.551121597964396" EFFECT_SIZE="8.599999999999994" ESTIMABLE="YES" MEAN_1="88.6" MEAN_2="80.0" MODIFIED="2009-05-19 09:58:36 +0200" MODIFIED_BY="[Empty name]" ORDER="570" SD_1="25.6" SD_2="44.7" SE="23.036709834522814" STUDY_ID="STD-Borg-2003" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.3373177956316724"/>
<CONT_DATA CI_END="1.483483163263926" CI_START="-5.883483163263932" EFFECT_SIZE="-2.200000000000003" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="48.2" MODIFIED="2009-04-07 10:32:58 +0200" MODIFIED_BY="[Empty name]" ORDER="571" SD_1="22.5" SD_2="22.8" SE="1.8793626782526485" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" WEIGHT="6.294942596113177"/>
<CONT_DATA CI_END="18.668175341387116" CI_START="1.3318246586128843" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="33.9" MEAN_2="23.9" MODIFIED="2009-04-07 10:33:40 +0200" MODIFIED_BY="[Empty name]" ORDER="572" SD_1="38.9" SD_2="32.2" SE="4.422619706158162" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" WEIGHT="5.657303219618723"/>
<CONT_DATA CI_END="20.234122544538565" CI_START="0.9658774554614364" EFFECT_SIZE="10.600000000000001" ESTIMABLE="YES" MEAN_1="51.7" MEAN_2="41.1" MODIFIED="2009-04-07 10:34:10 +0200" MODIFIED_BY="[Empty name]" ORDER="573" SD_1="41.7" SD_2="41.7" SE="4.915458967884764" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" WEIGHT="5.4974075587556195"/>
<CONT_DATA CI_END="40.08858726542353" CI_START="1.1114127345764722" EFFECT_SIZE="20.6" ESTIMABLE="YES" MEAN_1="46.6" MEAN_2="26.0" MODIFIED="2009-04-07 10:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="574" SD_1="43.5" SD_2="32.8" SE="9.943339479269527" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" WEIGHT="3.768418727290393"/>
<CONT_DATA CI_END="0.6927463803817657" CI_START="-10.692746380381767" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="52.0" MODIFIED="2009-08-03 11:32:39 +0200" MODIFIED_BY="[Empty name]" ORDER="575" SD_1="34.8" SD_2="35.2" SE="2.9045158101298916" STUDY_ID="STD-Mason-2006" TOTAL_1="335" TOTAL_2="257" WEIGHT="6.085080762510371"/>
<CONT_DATA CI_END="23.686039852136304" CI_START="-0.8860398521362924" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" MEAN_1="78.9" MEAN_2="67.5" MODIFIED="2009-04-07 10:37:04 +0200" MODIFIED_BY="[Empty name]" ORDER="576" SD_1="30.0" SD_2="37.4" SE="6.2685028648725245" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" WEIGHT="5.029956461377182"/>
<CONT_DATA CI_END="11.207648389815448" CI_START="-5.8076483898154425" EFFECT_SIZE="2.700000000000003" ESTIMABLE="YES" MEAN_1="81.2" MEAN_2="78.5" MODIFIED="2009-04-07 10:38:01 +0200" MODIFIED_BY="[Empty name]" ORDER="577" SD_1="23.7" SD_2="27.8" SE="4.340716695267203" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" WEIGHT="5.683082406839367"/>
<CONT_DATA CI_END="77.70461831163479" CI_START="26.89538168836522" EFFECT_SIZE="52.300000000000004" ESTIMABLE="YES" MEAN_1="88.7" MEAN_2="36.4" MODIFIED="2009-04-07 10:38:38 +0200" MODIFIED_BY="[Empty name]" ORDER="578" SD_1="41.7" SD_2="21.1" SE="12.961778130630547" STUDY_ID="STD-Niederhofer-2002" TOTAL_1="13" TOTAL_2="13" WEIGHT="2.9188594670231716"/>
<CONT_DATA CI_END="16.621290120479273" CI_START="3.7787098795207203" EFFECT_SIZE="10.199999999999996" ESTIMABLE="YES" MEAN_1="58.3" MEAN_2="48.1" MODIFIED="2009-04-07 10:39:04 +0200" MODIFIED_BY="[Empty name]" ORDER="579" SD_1="37.1" SD_2="35.0" SE="3.2762286302858583" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" WEIGHT="5.991506339867101"/>
<CONT_DATA CI_END="10.143776838034837" CI_START="2.2562231619651616" EFFECT_SIZE="6.199999999999999" ESTIMABLE="YES" MEAN_1="33.5" MEAN_2="27.3" MODIFIED="2009-04-07 10:44:50 +0200" MODIFIED_BY="[Empty name]" ORDER="580" SD_1="12.0" SD_2="8.2" SE="2.0121680138731355" STUDY_ID="STD-Pelc-1992" TOTAL_1="55" TOTAL_2="47" WEIGHT="6.272147026563828"/>
<CONT_DATA CI_END="23.669539718653997" CI_START="20.730460281345994" EFFECT_SIZE="22.199999999999996" ESTIMABLE="YES" MEAN_1="60.3" MEAN_2="38.1" MODIFIED="2009-05-19 09:53:33 +0200" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="4.9" SD_2="4.8" SE="0.749778939942542" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" WEIGHT="6.429215577933074"/>
<CONT_DATA CI_END="26.74806277678875" CI_START="5.25193722321125" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="55.1" MEAN_2="39.1" MODIFIED="2009-05-19 09:54:03 +0200" MODIFIED_BY="[Empty name]" ORDER="226" SD_1="44.4" SD_2="41.2" SE="5.483806264588583" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="122" WEIGHT="5.304852830033536"/>
<CONT_DATA CI_END="27.908677482678613" CI_START="8.891322517321399" EFFECT_SIZE="18.400000000000006" ESTIMABLE="YES" MEAN_1="66.9" MEAN_2="48.5" MODIFIED="2009-05-19 09:54:33 +0200" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="40.7" SD_2="39.3" SE="4.8514552092190675" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" WEIGHT="5.518593886227524"/>
<CONT_DATA CI_END="20.935764744290708" CI_START="2.464235255709296" EFFECT_SIZE="11.700000000000003" ESTIMABLE="YES" MEAN_1="61.1" MEAN_2="49.4" MODIFIED="2009-05-19 09:55:01 +0200" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="42.8" SD_2="42.8" SE="4.7122114575274034" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" WEIGHT="5.5642757364024735"/>
<CONT_DATA CI_END="16.4192195361751" CI_START="3.1807804638249007" EFFECT_SIZE="9.8" ESTIMABLE="YES" MEAN_1="38.6" MEAN_2="28.8" MODIFIED="2009-05-19 09:55:23 +0200" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="38.2" SD_2="33.1" SE="3.3772148816951018" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" WEIGHT="5.9646814183054735"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.146811406927777" CI_END="1.042788068846995" CI_START="0.9400206223437643" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9900718607506247" ESTIMABLE="YES" EVENTS_1="708" EVENTS_2="702" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.018196053505539718" LOG_CI_START="-0.026862618664281163" LOG_EFFECT_SIZE="-0.004333282579370721" METHOD="MH" MODIFIED="2010-11-23 11:22:53 +0100" MODIFIED_BY="Laura Amato" NO="3" P_CHI2="0.5284784269966569" P_Q="0.0" P_Z="0.7061895021616964" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1100" TOTAL_2="1032" WEIGHT="99.99999999999999" Z="0.37697860950682155">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0527422595128408" CI_START="0.8611081056302221" EFFECT_SIZE="0.9521160080609831" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="226" LOG_CI_END="0.022322056871481952" LOG_CI_START="-0.06494232272583918" LOG_EFFECT_SIZE="-0.02131013292717863" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1218" O_E="0.0" SE="0.05125952854111209" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0026275392662570853" WEIGHT="26.661388782270347"/>
<DICH_DATA CI_END="1.1026593433726504" CI_START="0.9566831786155262" EFFECT_SIZE="1.0270811289999715" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="242" LOG_CI_END="0.04244136181071774" LOG_CI_START="-0.01923186218108108" LOG_EFFECT_SIZE="0.011604749814818327" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1221" O_E="0.0" SE="0.036227157060164966" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="0.0013124069086618605" WEIGHT="53.378144732405374"/>
<DICH_DATA CI_END="1.124195745553654" CI_START="0.6177255581966629" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.050841937400551915" LOG_CI_START="-0.20920442949580154" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1219" O_E="0.0" SE="0.15275252316519466" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.02333333333333333" WEIGHT="3.002307682215494"/>
<DICH_DATA CI_END="1.0990722686641847" CI_START="0.7638179144714283" EFFECT_SIZE="0.9162374627270263" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="119" LOG_CI_END="0.041026250066957246" LOG_CI_START="-0.11701015996525463" LOG_EFFECT_SIZE="-0.03799195494914869" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1217" O_E="0.0" SE="0.0928313695457676" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="0.008617663171742868" WEIGHT="8.129100026567128"/>
<DICH_DATA CI_END="1.2975333545776278" CI_START="0.8203493377420609" EFFECT_SIZE="1.0317124735729386" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.11311853069993477" LOG_CI_START="-0.08600116817013673" LOG_EFFECT_SIZE="0.013558681264899017" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1220" O_E="0.0" SE="0.11696389677468587" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.013680553148719372" WEIGHT="5.120688115225751"/>
<DICH_DATA CI_END="1.3030974249659697" CI_START="0.7603132008622625" EFFECT_SIZE="0.9953703703703703" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.11497688658242604" LOG_CI_START="-0.11900746905307713" LOG_EFFECT_SIZE="-0.002015291235325575" MODIFIED="2010-01-09 11:22:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1216" O_E="0.0" SE="0.13744356874153482" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.01889073458840901" WEIGHT="3.708370661315903"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="29.90489138013863" CI_END="0.3006005528903781" CI_START="-24.123214916871262" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.911307181990441" ESTIMABLE="YES" I2="79.93639259969054" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-11-23 11:23:18 +0100" MODIFIED_BY="Laura Amato" NO="4" P_CHI2="4.097926167867527E-5" P_Q="1.0" P_Z="0.055912277049138065" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="191.26986526938364" TOTALS="YES" TOTAL_1="923" TOTAL_2="727" UNITS="" WEIGHT="100.00000000000003" Z="1.9117187578163757">
<NAME>Gamma-glutamyl transpeptidase</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.571983481930092" CI_START="-23.97198348193009" EFFECT_SIZE="-9.7" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="30.9" MODIFIED="2009-04-07 10:53:24 +0200" MODIFIED_BY="[Empty name]" ORDER="584" SD_1="13.6" SD_2="44.0" SE="7.2817580294871105" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="15.89125825813069"/>
<CONT_DATA CI_END="37.566469769032686" CI_START="-45.3664697690327" EFFECT_SIZE="-3.9000000000000057" ESTIMABLE="YES" MEAN_1="72.1" MEAN_2="76.0" MODIFIED="2009-04-07 10:53:59 +0200" MODIFIED_BY="[Empty name]" ORDER="585" SD_1="82.5" SD_2="94.5" SE="21.156750887319824" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" WEIGHT="6.0764920151331205"/>
<CONT_DATA CI_END="-8.052279570972903" CI_START="-41.1477204290271" EFFECT_SIZE="-24.6" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="73.0" MODIFIED="2009-04-07 10:54:32 +0200" MODIFIED_BY="[Empty name]" ORDER="586" SD_1="57.9" SD_2="131.1" SE="8.442869644316632" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" WEIGHT="14.786168792415559"/>
<CONT_DATA CI_END="-18.164913671669623" CI_START="-30.43508632833037" EFFECT_SIZE="-24.299999999999997" ESTIMABLE="YES" MEAN_1="74.0" MEAN_2="98.3" MODIFIED="2009-04-07 10:57:41 +0200" MODIFIED_BY="[Empty name]" ORDER="587" SD_1="18.8" SD_2="18.5" SE="3.1302036041086216" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" WEIGHT="19.3075782025495"/>
<CONT_DATA CI_END="14.714347326370312" CI_START="-20.114347326370318" EFFECT_SIZE="-2.700000000000003" ESTIMABLE="YES" MEAN_1="41.9" MEAN_2="44.6" MODIFIED="2009-04-07 10:58:36 +0200" MODIFIED_BY="[Empty name]" ORDER="588" SD_1="98.5" SD_2="96.0" SE="8.885034349474003" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" WEIGHT="14.36691364790276"/>
<CONT_DATA CI_END="18.894503818172858" CI_START="-3.0945038181728624" EFFECT_SIZE="7.899999999999999" ESTIMABLE="YES" MEAN_1="40.3" MEAN_2="32.4" MODIFIED="2009-07-10 17:13:12 +0200" MODIFIED_BY="[Empty name]" ORDER="959" SD_1="36.5" SD_2="25.7" SE="5.609543800241282" STUDY_ID="STD-Rousseaux-1996" TOTAL_1="63" TOTAL_2="64" WEIGHT="17.429253208981507"/>
<CONT_DATA CI_END="-0.7866591671325089" CI_START="-45.21334083286749" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="49.0" MODIFIED="2009-05-19 13:51:09 +0200" MODIFIED_BY="[Empty name]" ORDER="259" SD_1="32.0" SD_2="75.0" SE="11.333545416182893" STUDY_ID="STD-Sass-1996" TOTAL_1="75" TOTAL_2="49" WEIGHT="12.142335874886873"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="101.2266080831305" CI_END="0.13458338324525015" CI_START="0.09221801316658096" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RD" EFFECT_SIZE="0.11340069820591556" ESTIMABLE="YES" EVENTS_1="598" EVENTS_2="290" I2="85.18176170865912" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.8710085583169784" LOG_CI_START="-1.0351842388731234" LOG_EFFECT_SIZE="-0.9453842714921169" METHOD="MH" MODIFIED="2010-12-21 09:40:07 +0100" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="6.772360450213455E-15" P_Q="0.0" P_Z="9.342895787866445E-26" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2401" TOTAL_2="2085" WEIGHT="100.0" Z="10.492592600634364">
<NAME>Side effect: Diarrhea</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.36333152100778465" CI_START="0.21156674551789711" EFFECT_SIZE="0.2874491332628409" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="108" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.03871621537104475" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0014989453326571215" WEIGHT="13.94980647131155"/>
<DICH_DATA CI_END="0.15773122573880277" CI_START="-0.13630265431023136" EFFECT_SIZE="0.010714285714285718" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.07501002119639337" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.005626503279883382" WEIGHT="1.702100773583081"/>
<DICH_DATA CI_END="0.3764556957727322" CI_START="0.09627157695454053" EFFECT_SIZE="0.23636363636363636" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.07147685391880877" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="0.005108940646130729" WEIGHT="2.507559175367932"/>
<DICH_DATA CI_END="0.17035837254442365" CI_START="-0.003613969559349034" EFFECT_SIZE="0.08337220149253731" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.04438151503702219" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.0019697188769814264" WEIGHT="5.969417762097261"/>
<DICH_DATA CI_END="0.19568991445343975" CI_START="-0.19568991445343975" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.09984362773857929" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00996875" WEIGHT="1.823679400267587"/>
<DICH_DATA CI_END="0.3097344092277331" CI_START="-0.0769757885380779" EFFECT_SIZE="0.1163793103448276" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.0986523734150555" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.009732290780423552" WEIGHT="1.3871921995478036"/>
<DICH_DATA CI_END="0.11299003729878056" CI_START="0.014311903128855094" EFFECT_SIZE="0.06365097021381783" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.02517345597885624" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="6.337028859194129E-4" WEIGHT="12.966072080461375"/>
<DICH_DATA CI_END="0.23352081308444955" CI_START="0.09519563176102756" EFFECT_SIZE="0.16435822242273856" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.035287684471376354" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="0.0012452206753514159" WEIGHT="13.451532082173399"/>
<DICH_DATA CI_END="0.4587084448090817" CI_START="0.19941376085410753" EFFECT_SIZE="0.3290611028315946" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.06614781853142648" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.004375533896466529" WEIGHT="2.637260512024894"/>
<DICH_DATA CI_END="0.1649571252318352" CI_START="1.2223984752986194E-4" EFFECT_SIZE="0.08253968253968254" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.04205048834685277" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.0017682435702088006" WEIGHT="3.2363887948410697"/>
<DICH_DATA CI_END="0.10358147355548286" CI_START="0.022527733449540836" EFFECT_SIZE="0.06305460350251185" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.020677354468062573" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="4.275529877979073E-4" WEIGHT="10.829706564953346"/>
<DICH_DATA CI_END="0.1781639828653162" CI_START="-0.02865417894374757" EFFECT_SIZE="0.07475490196078433" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.052760704645702435" STUDY_ID="STD-Pelc-1992" TOTAL_1="48" TOTAL_2="34" VAR="0.0027836919547110464" WEIGHT="1.8147834031931107"/>
<DICH_DATA CI_END="0.21445777516548287" CI_START="-0.08388941879067485" EFFECT_SIZE="0.06528417818740401" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.07611037659607071" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="0.005792789425595708" WEIGHT="3.7889849667261672"/>
<DICH_DATA CI_END="0.056082218623610666" CI_START="-0.07078810097655185" EFFECT_SIZE="-0.00735294117647059" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.032365472172167294" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="0.0010475237889273356" WEIGHT="6.200509960909796"/>
<DICH_DATA CI_END="0.041555962904129946" CI_START="-0.02877312423236974" EFFECT_SIZE="0.006391419335880104" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.017941423335134356" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="3.2189467129050363E-4" WEIGHT="7.5224012110431495"/>
<DICH_DATA CI_END="0.14796648699213555" CI_START="0.012747798722150164" EFFECT_SIZE="0.08035714285714286" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-04 10:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.0344951971915232" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="0.00118991862928207" WEIGHT="10.212604641498487"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.99517853217198" CI_END="0.0464389645146121" CI_START="-0.03949113793488501" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.003473913289863544" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="66.63985919239299" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-1.333117472624328" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.4591810259015165" METHOD="MH" MODIFIED="2010-06-30 13:46:37 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.049907359300097265" P_Q="0.0" P_Z="0.8740851149081456" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="9.163580329585066E-4" TOTALS="YES" TOTAL_1="462" TOTAL_2="485" WEIGHT="99.99999999999999" Z="0.15847170524553347">
<NAME>Side effect: Abdominal pain</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.006483666272998637" CI_START="-0.05125978567598371" EFFECT_SIZE="-0.022388059701492536" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:42:58 +0200" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.014730743116826463" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="2.169947927739302E-4" WEIGHT="42.40034145386014"/>
<DICH_DATA CI_END="0.03297721323347332" CI_START="-0.04269171082338804" EFFECT_SIZE="-0.004857248794957358" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:43:09 +0200" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.01930365166241017" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="3.726309675036709E-4" WEIGHT="37.28080439904625"/>
<DICH_DATA CI_END="0.14732609854387357" CI_START="-0.0018715530893281124" EFFECT_SIZE="0.07272727272727272" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:43:23 +0200" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.03806132480240803" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.0014486644457144004" WEIGHT="20.3188541470936"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.323530645200726" CI_END="0.033087392804904865" CI_START="-0.11462418673849636" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.040768396966795746" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="28" I2="89.64992455715266" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-1.4803374526966766" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="6.36722727118677E-5" P_Q="0.0" P_Z="0.2792969164223962" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0033444226889620845" TOTALS="YES" TOTAL_1="462" TOTAL_2="479" WEIGHT="100.0" Z="1.0819001463439601">
<NAME>Side effect: Constipation</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.06197888580744046" CI_START="-0.30165747782892316" EFFECT_SIZE="-0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:47:00 +0200" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.061143621493057236" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="0.003738542449286251" WEIGHT="20.0473885105362"/>
<DICH_DATA CI_END="0.02896049502271048" CI_START="-0.013335495022710479" EFFECT_SIZE="0.0078125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:47:08 +0200" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="0.010789991647562489" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="1.1642391975446827E-4" WEIGHT="41.028964871028094"/>
<DICH_DATA CI_END="0.014821408572493519" CI_START="-0.053481648345080346" EFFECT_SIZE="-0.019330119886293413" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:47:23 +0200" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="0.017424569394218378" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="3.0361561857393185E-4" WEIGHT="38.9236466184357"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6945139330920913" CI_END="0.045933278003884956" CI_START="-0.01453313835012381" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.01570006982688057" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-1.3378725602820596" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.8040984160390794" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6101751391348884" P_Q="0.0" P_Z="0.30876969094417694" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="710" TOTAL_2="737" WEIGHT="100.0" Z="1.017807016552581">
<NAME>Side effect: Nausea</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.09331142277710741" CI_START="-0.038775872134664546" EFFECT_SIZE="0.027267775321221432" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:48:40 +0200" MODIFIED_BY="[Empty name]" ORDER="756" O_E="0.0" SE="0.03369635767638071" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0011354445206545813" WEIGHT="20.95590244790197"/>
<DICH_DATA CI_END="0.06842351889314789" CI_START="-0.06842351889314789" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:48:47 +0200" MODIFIED_BY="[Empty name]" ORDER="757" O_E="0.0" SE="0.03491060010942235" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00121875" WEIGHT="19.523499167050026"/>
<DICH_DATA CI_END="0.21718886456825953" CI_START="-0.028818676198071172" EFFECT_SIZE="0.09418509418509419" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:48:55 +0200" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.06275817890196116" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" VAR="0.003938589019090562" WEIGHT="6.041316952469548"/>
<DICH_DATA CI_END="0.045923253792783524" CI_START="-0.046294036143543625" EFFECT_SIZE="-1.853911753800508E-4" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:49:04 +0200" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="0.023525251143318285" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="5.534374413561983E-4" WEIGHT="42.99359391286281"/>
<DICH_DATA CI_END="0.13509412362722548" CI_START="-0.05163659754674857" EFFECT_SIZE="0.041728763040238454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:49:42 +0200" MODIFIED_BY="[Empty name]" ORDER="760" O_E="0.0" SE="0.04763626338210348" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.002269213589009133" WEIGHT="10.485687519715645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8017191855576298" CI_END="0.03944341175190004" CI_START="-0.001389663337939162" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.01902687420698044" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-1.404025526769869" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7206325530772564" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.406220368455221" P_Q="0.0" P_Z="0.0677662664353128" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="923" TOTAL_2="859" WEIGHT="100.0" Z="1.8265579117912383">
<NAME>Side effect: Vomiting</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.049543350684142055" CI_START="-0.03961031854597679" EFFECT_SIZE="0.004966516069082633" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 15:27:24 +0200" MODIFIED_BY="[Empty name]" ORDER="794" O_E="0.0" SE="0.02274370088770804" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="5.172759300695316E-4" WEIGHT="34.557100027567"/>
<DICH_DATA CI_END="0.053066397788658244" CI_START="-0.014505033309607444" EFFECT_SIZE="0.0192806822395254" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 15:27:41 +0200" MODIFIED_BY="[Empty name]" ORDER="795" O_E="0.0" SE="0.0172379267249961" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="2.971461177763348E-4" WEIGHT="32.12014810174068"/>
<DICH_DATA CI_END="0.05694929445787397" CI_START="0.009777527107657266" EFFECT_SIZE="0.03336341078276562" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 15:32:06 +0200" MODIFIED_BY="[Empty name]" ORDER="796" O_E="0.0" SE="0.012033835244499793" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="1.4481319069176542E-4" WEIGHT="33.32275187069232"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.633693757115942" CI_END="0.08069504863753438" CI_START="-0.007093423670843223" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RD" EFFECT_SIZE="0.036800812483345574" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="117" I2="70.38126975859477" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-1.093153112308499" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4341425929259817" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.00132110530595686" P_Q="0.0" P_Z="0.10033563121023385" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0023268609094735534" TOTALS="YES" TOTAL_1="1185" TOTAL_2="1118" WEIGHT="99.99999999999999" Z="1.6432286648251928">
<NAME>Side effect: Further gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.120071502074081" CI_START="0.013963585645217255" EFFECT_SIZE="0.06701754385964913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:41:44 +0200" MODIFIED_BY="[Empty name]" ORDER="740" O_E="0.0" SE="0.027068843424121424" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" VAR="7.327222843196017E-4" WEIGHT="16.392928436707788"/>
<DICH_DATA CI_END="0.2306311741084103" CI_START="0.008766712705889884" EFFECT_SIZE="0.1196989434071501" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:41:53 +0200" MODIFIED_BY="[Empty name]" ORDER="741" O_E="0.0" SE="0.0565991169104532" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="0.0032034600350431494" WEIGHT="9.069189445819433"/>
<DICH_DATA CI_END="0.36427982865620134" CI_START="-0.05609017348378753" EFFECT_SIZE="0.1540948275862069" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:42:01 +0200" MODIFIED_BY="[Empty name]" ORDER="742" O_E="0.0" SE="0.10723921598963394" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.01150024944607136" WEIGHT="3.627332613418522"/>
<DICH_DATA CI_END="0.15552412749463135" CI_START="-0.034312006282510146" EFFECT_SIZE="0.06060606060606061" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:42:08 +0200" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="0.04842847503182321" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" VAR="0.002345317193907924" WEIGHT="10.734935020072351"/>
<DICH_DATA CI_END="0.044572727194338094" CI_START="-0.06899492469773695" EFFECT_SIZE="-0.012211098751699428" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:42:18 +0200" MODIFIED_BY="[Empty name]" ORDER="744" O_E="0.0" SE="0.02897187213333566" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.393693749103514E-4" WEIGHT="15.840770833813327"/>
<DICH_DATA CI_END="0.08060640346617338" CI_START="0.010347803617065957" EFFECT_SIZE="0.04547710354161967" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="447" O_E="0.0" SE="0.017923441553849534" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="3.2124975713426014E-4" WEIGHT="18.94011793935087"/>
<DICH_DATA CI_END="0.19565097661952524" CI_START="-0.08045489818815267" EFFECT_SIZE="0.05759803921568628" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:42:51 +0200" MODIFIED_BY="[Empty name]" ORDER="745" O_E="0.0" SE="0.07043646643141552" STUDY_ID="STD-Pelc-1992" TOTAL_1="48" TOTAL_2="34" VAR="0.004961295803343925" WEIGHT="6.881785109504835"/>
<DICH_DATA CI_END="-0.0036968733386248676" CI_START="-0.08034661769869514" EFFECT_SIZE="-0.04202174551866" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-19 15:08:06 +0200" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.019553865521171224" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="3.8235365682004875E-4" WEIGHT="18.512940601312863"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.757895181505713" CI_END="0.045449845293987316" CI_START="-0.05295233850741483" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0037512466067137554" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="76" I2="57.4753820916466" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-1.3424675907276458" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.03826010029815263" P_Q="0.0" P_Z="0.8812113086549894" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001970009280460518" TOTALS="YES" TOTAL_1="722" TOTAL_2="722" WEIGHT="99.99999999999999" Z="0.14943384307660632">
<NAME>Side effect: Headache</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.17954688805882896" CI_START="-0.036689745201686094" EFFECT_SIZE="0.07142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:43:28 +0200" MODIFIED_BY="[Empty name]" ORDER="746" O_E="0.0" SE="0.05516342008479799" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.003043002915451895" WEIGHT="12.570557495656459"/>
<DICH_DATA CI_END="0.0579472156708768" CI_START="-0.054511299220499805" EFFECT_SIZE="0.0017179582251884984" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:43:37 +0200" MODIFIED_BY="[Empty name]" ORDER="747" O_E="0.0" SE="0.028688923821670962" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.230543500456396E-4" WEIGHT="22.561733770356046"/>
<DICH_DATA CI_END="-0.0490075663485168" CI_START="-0.27170778387503014" EFFECT_SIZE="-0.16035767511177346" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:43:43 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.056812323921037376" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.003227640149308876" WEIGHT="12.124010841173623"/>
<DICH_DATA CI_END="0.27234797818219947" CI_START="-0.049308762495924946" EFFECT_SIZE="0.11151960784313725" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:44:02 +0200" MODIFIED_BY="[Empty name]" ORDER="749" O_E="0.0" SE="0.08205679880225139" STUDY_ID="STD-Pelc-1992" TOTAL_1="48" TOTAL_2="34" VAR="0.0067333182296731645" WEIGHT="7.240490256372773"/>
<DICH_DATA CI_END="0.04119163805138042" CI_START="-0.07060340275726279" EFFECT_SIZE="-0.01470588235294118" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-19 15:09:32 +0200" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.028519667119005304" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="8.133714125788723E-4" WEIGHT="22.640222443424207"/>
<DICH_DATA CI_END="0.06186342077313616" CI_START="-0.048052077840429745" EFFECT_SIZE="0.006905671466353208" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-19 15:09:41 +0200" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.028040183258612232" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="7.862518771765577E-4" WEIGHT="22.862985193016886"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.0529910634340025" CI_END="0.05200741909306754" CI_START="-0.016804389356096863" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.017601514868485338" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" I2="40.629224110259834" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-1.2839346978777484" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7544499531681088" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.16795794404106001" P_Q="0.0" P_Z="0.3160121656285563" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.887830825501717E-4" TOTALS="YES" TOTAL_1="342" TOTAL_2="353" WEIGHT="100.0" Z="1.002686486319092">
<NAME>Side effect: Pruritus</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.17954688805882896" CI_START="-0.036689745201686094" EFFECT_SIZE="0.07142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:56:02 +0200" MODIFIED_BY="[Empty name]" ORDER="769" O_E="0.0" SE="0.05516342008479799" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.003043002915451895" WEIGHT="8.725199979077052"/>
<DICH_DATA CI_END="0.021444198434859004" CI_START="-0.020744571569187364" EFFECT_SIZE="3.4981343283582104E-4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:56:11 +0200" MODIFIED_BY="[Empty name]" ORDER="770" O_E="0.0" SE="0.01076263909358182" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="1.1583440025869572E-4" WEIGHT="50.96699978424823"/>
<DICH_DATA CI_END="0.06193548903348152" CI_START="-0.03067191977599129" EFFECT_SIZE="0.015631784628745114" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:56:23 +0200" MODIFIED_BY="[Empty name]" ORDER="771" O_E="0.0" SE="0.023624773092757886" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="5.581299036842971E-4" WEIGHT="29.434670809375884"/>
<DICH_DATA CI_END="0.15552412749463135" CI_START="-0.034312006282510146" EFFECT_SIZE="0.06060606060606061" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:56:39 +0200" MODIFIED_BY="[Empty name]" ORDER="772" O_E="0.0" SE="0.04842847503182321" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" VAR="0.002345317193907924" WEIGHT="10.873129427298826"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.006827661257190115" CI_START="-0.09281391580374179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.049820788530465954" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.023133521600838557" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="2.271222341664734">
<NAME>Side effect: Vertigo</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.006827661257190115" CI_START="-0.09281391580374179" EFFECT_SIZE="-0.049820788530465954" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 15:26:44 +0200" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="0.021935672090099684" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="4.811737100443783E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.665794194150095" CI_END="0.01258301026196257" CI_START="-0.004604860563464071" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0039890748492492495" ESTIMABLE="YES" EVENTS_1="900" EVENTS_2="872" I2="31.54242159686494" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-1.9002154492112597" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.399127814702707" METHOD="MH" MODIFIED="2010-07-13 11:54:03 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.04040911970446803" P_Q="0.0" P_Z="0.36294760929951553" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.9660366782970624E-4" TOTALS="SUB" TOTAL_1="7647" TOTAL_2="7766" WEIGHT="2600.0" Z="0.909762833986042">
<NAME>Other side effects</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.060116392642562085" CI_START="-0.007490017658011348" DF="0" EFFECT_SIZE="0.026313187492275368" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-1.2210070876731722" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.579826539734231" MODIFIED="2010-06-30 13:58:00 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12708938778973133" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.5256807623425057">
<NAME>Chest pain</NAME>
<DICH_DATA CI_END="0.060116392642562085" CI_START="-0.007490017658011348" EFFECT_SIZE="0.026313187492275368" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 13:57:45 +0200" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.01724685015486105" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="2.974538402642305E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.05389726910129718" CI_START="-0.002358522345642735" DF="0" EFFECT_SIZE="0.02576937337782722" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-1.2684332393454245" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5888961418627772" MODIFIED="2010-06-30 14:13:24 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07255479404249157" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.7956211236435824">
<NAME>Confusion</NAME>
<DICH_DATA CI_END="0.05389726910129718" CI_START="-0.002358522345642735" EFFECT_SIZE="0.02576937337782722" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:12:45 +0200" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.014351230913087794" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="2.059578287207667E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.03157462081011113" CI_START="-0.06615625472433682" DF="0" EFFECT_SIZE="-0.017290816957112848" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="-1.500661856324973" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-06-30 14:13:24 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.48798045824583935" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="0.6935245041833353">
<NAME>Daytime sleepiness</NAME>
<DICH_DATA CI_END="0.03157462081011113" CI_START="-0.06615625472433682" EFFECT_SIZE="-0.017290816957112848" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 13:59:30 +0200" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.024931803927351885" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="6.21594847071919E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4046145945305968" CI_END="0.07941221570317211" CI_START="-0.018090095462721122" DF="1" EFFECT_SIZE="0.030661060120225497" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="83" I2="28.806093579414465" ID="CMP-001.14.04" LOG_CI_END="-1.100112686434136" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5134128332910157" MODIFIED="2010-06-30 14:13:21 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.23595268489940713" P_Z="0.21769520679941012" STUDIES="2" TAU2="3.56445929833601E-4" TOTAL_1="582" TOTAL_2="599" WEIGHT="100.0" Z="1.2326799815280827">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="0.11345853905900205" CI_START="-0.0025930835814154674" EFFECT_SIZE="0.05543272773879329" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 13:56:02 +0200" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.029605549784541427" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="8.76488578044961E-4" WEIGHT="50.180344564715526"/>
<DICH_DATA CI_END="0.06403058370508513" CI_START="-0.05261048730167395" EFFECT_SIZE="0.005710048201705592" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 13:58:37 +0200" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.029755922028876284" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.854148957885648E-4" WEIGHT="49.81965543528448"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.399770272591474E-32" CI_END="0.08759501592982163" CI_START="-0.027355243342996792" DF="0" EFFECT_SIZE="0.030119886293412418" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" I2="100.0" ID="CMP-001.14.05" LOG_CI_END="-1.0575206040574354" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5211466719878295" MODIFIED="2010-06-30 14:13:17 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.3043636718476619" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.0271206472605034">
<NAME>Decreased libido</NAME>
<DICH_DATA CI_END="0.08759501592982163" CI_START="-0.0273552433429968" EFFECT_SIZE="0.030119886293412418" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:01:03 +0200" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.029324584578984972" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.599312607300432E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.04935162967229767" CI_START="-0.045774878554562956" DF="0" EFFECT_SIZE="0.0017883755588673604" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.14.06" LOG_CI_END="-1.306698501636687" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.747541274121368" MODIFIED="2010-06-30 14:13:14 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9412534508975082" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="61" WEIGHT="100.0" Z="0.07369453061080565">
<NAME>Depression</NAME>
<DICH_DATA CI_END="0.04935162967229767" CI_START="-0.045774878554562956" EFFECT_SIZE="0.0017883755588673604" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:01:38 +0200" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.024267412303799044" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="5.889072999225773E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.030572602034388104" CI_END="0.06130935710349567" CI_START="-0.020236805640876883" DF="1" EFFECT_SIZE="0.020536275731309395" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="0.0" ID="CMP-001.14.07" LOG_CI_END="-1.2124732379074772" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6874783132213886" MODIFIED="2010-06-30 14:13:12 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8611973579383855" P_Z="0.3235545336663025" STUDIES="2" TAU2="0.0" TOTAL_1="319" TOTAL_2="325" WEIGHT="100.00000000000001" Z="0.987179763102416">
<NAME>Drowsiness</NAME>
<DICH_DATA CI_END="0.094020905341822" CI_START="-0.04402090534182199" EFFECT_SIZE="0.025" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:03:13 +0200" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.03521539471452031" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.0012401240248994649" WEIGHT="34.89681287431145"/>
<DICH_DATA CI_END="0.0686763053573511" CI_START="-0.03238907262962894" EFFECT_SIZE="0.01814361636386108" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:03:31 +0200" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.02578245793906695" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="6.647351373797564E-4" WEIGHT="65.10318712568856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10772503328433007" CI_END="-5.556741407509239E-4" CI_START="-0.08424219432254923" DF="1" EFFECT_SIZE="-0.04239893423165007" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="48" I2="0.0" ID="CMP-001.14.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-06-30 14:13:09 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7427492038216226" P_Z="0.04703420085471806" STUDIES="2" TAU2="0.0" TOTAL_1="334" TOTAL_2="351" WEIGHT="100.0" Z="1.9859921023455533">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="0.01943167862314405" CI_START="-0.0932173664244047" EFFECT_SIZE="-0.03689284390063033" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:05:51 +0200" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.028737529346485456" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.258455929401128E-4" WEIGHT="55.189440366639836"/>
<DICH_DATA CI_END="0.013327632771905296" CI_START="-0.11168828850961021" EFFECT_SIZE="-0.04918032786885246" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:06:06 +0200" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.031892402683831214" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.0010171253489476442" WEIGHT="44.810559633360164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.05621627495820184" CI_START="-0.002663376244012812" DF="0" EFFECT_SIZE="0.026776449357094514" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-001.14.09" LOG_CI_END="-1.250137935297332" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5722470123447434" MODIFIED="2010-06-30 14:13:05 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.0746434542158794" STUDIES="1" TAU2="0.0" TOTAL_1="341" TOTAL_2="260" WEIGHT="100.0" Z="1.7826490239735648">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="0.05621627495820184" CI_START="-0.002663376244012812" EFFECT_SIZE="0.026776449357094514" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:06:53 +0200" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.015020595191199896" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="2.2561827989789741E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.08536238567907137" CI_START="-0.02593833426391872" DF="0" EFFECT_SIZE="0.02971202570757632" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" I2="0.0" ID="CMP-001.14.10" LOG_CI_END="-1.0687334558987454" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5270677378418518" MODIFIED="2010-06-30 14:13:03 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.2953601241214684" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.0464352849542466">
<NAME>Dyspnoea</NAME>
<DICH_DATA CI_END="0.08536238567907137" CI_START="-0.025938334263918728" EFFECT_SIZE="0.02971202570757632" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:07:47 +0200" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.02839356254015787" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="8.061943937218562E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.11415272689740702" CI_START="-0.02034479215510071" DF="0" EFFECT_SIZE="0.046903967371153155" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="55" I2="0.0" ID="CMP-001.14.11" LOG_CI_END="-0.9425137095583155" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3287904209410544" MODIFIED="2010-06-30 14:13:01 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.1716204930953654" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.3670153535488279">
<NAME>Excitation</NAME>
<DICH_DATA CI_END="0.11415272689740702" CI_START="-0.02034479215510071" EFFECT_SIZE="0.046903967371153155" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:10:04 +0200" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.03431122207178473" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="0.001177259960059328" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009123040422489" CI_END="0.01315592309707661" CI_START="-0.09335145048780265" DF="1" EFFECT_SIZE="-0.04009776369536302" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="66" I2="0.0" ID="CMP-001.14.12" LOG_CI_END="-1.8808786738495293" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-06-30 14:12:59 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9239060880132026" P_Z="0.14000575105807572" STUDIES="2" TAU2="0.0" TOTAL_1="334" TOTAL_2="351" WEIGHT="100.00000000000001" Z="1.475769612155127">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="0.02561165805895428" CI_START="-0.10248719878321579" EFFECT_SIZE="-0.03843777036213075" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="60" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:10:58 +0200" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.032678880288769974" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="0.0010679092169277589" WEIGHT="69.1303638173374"/>
<DICH_DATA CI_END="0.05203299059009043" CI_START="-0.13966339297459118" EFFECT_SIZE="-0.04381520119225037" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:11:10 +0200" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.0489030372692453" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.0023915070541571954" WEIGHT="30.869636182662617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.03038672396352248" CI_START="-0.04064503566788535" DF="0" EFFECT_SIZE="-0.005129155852181433" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-001.14.13" LOG_CI_END="-1.5173161193098923" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-06-30 14:12:56 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.7771343878156041" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.00000000000001" Z="0.28305537673667264">
<NAME>Fainting sensation</NAME>
<DICH_DATA CI_END="0.03038672396352248" CI_START="-0.04064503566788535" EFFECT_SIZE="-0.005129155852181433" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:12:06 +0200" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.018120679816490834" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="3.2835903701177826E-4" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13982315000397513" CI_END="0.04860802947595232" CI_START="-0.020066029953602522" DF="1" EFFECT_SIZE="0.014270999761174902" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" I2="0.0" ID="CMP-001.14.14" LOG_CI_END="-1.3132919844606676" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.8455456011283513" MODIFIED="2010-06-30 14:15:02 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7084570023954656" P_Z="0.41530630161548276" STUDIES="2" TAU2="0.0" TOTAL_1="405" TOTAL_2="352" WEIGHT="100.0" Z="0.8145912965571673">
<NAME>Increased libido</NAME>
<DICH_DATA CI_END="0.05181527059459119" CI_START="-0.03231211894460974" EFFECT_SIZE="0.009751575824990727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:14:52 +0200" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.021461463119421337" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="4.605943992262823E-4" WEIGHT="66.63625997475715"/>
<DICH_DATA CI_END="0.08274386375374258" CI_START="-0.03614888167488954" EFFECT_SIZE="0.02329749103942652" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:15:02 +0200" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="0.030330339324202617" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="9.199294835212717E-4" WEIGHT="33.36374002524285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0012558738712631144" CI_END="0.08639753391713946" CI_START="-0.008613420381729131" DF="1" EFFECT_SIZE="0.038892056767705165" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="55" I2="0.0" ID="CMP-001.14.15" LOG_CI_END="-1.0634986536028568" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4101390890138834" MODIFIED="2010-06-30 14:16:15 +0200" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9717302392692724" P_Z="0.10858305779611149" STUDIES="2" TAU2="0.0" TOTAL_1="334" TOTAL_2="351" WEIGHT="100.0" Z="1.60459456726659">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="0.10603967735492305" CI_START="-0.026840567232564908" EFFECT_SIZE="0.03959955506117907" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:16:05 +0200" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.03389864447398788" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="0.001149118097173829" WEIGHT="51.12419971667725"/>
<DICH_DATA CI_END="0.10610315139048132" CI_START="-0.02979912754547387" EFFECT_SIZE="0.038152011922503726" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:16:15 +0200" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.03466958576992613" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.0012019801774582647" WEIGHT="48.87580028332275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9222458882447594E-4" CI_START="-0.08586879114425644" DF="0" EFFECT_SIZE="-0.04278828327771598" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" I2="0.0" ID="CMP-001.14.16" LOG_CI_END="-3.534283243769628" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-06-30 14:16:58 +0200" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Z="0.05157441647761081" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.9466691164464067">
<NAME>Muscular pain</NAME>
<DICH_DATA CI_END="2.9222458882447594E-4" CI_START="-0.08586879114425644" EFFECT_SIZE="-0.04278828327771598" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-30 14:16:58 +0200" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.021980254844657352" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="4.83131603036083E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.05164615583897805" CI_START="-0.08914461091251655" DF="0" EFFECT_SIZE="-0.018749227536769247" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="73" I2="0.0" ID="CMP-001.14.17" LOG_CI_END="-1.2869619986371086" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:14:05 +0200" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Z="0.6016562821733302" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="0.5220201801283856">
<NAME>Noctural wakening</NAME>
<DICH_DATA CI_END="0.05164615583897805" CI_START="-0.08914461091251655" EFFECT_SIZE="-0.018749227536769247" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:14:05 +0200" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.03591667190367634" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="0.0012900073206363336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.042881400582057416" CI_START="-0.050148734656955435" DF="0" EFFECT_SIZE="-0.0036336670374490093" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" I2="0.0" ID="CMP-001.14.18" LOG_CI_END="-1.3677310382610566" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:15:04 +0200" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Z="0.878312640122932" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="0.1531085923268402">
<NAME>Palpitation</NAME>
<DICH_DATA CI_END="0.042881400582057416" CI_START="-0.050148734656955435" EFFECT_SIZE="-0.0036336670374490093" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:15:04 +0200" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.023732613449232404" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="5.632369411306868E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.0013000979176116534" CI_START="-0.0784675451425787" DF="0" EFFECT_SIZE="-0.039883821530095176" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" I2="0.0" ID="CMP-001.14.19" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:16:00 +0200" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Z="0.042764174512801935" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.00000000000001" Z="2.0260059539592508">
<NAME>Poor concentration</NAME>
<DICH_DATA CI_END="-0.0013000979176116534" CI_START="-0.0784675451425787" EFFECT_SIZE="-0.039883821530095176" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:16:00 +0200" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.019685935005350614" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="3.875360370348887E-4" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08787000641320794" CI_END="0.026182981069149867" CI_START="-0.04789720756089195" DF="1" EFFECT_SIZE="-0.010857113245871039" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" I2="0.0" ID="CMP-001.14.20" LOG_CI_END="-1.5819809082750584" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:17:16 +0200" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.7669026831292087" P_Z="0.5656291973462106" STUDIES="2" TAU2="0.0" TOTAL_1="327" TOTAL_2="324" WEIGHT="100.0" Z="0.5745004523206757">
<NAME>Poor memory</NAME>
<DICH_DATA CI_END="0.025891068127807476" CI_START="-0.04967057622322213" EFFECT_SIZE="-0.011889754047707327" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:17:08 +0200" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.01927628388762503" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="3.715751205163124E-4" WEIGHT="96.11725477713664"/>
<DICH_DATA CI_END="0.20268198318425426" CI_START="-0.1732702184783719" EFFECT_SIZE="0.01470588235294118" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:17:16 +0200" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.09590793622436156" STUDY_ID="STD-Pelc-1992" TOTAL_1="48" TOTAL_2="34" VAR="0.009198332230816203" WEIGHT="3.8827452228633565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08506840529001448" CI_END="0.0648029717632773" CI_START="-0.022641920201820764" DF="1" EFFECT_SIZE="0.02108052578072827" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" I2="0.0" ID="CMP-001.14.21" LOG_CI_END="-1.1884050776047232" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6761185613522172" MODIFIED="2010-07-01 09:18:29 +0200" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.7705428723388469" P_Z="0.34466636232992476" STUDIES="2" TAU2="0.0" TOTAL_1="312" TOTAL_2="327" WEIGHT="100.0" Z="0.9449853588220207">
<NAME>Sexual dysfunction</NAME>
<DICH_DATA CI_END="0.1303139176198574" CI_START="-0.06315585046179023" EFFECT_SIZE="0.03357903357903358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:18:16 +0200" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.049355439591674245" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" VAR="0.0024359594172874057" WEIGHT="20.42879117056435"/>
<DICH_DATA CI_END="0.0668864232025091" CI_START="-0.031143004589235086" EFFECT_SIZE="0.017871709306637007" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:18:29 +0200" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.02500796661698577" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="6.253983943162747E-4" WEIGHT="79.57120882943565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0851644834076713" CI_START="-0.008041754449569706" DF="0" EFFECT_SIZE="0.0385613644790508" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" I2="0.0" ID="CMP-001.14.22" LOG_CI_END="-1.0697414835892962" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4138476071541108" MODIFIED="2010-07-01 09:19:22 +0200" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Z="0.10485561294538237" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="1.6217559534893327">
<NAME>Skin rush</NAME>
<DICH_DATA CI_END="0.0851644834076713" CI_START="-0.008041754449569706" EFFECT_SIZE="0.0385613644790508" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:19:22 +0200" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.02377753841204224" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="5.653713329361443E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.676857219946701" CI_END="0.1716817032816106" CI_START="-0.11413300532329551" DF="1" EFFECT_SIZE="0.02877434897915753" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="73" I2="91.43605183172254" ID="CMP-001.14.23" LOG_CI_END="-0.7652759866518012" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5409944935177329" MODIFIED="2010-07-01 09:20:17 +0200" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="6.328306412332063E-4" P_Z="0.6931099875735729" STUDIES="2" TAU2="0.009734051464641612" TOTAL_1="358" TOTAL_2="370" WEIGHT="100.0" Z="0.3946381062963082">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="0.1474689959368895" CI_START="0.006973632792002762" EFFECT_SIZE="0.07722131436444613" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:20:08 +0200" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.03584131245601863" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0012845996785699563" WEIGHT="48.24858073197706"/>
<DICH_DATA CI_END="0.02910107346853322" CI_START="-0.061887958714434865" EFFECT_SIZE="-0.01639344262295082" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:20:17 +0200" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.023211914326150367" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="5.387929666845447E-4" WEIGHT="51.75141926802294"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.09402790779949621" CI_START="-0.17259933637092478" DF="0" EFFECT_SIZE="-0.03928571428571429" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.14.24" LOG_CI_END="-1.026743227203634" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:21:12 +0200" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Z="0.5635512451564292" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.5775747736995345">
<NAME>Strangury</NAME>
<DICH_DATA CI_END="0.09402790779949621" CI_START="-0.17259933637092478" EFFECT_SIZE="-0.039285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:21:12 +0200" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.06801840397924214" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.004626503279883382" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.041744314142711916" CI_START="-0.07860007980826623" DF="0" EFFECT_SIZE="-0.01842788283277716" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" I2="0.0" ID="CMP-001.14.25" LOG_CI_END="-1.37940266999134" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:21:56 +0200" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Z="0.5483437868845483" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="0.6002437750158884">
<NAME>Sweating</NAME>
<DICH_DATA CI_END="0.041744314142711916" CI_START="-0.07860007980826623" EFFECT_SIZE="-0.01842788283277716" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:21:56 +0200" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.030700664629615484" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="9.425308087001233E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.006827661257190115" CI_START="-0.09281391580374179" DF="0" EFFECT_SIZE="-0.049820788530465954" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" I2="0.0" ID="CMP-001.14.26" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:22:46 +0200" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Z="0.023133521600838557" STUDIES="1" TAU2="0.0" TOTAL_1="279" TOTAL_2="290" WEIGHT="100.0" Z="2.271222341664734">
<NAME>Vertigo</NAME>
<DICH_DATA CI_END="-0.006827661257190115" CI_START="-0.09281391580374179" EFFECT_SIZE="-0.049820788530465954" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:22:46 +0200" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.021935672090099684" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="4.811737100443783E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.501055351277966" CI_END="1.7954638789375503" CI_START="1.0137754270941295" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3491468269621352" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.2541766724329088" LOG_CI_START="0.005941760149603633" LOG_EFFECT_SIZE="0.13005921629125622" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.702051472378485" P_Q="0.0" P_Z="0.03999587336243691" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3022" TOTAL_2="2741" WEIGHT="100.00000000000001" Z="2.0537915270954503">
<NAME>Drop out due to adverse events</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.371505854281761" CI_START="0.7142340049756348" EFFECT_SIZE="2.2945544554455446" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8675562147793348" LOG_CI_START="-0.1461594767115504" LOG_EFFECT_SIZE="0.36069836903389213" MODIFIED="2009-04-07 11:27:21 +0200" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="0.5954616151553476" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.35457453512341525" WEIGHT="5.996438515026496"/>
<DICH_DATA CI_END="16.05241096789361" CI_START="0.06396823794869408" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2055402698509683" LOG_CI_START="-1.1940356120727853" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2009-04-07 11:27:39 +0200" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="1.409522751134196" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" VAR="1.9867543859649124" WEIGHT="1.0701797936784383"/>
<DICH_DATA CI_END="8.008396938080814" CI_START="0.013874326156682559" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9035455909130526" LOG_CI_START="-1.8577881003523773" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-04-07 11:27:48 +0200" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="1.6220210790715333" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="2.630952380952381" WEIGHT="0.8081424864451566"/>
<DICH_DATA CI_END="2.477634201110126" CI_START="0.9752278985316033" EFFECT_SIZE="1.554431727442108" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" LOG_CI_END="0.3940371873644249" LOG_CI_START="-0.01089388326639522" LOG_EFFECT_SIZE="0.19157165204901486" MODIFIED="2009-04-07 11:27:59 +0200" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.2378585153296706" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="0.05657667331483514" WEIGHT="37.58058355658301"/>
<DICH_DATA CI_END="6.109091490204688" CI_START="0.5494005952207645" EFFECT_SIZE="1.83203125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7859766292069016" LOG_CI_START="-0.2601108744004341" LOG_EFFECT_SIZE="0.2629328774032337" MODIFIED="2009-04-07 11:28:11 +0200" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.6144769778356051" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.37758195628997865" WEIGHT="5.631054035931677"/>
<DICH_DATA CI_END="22.740143545768014" CI_START="0.1911891461717587" EFFECT_SIZE="2.0851063829787235" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.356793201817775" LOG_CI_START="-0.7185367663042203" LOG_EFFECT_SIZE="0.3191282177567774" MODIFIED="2009-04-07 11:28:54 +0200" MODIFIED_BY="[Empty name]" ORDER="679" O_E="0.0" SE="1.2190590963238839" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="1.4861050803300044" WEIGHT="1.4307093266847064"/>
<DICH_DATA CI_END="131.2766945785389" CI_START="0.3732574175280195" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1181876330635214" LOG_CI_START="-0.42799155303500774" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-04-07 11:29:05 +0200" MODIFIED_BY="[Empty name]" ORDER="680" O_E="0.0" SE="1.4956382577045184" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="2.2369337979094075" WEIGHT="0.9504905334475033"/>
<DICH_DATA CI_END="77.95335151989555" CI_START="0.1396989326010007" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8918347919470073" LOG_CI_START="-0.8548069121912323" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2009-04-07 11:29:27 +0200" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.0" SE="1.6133909331065124" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="2.603030303030303" WEIGHT="0.8168112358839913"/>
<DICH_DATA CI_END="140.20208871572746" CI_START="0.3774952676155315" EFFECT_SIZE="7.275" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1467544837515926" LOG_CI_START="-0.42308848843570274" LOG_EFFECT_SIZE="0.861832997657945" MODIFIED="2009-04-07 11:29:39 +0200" MODIFIED_BY="[Empty name]" ORDER="682" O_E="0.0" SE="1.5095384827906901" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="2.2787064310260186" WEIGHT="0.9330663967557763"/>
<DICH_DATA CI_END="2.630935625442846" CI_START="0.3044808547328643" EFFECT_SIZE="0.8950248756218906" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4201102217622591" LOG_CI_START="-0.5164400099121341" LOG_EFFECT_SIZE="-0.04816489407493748" MODIFIED="2009-04-07 11:29:55 +0200" MODIFIED_BY="[Empty name]" ORDER="683" O_E="0.0" SE="0.5501342420839538" STUDY_ID="STD-Mason-2006" TOTAL_1="335" TOTAL_2="257" VAR="0.3026476843132863" WEIGHT="7.025278926835397"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:30:05 +0200" MODIFIED_BY="[Empty name]" ORDER="684" O_E="0.0" SE="0.0" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.52365960282181" CI_START="0.23762090670140365" EFFECT_SIZE="4.863013698630137" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.997926337162761" LOG_CI_START="-0.6241153512934844" LOG_EFFECT_SIZE="0.6869054929346382" MODIFIED="2009-04-07 11:30:21 +0200" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="1.540200267114884" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="2.37221686282076" WEIGHT="0.8962858464522738"/>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-05-19 14:24:00 +0200" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Niederhofer-2002" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="1.5794512677258061"/>
<DICH_DATA CI_END="1.6689846987710526" CI_START="0.501895519164091" EFFECT_SIZE="0.9152354570637119" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.22245235509161349" LOG_CI_START="-0.2993866816062402" LOG_EFFECT_SIZE="-0.03846716325731332" MODIFIED="2009-05-19 14:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.30653083330121134" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="0.093961151764335" WEIGHT="22.62833478451146"/>
<DICH_DATA CI_END="13.90320052871072" CI_START="0.15673645197704286" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.143114786726008" LOG_CI_START="-0.8048299885253013" LOG_EFFECT_SIZE="0.16914239910035345" MODIFIED="2009-05-19 14:19:21 +0200" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="1.1442324034647686" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="1.3092677931387608" WEIGHT="1.623949210393753"/>
<DICH_DATA CI_END="1.1725297866360893" CI_START="0.0550655323419705" EFFECT_SIZE="0.2540983606557377" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.06912388422923015" LOG_CI_START="-1.2591201579101812" LOG_EFFECT_SIZE="-0.5949981368404755" MODIFIED="2009-05-19 14:19:32 +0200" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.7802171252667377" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="124" VAR="0.6087387625594923" WEIGHT="3.492769854053559"/>
<DICH_DATA CI_END="21.79775745717547" CI_START="0.18350511550825907" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.338411815894934" LOG_CI_START="-0.7363518245669717" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-05-19 14:19:41 +0200" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.21872643265298" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="1.4852941176470589" WEIGHT="1.431490486362307"/>
<DICH_DATA CI_END="104.60780219777283" CI_START="0.24481666914504813" EFFECT_SIZE="5.0606060606060606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0195640776963804" LOG_CI_START="-0.611159015156989" LOG_EFFECT_SIZE="0.7042025312696958" MODIFIED="2009-05-19 14:19:50 +0200" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="1.5452997670313997" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="2.3879513699872983" WEIGHT="0.8903801080643329"/>
<DICH_DATA CI_END="5.243492697631193" CI_START="0.42910329617059695" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7196206675190225" LOG_CI_START="-0.36743814940766006" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-05-19 14:19:56 +0200" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.6385437300906612" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="0.40773809523809523" WEIGHT="5.214583635164369"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.343858319917686" CI_END="0.9923585036071325" CI_START="0.8288120828969698" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9069061243343479" ESTIMABLE="YES" EVENTS_1="1456" EVENTS_2="1391" I2="59.880680037663254" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-0.0033314044474223137" LOG_CI_START="-0.08154392615913608" LOG_EFFECT_SIZE="-0.04243766530327918" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.706449642089325E-4" P_Q="0.0" P_Z="0.03342586539920156" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.022816973517272604" TOTALS="YES" TOTAL_1="3200" TOTAL_2="2911" WEIGHT="100.0" Z="2.1269304137507454">
<NAME>Drop out</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6873309530980731" CI_START="1.070981730783712" EFFECT_SIZE="1.3442844284428443" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="88" LOG_CI_END="0.22720027346501773" LOG_CI_START="0.02978206253354126" LOG_EFFECT_SIZE="0.1284911679992795" MODIFIED="2009-04-07 11:10:10 +0200" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.11596443433705406" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.013447750031112923" WEIGHT="5.8202737275460645"/>
<DICH_DATA CI_END="2.932527422432911" CI_START="0.5328168418980048" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4672420819489003" LOG_CI_START="-0.27342205593278746" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-04-07 11:10:24 +0200" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="0.435069780938316" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.18928571428571428" WEIGHT="0.9951341017490729"/>
<DICH_DATA CI_END="1.2124062437405667" CI_START="0.7286488100700226" EFFECT_SIZE="0.9399033816425121" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="69" LOG_CI_END="0.08364816426362516" LOG_CI_START="-0.13748173999217883" LOG_EFFECT_SIZE="-0.02691678786427684" MODIFIED="2009-04-07 11:10:36 +0200" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.12989280037053896" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" VAR="0.016872139588100687" WEIGHT="5.318098621780835"/>
<DICH_DATA CI_END="1.3119615968094858" CI_START="0.7622174326076812" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" LOG_CI_END="0.11792112273946964" LOG_CI_START="-0.11792112273946966" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:10:50 +0200" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.13853490243227223" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="0.01919191919191919" WEIGHT="5.024427069919076"/>
<DICH_DATA CI_END="1.1382603303190697" CI_START="0.8968677690094573" EFFECT_SIZE="1.0103806228373702" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="189" LOG_CI_END="0.05624160045196912" LOG_CI_START="-0.04727158306822835" LOG_EFFECT_SIZE="0.004485008691870408" MODIFIED="2009-04-07 11:11:46 +0200" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="0.060804156398286284" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="0.0036971454353072588" WEIGHT="7.960687589992573"/>
<DICH_DATA CI_END="1.0388516888068933" CI_START="0.7199256334218868" EFFECT_SIZE="0.8648097826086957" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="92" LOG_CI_END="0.016553550126632108" LOG_CI_START="-0.14271236282228142" LOG_EFFECT_SIZE="-0.06307940634782465" MODIFIED="2009-04-07 11:12:04 +0200" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="0.09355358564517573" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.008752273387069229" WEIGHT="6.68595669529133"/>
<DICH_DATA CI_END="1.128099793924746" CI_START="0.6005155262367183" EFFECT_SIZE="0.8230683090705487" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" LOG_CI_END="0.05234751989007125" LOG_CI_START="-0.2214757594987743" LOG_EFFECT_SIZE="-0.08456411980435151" MODIFIED="2009-04-07 11:12:16 +0200" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.1608451497601012" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="0.025871162201349378" WEIGHT="4.335155055539746"/>
<DICH_DATA CI_END="1.0567795937507052" CI_START="0.5561971306539394" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.02398441852866084" LOG_CI_START="-0.2547712559327998" LOG_EFFECT_SIZE="-0.11539341870206953" MODIFIED="2009-04-07 11:12:28 +0200" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.16374246304150472" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.02681159420289854" WEIGHT="4.253006431608168"/>
<DICH_DATA CI_END="2.006858154886235" CI_START="0.5014203006694252" EFFECT_SIZE="1.0031347962382444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.30251667755615436" LOG_CI_START="-0.2997980870307048" LOG_EFFECT_SIZE="0.001359295262724807" MODIFIED="2009-04-07 11:12:40 +0200" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.3538026742244909" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.12517633228840125" WEIGHT="1.4262173316308016"/>
<DICH_DATA CI_END="4.22118128896597" CI_START="0.6700760292119776" EFFECT_SIZE="1.6818181818181819" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6254340043948347" LOG_CI_START="-0.1738759179052571" LOG_EFFECT_SIZE="0.22577904324478879" MODIFIED="2009-07-09 10:28:54 +0200" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="0.46951860500700127" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="33" TOTAL_2="37" VAR="0.22044772044772046" WEIGHT="0.8676582461068659"/>
<DICH_DATA CI_END="1.2265829270715392" CI_START="0.8018707216448698" EFFECT_SIZE="0.9917464075498997" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="109" LOG_CI_END="0.08869691540591486" LOG_CI_START="-0.09589564343888432" LOG_EFFECT_SIZE="-0.0035993640164847357" MODIFIED="2009-04-07 11:13:30 +0200" MODIFIED_BY="[Empty name]" ORDER="663" O_E="0.0" SE="0.10843058281333802" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="290" VAR="0.011757191289240153" WEIGHT="6.10486526244677"/>
<DICH_DATA CI_END="1.4793952951347453" CI_START="1.0590307858360573" EFFECT_SIZE="1.2516889238020423" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="114" LOG_CI_END="0.17008423319766736" LOG_CI_START="0.02490858515411869" LOG_EFFECT_SIZE="0.09749640917589299" MODIFIED="2009-04-07 11:13:59 +0200" MODIFIED_BY="[Empty name]" ORDER="664" O_E="0.0" SE="0.08527689429182825" STUDY_ID="STD-Mason-2006" TOTAL_1="335" TOTAL_2="257" VAR="0.00727214870005965" WEIGHT="7.014847963354886"/>
<DICH_DATA CI_END="1.3069837840613303" CI_START="0.41829394081207233" EFFECT_SIZE="0.7393939393939394" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.11627019925891341" LOG_CI_START="-0.3785184263372296" LOG_EFFECT_SIZE="-0.13112411353915807" MODIFIED="2009-04-07 11:14:08 +0200" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.290641287918372" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.08447235824285003" WEIGHT="1.967302939096506"/>
<DICH_DATA CI_END="1.4098108542249528" CI_START="0.5000714695028261" EFFECT_SIZE="0.8396464646464646" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.14916084990603382" LOG_CI_START="-0.3009679224788117" LOG_EFFECT_SIZE="-0.0759035362863889" MODIFIED="2009-04-07 11:14:18 +0200" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.2644078690722171" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.0699115212273107" WEIGHT="2.2762217621107124"/>
<DICH_DATA CI_END="0.9189151769611317" CI_START="0.6843636157396393" EFFECT_SIZE="0.7930145730458871" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="115" LOG_CI_END="-0.03672457553216082" LOG_CI_START="-0.16471308782693245" LOG_EFFECT_SIZE="-0.10071883167954665" MODIFIED="2009-04-07 11:14:30 +0200" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="0.07518108567530254" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="0.005652195643317181" WEIGHT="7.414006939042568"/>
<DICH_DATA CI_END="0.896050227163971" CI_START="0.5006457459668372" EFFECT_SIZE="0.6697788697788698" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" LOG_CI_END="-0.047667645729861804" LOG_CI_START="-0.3004694697232688" LOG_EFFECT_SIZE="-0.17406855772656527" MODIFIED="2009-04-07 11:21:41 +0200" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.14849704280293818" STUDY_ID="STD-Pelc-1992" TOTAL_1="55" TOTAL_2="47" VAR="0.022051371721217652" WEIGHT="4.704221129249997"/>
<DICH_DATA CI_END="0.9225760102224991" CI_START="0.44353391703304534" EFFECT_SIZE="0.6396825396825396" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="30" LOG_CI_END="-0.03499784255611491" LOG_CI_START="-0.35307316406882966" LOG_EFFECT_SIZE="-0.1940355033124723" MODIFIED="2009-05-19 14:08:14 +0200" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.1868390183548033" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="0.03490881877978652" WEIGHT="3.6564351792559546"/>
<DICH_DATA CI_END="0.9508822873519354" CI_START="0.5953402045764642" EFFECT_SIZE="0.7523951458377688" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="77" LOG_CI_END="-0.02187324238713517" LOG_CI_START="-0.22523478763787205" LOG_EFFECT_SIZE="-0.12355401501250363" MODIFIED="2009-05-19 14:08:28 +0200" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.11945557833616699" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="124" VAR="0.014269635195628128" WEIGHT="5.691289255897037"/>
<DICH_DATA CI_END="1.8911067161013053" CI_START="0.611800714038889" EFFECT_SIZE="1.0756302521008403" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.2767160369921748" LOG_CI_START="-0.21339002048149966" LOG_EFFECT_SIZE="0.03166300825533759" MODIFIED="2009-07-10 17:12:33 +0200" MODIFIED_BY="[Empty name]" ORDER="958" O_E="0.0" SE="0.2878907242241479" STUDY_ID="STD-Rousseaux-1996" TOTAL_1="63" TOTAL_2="64" VAR="0.08288106909430439" WEIGHT="1.9969207800852031"/>
<DICH_DATA CI_END="0.8959351513922653" CI_START="0.5527173499519256" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="81" LOG_CI_END="-0.047723423833097765" LOG_CI_START="-0.25749690257921887" LOG_EFFECT_SIZE="-0.15261016320615833" MODIFIED="2009-05-19 14:09:11 +0200" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.12322197981093838" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="0.015183656308527306" WEIGHT="5.5543978790079525"/>
<DICH_DATA CI_END="1.3319520995710672" CI_START="0.6357033541573495" EFFECT_SIZE="0.9201773835920177" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="44" LOG_CI_END="0.12448860676669621" LOG_CI_START="-0.19674549709843187" LOG_EFFECT_SIZE="-0.03612844516586783" MODIFIED="2009-05-19 14:09:24 +0200" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.1886945027448357" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="0.03560561536612081" WEIGHT="3.61282547965597"/>
<DICH_DATA CI_END="1.080451785125026" CI_START="0.7971580364011128" EFFECT_SIZE="0.9280575539568345" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="139" LOG_CI_END="0.03360539137534645" LOG_CI_START="-0.09845557128503872" LOG_EFFECT_SIZE="-0.032425089954846116" MODIFIED="2009-05-19 14:09:35 +0200" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.07757326317901835" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="0.006017611160241243" WEIGHT="7.320050559631925"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.100186609145224" CI_END="0.9563789632319168" CI_START="0.8733455784255648" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9139197660833365" ESTIMABLE="YES" EVENTS_1="864" EVENTS_2="784" I2="34.06728611509674" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.019369985309060277" LOG_CI_START="-0.05881387415712506" LOG_EFFECT_SIZE="-0.039091929733092654" METHOD="MH" MODIFIED="2010-07-01 09:24:02 +0200" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.16802163292038552" P_Q="0.0" P_Z="1.0235081427347975E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0011407033226549807" TOTALS="YES" TOTAL_1="1082" TOTAL_2="904" WEIGHT="100.0" Z="3.88495032313688">
<NAME>Post-treatment: Return to any drinking</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9836175456931882" CI_START="0.5252057212297221" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="-0.007173732953074504" LOG_CI_START="-0.2796705516515517" LOG_EFFECT_SIZE="-0.1434221423023131" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.16006598018449253" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.025621118012422357" WEIGHT="2.005944854549116"/>
<DICH_DATA CI_END="1.0104402626178592" CI_START="0.8739393113759735" EFFECT_SIZE="0.9397145669291339" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="127" LOG_CI_END="0.004510643054383447" LOG_CI_START="-0.05851872485947342" LOG_EFFECT_SIZE="-0.027004040902544983" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.037023762713002575" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.00137075900542872" WEIGHT="21.375091796189597"/>
<DICH_DATA CI_END="1.0733459776524263" CI_START="0.6380970759711626" EFFECT_SIZE="0.8275862068965517" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.03073973311809193" LOG_CI_START="-0.19511324549279208" LOG_EFFECT_SIZE="-0.08218675618735007" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.13266715762630807" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.017600574712643674" WEIGHT="2.864411792213491"/>
<DICH_DATA CI_END="1.0195447887205265" CI_START="0.9025996801551246" EFFECT_SIZE="0.9592918222329279" ESTIMABLE="YES" EVENTS_1="315" EVENTS_2="161" LOG_CI_END="0.008406309140070227" LOG_CI_START="-0.04450482471227122" LOG_EFFECT_SIZE="-0.018049257786100493" MODIFIED="2009-06-06 13:18:03 +0200" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.031080261939202016" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="9.659826822094094E-4" WEIGHT="25.482078336072092"/>
<DICH_DATA CI_END="0.9335804258191742" CI_START="0.7788506960171309" EFFECT_SIZE="0.8527131782945736" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="129" LOG_CI_END="-0.02984826262660942" LOG_CI_START="-0.10854578765543849" LOG_EFFECT_SIZE="-0.06919702514102394" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.04622731576096581" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="0.002136964722464038" WEIGHT="16.378332725122508"/>
<DICH_DATA CI_END="1.0553172849492605" CI_START="0.7132665365772299" EFFECT_SIZE="0.867595818815331" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="98" LOG_CI_END="0.023383051469049038" LOG_CI_START="-0.146748150745561" LOG_EFFECT_SIZE="-0.06168254963825599" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.0999359103438951" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="0.00998718617626304" WEIGHT="4.824161653535541"/>
<DICH_DATA CI_END="0.9790212057531495" CI_START="0.8737378440823826" EFFECT_SIZE="0.9248826291079812" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="213" LOG_CI_END="-0.00920790120826496" LOG_CI_START="-0.05861885334602459" LOG_EFFECT_SIZE="-0.03391337727714478" MODIFIED="2009-06-06 12:59:11 +0200" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.02902423787387777" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="8.424063841594408E-4" WEIGHT="27.06997884231765"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.421234296156438" CI_END="12.766373136176313" CI_START="5.079394866407749" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="8.922884001292031" ESTIMABLE="YES" I2="51.28259023822293" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2010-11-23 11:18:31 +0100" MODIFIED_BY="Laura Amato" NO="18" NOTES="&lt;p&gt;CCAD values refer to the entire study duration (treatment and post-treatment). Exception: Anton (2006) refers to the post-treatment period only. Whithworth (1996) reports both, values for the entire duration and the post-treatment period, and data for the entire study period are considered. &lt;/p&gt;&lt;p&gt;In Barrias (1997), Ladewig (1993) and Tempesta (2000), the simple sizes in the post-treatment phase were not provided for different treatment groups separately and thus estimated from the overall treatment under the assumption of equal distributions.&lt;/p&gt;" NOTES_MODIFIED="2010-11-23 11:18:31 +0100" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.03673284565964041" P_Q="1.0" P_Z="5.3602437390461475E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="16.789683800109238" TOTALS="YES" TOTAL_1="1617" TOTAL_2="1452" UNITS="" WEIGHT="100.0" Z="4.550170604628902">
<NAME>Post-treatment: Continuous abstinence</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.078578417599122" CI_START="-5.078578417599122" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="63.5" MEAN_2="63.5" MODIFIED="2009-06-23 11:23:11 +0200" MODIFIED_BY="[Empty name]" ORDER="291" SD_1="31.5" SD_2="32.6" SE="2.5911590507061866" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" WEIGHT="16.361279102143783"/>
<CONT_DATA CI_END="18.25440054672396" CI_START="1.145599453276045" EFFECT_SIZE="9.700000000000003" ESTIMABLE="YES" MEAN_1="41.7" MEAN_2="32.0" MODIFIED="2009-06-08 09:21:09 +0200" MODIFIED_BY="[Empty name]" ORDER="292" SD_1="39.0" SD_2="36.8" SE="4.36457027486218" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" WEIGHT="10.729941193044267"/>
<CONT_DATA CI_END="17.607550150067098" CI_START="-0.4075501500670935" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" MEAN_1="61.6" MEAN_2="53.0" MODIFIED="2009-06-08 09:22:43 +0200" MODIFIED_BY="[Empty name]" ORDER="293" SD_1="38.9" SD_2="35.3" SE="4.5957733004879175" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" WEIGHT="10.143597328922866"/>
<CONT_DATA CI_END="24.952220184507887" CI_START="-3.1522201845078914" EFFECT_SIZE="10.899999999999999" ESTIMABLE="YES" MEAN_1="30.2" MEAN_2="19.3" MODIFIED="2009-06-06 20:53:08 +0200" MODIFIED_BY="[Empty name]" ORDER="294" SD_1="31.4" SD_2="23.6" SE="7.169631837804168" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" WEIGHT="5.639146762168173"/>
<CONT_DATA CI_END="16.621290120479273" CI_START="3.7787098795207203" EFFECT_SIZE="10.199999999999996" ESTIMABLE="YES" MEAN_1="58.3" MEAN_2="48.1" MODIFIED="2009-06-08 13:17:21 +0200" MODIFIED_BY="[Empty name]" ORDER="935" SD_1="37.1" SD_2="35.0" SE="3.2762286302858583" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" WEIGHT="13.971843641980263"/>
<CONT_DATA CI_END="23.49032469671441" CI_START="2.709675303285593" EFFECT_SIZE="13.100000000000001" ESTIMABLE="YES" MEAN_1="46.6" MEAN_2="33.5" MODIFIED="2009-09-25 08:48:36 +0200" MODIFIED_BY="[Empty name]" ORDER="295" SD_1="42.0" SD_2="40.8" SE="5.301283482080264" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="122" WEIGHT="8.565913729040725"/>
<CONT_DATA CI_END="26.383004147210666" CI_START="9.016995852789325" EFFECT_SIZE="17.699999999999996" ESTIMABLE="YES" MEAN_1="53.8" MEAN_2="36.1" MODIFIED="2009-06-23 17:20:54 +0200" MODIFIED_BY="[Empty name]" ORDER="296" SD_1="38.9" SD_2="34.0" SE="4.430185562439463" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" WEIGHT="10.559908980235114"/>
<CONT_DATA CI_END="19.549289409454758" CI_START="1.250710590545241" EFFECT_SIZE="10.399999999999999" ESTIMABLE="YES" MEAN_1="57.4" MEAN_2="47.0" MODIFIED="2009-06-06 20:53:37 +0200" MODIFIED_BY="[Empty name]" ORDER="297" SD_1="42.2" SD_2="42.6" SE="4.668090578002037" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" WEIGHT="9.967458327836763"/>
<CONT_DATA CI_END="13.068927126374561" CI_START="0.3310728736254447" EFFECT_SIZE="6.700000000000003" ESTIMABLE="YES" MEAN_1="32.1" MEAN_2="25.4" MODIFIED="2009-06-06 20:54:52 +0200" MODIFIED_BY="[Empty name]" ORDER="298" SD_1="36.0" SD_2="32.7" SE="3.2495123260487655" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" WEIGHT="14.06091093462805"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.146811406927777" CI_END="1.030131995684268" CI_START="0.9186081097382446" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.972773152043379" ESTIMABLE="YES" EVENTS_1="708" EVENTS_2="702" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.012892876476525877" LOG_CI_START="-0.03686972482379687" LOG_EFFECT_SIZE="-0.011988424173635508" METHOD="MH" MODIFIED="2010-07-11 16:10:13 +0200" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.5284784269966569" P_Q="0.0" P_Z="0.3449862490790736" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1100" TOTAL_2="1032" WEIGHT="100.00000000000001" Z="0.9443589763287783">
<NAME>Sensitivity analysis: Return to heavy drinking</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0527422595128408" CI_START="0.8611081056302221" EFFECT_SIZE="0.9521160080609831" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="226" LOG_CI_END="0.022322056871481952" LOG_CI_START="-0.06494232272583918" LOG_EFFECT_SIZE="-0.02131013292717863" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1211" O_E="0.0" SE="0.05125952854111209" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0026275392662570853" WEIGHT="31.388921977083758"/>
<DICH_DATA CI_END="1.1026593433726504" CI_START="0.9566831786155262" EFFECT_SIZE="1.0270811289999715" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="242" LOG_CI_END="0.04244136181071774" LOG_CI_START="-0.01923186218108108" LOG_EFFECT_SIZE="0.011604749814818327" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1214" O_E="0.0" SE="0.036227157060164966" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="0.0013124069086618605" WEIGHT="33.768660307770986"/>
<DICH_DATA CI_END="1.124195745553654" CI_START="0.6177255581966629" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.050841937400551915" LOG_CI_START="-0.20920442949580154" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1212" O_E="0.0" SE="0.15275252316519466" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.02333333333333333" WEIGHT="4.207925227804973"/>
<DICH_DATA CI_END="1.0990722686641847" CI_START="0.7638179144714283" EFFECT_SIZE="0.9162374627270263" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="119" LOG_CI_END="0.041026250066957246" LOG_CI_START="-0.11701015996525463" LOG_EFFECT_SIZE="-0.03799195494914869" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1215" O_E="0.0" SE="0.0928313695457676" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="0.008617663171742868" WEIGHT="18.94103137205746"/>
<DICH_DATA CI_END="1.2975333545776278" CI_START="0.8203493377420609" EFFECT_SIZE="1.0317124735729386" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.11311853069993477" LOG_CI_START="-0.08600116817013673" LOG_EFFECT_SIZE="0.013558681264899017" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1213" O_E="0.0" SE="0.11696389677468587" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.013680553148719372" WEIGHT="5.7193926228498615"/>
<DICH_DATA CI_END="1.3030974249659697" CI_START="0.7603132008622625" EFFECT_SIZE="0.9953703703703703" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.11497688658242604" LOG_CI_START="-0.11900746905307713" LOG_EFFECT_SIZE="-0.002015291235325575" MODIFIED="2010-01-09 10:59:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1210" O_E="0.0" SE="0.13744356874153482" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.01889073458840901" WEIGHT="5.974068492432974"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-23 11:19:20 +0100" MODIFIED_BY="Laura Amato" NO="2">
<NAME>Acamprosate versus naltrexone</NAME>
<DICH_OUTCOME CHI2="1.1347399583361315" CI_END="1.104538162674073" CI_START="0.9571655668887115" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0282149078019365" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="311" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.043180725687255964" LOG_CI_START="-0.019012933104153976" LOG_EFFECT_SIZE="0.012083896291550981" METHOD="MH" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5670149010713403" P_Q="0.0" P_Z="0.44628618196148573" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.7616211036495006">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1196946561033325" CI_START="0.9520892550545833" EFFECT_SIZE="1.0324966106569162" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="241" LOG_CI_END="0.04909960548338721" LOG_CI_START="-0.02132233611060592" LOG_EFFECT_SIZE="0.013888634686390634" MODIFIED="2009-05-29 11:12:20 +0200" MODIFIED_BY="[Empty name]" ORDER="923" O_E="0.0" SE="0.041366197086544515" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0017111622614028438" WEIGHT="77.99669919283696"/>
<DICH_DATA CI_END="1.5410315328067663" CI_START="0.8639414044439961" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.18781152540490012" LOG_CI_START="-0.06351571190721128" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2009-04-07 10:01:56 +0200" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.14763086328702338" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.021794871794871787" WEIGHT="6.1236886102801416"/>
<DICH_DATA CI_END="1.1533188477883993" CI_START="0.8051503217024374" EFFECT_SIZE="0.9636363636363636" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.06194938942131728" LOG_CI_START="-0.09412302920822684" LOG_EFFECT_SIZE="-0.016086819893454805" MODIFIED="2009-04-07 10:05:13 +0200" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.09167771127392628" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.008404802744425389" WEIGHT="15.8796121968829"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.8227428882075514" CI_END="13.41890030479206" CI_START="-7.452040978241123" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.9834296632754684" ESTIMABLE="YES" I2="64.57346490260747" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-11-23 11:19:20 +0100" MODIFIED_BY="Laura Amato" NO="2" P_CHI2="0.09293756820375432" P_Q="1.0" P_Z="0.5752473505371558" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="39.780483053251395" TOTALS="YES" TOTAL_1="358" TOTAL_2="362" UNITS="" WEIGHT="99.99999999999999" Z="0.5603402943001881">
<NAME>Cumulative abstinence duration</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.127847110531202" CI_START="-5.127847110531202" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="76.9" MEAN_2="77.9" MODIFIED="2009-06-23 11:14:29 +0200" MODIFIED_BY="[Empty name]" ORDER="581" SD_1="26.0" SD_2="26.1" SE="2.1060831439205687" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" WEIGHT="64.1132462767976"/>
<CONT_DATA CI_END="22.37342024445639" CI_START="-2.1734202444563717" EFFECT_SIZE="10.100000000000009" ESTIMABLE="YES" MEAN_1="78.9" MEAN_2="68.8" MODIFIED="2010-01-10 19:04:32 +0100" MODIFIED_BY="[Empty name]" ORDER="582" SD_1="30.0" SD_2="34.8" SE="6.262064171213121" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" WEIGHT="35.88675372320239"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.049945919052275" CI_END="1.1451738096432997" CI_START="0.9475513855553496" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0416866275561028" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="266" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.0588714070604765" LOG_CI_START="-0.02339722900314297" LOG_EFFECT_SIZE="0.01773708902866675" METHOD="MH" MODIFIED="2010-07-01 12:19:52 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5915714503709815" P_Q="0.0" P_Z="0.39803542531462455" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.8451350927924429">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.158006914388587" CI_START="0.933135622549477" EFFECT_SIZE="1.0395082986559525" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="207" LOG_CI_END="0.06371115254499599" LOG_CI_START="-0.03005523101838692" LOG_EFFECT_SIZE="0.016827960763304527" MODIFIED="2009-12-04 11:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.05507883785621547" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0030336783795912744" WEIGHT="76.97935394595127"/>
<DICH_DATA CI_END="1.8499088141415099" CI_START="0.8446362264213071" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.26715032165102764" LOG_CI_START="-0.07333029563491479" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-12-04 11:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.2" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04" WEIGHT="5.838265043518415"/>
<DICH_DATA CI_END="1.2420613604153814" CI_START="0.7864553613196502" EFFECT_SIZE="0.9883449883449883" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" LOG_CI_END="0.09414305142152046" LOG_CI_START="-0.10432592260550373" LOG_EFFECT_SIZE="-0.005091435591991638" MODIFIED="2009-12-04 11:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.11658165778073999" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.013591282930905575" WEIGHT="17.182381010530307"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.223336163024154" CI_START="5.176663836975844" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-06-10 10:43:24 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="2.633828944636369E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="4.203015200472731">
<NAME>Gamma-glutamyl transpeptidase</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.223336163024154" CI_START="5.176663836975844" EFFECT_SIZE="9.7" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="11.5" MODIFIED="2009-04-07 10:59:56 +0200" MODIFIED_BY="[Empty name]" ORDER="650" SD_1="13.6" SD_2="5.3" SE="2.3078669805688543" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8065358563172493" CI_END="0.33086207000461826" CI_START="0.20722984101543301" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.26904595551002564" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="116" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.48035301746352627" LOG_CI_START="-0.6835477061894013" LOG_EFFECT_SIZE="-0.5701735321916571" METHOD="MH" MODIFIED="2010-07-01 09:31:13 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6681333057361811" P_Q="0.0" P_Z="1.4575692161717782E-17" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="8.530467941849427">
<NAME>Side effect: Diarrhea</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.36333152100778465" CI_START="0.21156674551789711" EFFECT_SIZE="0.2874491332628409" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="108" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:07:12 +0200" MODIFIED_BY="[Empty name]" ORDER="721" O_E="0.0" SE="0.03871621537104475" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0014989453326571215" WEIGHT="66.3623002357446"/>
<DICH_DATA CI_END="0.3965884043103607" CI_START="0.10341159568963931" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:07:22 +0200" MODIFIED_BY="[Empty name]" ORDER="722" O_E="0.0" SE="0.07479137650825796" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00559375" WEIGHT="17.782964952448708"/>
<DICH_DATA CI_END="0.3686257148019987" CI_START="0.05813243271086585" EFFECT_SIZE="0.21337907375643225" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:07:33 +0200" MODIFIED_BY="[Empty name]" ORDER="723" O_E="0.0" SE="0.0792089254037993" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.006274053863624642" WEIGHT="15.854734811806702"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19442953620342276" CI_END="-0.02716605412066138" CI_START="-0.13314180453645086" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.08015392932855613" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="113" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-07-01 09:33:12 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9073611797143534" P_Q="0.0" P_Z="0.0030287303639824283" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="2.9648068371673904">
<NAME>Side effect: Nausea</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.01830014908982483" CI_START="-0.1601740090055964" EFFECT_SIZE="-0.08923707904771061" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="101" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:50:17 +0200" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.03619297625743495" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0013099315303712502" WEIGHT="55.79666372968207"/>
<DICH_DATA CI_END="0.029805397358257588" CI_START="-0.17980539735825762" EFFECT_SIZE="-0.07500000000000001" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:50:24 +0200" MODIFIED_BY="[Empty name]" ORDER="762" O_E="0.0" SE="0.053473124090518596" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.002859375" WEIGHT="25.561463294962174"/>
<DICH_DATA CI_END="0.06269032502423058" CI_START="-0.18275893565887893" EFFECT_SIZE="-0.06003430531732418" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:51:03 +0200" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="0.06261575789636492" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0039207331369361855" WEIGHT="18.641872975355756"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.786218158255517" CI_END="-0.024893175501156026" CI_START="-0.07308682352055823" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.04898999951085713" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="249" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-07-13 11:55:17 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7801620049029327" P_Q="0.0" P_Z="6.756519425456515E-5" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1239" TOTAL_2="1245" WEIGHT="800.0" Z="3.984700830501931">
<NAME>Other side effects</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.04711782603036828" CI_START="-0.07864719255925416" DF="0" EFFECT_SIZE="-0.01576468326444294" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="63" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="-1.326814755674169" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:34:42 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6231689093334769" STUDIES="1" TAU2="0.0" TOTAL_1="303" TOTAL_2="309" WEIGHT="100.0" Z="0.4913641610758538">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="0.04711782603036828" CI_START="-0.07864719255925416" EFFECT_SIZE="-0.01576468326444294" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:34:42 +0200" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.032083502447402316" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0010293511292924704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6144318138487813E-32" CI_END="0.03311300153700628" CI_START="-0.10995691234318125" DF="0" EFFECT_SIZE="-0.03842195540308748" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.00000000000001" ID="CMP-002.07.02" LOG_CI_END="-1.480001450722504" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:35:24 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.29247339931261573" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="1.0527111782386278">
<NAME>Depression</NAME>
<DICH_DATA CI_END="0.03311300153700628" CI_START="-0.10995691234318125" EFFECT_SIZE="-0.03842195540308748" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:35:24 +0200" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.0364980976713615" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0013321111336282439" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.023484793065743276" CI_START="-0.09895649117895082" DF="0" EFFECT_SIZE="-0.03773584905660377" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="-1.6292132622127635" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:48:47 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.22700726817988326" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="1.2081040399604959">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="0.02348479306574327" CI_START="-0.0989564911789508" EFFECT_SIZE="-0.03773584905660377" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:48:47 +0200" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.031235595452389762" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="9.756624232653521E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.012901958385592827" CI_START="-0.25536562308953586" DF="0" EFFECT_SIZE="-0.13413379073756435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-002.07.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:49:24 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.030116796427168347" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="2.1685508983497854">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="-0.012901958385592827" CI_START="-0.25536562308953586" EFFECT_SIZE="-0.13413379073756435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:49:24 +0200" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.061854112273609485" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0038259312051562872" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0349764080890253" CI_START="-0.15092838064477146" DF="0" EFFECT_SIZE="-0.05797598627787308" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.07.05" LOG_CI_END="-1.4562247925478122" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:50:13 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2215326829319425" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="1.2224628084812963">
<NAME>Headache</NAME>
<DICH_DATA CI_END="0.0349764080890253" CI_START="-0.15092838064477146" EFFECT_SIZE="-0.05797598627787308" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:50:13 +0200" MODIFIED_BY="[Empty name]" ORDER="679" O_E="0.0" SE="0.04742556245935895" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0022491839745865574" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.07212899715013485" CI_START="-0.11398148428564084" DF="0" EFFECT_SIZE="-0.020926243567753" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.07.06" LOG_CI_END="-1.1418901060074984" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:55:31 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6593894335592394" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="0.44075630139791444">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="0.07212899715013485" CI_START="-0.11398148428564084" EFFECT_SIZE="-0.020926243567753" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:55:31 +0200" MODIFIED_BY="[Empty name]" ORDER="680" O_E="0.0" SE="0.04747803605162937" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0022541639073198182" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7192752946276761" CI_END="-0.01481132294619221" CI_START="-0.1266875950944814" DF="1" EFFECT_SIZE="-0.07074945902033682" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="117" I2="0.0" ID="CMP-002.07.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:56:32 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.3963817527914012" P_Z="0.013177935811232985" STUDIES="2" TAU2="0.0" TOTAL_1="358" TOTAL_2="362" WEIGHT="100.00000000000001" Z="2.47892406392937">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="0.02250936078583418" CI_START="-0.1269664084323465" EFFECT_SIZE="-0.05222852382325616" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="112" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:56:21 +0200" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.0" SE="0.03813227446963987" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0014540703562279486" WEIGHT="56.01887455605254"/>
<DICH_DATA CI_END="-0.00999161633317805" CI_START="-0.17868762894984083" EFFECT_SIZE="-0.09433962264150944" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:56:32 +0200" MODIFIED_BY="[Empty name]" ORDER="682" O_E="0.0" SE="0.043035487883276276" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0018520532173516193" WEIGHT="43.98112544394748"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.005769109720652629" CI_START="-0.10727520441949924" DF="0" EFFECT_SIZE="-0.056522157070075935" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" I2="0.0" ID="CMP-002.07.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 09:57:20 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.029053967072426662" STUDIES="1" TAU2="0.0" TOTAL_1="303" TOTAL_2="309" WEIGHT="100.0" Z="2.182753508831891">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="-0.005769109720652629" CI_START="-0.10727520441949924" EFFECT_SIZE="-0.056522157070075935" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 09:57:20 +0200" MODIFIED_BY="[Empty name]" ORDER="683" O_E="0.0" SE="0.02589488773760991" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="6.705452109434201E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.334043122070269E-4" CI_END="1.5799887633062295" CI_START="0.3664906443492899" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7609540721546456" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.19865399831426286" LOG_CI_START="-0.43593710740576835" LOG_EFFECT_SIZE="-0.11864155454575281" METHOD="MH" MODIFIED="2010-07-01 09:57:27 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9815740577066138" P_Q="0.0" P_Z="0.46364391378186387" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.7328598585247388">
<NAME>Drop outs due to adverse events</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7887879619939675" CI_START="0.3270358515169065" EFFECT_SIZE="0.7648514851485149" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2525588635446653" LOG_CI_START="-0.48540463491620583" LOG_EFFECT_SIZE="-0.11642288568577032" MODIFIED="2009-04-07 11:36:32 +0200" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.4334834119741476" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.18790786845674856" WEIGHT="73.94659817126762"/>
<DICH_DATA CI_END="3.138274863843685" CI_START="0.17923860222716867" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49669097832768017" LOG_CI_START="-0.7465684515442799" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-04-07 11:36:48 +0200" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="26.053401828732383"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 11:37:14 +0200" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="0.0" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.609127345193249" CI_END="1.3071868424384787" CI_START="0.9129822217566266" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.09244603878659" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="143" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.11633766779519271" LOG_CI_START="-0.03953767927640081" LOG_EFFECT_SIZE="0.03839999425939595" METHOD="MH" MODIFIED="2010-07-01 09:57:27 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4472832350715339" P_Q="0.0" P_Z="0.3342059276660775" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.9656768330452251">
<NAME>Drop outs</NAME>
<GROUP_LABEL_1>ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3496076658355525" CI_START="0.888981315101988" EFFECT_SIZE="1.0953428676200954" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="108" LOG_CI_END="0.13020753640132998" LOG_CI_START="-0.05110736707633316" LOG_EFFECT_SIZE="0.039550084662498416" MODIFIED="2009-04-07 11:22:37 +0200" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="0.1065052718260266" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.011343372926735816" WEIGHT="73.90738916150873"/>
<DICH_DATA CI_END="1.9721585701424056" CI_START="0.8278827443702059" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.2949418311778082" LOG_CI_START="-0.08203116934923461" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2009-04-07 11:22:50 +0200" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="0.2214358065560328" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04903381642512077" WEIGHT="17.09756935972216"/>
<DICH_DATA CI_END="1.4436307859204756" CI_START="0.4362429824808486" EFFECT_SIZE="0.7935828877005348" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.1594561349646518" LOG_CI_START="-0.3602715461516331" LOG_EFFECT_SIZE="-0.1004077055934907" MODIFIED="2009-04-07 11:23:05 +0200" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="0.30529061258121915" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="53" VAR="0.09320235813021605" WEIGHT="8.995041478769105"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-23 11:21:10 +0100" MODIFIED_BY="Laura Amato" NO="3">
<NAME>Acamprosate + naltrexone versus placebo</NAME>
<DICH_OUTCOME CHI2="14.346895770221755" CI_END="1.38560777107655" CI_START="0.3523636044508283" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6987401151870496" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="291" I2="93.02985108405409" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.14164031038790773" LOG_CI_START="-0.4530089561126056" LOG_EFFECT_SIZE="-0.15568432286234896" METHOD="MH" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.5203166352462105E-4" P_Q="0.0" P_Z="0.3047638500903189" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.22792516310023747" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="1.0262710574366658">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0389266781721378" CI_START="0.8894039084025911" EFFECT_SIZE="0.9612624241641926" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="254" LOG_CI_END="0.016584898482220792" LOG_CI_START="-0.050900966416262454" LOG_EFFECT_SIZE="-0.017158033967020862" MODIFIED="2009-05-29 11:12:47 +0200" MODIFIED_BY="[Empty name]" ORDER="924" O_E="0.0" SE="0.03964153110178796" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015714509880940222" WEIGHT="53.16437302812691"/>
<DICH_DATA CI_END="0.6929759451619714" CI_START="0.3415257097829695" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.1592818405176808" LOG_CI_START="-0.46657659740969704" LOG_EFFECT_SIZE="-0.3129292189636889" MODIFIED="2009-04-07 10:00:49 +0200" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.1805064613319495" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03258258258258258" WEIGHT="46.83562697187308"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.297348281519581" CI_START="-1.8973482815195757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-11-23 11:21:10 +0100" MODIFIED_BY="Laura Amato" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.29263047432761535" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="309" UNITS="" WEIGHT="100.0" Z="1.0523686222712236">
<NAME>Cumulative abstinence duration</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.297348281519581" CI_START="-1.8973482815195757" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="76.8" MODIFIED="2009-04-07 10:47:46 +0200" MODIFIED_BY="[Empty name]" ORDER="583" SD_1="25.9" SD_2="25.9" SE="2.090522230938394" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.096267357246875" CI_END="1.3490292302928903" CI_START="0.3783080470023612" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7143868794016319" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="256" I2="87.64862922782667" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1300213599145841" LOG_CI_START="-0.4221544207174267" LOG_EFFECT_SIZE="-0.14606653040142134" METHOD="MH" MODIFIED="2010-07-01 12:19:59 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.004435679001331683" P_Q="0.0" P_Z="0.2997662630607679" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18672701164993363" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="1.0369347913297964">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0507812730995194" CI_START="0.8595275460703318" EFFECT_SIZE="0.9503554330480197" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="226" LOG_CI_END="0.02151232423773458" LOG_CI_START="-0.06574020051893598" LOG_EFFECT_SIZE="-0.02211393814060068" MODIFIED="2009-12-04 12:17:32 +0100" MODIFIED_BY="[Empty name]" ORDER="380" O_E="0.0" SE="0.05125256494903154" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0026268254138546968" WEIGHT="55.55917670662249"/>
<DICH_DATA CI_END="0.7750049130173529" CI_START="0.3225786002138575" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" LOG_CI_END="-0.11069554434586686" LOG_CI_START="-0.4913644469820954" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-12-04 12:17:32 +0100" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="0.223606797749979" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.05000000000000001" WEIGHT="44.440823293377505"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.462277061330209" CI_START="-24.862277061330207" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2010-06-24 13:46:13 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2914116341409515" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="1.0550299689080482">
<NAME>Gamma-glutamyl transpeptidase</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.462277061330209" CI_START="-24.862277061330207" EFFECT_SIZE="-8.7" ESTIMABLE="YES" MEAN_1="22.2" MEAN_2="30.9" MODIFIED="2009-04-07 11:03:49 +0200" MODIFIED_BY="[Empty name]" ORDER="651" SD_1="28.0" SD_2="44.0" SE="8.246211251235321" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5486814204197937" CI_END="0.273955142370748" CI_START="0.12933662743515717" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.20164588490295257" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.5623205430764" LOG_CI_START="-0.8882784678468997" LOG_EFFECT_SIZE="-0.6954106364492011" METHOD="MH" MODIFIED="2010-07-01 12:01:31 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4588570601906826" P_Q="0.0" P_Z="4.6115680367956365E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="5.4656718362308725">
<NAME>Side effect: Diarrhoea</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2686313831998181" CI_START="0.11430670370134384" EFFECT_SIZE="0.19146904345058097" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="108" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-07 12:08:20 +0200" MODIFIED_BY="[Empty name]" ORDER="724" O_E="0.0" SE="0.03936926410785291" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015499389563938752" WEIGHT="87.81668273324426"/>
<DICH_DATA CI_END="0.48216249120543564" CI_START="0.0678375087945644" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:55:52 +0100" MODIFIED_BY="[Empty name]" ORDER="725" O_E="0.0" SE="0.10569709078304852" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.011171875000000001" WEIGHT="12.18331726675573"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.984643746328457" CI_END="0.14520890256852356" CI_START="0.08447561670436182" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.11484225963644269" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="205" I2="59.93848051443121" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.8380067567911448" LOG_CI_START="-1.073268629025411" LOG_EFFECT_SIZE="-0.9398982709126997" METHOD="MH" MODIFIED="2010-07-13 11:55:32 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.040687231120436484" P_Q="0.0" P_Z="1.2412678570504757E-13" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0019007099118950803" TOTALS="SUB" TOTAL_1="1260" TOTAL_2="1276" WEIGHT="400.0" Z="7.412300835955513">
<NAME>Other side effects</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.17458494035659217" CI_START="0.05184617004714275" DF="0" EFFECT_SIZE="0.11321555520186746" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="41" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="-0.7579932211236126" LOG_CI_START="-1.2852833200623377" LOG_EFFECT_SIZE="-0.9460938993471506" MODIFIED="2010-07-01 10:00:38 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.994405553067197E-4" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="309" WEIGHT="100.0" Z="3.61578350713333">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="0.17458494035659217" CI_START="0.05184617004714275" EFFECT_SIZE="0.11321555520186746" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:00:38 +0200" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.03131148614913263" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="9.804091648673244E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.528333732023368E-5" CI_END="0.2630856757404793" CI_START="0.13609412264822418" DF="1" EFFECT_SIZE="0.19958989919435174" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="66" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-0.5799027973579324" LOG_CI_START="-0.8661606298044517" LOG_EFFECT_SIZE="-0.6998614411806876" MODIFIED="2010-07-01 10:02:06 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.994630844317135" P_Z="7.234788251177444E-10" STUDIES="2" TAU2="0.0" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="6.160866680868509">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="0.27097388300693404" CI_START="0.12798627403057458" EFFECT_SIZE="0.19948007851875432" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:01:56 +0200" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.03647710113660952" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0013305789073304393" WEIGHT="78.87744985371278"/>
<DICH_DATA CI_END="0.33815660865598846" CI_START="0.06184339134401157" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:02:06 +0200" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.07048936089935842" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00496875" WEIGHT="21.122550146287224"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13505337707185855" CI_START="-0.004351483072176865" DF="0" EFFECT_SIZE="0.06535094699984084" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="72" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="-0.8694945516073266" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.184748114681366" MODIFIED="2010-07-01 10:02:47 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.06612069823057179" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="309" WEIGHT="99.99999999999999" Z="1.8376045475449552">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="0.13505337707185855" CI_START="-0.004351483072176865" EFFECT_SIZE="0.06535094699984084" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:02:47 +0200" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.035563117803093104" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0012647353478766775" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13868739937590746" CI_START="0.03401141753745664" DF="0" EFFECT_SIZE="0.08634940845668204" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="-0.857962995524441" LOG_CI_START="-1.46837526704211" LOG_EFFECT_SIZE="-1.063740633254354" MODIFIED="2010-07-01 10:03:20 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0012222742339987732" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="309" WEIGHT="99.99999999999999" Z="3.233630632146931">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="0.13868739937590746" CI_START="0.03401141753745664" EFFECT_SIZE="0.08634940845668204" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:03:20 +0200" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="0.02670354727538914" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="7.130794370889427E-4" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4136525773053401" CI_END="10.554865052564912" CI_START="1.3299805442198132" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7467005707391365" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.0234526850808083" LOG_CI_START="0.12384528788454556" LOG_EFFECT_SIZE="0.573648986482677" METHOD="MH" MODIFIED="2010-07-01 10:03:26 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5201214150457666" P_Q="0.0" P_Z="0.01243320207002867" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="2.499604509207168">
<NAME>Drop out due to adverse events</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.985303764810133" CI_START="1.0857322072134867" EFFECT_SIZE="3.292622950819672" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9993612811620728" LOG_CI_START="0.03572272095177356" LOG_EFFECT_SIZE="0.5175420010569232" MODIFIED="2009-04-07 11:37:49 +0200" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.5660460603553338" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.3204081424437942" WEIGHT="87.15206775609633"/>
<DICH_DATA CI_END="161.85818338602556" CI_START="0.5004380891067964" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2091346617833825" LOG_CI_START="-0.3006496429047325" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-04-07 11:39:12 +0200" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="1.4742597242064726" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="2.1734417344173442" WEIGHT="12.84793224390367"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.531407777041895" CI_END="2.4903329609909477" CI_START="0.27768392733941555" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8315800845323088" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="118" I2="94.6037558936085" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.3962574167558999" LOG_CI_START="-0.5564492569793439" LOG_EFFECT_SIZE="-0.08009592011172202" METHOD="MH" MODIFIED="2010-07-01 10:03:26 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.6712914632899256E-5" P_Q="0.0" P_Z="0.7417354449751301" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5932200868674979" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.3295560387166943">
<NAME>Drop out</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>PLACEBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7837134289588956" CI_START="1.1425368711092618" EFFECT_SIZE="1.4275707898658718" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="88" LOG_CI_END="0.25132508198021336" LOG_CI_START="0.05787022420001712" LOG_EFFECT_SIZE="0.15459765309011525" MODIFIED="2009-04-07 11:24:07 +0200" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="0.11363634107707754" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0129132180133859" WEIGHT="51.668454521883575"/>
<DICH_DATA CI_END="0.7382418844012765" CI_START="0.2949951531866799" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" LOG_CI_END="-0.13180131859805616" LOG_CI_START="-0.5301851194847926" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2009-04-07 11:25:30 +0200" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.23401261667248788" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.054761904761904755" WEIGHT="48.331545478116425"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-11-23 11:21:36 +0100" MODIFIED_BY="Laura Amato" NO="4">
<NAME>Acamprosate + naltrexone versus acamprosate</NAME>
<DICH_OUTCOME CHI2="6.298939497758108" CI_END="1.298202610230435" CI_START="0.48719354604954085" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7952835551983554" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="274" I2="84.12431171380649" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.11334247800996765" LOG_CI_START="-0.3122984735230386" LOG_EFFECT_SIZE="-0.09947799775653547" METHOD="MH" MODIFIED="2009-10-28 09:53:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.012081123853831977" P_Q="0.0" P_Z="0.35959362330734723" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.107456157020632" TOTALS="YES" TOTAL_1="345" TOTAL_2="343" WEIGHT="100.0" Z="0.9161397283543411">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0630203025721496" CI_START="0.9057293716999142" EFFECT_SIZE="0.9812281644719162" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="244" LOG_CI_END="0.026541559171323052" LOG_CI_START="-0.04300154838800677" LOG_EFFECT_SIZE="-0.008229994608341852" MODIFIED="2009-09-24 16:13:54 +0200" MODIFIED_BY="[Empty name]" ORDER="1095" O_E="0.0" SE="0.04084996562428464" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.0016687196915052367" WEIGHT="57.28464799601975"/>
<DICH_DATA CI_END="0.8831011664811572" CI_START="0.4076543137571331" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="-0.05398954157780295" LOG_CI_START="-0.3897079576549099" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-09-24 16:14:04 +0200" MODIFIED_BY="[Empty name]" ORDER="1096" O_E="0.0" SE="0.19720265943665385" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03888888888888888" WEIGHT="42.71535200398026"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.225433279202071" CI_START="-2.0254332792020824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-11-23 11:21:36 +0100" MODIFIED_BY="Laura Amato" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.31842726688160505" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="303" UNITS="" WEIGHT="100.0" Z="0.9976950513983799">
<NAME>Cumulative abstinence duration</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.225433279202071" CI_START="-2.0254332792020824" EFFECT_SIZE="2.0999999999999943" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="76.9" MODIFIED="2009-09-24 16:18:17 +0200" MODIFIED_BY="[Empty name]" ORDER="1099" SD_1="25.9" SD_2="26.0" SE="2.1048515746937024" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.474965501078241" CI_END="1.3370720095491062" CI_START="0.49638049051802613" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8146756777748482" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="236" I2="77.65345900970522" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.12615479732008084" LOG_CI_START="-0.3041852961234897" LOG_EFFECT_SIZE="-0.08901524940170445" METHOD="MH" MODIFIED="2010-07-01 12:20:05 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03439494065266968" P_Q="0.0" P_Z="0.41746236652941837" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10345661336158656" TOTALS="YES" TOTAL_1="345" TOTAL_2="343" WEIGHT="100.0" Z="0.8108316448328733">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.108804648676987" CI_START="0.8985398682098998" EFFECT_SIZE="0.9981508818273639" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="211" LOG_CI_END="0.04485503805645036" LOG_CI_START="-0.04646264848329445" LOG_EFFECT_SIZE="-8.038052134220351E-4" MODIFIED="2009-12-04 13:49:26 +0100" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="0.05364046110328473" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.002877299067373002" WEIGHT="60.09343510363884"/>
<DICH_DATA CI_END="0.9567043464279313" CI_START="0.37629179938832735" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="-0.019222252978552512" LOG_CI_START="-0.4244752462541603" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-12-04 13:49:26 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.23804761428476165" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.056666666666666664" WEIGHT="39.906564896361154"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.64652779358949" CI_START="-8.64652779358949" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2010-06-24 13:46:35 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.838995765137834" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="0.20317818250029093">
<NAME>Gamma-glutamyl transpeptidase</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.64652779358949" CI_START="-8.64652779358949" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="22.2" MEAN_2="21.2" MODIFIED="2009-09-24 16:19:24 +0200" MODIFIED_BY="[Empty name]" ORDER="1100" SD_1="28.0" SD_2="13.6" SE="4.921788292887048" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.096719103713895" CI_END="0.4328803189904449" CI_START="-0.26824257470771007" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08231887214136739" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="204" I2="90.09579260621237" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.36363215904281215" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.084500588514526" METHOD="MH" MODIFIED="2010-07-01 10:03:51 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.001485345392331472" P_Q="0.0" P_Z="0.6453447332069313" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.057968214671777166" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.46023892842528724">
<NAME>Side effect: Diarrhea</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.005877927604313979" CI_START="-0.16134579779225872" EFFECT_SIZE="-0.08361186269828635" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="193" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-24 16:47:44 +0200" MODIFIED_BY="[Empty name]" ORDER="1107" O_E="0.0" SE="0.03966089974465232" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015729869685553622" WEIGHT="53.72971390540488"/>
<DICH_DATA CI_END="0.48216249120543564" CI_START="0.0678375087945644" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 14:50:40 +0100" MODIFIED_BY="[Empty name]" ORDER="1106" O_E="0.0" SE="0.10569709078304852" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.011171875000000001" WEIGHT="46.270286094595114"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.538322316287147" CI_END="0.11300281815917419" CI_START="0.050269692252060474" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08163625520561733" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="251" I2="74.2571950910863" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-0.9469107255810326" LOG_CI_START="-1.298693773487681" LOG_EFFECT_SIZE="-1.0881169253283" METHOD="MH" MODIFIED="2010-07-13 11:55:49 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.003705579320935626" P_Q="0.0" P_Z="3.3767678080201384E-7" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.003919281733364644" TOTALS="SUB" TOTAL_1="1260" TOTAL_2="1252" WEIGHT="400.0" Z="5.101104646774395">
<NAME>Other side effects</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.12314226988641994" CI_START="-0.007576614960271573" DF="0" EFFECT_SIZE="0.05778282746307418" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="57" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="-0.9095928453030799" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2382012108205345" MODIFIED="2010-07-01 10:05:10 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08313824457126118" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="303" WEIGHT="100.0" Z="1.732760509475594">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="0.12314226988641992" CI_START="-0.00757661496027158" EFFECT_SIZE="0.05778282746307417" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="57" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:05:10 +0200" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.03334726706148312" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.0011120402204698769" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12886943582228177" CI_END="0.24290018468819807" CI_START="0.1136791594484537" DF="1" EFFECT_SIZE="0.17828967206832588" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="73" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="-0.6145721549806463" LOG_CI_START="-0.9443191462720706" LOG_EFFECT_SIZE="-0.7488738138277116" MODIFIED="2010-07-01 10:06:19 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7196072176973369" P_Z="6.358016993422625E-8" STUDIES="2" TAU2="0.0" TOTAL_1="345" TOTAL_2="343" WEIGHT="100.0" Z="5.4084284723953475">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="0.24530875071504504" CI_START="0.09911585568002074" EFFECT_SIZE="0.1722123031975329" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:06:06 +0200" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="0.03729479117682141" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.0013909014489227162" WEIGHT="78.12928176813328"/>
<DICH_DATA CI_END="0.33815660865598846" CI_START="0.06184339134401157" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:06:19 +0200" MODIFIED_BY="[Empty name]" ORDER="692" O_E="0.0" SE="0.07048936089935842" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00496875" WEIGHT="21.870718231866714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.06127059290302622" CI_START="-0.08501132763223679" DF="0" EFFECT_SIZE="-0.011870367364605283" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="94" I2="0.0" ID="CMP-004.06.03" LOG_CI_END="-1.2127479170686217" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-01 10:06:51 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7504157933659324" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="303" WEIGHT="100.0" Z="0.318091154843398">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="0.06127059290302622" CI_START="-0.08501132763223679" EFFECT_SIZE="-0.011870367364605283" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="94" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:06:51 +0200" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.03731750218093703" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.0013925959690242401" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13439509117337076" CI_START="0.028370693601828055" DF="0" EFFECT_SIZE="0.08138289238759941" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="27" I2="0.0" ID="CMP-004.06.04" LOG_CI_END="-0.8716165937468586" LOG_CI_START="-1.5471300465177058" LOG_EFFECT_SIZE="-1.0894668791712119" MODIFIED="2010-07-01 10:07:16 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0026220951355970727" STUDIES="1" TAU2="0.0" TOTAL_1="305" TOTAL_2="303" WEIGHT="100.0" Z="3.008883647365446">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="0.13439509117337076" CI_START="0.028370693601828055" EFFECT_SIZE="0.08138289238759941" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 10:07:16 +0200" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.027047537201665344" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="7.315692686754708E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.00755543251580633" CI_END="2.897000440355344" CI_START="0.6847626156165266" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4084592997243317" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.46194856121821865" LOG_CI_START="-0.16445995784410214" LOG_EFFECT_SIZE="0.14874430168705827" METHOD="MH" MODIFIED="2010-07-01 10:07:41 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.930733519685769" P_Q="0.0" P_Z="0.3519521686158894" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="343" WEIGHT="100.0" Z="0.9308094169874794">
<NAME>Drop out due to adverse events</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3070036772657945" CI_START="0.6226623210617213" EFFECT_SIZE="1.4349726775956284" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5194346778333748" LOG_CI_START="-0.20574741378731273" LOG_EFFECT_SIZE="0.15684363202303106" MODIFIED="2009-09-24 16:23:33 +0200" MODIFIED_BY="[Empty name]" ORDER="1104" O_E="0.0" SE="0.4259755503272395" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.18145516947659457" WEIGHT="74.61414547614149"/>
<DICH_DATA CI_END="5.579155313499883" CI_START="0.31864640395941085" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-09-24 16:23:36 +0200" MODIFIED_BY="[Empty name]" ORDER="1103" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="25.385854523858512"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.129678332483706" CI_END="1.4446970558455536" CI_START="0.4937285347545388" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8445638877828139" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="139" I2="75.78503894276501" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.15977678773752682" LOG_CI_START="-0.3065117722572291" LOG_EFFECT_SIZE="-0.07336749225985109" METHOD="MH" MODIFIED="2010-07-01 10:07:41 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.04213747354608022" P_Q="0.0" P_Z="0.5373829233350821" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11738331093039023" TOTALS="YES" TOTAL_1="345" TOTAL_2="343" WEIGHT="99.99999999999999" Z="0.6167753395749042">
<NAME>Drop out</NAME>
<GROUP_LABEL_1>ACAM + NTX</GROUP_LABEL_1>
<GROUP_LABEL_2>ACAM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.293234791107518" CI_START="0.8720383620882327" EFFECT_SIZE="1.0619559072922555" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="116" LOG_CI_END="0.11167737965647681" LOG_CI_START="-0.059464409474805226" LOG_EFFECT_SIZE="0.02610648509083577" MODIFIED="2009-09-24 16:22:27 +0200" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="0.0" SE="0.10052953410123418" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="303" VAR="0.010106187226611206" WEIGHT="58.84510112194956"/>
<DICH_DATA CI_END="1.002903804783695" CI_START="0.369437622240686" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.0012592789275755888" LOG_CI_START="-0.43245887960628526" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2009-09-24 16:22:32 +0200" MODIFIED_BY="[Empty name]" ORDER="1102" O_E="0.0" SE="0.2547681932623" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.06490683229813665" WEIGHT="41.154898878050425"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-07-13 11:45:03 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Risk of bias related to founding source</NAME>
<DICH_OUTCOME CHI2="110.1147271209413" CI_END="0.9123468791755274" CI_START="0.8128121573418007" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8611426334276567" ESTIMABLE="YES" EVENTS_1="2416" EVENTS_2="2447" I2="79.11269400437362" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.03984000918292748" LOG_CI_START="-0.09000980921004202" LOG_EFFECT_SIZE="-0.06492490919648475" METHOD="MH" MODIFIED="2010-07-13 11:45:03 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.4091839634365897E-13" P_Q="0.0" P_Z="3.9202062976244733E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.012384687889882205" TOTALS="YES" TOTAL_1="3233" TOTAL_2="2939" WEIGHT="99.99999999999999" Z="5.072792144113404">
<NAME>Funding source</NAME>
<GROUP_LABEL_1>Acamprosate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="66.02048033694118" CI_END="0.9711666250256495" CI_START="0.7976384526552912" DF="10" EFFECT_SIZE="0.8801362644817678" ESTIMABLE="YES" EVENTS_1="1139" EVENTS_2="1131" I2="84.85318502839702" ID="CMP-005.01.01" LOG_CI_END="-0.012706250914874404" LOG_CI_START="-0.09819391766848122" LOG_EFFECT_SIZE="-0.05545008429167784" MODIFIED="2010-07-01 11:38:23 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.5846580431476696E-10" P_Z="0.011003333979383984" STUDIES="11" TAU2="0.018297833053921003" TOTAL_1="1493" TOTAL_2="1365" WEIGHT="45.864857869276776" Z="2.5425929207925995">
<NAME>Fully industry sponsored</NAME>
<DICH_DATA CI_END="0.945603862138756" CI_START="0.7123227766253974" EFFECT_SIZE="0.8207162534435262" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="121" LOG_CI_END="-0.02429076266615661" LOG_CI_START="-0.14732316880357127" LOG_EFFECT_SIZE="-0.08580696573486392" MODIFIED="2010-07-01 11:36:33 +0200" MODIFIED_BY="[Empty name]" ORDER="719" O_E="0.0" SE="0.07226984438534992" STUDY_ID="STD-Barrias-1997" TOTAL_1="150" TOTAL_2="152" VAR="0.005222930407482694" WEIGHT="4.932411811445138"/>
<DICH_DATA CI_END="2.751430751085456" CI_START="0.36344727178959313" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.43955858681829196" LOG_CI_START="-0.4395585868182919" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-01 11:36:41 +0200" MODIFIED_BY="[Empty name]" ORDER="720" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Borg-2003" TOTAL_1="5" TOTAL_2="5" VAR="0.2666666666666666" WEIGHT="0.3112259555211752"/>
<DICH_DATA CI_END="1.0467844105660349" CI_START="0.9307509935301755" EFFECT_SIZE="0.9870641469257386" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="260" LOG_CI_END="0.01985724620364623" LOG_CI_START="-0.031166491521665157" LOG_EFFECT_SIZE="-0.005654622659009467" MODIFIED="2010-07-01 11:36:54 +0200" MODIFIED_BY="[Empty name]" ORDER="721" O_E="0.0" SE="0.02997159611142309" STUDY_ID="STD-Chick-2000" TOTAL_1="289" TOTAL_2="292" VAR="8.982965734662717E-4" WEIGHT="6.53829150376397"/>
<DICH_DATA CI_END="0.9866432382495657" CI_START="0.8048838666190908" EFFECT_SIZE="0.8911415289256198" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="121" LOG_CI_END="-0.00583985611315904" LOG_CI_START="-0.0942667776755182" LOG_EFFECT_SIZE="-0.050053316894338624" MODIFIED="2010-07-01 11:37:09 +0200" MODIFIED_BY="[Empty name]" ORDER="722" O_E="0.0" SE="0.05194241144605096" STUDY_ID="STD-Geerlings-1997" TOTAL_1="128" TOTAL_2="134" VAR="0.0026980141068308457" WEIGHT="5.758121089992152"/>
<DICH_DATA CI_END="1.026140351842458" CI_START="0.7545922437568355" EFFECT_SIZE="0.8799531524497365" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="109" LOG_CI_END="0.01120676609936106" LOG_CI_START="-0.12228766310390542" LOG_EFFECT_SIZE="-0.05554044850227217" MODIFIED="2010-07-01 11:37:21 +0200" MODIFIED_BY="[Empty name]" ORDER="723" O_E="0.0" SE="0.07841528852208064" STUDY_ID="STD-Gual-2001" TOTAL_1="141" TOTAL_2="147" VAR="0.006148957474001152" WEIGHT="4.68596559156039"/>
<DICH_DATA CI_END="1.0239873192349025" CI_START="0.5155439869712267" EFFECT_SIZE="0.7265745007680492" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="31" LOG_CI_END="0.010294578494882533" LOG_CI_START="-0.28773427415564323" LOG_EFFECT_SIZE="-0.13871984783038036" MODIFIED="2010-07-01 11:37:30 +0200" MODIFIED_BY="[Empty name]" ORDER="724" O_E="0.0" SE="0.17506362331353223" STUDY_ID="STD-Lhuintre-1985" TOTAL_1="42" TOTAL_2="43" VAR="0.030647272207662307" WEIGHT="2.0182214397037397"/>
<DICH_DATA CI_END="1.0856011587689278" CI_START="1.000213803463549" EFFECT_SIZE="1.0420332355816226" ESTIMABLE="YES" EVENTS_1="328" EVENTS_2="240" LOG_CI_END="0.035670298217158336" LOG_CI_START="9.284373962823689E-5" LOG_EFFECT_SIZE="0.017881570978393286" MODIFIED="2010-07-01 11:37:44 +0200" MODIFIED_BY="[Empty name]" ORDER="725" O_E="0.0" SE="0.020898372871341074" STUDY_ID="STD-Mason-2006" TOTAL_1="341" TOTAL_2="260" VAR="4.3674198866960456E-4" WEIGHT="6.773661384415707"/>
<DICH_DATA CI_END="1.1576380046280659" CI_START="0.7176304596787051" EFFECT_SIZE="0.9114583333333334" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="48" LOG_CI_END="0.06357277599740507" LOG_CI_START="-0.14409913603191538" LOG_EFFECT_SIZE="-0.04026318001725515" MODIFIED="2010-07-01 11:37:54 +0200" MODIFIED_BY="[Empty name]" ORDER="726" O_E="0.0" SE="0.12198750911856665" STUDY_ID="STD-Namkoong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.014880952380952382" WEIGHT="3.18525527362141"/>
<DICH_DATA CI_END="0.8214845089550527" CI_START="0.5745854321408876" EFFECT_SIZE="0.6870320455226115" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="53" LOG_CI_END="-0.08540062180746154" LOG_CI_START="-0.2406453891707822" LOG_EFFECT_SIZE="-0.16302300548912188" MODIFIED="2010-07-01 11:38:03 +0200" MODIFIED_BY="[Empty name]" ORDER="727" O_E="0.0" SE="0.09119154482320685" STUDY_ID="STD-Pelc-1997" TOTAL_1="126" TOTAL_2="62" VAR="0.008315897847242945" WEIGHT="4.195438021136952"/>
<DICH_DATA CI_END="1.3403774575260177" CI_START="0.843217963949116" EFFECT_SIZE="1.06312292358804" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.12722711525814343" LOG_CI_START="-0.07406014980601817" LOG_EFFECT_SIZE="0.026583482726062653" MODIFIED="2010-07-01 11:38:13 +0200" MODIFIED_BY="[Empty name]" ORDER="728" O_E="0.0" SE="0.11823713588672015" STUDY_ID="STD-Rousseaux-1996" TOTAL_1="63" TOTAL_2="64" VAR="0.013980020302694726" WEIGHT="3.2941014869943643"/>
<DICH_DATA CI_END="0.8802794231107174" CI_START="0.6141884329589351" EFFECT_SIZE="0.7352941176470589" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="102" LOG_CI_END="-0.05537944983509481" LOG_CI_START="-0.2116983669053401" LOG_EFFECT_SIZE="-0.13353890837021748" MODIFIED="2010-07-01 11:38:23 +0200" MODIFIED_BY="[Empty name]" ORDER="729" O_E="0.0" SE="0.09182250567818115" STUDY_ID="STD-Sass-1996" TOTAL_1="136" TOTAL_2="136" VAR="0.008431372549019609" WEIGHT="4.172164311121781"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.555557642066374" CI_END="0.893672641315186" CI_START="0.7804654480700759" DF="5" EFFECT_SIZE="0.8351530509026623" ESTIMABLE="YES" EVENTS_1="602" EVENTS_2="737" I2="33.82354768677872" ID="CMP-005.01.02" LOG_CI_END="-0.04882153725128163" LOG_CI_START="-0.1076463187958733" LOG_EFFECT_SIZE="-0.07823392802357744" MODIFIED="2010-07-01 11:40:42 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18249072340752603" P_Z="1.855083269224414E-7" STUDIES="6" TAU2="0.0022329940784286168" TOTAL_1="873" TOTAL_2="892" WEIGHT="26.918791527171244" Z="5.213302192344763">
<NAME>Partially industry sponsored</NAME>
<DICH_DATA CI_END="0.9317396468520065" CI_START="0.6672159972300499" EFFECT_SIZE="0.7884615384615384" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" LOG_CI_END="-0.030705424267736377" LOG_CI_START="-0.175733549562391" LOG_EFFECT_SIZE="-0.10321948691506368" MODIFIED="2010-07-01 11:39:43 +0200" MODIFIED_BY="[Empty name]" ORDER="730" O_E="0.0" SE="0.0851902386988785" STUDY_ID="STD-Besson-1998" TOTAL_1="55" TOTAL_2="55" VAR="0.007257376769571895" WEIGHT="4.421532357574159"/>
<DICH_DATA CI_END="1.0717706234275655" CI_START="0.5253151635046895" EFFECT_SIZE="0.7503448275862069" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.030101849126561553" LOG_CI_START="-0.2795800628721891" LOG_EFFECT_SIZE="-0.12473910687281378" MODIFIED="2010-07-01 11:39:53 +0200" MODIFIED_BY="[Empty name]" ORDER="731" O_E="0.0" SE="0.18190868805825366" STUDY_ID="STD-Ladewig-1993" TOTAL_1="29" TOTAL_2="32" VAR="0.033090770791075044" WEIGHT="1.9097778665772445"/>
<DICH_DATA CI_END="0.9637887882514153" CI_START="0.8135611523108403" EFFECT_SIZE="0.8854948430985298" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="245" LOG_CI_END="-0.01601813015025378" LOG_CI_START="-0.08960979722866853" LOG_EFFECT_SIZE="-0.05281396368946116" MODIFIED="2010-07-01 11:40:06 +0200" MODIFIED_BY="[Empty name]" ORDER="732" O_E="0.0" SE="0.043228109526487986" STUDY_ID="STD-Lhuintre-1990" TOTAL_1="279" TOTAL_2="291" VAR="0.0018686694532340413" WEIGHT="6.093162640259209"/>
<DICH_DATA CI_END="0.8849317865993751" CI_START="0.6007947517130143" EFFECT_SIZE="0.729151817533856" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="92" LOG_CI_END="-0.05309020483351675" LOG_CI_START="-0.2212738697988827" LOG_EFFECT_SIZE="-0.13718203731619974" MODIFIED="2010-07-01 11:40:17 +0200" MODIFIED_BY="[Empty name]" ORDER="733" O_E="0.0" SE="0.0987919173232243" STUDY_ID="STD-Poldrugo-1997" TOTAL_1="122" TOTAL_2="124" VAR="0.009759842928398786" WEIGHT="3.9218724105748244"/>
<DICH_DATA CI_END="0.9131528738872305" CI_START="0.6421371767109594" EFFECT_SIZE="0.7657476139978792" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="115" LOG_CI_END="-0.039456509729811545" LOG_CI_START="-0.19237218575546028" LOG_EFFECT_SIZE="-0.11591434774263591" MODIFIED="2010-07-01 11:40:29 +0200" MODIFIED_BY="[Empty name]" ORDER="734" O_E="0.0" SE="0.08982342504227021" STUDY_ID="STD-Tempesta-2000" TOTAL_1="164" TOTAL_2="166" VAR="0.008068247686324335" WEIGHT="4.2462376189349"/>
<DICH_DATA CI_END="0.9453414379842228" CI_START="0.8188169314722302" EFFECT_SIZE="0.8798076923076923" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="208" LOG_CI_END="-0.024411304876400534" LOG_CI_START="-0.08681318558826366" LOG_EFFECT_SIZE="-0.05561224523233209" MODIFIED="2010-07-01 11:40:42 +0200" MODIFIED_BY="[Empty name]" ORDER="735" O_E="0.0" SE="0.03665517362443969" STUDY_ID="STD-Whitworth-1996" TOTAL_1="224" TOTAL_2="224" VAR="0.001343601753437819" WEIGHT="6.326208633250907"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.27009904917983" CI_END="0.9627852701118713" CI_START="0.8112465917743797" DF="6" EFFECT_SIZE="0.8837738788789988" ESTIMABLE="YES" EVENTS_1="675" EVENTS_2="579" I2="54.78556732874699" ID="CMP-005.01.03" LOG_CI_END="-0.016470562724041852" LOG_CI_START="-0.09084711475451947" LOG_EFFECT_SIZE="-0.05365883873928064" MODIFIED="2010-07-01 11:43:20 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.038941767934035254" P_Z="0.0046836081520665864" STUDIES="7" TAU2="0.005703845387217931" TOTAL_1="867" TOTAL_2="682" WEIGHT="27.21635060355196" Z="2.828025459909382">
<NAME>Non profit sponsored</NAME>
<DICH_DATA CI_END="1.056879765686625" CI_START="0.908067929859167" EFFECT_SIZE="0.9796522959382552" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="254" LOG_CI_END="0.024025583268712094" LOG_CI_START="-0.04188166198607007" LOG_EFFECT_SIZE="-0.008928039358679023" MODIFIED="2010-07-01 11:42:22 +0200" MODIFIED_BY="[Empty name]" ORDER="736" O_E="0.0" SE="0.03871424210878468" STUDY_ID="STD-Anton-2006" TOTAL_1="303" TOTAL_2="309" VAR="0.0014987925420575968" WEIGHT="6.255493706141649"/>
<DICH_DATA CI_END="1.0130208111642" CI_START="0.385604121549171" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.005618367453996923" LOG_CI_START="-0.4138583327658465" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-07-01 11:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="737" O_E="0.0" SE="0.24640269015229055" STUDY_ID="STD-Baltieri-2003" TOTAL_1="40" TOTAL_2="35" VAR="0.06071428571428571" WEIGHT="1.1880881519845077"/>
<DICH_DATA CI_END="0.9898281663574834" CI_START="0.6641699976541734" EFFECT_SIZE="0.8108108108108109" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="-0.004440192149851486" LOG_CI_START="-0.1777207465448136" LOG_EFFECT_SIZE="-0.09108046934733253" MODIFIED="2010-07-01 11:42:40 +0200" MODIFIED_BY="[Empty name]" ORDER="738" O_E="0.0" SE="0.10178585540417863" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.010360360360360359" WEIGHT="3.8183266751440708"/>
<DICH_DATA CI_END="1.1649399043442055" CI_START="0.8177039832249937" EFFECT_SIZE="0.976" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="50" LOG_CI_END="0.0663035220273809" LOG_CI_START="-0.08740388669399729" LOG_EFFECT_SIZE="-0.010550182333308195" MODIFIED="2010-07-01 11:42:49 +0200" MODIFIED_BY="[Empty name]" ORDER="739" O_E="0.0" SE="0.09028849274688178" STUDY_ID="STD-Morley-2006" TOTAL_1="55" TOTAL_2="61" VAR="0.008152011922503723" WEIGHT="4.228918241720662"/>
<DICH_DATA CI_END="1.0254293219736905" CI_START="0.2901425332604818" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.010905731857356866" LOG_CI_START="-0.5373886014065197" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2010-07-01 11:42:58 +0200" MODIFIED_BY="[Empty name]" ORDER="740" O_E="0.0" SE="0.3220708054599232" STUDY_ID="STD-Niederhofer-2002" TOTAL_1="13" TOTAL_2="13" VAR="0.10372960372960371" WEIGHT="0.7479529285330938"/>
<DICH_DATA CI_END="0.9580422762523515" CI_START="0.8367396782221287" EFFECT_SIZE="0.895339034084066" ESTIMABLE="YES" EVENTS_1="294" EVENTS_2="161" LOG_CI_END="-0.01861532605923689" LOG_CI_START="-0.07740963626785052" LOG_EFFECT_SIZE="-0.04801248116354371" MODIFIED="2010-07-01 11:43:10 +0200" MODIFIED_BY="[Empty name]" ORDER="741" O_E="0.0" SE="0.03453606885306898" STUDY_ID="STD-Paille-1995" TOTAL_1="361" TOTAL_2="177" VAR="0.0011927400518239213" WEIGHT="6.396500488473733"/>
<DICH_DATA CI_END="0.9349406367664539" CI_START="0.6803930260990964" EFFECT_SIZE="0.7975757575757576" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="-0.029215963398299988" LOG_CI_START="-0.1672401464736392" LOG_EFFECT_SIZE="-0.09822805493596957" MODIFIED="2010-07-01 11:43:20 +0200" MODIFIED_BY="[Empty name]" ORDER="742" O_E="0.0" SE="0.0810760883691795" STUDY_ID="STD-Pelc-1992" TOTAL_1="55" TOTAL_2="47" VAR="0.006573332105247003" WEIGHT="4.581070411554244"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-23 11:22:32 +0100" MODIFIED_BY="Laura Amato">
<FIGURE FILENAME="PRISMA 2009 Flow Diagram Acamprosate for alcohol dependence.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-06-30 12:07:17 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart of studies</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-07-12 16:07:28 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-07-12 16:07:28 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUsAAAQ8CAIAAACUyisXAAAyUUlEQVR42u3dva4dSdnF8SMhIQIHDnwFXIMjdEQE0XtPODzBSEzou0BcAmIgHCYiQ4CNGAcTeCDjY9TvNpZG23v37l39UU/XU/1bOkLmjL1One76d3107Wc9PBBR3xqIqEchnAjhRIRwIkI4ESGciBBORAgnQjgRIZyIEE7UWP8+8NlNhFPPPbvkmwgnytetF/9XhBMRwolaGsytw4l6xvuA83OEE8IRToRwhBO13L8PizfCiRBORAgnard//6+Hm6UT9da5b/0B4UQIRzgRwhFOtPs63KlVIkI4ESGcqM1ZunU4UVed20VAOCEc4UQgRziRdTjCiQzgCCdCOMKJQI5wsgi3DicihBMFDLYuCMKpq/5X8k3PDoRTvs63+L8u87cOJ+r5CYJwoj1R3LY3Ihzh1Bbem3NoHY5w6plwQjghHOFE9XthDbzP3czSifqcHRwZcoQTwhFOFNALK6SL2UtHOLUy0tppQzgh3Cwd4XR4wh9uC+FEu63Da59aNUsnIoQTJZwamKUTtYJi1QU/wolCu2CXPwvhRAhHOIG87ck/womgiHAygBPCCeFrZgcIJ+pqHW6+gHBqbhHukycIJ0I4wgnk1uEIJxwinMhcGuFECEc4EcIRTtbhhHCisgmCvXSinvE+7Pwf4dTWUrxGJUaEI5yawHtbDhGOcOqZ8KFmqinCiWb2QnvpCCcihJNZ+sjUQL10oj0n5+qlI5wOMYb38bMQTtTz0wThRHVXyxbhCCfDLMKJQI5wogYJN0tHODW3Dq/3pLDTRtTzXADhRAhHOFHNiXoKZ4QTGWkRTrogwhFOCF8/RffZMqLe1uGmBginQ88XEE6EcIQTNT/5N0snIoQTVeiCrgPC6RAzahN1hBPUS61cT4RTo2Cv75Y6NsKp83W4vo1w2r8L1p4XWIcjnPqEnBBOrazAhRMinGjGpMCzA+FECCcKn6hXWt4bw4n2mVGfT60rre3N0on2J3zYtMaLy4tw6pZwQjg1B3nVaspm6UQdPjiM4S4EIRzhRFV7YUg4IcKJOhlpvS1DOJlLI5wI5AgnanAu7SNrCKcDTQ2sw4kQjnCi7QisN0tHOMLpWIt863AiQjiRkRbhRLuvlreNWEA4UUOE22lDODUHedWPnSCcaLfltzNtCCcihFPaFfhWM+p6zggnmt3/Sr7ZjjPCiVpZLVuHI5wI4USEcCJCOBEhnIgQTp30vwo90CfVEE77d77RP7fsjHCiJRwOZ8dRNjnuUskZ4UQLOUzhjHCi2f0vlzPCiQjhRIRw6r/zVagAEVBbAuFEM3rh6J9bdkY40WwIt0VRnTaEE8IRThS7IE/hjHAiQjgRIZwOMksfKuylH/lQOsKpiS546w/NOiOcCOEIJ0I4wuk463BvyxBORAgnIoRTg0vxSp88MUsn2h/viz8064xwIoQjnAjhCKeD9MIaENZzRjgRIZyIEE7HWYp7W4Zw6hbvbRfMdtoQvt8Vd80RjvCOe/MgWwvhCO+b8OHYmZij12HwtgzhPRFOhPCexysihNNheqFKjAinjlcudtoQ3uGo5eUZwhHebZ8mhCMc4Yeb0aRwRjiBnBBuyLIOr/a769gIJ5AjnCjnjMZcCeGtdGsXhBDe86TULSCEI/wQ8/NNOmQ9Z4QTwlddkEpVnAbn0sk6vLPnnScpwgnhCCdKO6MxV0L4DuOVHSBCOBEh3Mqzo8m5t2UI16f7f+R5W4bwDsdwV6PG9TFXQjghHOEUMl13NbwtQ3hvo5bAE0J4/4SDnBCOcGsWqyGE54Qc3pXWLJWccz0sEE7dzmhqOKd7wY7wPfs0pSZ8yJAPjXCQ97xm2dw53Y1D+H4X3fvwzLcP4USEcCJCeMcTdWvybtZZbd5HhO9z0W/9gdLdxMbvI8IR3uKQ2LjzrU+tIZwQfudqtH+mDeE0e2zxvBuSnHiZvoMIJ+qE8GRjiX5GjUDe+Jk2hNOSOd5WByrdzdR3EOG9DVmVPHPd0Ix12pxapT0JHzJ85mnIXC8d4RTdRfLexHotr3pNVICgeSPMVrYub947iHA6CjDtO5ulUxMz3vZvbsYzbQin0rFlq56XNxEtYxUns3TauU+7GoMzbQjvr093cEFSnGlLtBpCeG+E21uKWV6ZpdOMjlJvbKGqz2izdNLzdhgPnWlDOMgbbXOldXhVZ4RT0QhTyTndIynFJ0+sw2n22HLYIxnpCM83nECuhT592BtRbzD0WgHhvRGuEnv2pxLCu+0fGyZjOkuTdGWBcEI4whGOcIQjHOHWh2QdThRHy1DhXMrB9x0RTt2uLKxZEN7zqKUCRHyqEcIpqE+7GsHX2U4bIXyH8TDsU7oIp7jZoysceROHFLETblivo5abG3D7Wr7aOkG3A0tqYDzvEE6dEJ401QjhtM8qLt3dzJtbtvn7zoqrNsjt26cPWHskNeT1shY2bzbCuyI890wyzzq8NuHDdvnQCG+iT3veJXWuR7gxnO7Pz5NWYsy1Dt92alAjWB7hBPLeH/06WTcrzz5mH+07I5yamD26uakX+ZvFv7hh/XUOc9Sk845bf0A4yLPWPFAvHeFGgG4Jl3mCcNptFYfwvQaArRqMcEL4ASaM+tleE/XBfph1OMI7nkhvPrZ4dmR/Rm+7R4PwrghXP7izO2gdrn/0QHjMp+VrFMNr/w4ivKuVp7dlwc4Ip06eHQgPu85OrZKnUrfPu1rXVifbsUO7BUnvIMJp4WRyKzez9NqXevMTx5s//RHeFeS5TnHVq0sTXPGmZYgQjvCupjCRv3uKFRbCmxi76pm72ukG7SrTGfeMmpqrN+6caFcC4WTSPtsksgIcwjsZtba6ER28hzt46dVt34YgvIe7mKsHd0B4jR3NSs99hPew1kpNeK5Io3TJEwjvivDBx0WTzzIQ3udSvOoK39XW03QC6vB5N4R8AmxIcXBQJ6Mj7EpkdEZ47lFrqFzlC+G5nGv1B8jt0qfrVQhJMYHMzmGKnRSEI9w6/ACzRdQhnBBORi26vM5DzcISTq0S9TkLU2uVCOEIz9BFDl6nDeEI1z+W4J0I8ixr2pj9DjVeEN4V4TKeIp6eqOujTw+Zz7QhHOG9XXer5XSEB3w+3Jk26nSccTrAJ0+IDjKjQTh126dzffJkqJlLhXDqZ3KeKNUo0Qof4f1jc7R5aaRz+9ulCN+ZwyFDGUafYwkjXCKC/hFNeMAxWGfazNIRvhvkF4abA+PES+3bh/CuxvAau1bZZzTOtCF8t3V4ls2wjLtWMXMlnzwh2u15V+9gadhOinV44ll6jZmwKk7Z11kI72ewaj99+m7LEY5wGipRFz87mOjiTT3vwj4BVuOGWofTPmP46Hd0nhzTRhdi9+l64+twhCOcFq7islz/0WdHjeNczc54EU5LCD/4SJjr06PpPieD8E4I/3460MFny9onvN75f6dWO4Q86Sy99i59s871dul98oQaGg/rPTjaf2eWaK6O8L42VALP0lCmjuFC7E5j+xzqJxM3sVlnhLc4tT7UU2kIPB2Q4nTwts4I7w1yddp2cUY4RfTFjGdpEI7w/tfhm/e8XG/ak0JuHU67jYe5TstlXOEnG06w0SXkZun6A8KbGLJaHmHyvmnXsRHexMCV6NRqpTaDHOHd4r15R6zEYXB9qMadEU670ZLOOftSa2g7pwXhTSxus8wO1GC8uKrt13h3tzw7em5z3nrpCCdrlv2dEU7Rq7iwkfbgewfOtNEOI0DkCv/IY3i+sQR1fRCescbLoNYqwhHeyLzUvQtYZ3lb1lX/yPK2zOmR4Ge0nTbqZ16aq9Yqwoka3TvwtoxCB9gUg23tChDellV1Rngn89KMz450tCQeVCDXx7yU9rqDzTojHOE9zw5A7lZ1Mi/taZaeol56FmeEk8HQOpzq34OWnS9OWSmljHCah03Lzre2/Y8JebrnEcL3BLvl88xhhOeq05bx+B3Cd1tz1hsGExGe9w4inIzhCEc41Jtfh1d6D8c5wBnhraCey5mSDSQuBBHCiQjhRIRwIkI4ESG8wQtKFCuExxHOmXM7zgjXPzgjnPQ8zggnPY8zwhHOmTPCEc6ZM8IzEv7+P++f3jw9fvX4/HfPH37z8OyLZy+/fPnqL6+++fc3K52/++79t98+vXv3+Pbt87/+9eHNm2dff/3y/ftX3333jTZv2OZczggPJfz131+/+P2L0827/jrd1M//9vli53/+8/Xbty9OkFx/neD5xz8+1+ZN2pzOGeFxhJ8exqP37/zr9HcWOJ8GvVFOzr9Of0ebV7Y5ozPCgwg/PaHv3sKPX7ee1recTyPhXVQ+ft0aFbW5V+cWCS9pzDZVL64Km6355nTbTuurWxOw0SnZu3+9K3Q+rWPPJ7q//e3DT3/68KMfffj6v/97+MMfLqe+//3vO21e0OaMzi0SXlhjbE2DR6thrfzm3bY9vXkqvIUT87FR52+/fTrn4cc//nA3f/3rh1/96sMffvKTonmvNnfpnIPw8yr8o0Po9Yh6/U/u0r6M8PKnz+NXjyN366PG7uLLL18WOr979zg6uf3Tnz54//CHl9//+uuX2rygzRmd0xA+kZl+C8JCIBcTPneW/vHlR/ldfPbFs0Lnjy+ZLr7++MeHn/3sg/cvf3n5n968eabNC9qc0bk5whcMpMsm0tN/beXjY/ybo/fvXFc3stB5dDD8+c8/WP7iF+N7V9q8oM0ZnVsk/Przrg0SvmAdHjwe/uAHH4z//OcRVJodwxtvszE82Rg+kRBSg/D4Ne2tr5bX4S232Tp8+5dkt3bdakDYzV76x6+PKj9Dos320psj/O5e+oTtaO2bPt6HT9PS5vvwFG32PpzuXGvnw7K32Zk2unOtnfHO3mbn0un+54fG907/NwH77O1ni53/9zmt57c/p/WZNm/S5nTOCA8lfLj9GeDR9dUs51uftR5dx2rzQZwRHk04Z86RzgjXPzgjnPQ8zggnPY8zwhHOmTPCEc6ZM8LbJJxI9qgxnDNnYzjCOXNGOMI5c0Y4wjkjnPQPzggnPY8zwhE+rnppmxmdpZrWbjPCQwmvl7aZ0VmqaUCbER5HeL2qJhmdVY+JaTPCgwivV5kso7MKcDFt3o3wwgN3F60vDw+b/s3js0frpW1mdJZqGtPmnQkvX58sALvwR4dlj9ZL28zoLNU0ps2NEj6dJXorunD07w8VkglLJgjX36yXtpnRWappTJtbJLww4WTH7NFlhNdL28zoLNU0ps2tr8PXEF74my+Yul8/REqudb20zYzOUk1j2tz6LL2Q8MK40m0J32QM3yRtM6OzVNOYNvc2S7+LbvkjJmwdvj5tM6OzVNOYNjdNePkYvgmZwXvpG6ZtZnSWahrT5kbX4dcb5tfYl+ylT8Acnz1aL20zo7NU05g270l4x3KmrcTZmbaYNiM8jvDBufRP5Vx6TJsRHkf4UDNtM6OzVNOANiM8lPChZtpmRmepprXbjPBowjlzjnRGuP7BGeGk53FGOOl5nBGOcM6cEY5wzpwR3ibhRLJHjeGcORvDEc6ZM8IRzpkzwhHOGeGkf3BGOOl5nBGO8HHJHj1XvRxPzgjfgXDZo+eql+PJGeE7EK7Gy7nq1UvhjPAdCFen7WK8qlTzjPPOhM9KHa23YzFRg3X6m3fbL3v0rnO9uqWcmyA8Znfx7lPmVjNqJCLIHj1XvdrjnJsmvCRFtKRe+jBZ0nw0k3QB4bPqpcsePVe9/BDO7RJekiK6YTLhSsIL49C+l+zRc9XLAOOcYx1+l7Hp6XHJrzPxoJmOWFpGuOzRT75ZLceTc45Z+izCyyOKSnbaRs0rjeGyR420fY7hs2bpNTbDFiBamFg8yB61WrYOnyZ81hg+619ttQ5fQLjsUTveB9pLX5A6eneWXrLBvsn78GWEyx711voo78O7lzNtJc5OnsU4IzyO8MG59E/l9HiMM8LjCB9kj16NXZVyPDkjfB/CB9mjV6vQSjmenBG+D+GcOUc6I1z/4Ixw0vM4I5z0PM4IRzhnzghHOGfOCG+TcCLZo8ZwzpyN4QjnzBnhCOfMGeEI54xw0j84I5z0PM4IR/i4ZI9md66XPVqjzQgPJVz2aHbnetmjldqM8DjC1XjJ7lyvEku9NiM8iHB12rI716umVq/NcYRvEjlalcNZtVZLAlsu1leyR1M716uIWq/N0YTHbCqWP25utWdlKJrs0S6d61U1r9fmVghfOXhOJJbWyB5dRrjs0ezO9ZJJ6rW5CcJXolWSWLrgibM54bJHszvXSxer1+Ym1uF3KSrHaZNUo5Ls0QXrcNmj2Z3rJYTWa3MrY3h5eOiCB0Q5h4XZoxuO4YfNHpWXGtPm5mbp5UPiyon0sCJ7dNt1+DGzR+WlxrS553X44ll6zF76wbNH5aXGtLmV9+GV9tKXzdJj3ocfPHtUXmpMm0MJP46cD+vV2Zk2unOtnfHO7uxcOske7dy5XvZopTYjPJTwQfZofud62aM12ozwaMI5c450Rrj+wRnhpOdxRjjpeZwRjnDOnBGOcM6cEd4m4USyR43hnDkbwxHOmTPCEc6ZM8IRzhnhpH9wRjjpeZwRjvBxyfHkHOmM8FDC5XhyDnZGeBzh6qVwjndGeBDhap5xVqdtrGUV4kprlHydvtZyPDkPfWePrh8Mt2pk7WLscjw5N+KcmPCJvNHzv3D3uVADZjmenBtxzkp4ed7o3V8tjHA5npyHvrNHN1yHz6KxMJ9sLuGyRzm379zbGB5J+CZjuIRQzkM32aOtEb44mXDbdbiEUM6dZI/uQvitX200ljByL11CKOcA58Tvw6cX59N76RPLe9mjnHtybp3wGhOBHX+is1acnWnbfvBv6pnivDTneGfn0kNnDXI8OQc7Izx6XSDHk3OkM8LTrPw5c0Y4wjlzRjjCOSOc9A/OCCc9jzPCEc6ZM8K7IZxI9qgxnDNnYzjCOXNGOMI5c0Y4wjkjnPQPzggnPY8zwhE+LpmY53r/n/dPb54ev3p8/rvnD795ePbFs5dfvnz1l1ff/PuIba7hjPBQwmVinuv131+/+P2LU1e+/jp18c//dqw2V3JGeBzhao+c6zQ0jfbm86/T3zlIm+s5IzyIcPXDLsarux3649etsaunNtdzbpHwW+VN5/5WC36E7NEY59Nq89Z0dHSC+u5fPbe5nnOLhC+ILlnwSLv+s+zRSOenN0+FHXpidtpNm+s5N0f4RFDB98XPJx4Ba4KNahMuE/Ncj189jvTdjxrr0y+/7LnN9ZwTED4K8LI/7Eu4TMxzfXwVVN6nn33Rc5vrOScjfAK2W4N/Id4BhMvE/OSbo735XFfduuM213PunPDy8PC9xvDDZmIGj+GNt/nQY3ghbIX/cOJn7bUOP2YmZvw6vOU2H2gdXriXvn4dLnt0X+ewvfQUbT7QXnrh+/BbsBXupcse3d057H14ijYf6314B3KmrcTZmbYYZ4SH7hc6l34u59JjnBEeR/ggE/Nq7BrfSf7fdPSzt8dqcyVnhIcSPsjEvFqFjn4ienS12X2bazgjPJpwzpwjnRGuf3BGOOl5nBFOeh5nhCOcM2eEI5wzZ4S3STiR7FFjOGfOxnCEc+aMcIRz5oxwhHNGOOkfnBFOeh5nhCN8XLJHz5Urx7O2c43rjPBQwmWPnitdjueQMC8V4XGEq/Fyroz1UjLWpUF4EOHqtF2MhOlqnmWsLbcx4SU5BHM5qfT0KQxRmCjJeus3lT161zlj3dKMeakbE74mKjRy13G4Kr08bFoaXfboXeeMtccz5qVuSfjdjIHC4XG4ihybjh89/87dn3j9U9YQPqteuuzRc2XMD8mYl1qX8AXw3A0YnftfhwqpRrN+3+8le/RcGTPAMual1iL8YvxcGRi00qeQw7vPkZWEyx795JsJczwz5qUGzdJHt6ZufXMTwkv2/G7ttA03wpJqjOGyR43hVa9zHOEL9qhWEr5stTy3bevX4bJHrcPrXeegvfSYWXrkOnwB4bJH7aXHX+e49+Gz9tJnEb5gL33l+/BlhMse9T48/jpvT/i+auS3cKatxNmZtpjrnJ7wkkp07TxonEs/l3PpMdfZufTQqYTs0YtRMVeO55AwLxXh0YsF2aMX69tEOZ61nWtcZ4Sn2Q7gzBnhCOfMGeEI54xw0j84I5z0PM4IRzhnzgjvhnAi2aPGcM6cjeEI58wZ4QjnzBnhCOeMcNI/OCOc9DzOCEf4uGSPnkv2aG1nhIcSLnv0XLJHA5wRHke4Gi/nUuMlxhnhQYSr03YxXqnTFuCcgPCVZdhuFT8vL6t6q3rsrJ8oe/RitanWaoBzAsLX55nejUyc+81hLOTo7rWWPXou9dJjnFsnvDBHZbpMemFt87nYzyVc9ui5ZJ7EOOcjfOU4vAnhy2bpskfPJbcsxjkT4SUZhnfRLVwC1CBc9ugn35Q9GuLc8yy9NcJljxppjeFrCZ81S1+TTLjhOlz2qNXycdfhhcNseQ7pJhvsywiXPWrH2176ZPtuRIUO93JIJzJGr3fdw96Hyx711tr78Kxypq3E2cmzGGeEh77kcy79XE6PxzgjPI7wQfbo1dgle7S2M8JDCR9kj16tQmWPVnVGeDThnDlHOiNc/+CMcNLzOCOc9DzOCEc4Z84IRzhnzghvk3Ai2aPGcM6cjeEI58wZ4QjnzBnhCOeMcNI/OCOc9DzOCEf4uGRixjjLS0X4DoTLxIxxlpeK8B0IV3skxlldGoTvQLj6YTHOass1SviteqZ327ag/SuzR6fPCaoBuqOzvNQ0hBc2aUHLV2aPlgcqnUsd7xhneak5CC+MFp3+v8OcnNANYZbFsaOzvNQEhN8azKchvJuIsi/h8rRinOWltk744qyyNdHCw6JUo1nrcJmYMc7yUpsmfBTy60n4RFZZefDoSsKN4YnG8MPmpSZbhy/ICS9PF7MO73sdfsy81Bx76TVm6WuyR+2lJ9pLP3hear734bd2y0v+6/VfW5w96n14lvfhB89LbYvwbuTk2b7OzrQhfB/CB6fHo5ydS0f4PoQPMjGjnOWlInwfwgeZmFHO8lIRvg/hnDlHOiNc/+CMcNLzOCOc9DzOCEc4Z84IRzhnzghvk3Ai2aPGcM6cjeEI58wZ4QjnzBnhCOeMcNI/OCOc9DzOCEf4uOplYmZ0lpda+zojPJTwepmYGZ3lpQZcZ4THEV6v9khGZ3VpYq4zwoMIr1c/LKOz2nIx17ku4ctsFzdm1j8cLe1ar9ZqvUzMjM7qw8Zc594In/UjFiciLKuXXi8TM6OzGu8x13k3wicGxuFe2OgEk9f/cCiOJa+deVIvEzOjs5yWmOu8D+F3o0smACskvCR7NJjwepmYGZ1lrcVc5/1n6Qvmw+cwT4BdMo+41ZKSJ8XcdXi9TMyMzvJSY67z/rP0kvTv0b+5OeHTy4RKY/gmmZgZnY3hMde5xVn6UBYnWoPwrSbkwZmYGZ2tw2Ou886E350P380bnrWq32odvsle+oaZmBmd7aXHXOcIwm/NtAvnw7d23Uv+PDG73v19+IaZmBmdvQ+Puc7VCW9B8b+aM20lzs60xVznPgkvKU+3yzPFufRzOZcec52dSw+dNdTLxMzoLC814DojPHpdUC8TM6OzvNTa1xnhaVb+nDkjHOGcOSMc4ZwRTvoHZ4STnscZ4QjnzBnh3RBOJHvUGM6ZszEc4Zw5IxzhnDkjHOGcEU76B2eEk57HGeEIH5fs0XP95/37N09PXz0+/u758988PHzx7NmXL1/+5dWrf3/TrnOuVFOEhxIue/Rcf3/9+vcvXoxWUjhh+bfPW3ROl2qK8DjC1Xg512k4vVsQ6fR3mnLOWD0G4UGEq9N2McYWli29Nd7GO2esABdBeHnJ4QUTmw2DShfUWi3/1WSPXqyQb02hRyfV/3q3v3PGKq45CK+xObkme3TZQ0f26LnePD3NKT0+PqMOds5YiX1/wi9+9N14g+EqMuGiLvrof7r1o5cRXh7Gdi7Zo+f66vFxFodfvtzfOWOays6EF6YR3c1Imfivw/xkwpL2LEhEkD16ro+vr8q/vni2v3PGRLRWZunlhM/9r8O67NHRucCyVCPZo+e67rcv7sR47u+cMdW0Z8IXjLTXQUi188MPmz1qDDeGbzaGL3t/uDnhsketww+3Dl+85K46Sx9kj9Z3tpfe21769bS5PDO0ZN9rlNi7pW3Wvw8vf6LJHvU+vNv34UeTM20lzs60xTgjPI7wwbn0T+VceowzwuMIH2SPXo23t3a/T99/+1mLzulSTREeSvgge/Rq5Tz6Ke7RFXIjzrlSTREeTThnzpHOCNc/OCOc9DzOCCc9jzPCEc6ZM8IRzpkzwtsknEj2qDGcM2djOMI5c0Y4wjlzRjjCOSOc9A/OCCc9jzPCET4u2aPnqpfjqc0I34Fw2aPnqpfjqc0I34FwNV7OVa+qiTYjfAfC1Wm7GAkrVSbT5mjCO84eLW+S7NGLdWyl6qLanI/wGpuTa7JHN6mXfvDs0XoVwrW5LcKzZ4+uzzw5ZvZovZQPbW6I8LzZowsIlz16rnpJXdrc4iy92ezRZY8P2aP37361tE1tPgrhm2SPDtsFksoe3XE8PGybDzGGL3t/OPHNbdfhx8wejV/THrPN7RIue7Tv7NGwfemDtzmOcNmjskd3ebd88DYHEX40OdNW4uxMW0ybER5H+OBc+qdyLj2mzQiPI3yQPXo1KlbK8dRmhO9D+CB79Gp9WynHU5sRvg/hnDlHOiNc/+CMcNLzOCOc9DzOCEc4Z84IRzhnzghvk3Ai2aPGcM6cjeEI58wZ4QjnzBnhCOeMcNI/OCOc9DzOCEf4uDJmYtZz/s/792+enr56fPzd8+e/eXj44tmzL1++/MurV//+pl3nXNcZ4aGEZ8zErOf899evf//ixWglhROWf/u8Red01xnhcYRnrD1Sz/k0nN4tiHT6O005Z7zOCA8iPGP9sHrOpzG2sGzprfE23jnjdd6T8NFqp2E/ek1Z1aayR+vVAK3nfFoh35pCj06q//Vuf+eM13l/wkfrKEc+WRaURm8te7ReHe96zm+enuYYj8+og50zXuemCV8zoo4Gm07Tvozw8jE8YyZmPeevHh9ncfjly/2dM17nJmbpt7KBV0JYCOTinzh3lp4xE7Oe88fXV+VfXzzb3znjdW6X8LsQLphyF/7b9Y+PbjIx6zlf99sXd4z3d854nZsmfPSDr7cm5MGEL1iHZ8zENIYbw0Nn6Stn19NXpDbhGTMxrcOtw7fZ057+Q8x2d97sUXvp9tLzET7cCBWdtZc+AXPhEmDIkD3qfbj34YMzbbs8uS7kTNu5nGmLcUZ4HOGDc+mfyrn0GGeExxE+5MzErOd8Gm9v7X6fvv/2sxad011nhIcSPuTMxKznfOtT3KMr5Eacc11nhEcTzplzpDPC9Q/OCCc9jzPCSc/jjHCEc+aMcIRz5ozwNgknkj1qDOfM2RiOcM6cEY5wzpwRjnDOCCf9gzPCSc/jjHCEjytjQijnvM4IDyU8Y0Io59TOCI8jPGOFEM7ZnREeRHjGKl+cszvvT/iaBNLFzY7PHs1YqZNzdudWCF+cQLqs2btkj2asts05u3MCwidyRYfJUupzg41qZ49mTMzgnN25oVn6rATSu1EKAYTPnaVnTL3inN05K+FzUZw1XR/qZI9mTK7knN25K8KvPyhbj/AF63BjC2dj+DZj+MR0feKK1Cbc+pDzodfhQ0FQ4QLqypfK9tI520uPJnyYkyt668X1xMvwyOxR72k5D7JH6z0+Wvihzlpxlj2aHu/BeWnOzqX3rf4SQjmndkZ49NwhY0Io57zOCE+zOuDMGeEI58wZ4QjnjHDSPzgjnPQ8zghHOGfOCO+GcCLZo8ZwzpyN4QjnzBnhCOfMGeEI54xw0j84I5z0PM4IR/i46iVX/uf9+zdPT189Pv7u+fPfPDx88ezZly9f/uXVq39/c8Qcz+++e//tt0/v3j2+ffv8r399ePPm2ddfv3z//tV338kepWqE10uu/Pvr179/8WK0dsAJ+L99fqwcz3/+8/Xbty9OYF9/nYD/xz9kj1IFwuvV8TgN1HdLAJ3+TlNtrud8GqhH2T7/Ov2dg1wNhAcRXq8W12n0LizUeWsk76ky2Wn0vov3x69bI/nR67StSQsN3n648zt3kT16WnvfmpyPTtf/9a7n6qKntff55Py3v3346U8ffvSjD1//938Pf/jD5XT9v/9Va/XGP8hLeGfZo2+enuYYj8/Vu6kQ/u23T+cM//jHH/rqr3/98KtfffjDT35SNFc/er306ei/ibTQ0eiv4V5Q0fTgeSsn8PvvTP9qNWAOzrX46vFxFuFfvuw55ePdu8fRCfmf/vTB+4c/vPz+11/LPJlDeEmUX0nIycqcwFuPkh0Jr5dN9fHFWPnXF896Tur6+GLs4uuPf3z42c8+eP/yl5f/6c0buWUFVEx39MIAwA1zAudGCy/wmbsOr5cved0HXtwx7jltc3QA//nPP1j+4hfj+20dX40NdtpG4RzNAJ01IW+fcGN4ojH8Bz/4YPznP4/gbQyfR/iy2MDNMwkXhBNah/e9Dr/1ZR1exMb0AnhHwm/9aj1lj9pLn9hL//j1UeXnXuyl38GjZGAv3EIr3EsvacboOqKD7FHvwyfeh08T7n14D9rlOM3o951pi3F2pq1/wkvK0+3yTHEuPcbZufQDjeGtzRrqJVeeRvJb++qn77/97Fg5nv/7bNnz258tkz1K1dYF9ZIrb30+fHTt3Uib6znf+nz46Nq746uB8DQrf86cEY5wzpwRjnDOCCf9gzPCSc/jjHCEc+aM8G4IJ5I9agznzNkYjnDOnBGOcM6cEY5wzggn/YMzwknP44xwhI8rY9qmHM+8dxDhoYRnTNuU45n6DiI8jvCMVU3US8l+BxEeRHjGymRqnmW/g6WET9RXLX861PibQ0F00c3fuYvs0Xppm3I8s9/BeYSvzxvd/Vlw/U86yB6tl7YpxzP7HZw9hpf0+MIY0IkU0eFeouitmurTntO05808qZe2Kccz+x3cmPDy+JGVEaWzfnr32aP10jbleGa/g0vW4fFhYysJnztdLye8kezRemmbcjyz38GFO223QotGP606nVi0LN5s2U/fl/CMaZtyPLPfwe0JX7CttZK3cs/p/7QgP3zW5l/GtE05ntnv4PK3ZcvWye3M0tdkj86aGsTvxG6YtinHM/sd3P59+Pq99Lt/nv5XE//1+q8tyx69Wzqnm7RNOZ7Z7+AMwmn9a39n2mKuhjNtCN+H8MG59Kir4Vw6wvchfMiZtinHM/UdRHgo4UPOtE05nnnvIMKjCefMOdIZ4foHZ4STnscZ4aTncUY4wjlzRjjCOXNGeJuEE8keNYZz5mwMRzhnzghHOGfOCEc4Z4ST/sEZ4aTncUY4wsclIZRz5B1EeCjhEkI5B99BhMcRrhIL5/g7iPAgwlVT43z0Om2Fp/AufqUFKajDjeqxc7NHy2utSgjlPLScPbrL6FfYqmU5x2sSERbUS5cQynloOXt0d8InaqGXV24//2uLCV9QW36QEMp5jzuYhvBCsMszQ1cSPr2OkBDKOV/2aDvr8NqE3wpsWhk5LCGU89By9uju75kmckULc0gLd9pGZ/vD6vxwCaGch5azR/clfM0sfdnTZPNvSgjlPLScPdoI4eVjeNV1+ALCJYRyHlrOHm1klj4L7Lulbda/Dy//LSSEch5kj/YhZ9o4O9N2RMIH59I5O5feN+GDhFDO4XcQ4aGEDxJCOcfeQYRHE86Zc/wuNcL1D84IJz2PM8IRzpkzwhHOmTPCEc6ZM8JbI5xI9qgxnDNnYzjCOXNGOMI5c0Y4wjkjnPQPzggnPY8zwhE+rozZo1JNY5xlj6YnPGP2qFTTGGfZo+kJz1jjRfWYGGc1XtITnrFOmwpwMc6HrtO2LJB0AYeRtVZTZI9KNY1xPlD2aAkwC3I/b/3Ot/5hQL30FNmjUk1jnA+UPTqX8IlA0lGMz//OmnThBd/MmD0q1TTG+UDZo7MInxt1NOvBsTnhGbNHpZrGOB8oe3TWOrw8S3zug2M6e/TuNe0me1SqaYzzgbJHZy2tR8lfTPgwP3t0fX5449mjUk13HMP7zB6dS/jEN9fsupfMvef+84zZo1JN912Hd5g9upjw4HX4gv38jNmjUk132UvvOXt0wWC7YC99epZ+99X33ffz3WSPSjWNcZY9mkzOtJU4O9MWc50RHjrpcC79XM6lx1xnhMcRPuTMHpVqGuMse7QHwoec2aNSTWOcZY/2QDhnzjtsSCNT/+CMcNLzOCMc4Zw5IxzhnDkjHOGcOSO8McKJZI8awzlzNoYjnDNnhCOcM2eEI5wzwkn/4Ixw0vM4Ixzh45I9ei7Zo7WvM8JDCZc9ei7ZowHXGeFxhKvxci41XmKuM8KDCFen7WIkVKct4DoPskevf9D0NzeptSp7VK3VgOuchvByhgOyR+/+ONmjd53VS4+5zukJ3zd7dFYYi+zRc8k8ibnOuQnfN3t0bqqR7NFzyS2Luc651+H7Zo/OJVz26CfflD0acp1TjuHT5Idlj24yhsseNYYPskcbzB5dsNsne9Q6fJA9uphw2aOyR7vZS5c9OqzcS5+epd99H76McNmj2d9ayx6lO9fambZzOdMWc50RHjrpcC79XM6lx1xnhMcRPsgevRoVZY/Wvs4IDyV8kD16tb6VPVr1OiM8mnDOnHfYkEam/sEZ4aTncUY4wjlzRjjCOXNGOMI5c0Z4Y4QTyR41hnPmbAxHOGfOCEc4Z84IRzhnhJP+wRnhpOdxRjjCxyV79FyyR2s7IzyUcNmj55I9GuCM8DjC1Xg5lxovMc4IDyJcnbaL8UqdtgDnKoSvTwsNeOLIHt3RWa3VGOeKhJfjugvhskf3dVYvPcZ5B8ILK5xfMDYaNjTxr24NyNeeawiXPSrzpHHnaMLLU0qmcwJL/tVcDmWPRjrLLYtxjl6Hl6eFlucKLZtdD7JHd3WWPRrjHDSGpyB8kD0a6GykTT+GZyS8fP9M9qjsUevw5YSXrL33XYfLHpU9ai/9zhJ91l76gol0SWmbZe/DB9mjskcP/j58LzXyWzjTVuLs5FmMc3rCyw/PtfCgcS79XE6Pxzg7lx46lZA9ejF2yR6t7Yzw6MWC7NGLVajs0arOCE+zHcCZM8IRzpkzwhHOGeGkf3BGOOl5nBGOcM6cEd4N4USyR43hnDkbwxHOmTPCEc6ZM8IRzhnhpH9wRjjpeZwRjvBxSQiNcc54NWq0GeGhhEsIjXHOeDUqtRnhcYSrxBLjnPFq1GszwoMIV00txjnj1ajX5nmElx+Uy8jhrFqrE7++hNAdnTNejXptXkJ42N5gbbwX10tfFkgqITTGOePVqNfmjQkvDCpbP1qW/KC7oYKbEF4+hksIjXHOeDXqtXlLwleOgfW+uXnmyfe2s2bpEkJjnDNejXpt3nIdvnIMXBYVVoPwksikBb+LhNAY54xXo16bV43hK3O/Cufet54mF99cEDC2OHt02TpcQuiO42HjV6Nem9fO0peN4eVDd/nAfjfAcO4VmTtfWLzWkhAas6Zt+WrUa3Mc4SVxonO/WZhAWmkdvnIvXUJozL50iqtRr83V99KHOcGgc785PZ1ewGHk+3AJoTHvllNcjXptnk04LXsOfpQzbTHOzrQhfB/CB+fSo5ydS0f4PoQPEkKjnDNejUptRngo4YOE0CjnjFejRpsRHk04Z86RzgjXPzgjnPQ8zggnPY8zwhHOmTPCEc6ZM8LbJJxI9qgxnDNnYzjCOXNGOMI5c0Y4wjkjnPQPzggnPY8zwhE+rozZo1JN8zojPJTwjNmjUk1TOyM8jvCMNV5Uj8nujPAgwjPWaVMBLrtzo4QHxJvKHt3ROWMV14zOjRI+Ucl82yfIrZ8ie7S2c8ZK7Bmd8xG+yTAre3R354xpKhmdcxBeY5gdZI/u6pwxES2jc+J1+IL0z0LCZY8GOGdMNc3onGMvfTp1dNlm2CB7dFdnI+2hx/CJ0XUBWrPm0iU+x8kelWpqHb4P4cuSTLddh6/cS0+RPSrV1F569Dp8ZZJpO+/DU2SPSjX1PpxmzP+daTuXk2cxzgiPI3xwLv1TOT0e44zwOMKHnNmjUk1TOyM8lPAhZ/aoVNO8zgiPJpwz50hnhOsfnBFOeh5nhJOexxnhCOfMGeEI58wZ4W0STiR71BjOmbMxHOGcOSMc4Zw5IxzhnBFO+gdnhJOexxnhCB+X7NFzSQit7YzwUMJlj55LQmiAM8LjCFfj5VwqscQ4IzyIcHXaLsYr1dQCnNcSPuv0XDtbXCvLqsoelT16uFqrLcwCCtuwsjS67FHZo0esl15Sfvw60+/uXygfSKf/791m1yZc9ui5JJPEOFck/BYbswIAF7NXknkSTLjs0XNJF4tx3oHwGlPlBbxt3p67P1H26CfflBAa4lyX8Ou9t8VEFUaO3k0p3ZFw2aNG2m7H8A2JKpxpN5hMKHvUavkQ6/BZC/X16/Bbv9rovmDkXrrsUTve3e6l34Vn8Uvp0Z28iYbdnfYPskdlj3ofHv9Cu3E501bi7ORZjDPCQ38L59LP5fR4jLNz6aHPKdmjF2OXhNDazgiPnonIHr1YhUoIreqM8DRrDc6cEY5wzpwRjnDOCCf9gzPCSc/jjHCEc+aM8G4IJ5I9agznzNkYjnDOnBGOcM6cEY5wzggn/YMzwknP44xwhI+rXnKl7FHOCN+Z8HrJlbJHOSN8Z8Lr1fFQ44UzwncmvF4tLnXaONclfLpY+q2ap8OcouizmlHiVlIcdtiu1mq9epqyRzmHEn7N8wTh2+4xzgpRCE5EqFcTW/Yo5z0Jn66Ffv7NkuLq03mmFzXSp+MQNiG8/GlVL9dC9ijnITIRYYLw6XCS4V5kwqyYlLtAriR87iy9XjaV7FHOcYSXDObDvRyi0f/ddiI9QXjJI2NJBGq1fEnZo5wRPmOnbRjLMF2/Dg8ew2WPckZ4UerwVjtt8etw2aOcN34fXhjoOczJA64U8T2EpwuH7aXLHuXcKOElCN3dcp/esTvC+3DZo5xrEU7T19qZtpirwRnh+xA+OJcedTU4I3wfwoeayZWyRzkjfH/Ch5rJlbJHOSN8f8I5c450Rrj+wRnhpOdxRjjpeZwRjnDOnBGOcM6cEd4m4USyR4kocMhxIYgQTkQIJyKEExHCiQjhRIRwouMSTkS96v8BrmTku4t/0nQAAAAASUVORK5CYII=</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of publication bias.JPG" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2010-07-13 11:43:33 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk of publication bias</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAL0A7wDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD27Qv+QBpv/XrF/wCgCtE1naF/yANN/wCvWL/0AVomh7iWwUUUUDCiiuJ8QR3F1r7I1tqt9apbRGO10vUBayQuXk3PKPOiLK4CBeWwY34XncAdtRXmKzzapq0BYa/r0B0OwnSfTL42CuztPulaPz4gC4VTjnG3HHez4jvbwaXq8VtNe2K6P4de7WNrkmYzSxyoheRWJLRiF/4mDNIGzlFYgHotFcddeIdSh1S8kjFr9gsdStdNlgaJjLK0/kfvFk3AIF+0L8pRs+WfmG75WW3iLV5tX05tln/Zt9qt1p+3a4mh8hbgZzna+9oN2cLsHy4fO5QDtKK848KLNrelaZp99fak0MOh2N+zR38ySzT3Hm72eVXDkDy/lXcFG85Bwm2Ca/v9S1DR4LmHV9RCJqsMkemXv2N5Tb3cUKSyESxKTtByAcZc4UDoAenUV5pYefenQZvtGqW+n3uqXFvBbTX8vnxwGyl3xzMshJkE8TsNzM8fABQgqOr8NXk99okb3cnm3UEs1pNNtC+a8MrwtJtHC7zGW2jpuxk4zQB0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/yANN/69Yv/QBWiaztC/5AGm/9esX/AKAK0TQ9xLYK8/8ACc1y9x4bnkvLuZ9Y0OS/vRNcPIrTg2xDIrEiIfvpPlQKvI4+VcegVh6d4e0zS7hprS3kRyhjQPPJIsKEglIlZiIk4X5UCj5V4+UYBme/i27TUYrJ/CmuC5likljj8yz+ZEKBjn7RjgyJ+fsauXWi2WsPDdXEF9Z3LRKHEF5JbSAdQkjQSAPtJbHLAEtg/Mcl5/yUPRv+wVf/APo20roKAOeuPCOjz3CTLHd2zpBHbKLK9ntVESFiibYnUYXe2OOM0l94atbuWNWeQ272cmnXcUju5urdlwAz7t5dTnDkkgPL3fcOiooAw5fD+m3GqDUJbeQzB1kZRPIIpHXG13iDbHcbVwzKSNiYPyrjItvBjL4qTWbi5tykFxLcW0MNvIjRs6ujDLSugDCRmfYib3CsemD2dFAHKWXhGCLw7pOmX8z3E+mW4to7y0kls3KABcZjk3AEKm4bsEqDjgAa0elWMNzaTxWyRSWcDWtuIxtWOJihKBRxj92nbjbxjmtWigDmL7w7JJfWVxplzDZrbXc160bwNKrzvC8QIAkUKuZGdlA+ZiTkEsTpaVp8Wk6fBYQNI6RJgySkF5G6s7kAbnZiWY9ySe9atFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlZd1qMVndafBIrl76cwptAwGEbyZPPTEbdM8kVqdqxtUazTUdFW5geSV7xltWU8Ry+RMSx5HGwSDvyw47gSVwNqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7Qv+QBpv/XrF/wCgCtE1naF/yANN/wCvWL/0AVomh7iWwUUUUDOfvP8Akoejf9gq/wD/AEbaV0Fc/ef8lD0b/sFX/wD6NtK6CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAErG1SSyTUtFW5geSV7xltWU8Ry+RMSx5HGwSDvyw47jZrG1R7JNS0VbmB5JXvGW1ZTxHL5ExLHkcbBIO/LDjuCO4M2qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAztC/5AGm/9esX/oArRNZ2hf8AIA03/r1i/wDQBWiaHuJbBRRRQM5+8/5KHo3/AGCr/wD9G2ldBXP3n/JQ9G/7BV//AOjbSugoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5yfxl4Ytrh7e48R6RDPE5SSKS+iVkYHBBBbIIPagDo6Kz9Pv7TU7KO8sbqC6tpM7JoJBIjYJBww4OCCPwpmo6tp2j263Go39rZQs+xZLmZYlLYJwCxAzgE49jQBpVy3iLWtG0nVdDh1OO6lu5Z5ZLJLWCWZlZImDvtjBJAWQrjB+/nGASvO+Hp/DniF51k8Sz3Opz6he7Le38RTozRrPLs2RJMAF8sKRgY281SguYdP1vwze6lBqd5HbXWt2ltcKk148UguSqBiNzt+6jkUZ3HjOMKSBLUGd1ZeJNP1LURYwC+jumiaZUudPuLfcilQxBkRQcF1yBzyK364221BNY8a6fcW9rqKQW+m3iSSXGnT26hnltioBlRQSQjcDPQ12VABRXN/8JfpXmTRompy+TK8LPBpN1Km9GKMA6xFThgRwT0rR0vU7bV7BL2yZ2gd3T95E8TBkYowKuAwIZSMEDpQBp0UUUAZer6kmj6NfanOsjxWcElxIsYBYqiliBkgZwPUVjX/i670/T7m8u/CutRwW0TzTOZLM7UUEscC4ycAHpTvH0wg8Ba4hEjtcWclrGkcbOzyyr5cahVBJLO6j8a5XxF8QW1nw3qOkxeD/ABZBNqMD2MEt3pywxCWYeXHudnwoLOoyfWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAztC/5AGm/wDXrF/6AK0TWdoX/IA03/r1i/8AQBWiaHuJbBRRRQM5+8/5KHo3/YKv/wD0baV0Fc/ef8lD0b/sFX//AKNtK6CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuN13StO1nxtolvqNha3kC6dfOsdzCsqhvNtBkBgRnBIz7mmW+h6Tovj/TP7K0qysPO0u98z7LbpFvxLaYztAzjJ6+poA7WvLtKn8HJHqC6p4m+xXw1S/wDMt/8AhIprXZ/pUuP3SzKFyMHoM5z3r1Gua/4Q/SvMmkSTVIvOleZ0g1a7iTe7F2IVZQoyzE8AdaAOY8A+JZpfCMU2m+Gtau7Ka6u5YJzPbMWRrmVhuMk4csAcEt1IPJ6nW1fX9PmtfBev3FxHZWE96LgSXTrGEWSyuCoYk4B+YDr1qr4POpeGvCel6QPB+sB7WBVl8u4tGVpT80jAtcZwXLHt16DpXR+FLSfTfCWi2N2vl3NtYQQyx8Ha6xqGGRwcEHpQBxV5b+ENU8SaFBo2ufaJrjVZ55rey12Y7d1vcu7qiS/u8ueSoH3iOjEHq/7P0vRW0SwS3nIN/K1ozSvIUmeKeR3dnYs2QZeueWH1HTVjapJZpqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdw0DNqiiikBw+h67Bo9rdWV7Zawk66lfSYj0i7lUq91K6kMkZVgVZTkE9a0vB4f+wnZ4J4fOv76ZEnhaJ9j3UrqSjAMMqwOCB1rpqKACisfU9d0jRWi/tXVLGw87Pl/arhIt+MZxuIzjIz9RUeneJdD1WZrfS9a06+nVS7R2t0krBcgZIUk4yQM+4oAqeLw/8AYKFIJ5vJ1CxmdLeFpX2JdROxCKCxwqk4APArO13W7fWLO0srSy1h521Gxk/eaRdRKFS6idiWeMKAFUk5Pau4ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDO0L/kAab/16xf+gCtE1naF/wAgDTf+vWL/ANAFaJoe4lsFFFFAzn7z/koejf8AYKv/AP0baV0Fc/ef8lD0b/sFX/8A6NtK6CgAooooAKKKKACiiigAooooAKKKKACiiuD8N+FfDupWF7eX/h/S7u5k1TUN809nHI7Yu5gMsQSeAB+FAHeUVy/gmCK18OyW8EMcUMWpagkcUahVRReTAAAcAAdq6igAooooAydS0LSda8r+1NKsb/yc+X9qt0l2ZxnG4HGcDp6CodO8NaHpUzXGl6Lp1jOylGktbVImK5BwSoBxkA49hW5RQAUUUUAcVaaPBrOueInvLvVP9H1COGJIdUuYERPstu+Akcir952PTqat+F4ja3niCyFxdzRWupKkP2m5knZFNrbuQGkZmxudjjPc1ZufCunXN7cXjNqMU904eb7LqdzArsEVASscirnaijOOwq3pOiWejJOlmJ/9Il86V5riSZ3faqZLSMzfdRR17UAatY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQBx2u6rp2j+NdEuNRv7WzgbTr5FkuZliUt5tocAsQM4BOPY1Hb65pOteP9M/srVbK/8nS73zPstwkuzMtpjO0nGcHr6Gu1ooAKKKKACiiigArA1XXW03ULayg0u8vrm5ilmVLUwjakZQMSZZEHWVeme9b9cprBv7bxNpuqWuk3d/BFZXdvILaSFWRpHt2UnzZEBGIn6E9qALFj4ikutXj0660fUdPmlgkuI2uWgZXWNo1YDypXIOZU6gd66OuRtn1LUvGNlfTaHe6fbW1hdQtJcyQHc8kluVAEUrnpE3XHauuoAKKKKACiiigArlfE8Rurzw9ZNcXUUNzqTJN9mupIGdRa3Dgbo2VsblU4z2FdVWTq2iWespAl4J/9Hl86J4biSF0fayZDRsrfddh170AYF3pEGj674dayu9V/0jUJIZkn1O5nR0+y3D4KSSMv3kU9M8V2tc9beFdOtr23vFbUZZ7Vy8P2rU7mdUYoyEhZJGXO12GcdzXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdoX/ACANN/69Yv8A0AVo1naF/wAgDTf+vWL/ANAFZ3iqeeDRFEMjxefe2ls7RsVby5biKNwGHKkq7DcMEZyCCAaOolsdFRXMeGjJHc65p/nTy29jqCw2/nzNK6o1vBIQXclm+eRz8xOM4HAAGV4SXUrLVIU1yCeLU761mujt1Sa5hXEkZkTymxHFtMqKgTf8oI3nGWBm5ef8lD0b/sFX/wD6NtK6CuButb1F/HOlSnwrq4ddNvVERls9zAy2uWH7/GBgA5IPzDAPOOxt5Gkgjkkt5IGZAzRyFSyEj7p2kjI6cEj0JoAu0UUUAFFFFABRRRQAUUUUAFFFFABXOS+DfDFzcyXFx4d0iWaVy8kkljEzOxOSSSuSSec10dFAGfp9haaZZR2djawWttHnZDBGI0XJJOFHAyST+NaFFFABRRRQAUUUUAYmv6lNpWlfareFLmdriC3jiklMSlpZkiBLBWIAL56HpXI+Ktf8U2EmgQ3ENrpsF/q8NjJPp18J5cSK4GBNbbQAcMTyflxxnI6zxHp95qOjCCwWF7mO7tblFnkMaN5U8cpUsFYjIQjOD1rnvEmg+JvFS6ZBdWunaeLPUYL1bm11JpZEMbckI9rtY7WbAJAzjORkEAvXEGqaRrWhIfEWo3sF5evbzQXMVsFKi2mkBBjhVgd0a9/WuwrmYvDk39p2F5e6/qt+bGZpooZ0t1TeY3jyfLhVj8sjd8ZrpqAErG1R7JNS0VbmB5JXvGW1ZTxHL5ExLHkcbBIO/LDjuNmsbVHsk1LRVuYHkle8ZbVlPEcvkTEseRxsEg78sOO4I7gzaooooAKKKKACiiigDB17VbzTW02Gws4bq4v7s2yLPcmBFxFJKWLBHPSIjGO9U/7a1211TTLXUNJ06GG/uGt1ltdReVkYQyS52tAgIxER17irHiCw1K6n0i602O0lmsb03DR3M7Qq6mCaLAZUcg5lB6djVN7XxHqOsaNPf6fpdta2F29w7QahJM7ZgliChTAg6yg5z2oA66iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAztC/5AGm/wDXrF/6AKS+s4dQtZLa6j8yF8EgMVIIIKsrDBVgQCGBBBAIIIpdC/5AGm/9esX/AKAK0TQ9xLYx7LR7OwRIrcTqFlMzO1zI7yuVKZkdmLSfLgDeTjauPuriPTvD2maXcNNaW8iOUMaB55JFhQkEpErMREnC/KgUfKvHyjG5RQM5+8/5KHo3/YKv/wD0baV0Fc/ef8lD0b/sFX//AKNtK6CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDD1nWf7GWyVbG6vpry4+zww2pjDFvLeQnMjqoAWNu/pVZPE051Cxs7rw9qlgb2VoYprh7Zk3iN5MHy5mYfLG3ajxJHem70K8stPuL77HftNLDA8avsNtPHkeY6qfmkXvVO4n1TV9b0Jm8OajZQWV69xNPcy2xUKbeaMACOZmJLSL29aAOxooooASsbVHsk1LRVuYHkle8ZbVlPEcvkTEseRxsEg78sOO42axtUeyTUtFW5geSV7xltWU8Ry+RMSx5HGwSDvyw47gjuDNqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7Qv+QBpv/XrF/6AK0TWdoX/ACANN/69Yv8A0AVomh7iWwUUUUDOfvP+Sh6N/wBgq/8A/RtpXQVz95/yUPRv+wVf/wDo20roKACiiigAooooAKz76/tNMtZLy+uoLW2jxvmnkCIuTgZY8DkgfjWhXLeN54bXw9HcXEsUUEWo2EkkkjBVRReQksSeAAOSaAJoPGXhi5nS3t/EWkTTyuEjijvomZ2JwAAGyST2ro64LxD4p8Palp9nZ2Ov6Vd3Mmq6fsht7yOR2xdwk4UEk4AJ+grvaACiiigAoormpPE04v76ytfD2q332KVYZpYHtlTeY0kwPMmVj8si9qAOlorD0bWjrQvQ1jdWUllcfZ5oLoxlg3lpICDG7KQVkXv61uUAFFFFABRRRQAUUUUAFFFFACVjao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3GzWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcEdwZtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/yANN/69Yv/QBWiaztC/5AGm/9esX/AKAK0TQ9xLYKKKKBnP3n/JQ9G/7BV/8A+jbSugrn7z/koejf9gq//wDRtpXQUAFFFFABRRXM3usax/wkM+laXpdnc/Z7WG5klu754P8AWPKoUBYXzjyickjqKAOmorm9J1jUrrWb3TNS0+1tZ7W3guFa2vGnV1laVcHdGhBBhPY9RXSUAFFFFABRRRQAVxkE+qaVrevMvh3Ur6C8vUuIZ7aW2Clfs0MZGJJlYENG3b0rs6KAOa8MxX32nXLu90+ex+236zRRXDxs+wW0EeT5bMo+aNuM10tFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf8Ar1i/9AFaJrO0L/kAab/16xf+gCtE0PcS2CiiigZz95/yUPRv+wVf/wDo20roK5+8/wCSh6N/2Cr/AP8ARtpXQUAFFFFABXK3dprtr4nu9U0uz0+7gubK3tyLq9eBkaJ5myNsLggiYdx0NdVRQBzOlWWrLr2parqtvZ2/2i2traOK1uXn/wBW8zFiWjTGfOAwAehrpqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooASsbVHsk1LRVuYHkle8ZbVlPEcvkTEseRxsEg78sOO42axtUeyTUtFW5geSV7xltWU8Ry+RMSx5HGwSDvyw47gjuDNqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7Qv+QBpv8A16xf+gCtE1naF/yANN/69Yv/AEAVomh7iWwUUUUDOfvP+Sh6N/2Cr/8A9G2ldBXP3n/JQ9G/7BV//wCjbSugoAKKKKACiiigAork/F9haane+GLO+tYLq2k1Vt8NxGHRsWlyRlTwcEA/hVG+8OaHpHiHwxNpei6dYztqUiNLbWscTFTZ3JxlQDjIBx7CgDuqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBKxtUeyTUtFW5geSV7xltWU8Ry+RMSx5HGwSDvyw47jZrG1R7JNS0VbmB5JXvGW1ZTxHL5ExLHkcbBIO/LDjuCO4M2qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAztC/5AGm/9esX/oArRNZ2hf8AIA03/r1i/wDQBWiaHuJbBXKeGGvhe69Bf30t7JDqSqHZdqqDa27lUXnagZmwMk88liSx6us62s7eCe8mgj2SXUolnO4ne4RYweenyoo49PXNAzkrrW9RfxzpUp8K6uHXTb1REZbPcwMtrlh+/wAYGADkg/MMA847G3kaSCOSS3kgZkDNHIVLISPunaSMjpwSPQmsy8/5KHo3/YKv/wD0baV0FABRRRQAUUUUAZepaVp+s262+pWNrewK4dY7mFZVDYIyAwIzgkZ9zVO28J+HtNuY7uw0DS7S6jzsmgs443XIIOGAyMgkfjXQUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf+vWL/wBAFaJrO0L/AJAGm/8AXrF/6AK0TQ9xLYKKKKBnP3n/ACUPRv8AsFX/AP6NtK6CufvP+Sh6N/2Cr/8A9G2ldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACVjao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3GzWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcEdwZtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/yANN/wCvWL/0AVoms7Qv+QBpv/XrF/6AK0TQ9xLYKKKKBnP3n/JQ9G/7BV//AOjbSugrn7z/AJKHo3/YKv8A/wBG2ldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACVjao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3GzWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcEdwZtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/yANN/69Yv/AEAVoms7Qv8AkAab/wBesX/oArRND3EtgooooGc/ef8AJQ9G/wCwVf8A/o20roK5+8/5KHo3/YKv/wD0baV0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcbNY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35YcdwR3Bm1RRRQAUUUUAFFFFABRRRQBzeraxqVrrNlpmm6fa3U91bz3DNc3jQKixNEuBtjckkzDsOhptlrGsf8ACQwaVqml2dt9otZrmOW0vnn/ANW8SlSGhTGfNByCeho1Wy1Zte03VdKt7O4+z21zbSRXVy8H+seFgwKxvnHkkYIHUVHaWmu3Xie01TVLPT7SC2sri3Atb152dpXhbJ3QoAAIT3PUUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/wAgDTf+vWL/ANAFaJrO0L/kAab/ANesX/oArRND3EtgooooGc/ef8lD0b/sFX//AKNtK6CufvP+Sh6N/wBgq/8A/RtpXQUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf+vWL/0AVoms7Qv+QBpv/XrF/wCgCi+huJreSK1ufss0mAJvLDlBkbioPG7GcEggHBIYDaR7iWxo0Vzng2eW68E+H7ieWSaaXTrd5JJGLM7GJSSSeSSec1jeEl1Ky1SFNcgni1O+tZro7dUmuYVxJGZE8psRxbTKioE3/KCN5xlgZuXn/JQ9G/7BV/8A+jbSugrgbrW9RfxzpUp8K6uHXTb1REZbPcwMtrlh+/xgYAOSD8wwDzjsbeRpII5JLeSBmQM0chUshI+6dpIyOnBI9CaALtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf8Ar1i/9AFaJrO0L/kAab/16xf+gCtE0PcS2My1021sbKxs7VHit7FFS3jWV8BVQoA3PzgKejZ5APUAitp3h7TNLuGmtLeRHKGNA88kiwoSCUiVmIiThflQKPlXj5RjcooGc/ef8lD0b/sFX/8A6NtK6CufvP8Akoejf9gq/wD/AEbaV0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcbNY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35YcdwR3Bm1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdoX/IA03/r1i/8AQBWiaztC/wCQBpv/AF6xf+gCtE0PcS2CiiigZz95/wAlD0b/ALBV/wD+jbSugrn7z/koejf9gq//APRtpXQUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf8Ar1i/9AFaJrO0L/kAab/16xf+gCtE0PcS2CiiigZz95/yUPRv+wVf/wDo20roK5+8/wCSh6N/2Cr/AP8ARtpXQUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlY2qPZJqWircwPJK94y2rKeI5fImJY8jjYJB35Ycdxs1jao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3BHcGbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ2hf8gDTf+vWL/wBAFaJrO0L/AJAGm/8AXrF/6AK0TQ9xLYKKKKBnP3n/ACUPRv8AsFX/AP6NtK6CufvP+Sh6N/2Cr/8A9G2ldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACVjao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3GzWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcEdwZtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBnaF/yANN/wCvWL/0AVoms7Qv+QBpv/XrF/6AK0TQ9xLYKKKKBnP3n/JQ9G/7BV//AOjbSugrn7z/AJKHo3/YKv8A/wBG2ldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACVjao9kmpaKtzA8kr3jLasp4jl8iYljyONgkHflhx3GzWNqj2Saloq3MDySveMtqyniOXyJiWPI42CQd+WHHcEdwZtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWXqWq6fo1utxqV9a2UDOEWS5mWJS2CcAsQM4BOPY1qVyF7f2mjeMJ9R1q5hs7KSyhhs7m6cJGsgklaZAzcKzDyDjguEGM+WdoBs6lruk6L5X9qarY2HnZ8v7VcJFvxjONxGcZHT1FTaff2mp2Ud5Y3UF1bSZ2TQSCRGwSDhhwcEEfhXB2FtrEer6DBYvBYyfZdWeFby0eQJbNdwGFBGHjKYjMYCkjaBtKgjA6PwgJms9QuL6SP+1p71jqMcSFEjmREiARSSwQpHG6ljlg4bChgoAOpooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7Qv+QBpv8A16xf+gCtE1naF/yANN/69Yv/AEAVomh7iWwVyGkwPb+K57e1vL24ggtv9Pe6uWmEly7KY9gJKxsqCRmRAgAmi+Ujbt6+uKn0uHwvcWFvoLzxXOp3UluHvbu5u4YiUkuHcwtLhmYxMMgqcuTk8ggytda3qL+OdKlPhXVw66beqIjLZ7mBltcsP3+MDAByQfmGAecb3/CQ6p/0Jmuf9/rL/wCSKi0m4/tKzGtT2XnalY/a7IC3O3zNk2x9is20b2t0IDMdvTd1Jn8M6neatpRub+GCG5W6urd44HLIvlTyRjDEAnhBzgZ64HQADf8AhIdU/wChM1z/AL/WX/yRR/wkOqf9CZrn/f6y/wDkiugooA5//hIdU/6EzXP+/wBZf/JFH/CQ6p/0Jmuf9/rL/wCSK6CigDn/APhIdU/6EzXP+/1l/wDJFH/CQ6p/0Jmuf9/rL/5IroKKAOf/AOEh1T/oTNc/7/WX/wAkUf8ACQ6p/wBCZrn/AH+sv/kiugooA4LxX4i1ePwjrUkXh3W7ORbCcrc+faDySI2w+UuCwx1+UE8cDNbv/CQ6p/0Jmuf9/rL/AOSKxdN1W58Q21nZ61Hazaf4i0mW8SGFHjaCIiINE7bz5hK3AG9RHjYTj5vl1dUv9V07U7eVTZPZy3UNrHaCN2uJ95AZw+4BdgLuV2P8kTHcMnYAS/8ACQ6p/wBCZrn/AH+sv/kij/hIdU/6EzXP+/1l/wDJFdBRQBz/APwkOqf9CZrn/f6y/wDkij/hIdU/6EzXP+/1l/8AJFdBRQBz/wDwkOqf9CZrn/f6y/8Akij/AISHVP8AoTNc/wC/1l/8kV0FFAHP/wDCQ6p/0Jmuf9/rL/5Io/4SHVP+hM1z/v8AWX/yRXQUUAc//wAJDqn/AEJmuf8Af6y/+SKP+Eh1T/oTNc/7/WX/AMkV0FFAHP8A/CQ6p/0Jmuf9/rL/AOSKP+Eh1T/oTNc/7/WX/wAkV0Fc/r19e2p0y0sDBHdahdm2SaeMyJFiKSUsUDKWyIiuNwxuzzjBAMK68Rav/wAJdpsY8Oa2iGxui1r59p+8IktsPgXG35ckcnP7zgEbsXrjUbu5ntZZvBmuNJbSmaE+fZja5RkJ4uefldhz6/Slg1W3/sG48UahbZudIiv4JHt8jckUpWUohbA3m3VgCTt6bjyTL4T1XUNSt5f7UvLWS4RIy9vDp1xZNCSDk4nbe6EghX2qDsbuCAbbAWf+Eh1T/oTNc/7/AFl/8kUf8JDqn/Qma5/3+sv/AJIroKKAOf8A+Eh1T/oTNc/7/WX/AMkUf8JDqn/Qma5/3+sv/kiugooA5/8A4SHVP+hM1z/v9Zf/ACRR/wAJDqn/AEJmuf8Af6y/+SK6CigDn/8AhIdU/wChM1z/AL/WX/yRR/wkOqf9CZrn/f6y/wDkiugooA5//hIdU/6EzXP+/wBZf/JFYXhTxFq8nhHRZJfDut3kjWEBa58+0PnExrl8vcBjnr8wB55Ga626muYLSSS0tftVxwI4jIEBJIGWY9FGckgE4BwGOAcvwY6z+C9ClSKOFH022ZYYyxVB5S/KNxJwOnJJ9SaAJP8AhIdU/wChM1z/AL/WX/yRR/wkOqf9CZrn/f6y/wDkiugooA5//hIdU/6EzXP+/wBZf/JFH/CQ6p/0Jmuf9/rL/wCSK6CigDn/APhIdU/6EzXP+/1l/wDJFH/CQ6p/0Jmuf9/rL/5IroKKAOf/AOEh1T/oTNc/7/WX/wAkUf8ACQ6p/wBCZrn/AH+sv/kiugooA5//AISHVP8AoTNc/wC/1l/8kVh2viLV/wDhLtSjPhzXHjFjalbXz7T92TJc5fBuNvzYA4Of3fIA257yuT331h4zgmnSyf8AtTNr5UCyGWKCESukruW2ldz7SBGuGnUb2wNwBc/4SHVP+hM1z/v9Zf8AyRR/wkOqf9CZrn/f6y/+SK6CigDn/wDhIdU/6EzXP+/1l/8AJFH/AAkOqf8AQma5/wB/rL/5IroKKAOf/wCEh1T/AKEzXP8Av9Zf/JFH/CQ6p/0Jmuf9/rL/AOSK6CigDn/+Eh1T/oTNc/7/AFl/8kUf8JDqn/Qma5/3+sv/AJIroKKAOf8A+Eh1T/oTNc/7/WX/AMkUf8JDqn/Qma5/3+sv/kiugooA5/8A4SHVP+hM1z/v9Zf/ACRR/wAJDqn/AEJmuf8Af6y/+SK6CigDn/8AhIdU/wChM1z/AL/WX/yRWF4U8RavJ4R0WSXw7rd5I1hAWufPtD5xMa5fL3AY56/MAeeRmt3xRrEuh6Fd38MZe4GyKBTE0g82R1jj3KnzMu91yFy2M4BOBVfwjhfD0VqtxDNHZ7baOOKymtWgRUULG8cztIGxg5YjKspxg5IBY/4SHVP+hM1z/v8AWX/yRR/wkOqf9CZrn/f6y/8AkiugooA5/wD4SHVP+hM1z/v9Zf8AyRR/wkOqf9CZrn/f6y/+SK6CigDn/wDhIdU/6EzXP+/1l/8AJFH/AAkOqf8AQma5/wB/rL/5IroKKAOf/wCEh1T/AKEzXP8Av9Zf/JFH/CQ6p/0Jmuf9/rL/AOSK6CigDn/+Eh1T/oTNc/7/AFl/8kVmW+raheeN9OguNL1HT4Tpt45juZYSszCW2AIEUjjKhmGWx9846mujuprmC0kktLX7VccCOIyBASSBlmPRRnJIBOAcBjgHl49TutR0nwlq0Udqms6rbrAlw6O8VuJYPtMn7sOpYE26qMsCMg5OCGAO4orD8PX0+p6X59wEE8dxcW0hjBCu0MzxFwCSVDFN23JxnGTjJ3KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDO0L/kAab/16xf+gCtE1naF/wAgDTf+vWL/ANAFaJoe4lsFYWs6bLqYsprW5S2vLKf7RbvLEZY9xjeMh0DKWG2R8YYc4PIBB3aKBmJpGnTaTbRW/wBoSZC88058oqXmllMpKfMdqBmkAU7jgr83yktJo+mHS7aS287zd91c3O7btx50zy7cZPTfjPfGeOla9FABRRRQAUUUUAFFFFABRRRQByel+FrzShbbdShk/s2wfT9MzaEeXG3l8zfvP3rDyY+V8sfe45G2a40bWJ/EkOp/2nZGygKiG0msndosjEjq4mA8xgSoYqdq8AfM+/pqKACiiigAooooAKKKKACiiigAooooAKwtZ02XUxZTWtylteWU/wBot3liMse4xvGQ6BlLDbI+MMOcHkAg7tFAGBpukXGnaf8AY49Q2mT7TLNNHCA/nzSGQvHuLKqqzvhWD9VyTg7jTNNu7PULvUtTvYbq+uYorcm2tjBGscZkZflZ3O7Mr5O7GNvAwSd+igAooooAKKKKACiiigAooooAKyNB006LoOm6V53nfYbWK283bt37EC7sZOM4zjJrXooAKKKKACiiigAooooAKKKKACuZttK1iLxPPql1qFncW7lo4ofsDLJBDjiNH84qMsFZm2ZcgA4CoE6aigAooooAKKKKACiiigAooooAKKKKACiiigDPuobme0kjtLr7LccGOUxhwCCDhlPVTjBAIOCcFTgilo2my6YL2a6uUuby9n+0XDxRGKPcI0jARCzFRtjTOWPOTwCAN2igAooooAKKKKACiiigAooooAK5WPwxJbeHtA0+1v41vdESL7PPLAXjdlhaEl4w4JBV3IAcYOOSAQeqooAxtFsf7J08WpkM0jSyzyyBdoaSWRpH2rk4Xc7YBJIGASTydmiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAz9D/5AGm/9esX/oArQoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-11-23 11:22:32 +0100" MODIFIED_BY="Laura Amato" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 ACAM versus PBO, outcome: 1.1 Return to any drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-11-23 11:16:22 +0100" MODIFIED_BY="Laura Amato" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 ACAM versus PBO, outcome: 1.2 Cumulative abstinence duration.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwMAAAGgCAMAAADB60t4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///80TKWtAAA+D0lEQVR42u19fYxdx3Xf2Y/H2Q+Ku8vlyvwSSYmMAiSKGpO0VuRSDRxSsWutISRS3SBGXCGFkRYJEvUfI2kByW4LNG3RNgVitWn/KBI3QI3GDpysXBsx06jeZUSGpAyXTSGHHyIlUY6o1e5SXPKNdsnt/Xx35s73vXPfu2/3HFt8b++be87MmTkzZ+49vzk9BJCQNjT1ogqQ0AaQkNAGkJA2MPXXrkaNTwD8n6slGOxZni9x9zTAd3v7/9cj0zCj+H2mndoIqvPtlT2PglpqUGKuZ+itsGK7b9/rGwz+m+98L3ZTveu3Dnwk+O9uGQaPHilXgZmlgcmP10ghr8CqocLv9P3kOZiZgVtHf/j2raPLb2O9u9wGPoTTQAGag2OjE3uhMTE6Nn4Opqd3j4/t2Dn2zO7g666x8QvBx/3jAC+MjW0H2DselF1Kyo6EU0xz+9joC82iVbgS914iO+Q10YDmC6NjgyHLXWPbGgDbR0PJbaBTPwerp4LPRH4jaOt4pIWJsZ6kyMC34JPBldFj8Oz2Y/CJgVB325vBlW3boPU9Kh+0ZYRtC9a7ljZwF74F9wD2HR9anrwFI/9z8daRrwSXV29OHbp3i94OS7x85GPBx423Ycf5oZcP74CbR94ZmXwoKbsUrr/7Dr+8+fyDxSuxFv6TyH7w8J8uT47Ag+c3Dx3fF4offrwfdh4eHgwkt8Nb/Rz8QuixJvK3vL+wfCTUwr3BqV9Py/x4ZLSLQcsXo9YfH1o6HLZ+fin7HpUP9DIat+VPo7ZgvetoAxeO9BzqOdKEj8GllZl5eK93+xb4veD6d1ai/0Iv6Y0tcCL4uDMATbi0JVw0YNfKbwVln0nKhovJlotQdMJoPgSbws+EH4VHVmbeC7hdvBTwDcRfBAJ34NJlONyW/dFf7bnYCGsVy59/YPt94RwBV64lbQ0n1NhoUwp0dydSy52V7HtU/kM4eDVuyyNRW7DeAfXU7R3Z7p88fWNi8rW3k73nro+e+evPwkz4V/Jf9PHdpej30WPR9123p2BucY0pO/JEcO/cQrHN3Bw0V1cCLgw/CGUF/8Ryp2cXx6aijzbsLX/rN8489u1PwEwif+fB00M/kSkk3qQ3n51bmM4uRkVnFxMVtb5P59uC9a7nOrAKk9OT8A/gVDyNL8M1wUqbTeiLvz0Xfj8Bb7/zpTNTI2zZPvjDmZmFYjWYWVgI5qFMNolr0hOyXIrFJ7Voi/IeOfXh3Eom/za8+bpQ5mH++V5vWHRR/A6pVlttwXrX0QZW4HszX4SXAm9kf2N6PKjfj57PF9l3IXBFIvoq7D8f6Gf82Z+9Fgz7pOyBQF+b4Pze6YnSuon4zYW8tgXr9v6l4CMQfyBYo4O/Eo+pcvpXx/517DdE8p+DH90vmRQG2b83wUONqKq57xDrhWkL1ruGNtC8B38TNHW1+cbZ5eEzN2Ho1NLPCXV+8tVkir9ydvmps+/AK6dvbj+9GQbjsn84+wC8cfKppdNlPZWEX8RrKZS17/Sfh5u9Z8kqXDm4fOjsD9uikhfhi0lbQ/lH5h59P+937Fj93jX2whtnDw2fWRK/821ZwnrXdD9g4WnOABLSRraBkd4F7DakDW0DSEjrfE+MhIQ2gISENoCEhDaAhNQ26ste1DX/86aBJxfOvLSn/w5bYvrhH6huvvBf/867g/et3DOXNNL0ww9fubfniYftWTTI5sGB599cCu68MTR+k+f1cMbo3NdvS5sSlPr6Sy4SU/0EN747tPUDpUBGf7zAK/eav3PixuK/aHzqvTv535Nvgu7fO06XAPY+kdwRyh4YXr0nU+APNJp68s3vvdT8XlTLnX1jt+D+sZtJXQcGenrulek5oR7zx68E9Tv/9nyryjcGNm9bcqpy83fJwCi91/hUVOVdfYG677+d9mdjaMvplzxWmVkHvvLYfYszk3/bIf7+48f/2+Li5K94qoox3pynseMjC1su3II0Dj2jmZn4v5hefFzJ4hPw3x0EpvoJmP+w96M9SoFK/X0EHj4GUw8Hn3eYGzkS7h2MQsTC99LpLYtLR+5zU2z/8S2/efwE7IfTM4HA5tUmXFh9K7aOm33vnDw+6nda3QThm9xPZW/RZxa2PL7sxmPP5OLmw+PBgDgTVvn28megcTcOr9tzoudvFh/7qYp8oS8EItdm3o/i76enIfyvMbF1F8D49F5oTG8Ny8Tx+nHsfhjX8GPBHb+dlgbY8cx4Ay5s27pzejqOAoftY6M7IC0wPf3VKPZeShbx5hzRYHRcm4mgR1EcukiR7NGwOXsnRke3nhMkvg/HI4khFiAYGNtGR7b1hFCFbWNflbBL9BMJHAbZG/sIUxDpL+HF04fB/2ajf8cSfEOgk+b4Mzsj3fUE7Ywqy9G7UaAMhRvZpTW4l6trwGNXS36KtXh+6+7kBgLXDgZC78Wj8u7IGpxIQhRGjw0MHJq54dcG/jQK9/ww+GzRNbgb98GecAyMB4OqsW1sV6uPwl7eNrpz59hY2kcrsHYxYPERiEbL2srvwXjyEL85tTiwNjNfkQ30wsHxoA5LDP6tf3Lo/dCwV+ArENYhidePYvdDRwo+Os6NrLVXj7wEH3t8Jp7Q59+EHYdfHj60Myvw62HsvWK2sog351Z4OPSFPcn3H5ctIbHsKDD91nuLV4+eyBe488swEM7IDx4eHj68D35qfvH242PhKLk09Y+kqjrYau3r8FmxQIQp2B7pr8WLpbtBLWnw3124keEbvnIkCfwYGJr69UUBe7jy6tQ56Jl6dSW7dC7QO1vXfxjyuNeSDwnW4stHUx+wJ7SjzwWCl8cmmtC7t7fx4aX4l1X4AXinR04fPQd7jr76CFvlfrhFgj4IPcjnNx+9A/2PD91t9VHYy5eOHbz3xtSTLTtvxsZ++/mJO/BcA5o/fzn+5Rfggwr3xDdPwZEXJy6wvxK4+JcAPwws8lejSaQVr38nWptfyd/xxiX442DZ3hL36p3BoOyWS8C4uFHsvcJrtYg3Z2mJwF89OhGvKrk49HShaMkOmP2SWGTrxb1TY3GrLsIUzJ99YUuET7gyAhKHm9PPgKxOEabgY7HAlBdDc0curM4uzK02j8ytZPiGP4ZLsf0uXJW288vwVDAd/vvMiZ5+8dVXuLquBSvUpSusfAZrEc0ucGAw5D03OzT5AAwuDUyQh0ZDXFLQ6IEK9pgNOBaFLTJVPj0M871JH1y5GqiXwKU32D4K2gHzmd43wTcGgz/W5rYcmfwSHBoefPCrD41Gc+lF/1VmbGDl+vlTMMl5WsdgILDmtbnVpdVTVyPzDP6+G42ByOKvn+PvGBiA7wZVf2QlGShB2Ue4KgcFehQ1+Xagt3cjGc8+G9y389G798GxmMuUrPzKH7w2B5Mj8QIp48rI3vXovb+MmOX8jHcTHyOQeBJOvfgfN8MTscRjMoGMfhTwnKj9kZuV8mIXOvjpY/0D/cf2BN/uwm88G1/9Lgy0tCVr59NzP9+ks7+U7T2+/104kKvrVCiYkf9I/F8q/83Tt7bOBWv3wiOXgpn/+uLl5pXPLP9aZJZQBaDy8uxgc2X2clbll2fvvp71QVTlY3GVW300EDlALb0vnPnlidneoMpXn4b/BL+4ePnD98J9TDVVZp+NDly//loyecxB5InNxsHyjWM/ciwy6yReP7vjnevngzE/mw6KZjgY+6DZ8vn74kvfTQtcUDfAJt6cH3Bvv3Mu8YEelp2PcSKWHdItuCZZ9FfmNp2Kx18Uqv6USSKjn/vkB3K0MAUyXpuC1Y0Eal0N/svwDT0pHkEltP/inql+xhW6tvnxfTn+c3pMw8CNxfk1pr77Nw1cXFmLzfLhCmxgYNPRfVMNZu5bGzy6L0Rj/ECocl/WR3zXvLv4bk9f6soBHLi9cnTkXrzI3FehDWyd3j3wx+HCGU2rS9uiperAvuDjm/AYRCpP4vWzO3oG/iS44znYsy+68OD+oI534Hx/1u/n9wc23gd74wInDih9IYt4c47Gp88NNOI9Uz4OPVVzJDucOPokKIRwCDzR15IYbvKpVmKqn1DgGLwn6fsQU0Ai/cl49QWz3Lvw/+Ao/AmDb/ht2L8vK3NAnOXeC5Q/kDxziOjtv7jT4Pk3Yh6JfPbpY3TTtucbu4I5bHxsKdY+fR3mGs+FvwzNNps9pXEWEmfocOgKZVV+51RzqRfuO8962VGVk/EhVDmo6+6peRgf3XshqvKdVZjbG43Vv54bbZ71iyFgbOCD08ujXzzz51H8/cLcL4Wja/XVW/8hVO4snIqcjiReP6X/fWZ65MSZRTgydyv2/vpun/ozWPiLfzsWLg2R/3/2qeWz12Hh1AffjMXdOq3c0hvjzXPu+ZnjYzdPhhgBIQ49k33uOgzP7oKhuaVvSVj8u9iErhxc3hv42MMH9mnPdEn1Ewjc/sRrkg1IhCl4J9Lf4pzI61qgxRUYOQWzP87gGw69eqc31VaMfcjvMnpg7mK0JrcmlidGef5/9he3ezP5LEU3ffvN4Tvn34bNfftunQ2c8D0wAoPDh8Jfrp5c3TF60jsi9NIszF6KvYl0ejj2I0Nzw0wfzJPbfdn4EKo83LPvdqDizY2lJ8Mqn+tdCfYxkXmPfOfeR7508i2f1bWJG23CzqPfv2bNcnTo8sXfOC174Iah/5LXHIOX7/vEafPjyUInh+394P0ONq2Q9HInpFVmA2NrvUMOhnfuZ+5CY0h2UtwoLOKgz3fA2NqaXFs8Tby35s58YuhqB5s2MXitwE1F2lm9DSAhISEhVUnPdFR6P64DSJ2njo5CjJ1G2uiENoCENoCEhDaAhLSRiQ97oUT+PbsYb1+kH16IJjukjKeOu6ECVtW0kJgxSH4oJTAvpFWaKJQuvy0pS7M6kVzPpT/xTGW/UtjIj0a49wOUMOqSdQeNu0n64Y84njruhgrYV1MvMb1ASe5CcYGiuOj/ZhPIeMbjlufDGUOr2twAl/9KO2kDK3GAZk3WgdQSAr3QqFfiGZKkilNqyrMJWPIk+goQ2yoaJBLNwlhGC6SM6sJOKVOQOLKpiqYB/ihGz83UyAbiKYkwM1nyVbNAE+8m4MSzXAVsJVKvti4R5zIbE9sxTxx+7QDNMP/WYE8cdAGhMr0QfT+FBuO7XixPahq/ygpQ3qfRG3LKhFCxYHSBmOuUu5NaNTC6iUT/0nbOyrQmm4BG42frsycu2AFVqLLFM/TDaNEK8OuXfjUjYPD2s0vqOrEi9DUX6kXAvOBarFP6+ymGBRhsgJjNoHIlCgIq71MLHvkipJK5oaxv3npmRbWPoyhBe1D5QvF6T2u2fNLi1aH2jGxMgBpZFRLo2fsJHDaN8TG/ogno9sScx5rzb6MryXX+w29Ppk+ktNz56qiY2FVTI5EXQ70IlDCLvxNLvfAXZGbL/5R/2kuBAqAZhIT4gfVChnm91vuE6do8F0LqbiPoyK3r2xdC6ioiJX7e2M4ArgNIG53QBpDQBpCQ0AaQkHBPzDwdkIUDyW7kotdp9o65/PaKcrH3UqZCtLBCbPZyi9gE/QORSxSaV04gAEjACFr8QA4rICAU+AhoGX5BuMZe2Nj4gXyshKQXVAMH8gHzBHw8ZaMMYwApU8r8CxqIAWVbYAj6z9opSBSaV05gTq02+IG8WBGhwFZahl8QrnEXSJ0ejrYdTtCvnhnDLon/J5l3VIGaVcwnqoXIHNtELeokCx3gbyG2zeMFOryUIlYNKaNba0xGx4gy7jm11UxlNsDiphTzDoGqTEAc2pJAZgouEBu7oAABpejePBeBrDhTCA8pqLmuIsKsA+011X6Jj8o6BcKURuTm6zvyyzGYhRq0awEB0iIf+cqYaifiG3WViieXONLa4JiX8tszcfWmtuMqpfsBqhhjQt8nIfI2Mf7uHWU9GxvEW0AgKTG9R5UCjIsKlM4qNvgB3c8YB+rdF5JeIQpH1mM4LlWdg6Ap4rn3qS9Pz/GGks6MHjjQNctA+6nX1regsqv+HSF9+Lu8CC3hJ9m0gboPRuNwo8UGeXHNoQm47QcE3yLzeaSOsX8EgRAnr+tbO2SAXdC/FESZD8S3hCLo9sZF8APCPbJ6CL+mrxaSFwEp4LJC8Ee3EeIH1gXp0JOk3P3tIMQPIHnZRnXs7vW4J0bqOiKFfqrqocL62BMjIaENICGhDSAhoQ0gIW2wPbFrcKIEQuDz0Borjsa4HGDD+YHYyNGeaGTTSoNAruoO+AERwMDhB/KQC747ET9gZQOOJ9HLIAQecxFYccwhCfSPPYidHI1E21baRCqL0f4m/ABRKD0Z8nnIBYeD6CL8QETtBBH0m2c7HitGqAFC4IuIg7XYHMhYLjDZpaz3sISsgRpoAtFWgSiaU5/5n+Z9dFq8n8rbgDbbTCu0sQ7as0MSVJAyqrxAmeEazdTWrKyssGYOEMmvA22rnSxeSLuoE6UFR3f7zU3mJ6AlsV69i8MU12dAIx4ESsRZ4Qf09kLBJVFKOpnVcy/QThCBBj9gfVYtAyHwmpuMWKQRs59g7Pc5ujYQ+5RMllhKmllMyfwDpvwK8oBzsuFjSfv1nWgxnXUSqUo9wTfrUXXjDotaIpsxTtqJejVdBDYPXarBUtpxtAAbWNTQYahQl1K0fNXdPKEiNadoAir8gPJD4856Dkf3xtHAyDq7ADimMrCpuWv+gdSRlyReUAEgkicYeUwB4gdahPiBdUGIH6jAF0LqMiPo4N3rck+M1G2E+AFcB5CQ0AaQkNAGkJDQBpCQSu6J9fgBTTCpT7KI5s8nDLA/VNdQTN0o/s2rJdBCLzCfPUGFHzAlHZCrTMAv5HMipG1IorwQP8A8HtDF5iiDST2agDmaX0gYYFsL4iqbnx349AI2jxNNOJucVCl+wJR0QFptWfxKTpscKIds6IejhvwD4VyjCZVu0+whjWV1PXLUv62WKZLFBpHimhCuEcmixVVGPplUQw529bXMNb9Xdnj4sQEeKtDxKUK1UMtO8LfwdAoNeMqPW8uXrxqBpIhh2Z7MrsnFJEirLlbCgW3rPfFKJ5wyHX4gmTq0HU+rOWiUCWORxRNTPmGAXcixcdbzHTtDrG1Fgx8waILphOxnWcAvATlcgNQqvrTRCaEl8MTJLRXvB9Sn1jrOOMRWtmp6dm0ocdOhAj+g1QRNE6VQFhap3A1IOgzDxZxiJeozXbS7JrQFLao0Mt8doU26SIn1pV6bAaDxhDpnAkWzAhTwaeJYf9eQf1p1vVQMZPgFqi+L60BuP8C4oFkqAj5kverEA7pofpeAfydv365R1vOnH/yAOeLfAA1Q4Acq2gN1I/W0+6EiUptdQsQPlNwP2CVBReryfRHiByradCFVTMRbKcQPICGhDSAhoQ0gIaENICHhnjgLtsq9DaWKU+yrPsyWyrmr4uXF+y2rSQ2IBesMBQ56kcACbEJ3rNAEKlwB35dMsxE/wCmF0ZEymL1qEEHW3xr8gCRe3qa2ZjlCQesMBQ56kcEC1PkHtLflw4mIWk/cU1Cm2Z3ED6x0KFJO7gvRDE5BaaIkSlmNdWi2MJyF7SOzgO426xNViZt44l5LYuROLY/6rQfReKB9jdbFBjLltmYG5kv79ZMu+tROk2XltL37q6mJVhmkZuYQxmAF/z7T0br0Gye0XMKvtqtOiR/gXCFNZgHCY2hVvUF1uS54gcSwtchC1IhNs6hT/gFTVyhChGya3RFqdNwQ7WKnO7FU0YIuiMqHzsL/lMPbJc0L1Y4rs4PNwR9s8g+YB2scSqjbN5Vr9sZ4LqSaXZg5q336oqa8MdRhzgRtrklK9CpwFEiKrZl6/AAxLgPEk3o3GvXm1kVJ/3fId1aH6wuPbq1MgFrLKWsC1ElZ1NFODF1BS6t3Y68DonPYCmgnycPktoAI9HWi6TNtmixQdpkF7JIGZIf7lxZIde6LBP1gk38gq4MsBYGUsSwvAeIHWML8A+uFDKtOrZ+ZYv4BJF/7pw7cui73xEjdSaTEz4gfQEJCG0BCQhtAQkIbQELCPbHmfbzpRE/u/FbaOti+wGbLKf8AMVcbjOH8ZnYFBerjhVLtZIkAiP7keyN4QMxoIMbI5VnE0hE/wKmJWpzvKe3QfICK7SH9Ymfb5R8wh/NLq1VAYkGBpkz1zCcFPX4gx1cOHqDK+mpYJOid2jwc7QSaoD8/2RBK8hN68o446qSW0ricJgodFnjzYhEoR+ztyWYtMksUSpBSAkXVGM9ctxmjQkYDYmRR5eGpzqt/yzenzh3t1RdKZxR+IuFiVLKkBHxOEz8m4JVIhwVqhy6VhNaVAgMR119pPiy+Dl210oFu61d3jUR/XJiJTLWqo12dpgTCfEi5USH+h5pnXWPQv0YiFaZMapcNQ9vrfFSrLX6gmA6ZfjNlM+godQJN0C90DbUdyrJwrehaOf+SpBk2WkgQgRvh3V07gcZIeY1E1+FCjCOMSK/4Gpc5HUqVgIFial/I0iuXTGW52zzNMp6S7Tn8TMwFbXMx2ZRjXKEObE0RQ6DGD+iXAgqW594X3BxRUHs5zmfoW5kANfO394Rideoi9Ksc7bR6Eet3HUi9G0PEfebz6A7CLzjrm/MPWBTJDQl5pL30Z6oJyc/H7ls7ieoylH+Ar39Qb05FACbggGvShg1BPYVTNaLuakSUlOspzD9QYK1FE+gaI7D3ntAX8rlLRWovkXK9hfgBJCS0ASQktAEkJLQBJCTcEyvi4qnsNHsKFUVcpQ+duHd18kOvtEWAK6GvKzWeqVpEoD6GlEsT4AU/IIcG5LpWzgLxA5ymdb0gnq1fwUO13PG4sjh8ai7ClciVBz075atpR4EGBEEuErE0fkABDZB2X/5CffADsFIT/AAzwonYZdwdvpVHJYgEapYtR7RwtTPUNftZjYZwE6hdJZ1CjzTB/1bahDJJFdpClHHOqVsbfftCvFzzmcSkEm2Q3FGHRDokzCAUoiyvZUeMJewE6pUnA2Y64AesvJfueZlPmHWgVvgB0gmVbpSzwHkYJHHEDxjx3TYWQYm1NbWPOgAgkOMHNJps24TgbXYrdRBnBQJluwFwxA/oV2cnAAfB/AOGvqTFh4LfHQI/yYkoe/2kaPBKXBnYlXe3Hep1IjHUGcMeW1sQbv4Qkgm1W2UWo8D15HxDeTM7zwKNT6Eq0aHSE0JS4QcEUKTTYf4lpjBqk3GyutnMv2ekbadT/gE9fkAFDUjHeg4lYUBVbCTC/APrghA/4MkXQupiI+jg3et5T4zUNYT4AVwHkJDQBpCQ0AaQkNAGkJBK7olVYfO6S7IT/ks+cqbms/7FImAOTzNXS1XQPv+AvUBJID/RJd5WB/+DeLM0qThF/IDZBgo8gZCd8E/Lhb1RhiPIgw5o/gdj7l2raqkK2ucfsBcoC+RX4gf0wf+pBoRXz9RCr7XDDzDUrlwE/bpZJ5vjs2PY4yAikiqyYGC7m7UR/c/U+dhxY0HNMarWfPxFnRObiwIAgpLueexPFX46La+8QjbATEzyOY+2gkurwA+ksfdZNL7xXH/f7/s75Ro4rJ6SY9X1NlhviyCKdaAt/dCvnX8z9CBN/if8Ilt+PYyhLIpYHU9Mmd42ezlg8zqUyiOYc/kHjEE21CLFS1omi/3R4Qck0xDxZvE1pXZBCfqNSrGJ5MzF2JXoIGpOfJQZoj4NjryShSYlIt0g6DhQiyQc/ObCH37AZYkhdUpGVp89cQ424PCu3cfMZHFoP3Xdc1ubSmm4TanyGnel/KSvUhrGTCreD+QeLNAYak8o0S4VPs69t4i9T4rYR+BbR8qrn0w6DUSb8rRKY3LQK+IH8merxNriPBuJ7yusn3w4u4+QdItz8n3lHzAXFPIPGFjx5a0bqMYPqFIkKPIPaC5YsdhohPkH1gUhfsDznthmrUcT6Boj6OZHQ7W1ARz/tSPED3jfEyMhoQ0gIaENICGhDSAhbbQ9MbXNKCCFC1TwoFlxin8WNW8I5xcqaHxBkAYhq/ADQCwFpodWEoMOGb3rw54E4Tx2gOWjAhmof0X8gDjmLIYm8YsaUHW75BT/liSav6Ctp42JytEBAgODwKSgNv8Aw6KFwVDnHwBROI8d4PgoQQb1ww+sdOKMXa0NaCd62nqJSUzdVMFyUEQKH8VkfYKc6qh+Skw1EAranFxvF9RsU3tnLEcnJ3+auOLR59dIbWwgjo9W5pwxnvft+9hD/Sn+rhHx1ljK4gxyBa3URewGOi0woCm0s7/ciCTrQPRZw/fExPRVATRu1xt3Ko3nUReMP4gN4ky+JxIZaBOH2biFeXWZ8g8UOsdaFy6o/7VNVANPSOMLgWs8VRUbYqUobgSptyIkHZOU2O4G1AKJV01IPS7pPBLHyxVYvwhjXK6/btg9cX5vTNS5wNrjMeph6ZXVo/jh05SU0JLCuSMlja6+e4KaEP9+IHswQU0PNap3GFVIAmr4PV/QGtagivu3z8VQnXNBK7oT8QOq/QAHHRBcImkqgvYFogvH66tEu1ZQFffPM8jO7pcMKOsz/TNmuZYQU3lDc1QFEywd4gdEwvwDXU92q7LVoQOdIsw/gNQpPwk9IqUvhNRNRMqXQvwAEhLaABIS2gASEtoAEhLuiWWxMrLAoCrRA2m8tN1Z/3bCM1iA6pgpHqcgFBRKGMPhzDFzEjyAJiKbZ0al+AEr4ADiB/Q2YIcfqBY9kHSL3Vn/tsK1R0Emd7PR/sRYglpoyKBKEQ8gxw9I3lLn9EKAv6ABDtQ//8BK+wPpdPiBtE+4DATVoweo3+A0eVIWGSNVQVKsatrYbmtOnpIJSKeBmkz+FL7GOee0zZXU4Qfssq60GkLabQIO/pXWY6I5z4XqlgywGZERR2JTKWPTxcHrK5NAbRwgwr4nXmm/afbbzrNs9oHq0QNcGAst2Y/Z4ebSKgpVl2QdAddzro3KIOCGHyikPCpaGIs+7jx+QKQOIAr6rSYMX26J02LQivLSzHt2B/3ra0jMTSFuQdGkiL5s8w+on1Lk9y9SzRF+F4H4ATsbIOZe8Dv6O+K0uoAGqoEuWDo51BZhTWzahzGTSvyAZKahpA0m4LQIURcOtLBE4YJFkgQfa6tiZNsKpyDzhLzVY52vA3xQeS7EvC3oAbvkAnbC7QLus6Giyj9gvV644Qcs8g/IJnNllgQ5cMAlhcFGIwf8AKYcqCf5SCCF+AE0ge42ghpwWO97Ytw81ZrKP6RC/AASEtoAEhLaABIS2gASEu6JdfkHqO1bmdLIAiH2XrxfPIBfu60TIQmGn834AVNCZK3AnJCstCn/AJFzpwLsQYpfyEfFsoUQP+A40tXd6gFZIMTei/cLjLUH/UsgCcafTfgBQ5sMAoEXkpXW5R8QWivmHxDSI1DBMCV6jU2q0w9HVzp5/G4+dpqb+KLXllygoSwhAU3vI7qudjUnqrxfNlAt3hMR/c8aXgXwA26Rb9TxSFG7pZoLPxJgCERSqP2UCP8aixogHbUBYY6ILaDlI0kTElBSwSsW91PGPf5sxg+UNgFJLiZ7/pSYOIo6VAXPdtgHSsRP/1Ena8LbQG5Cz+cfUumPUF33ODmbsvgVqgCbUJ+mwgiW+DDUMuGBU+874gcsIra5Q0V9WGq7qKN5CPpBZgRUtWgV6+0C+wHvjO0FE6+VtF7obPEDqhWA+Kzext0Tc0osMt4q0Tw1Yg4tfR1a2MOxzthZRA2WCE2Nx0Q86XWDUq/EJXCe96nWE6rIBGhVfU7bMVr8156iCfhaB5LEA+KUROIjOIgEXpAmz/OALBBi9cWz/oVQeNtRp62JBrHA30mJZZu0pVzzD9DsdA8Fd1UDFEcWUUDkQEJ+8g/gnNJBQvxAFfsB51UdTaDGRlCFZ7b+98Qln3AgtZUQP+B5T4yEhDaAhIQ2gISENoCEtDH3xFxsXP6y/C8xwKUshsAKHMC/t6WmbR1zfLaFRFkj8/H4Vs8jTfiBfCIAIk8PTnSpBeLIXk1qAeB0lKmKgyEgfkAY3yXOHCqLIbACB1DmXzDiBwxB/5I6UmkJ5jI12jEYwnZkiQBk+AGiKpyBB/SpBXgdZariYAgb+8hRKX6AEn524hMSUDZ/SQtUkHSgRwwB6CfdXHi87nbtQkGM9RRC7Q1B9waBDirJgWQUB+VZchXSK3TLm02qd+bvldVzv3E+psAnJGihBqL5g+SSFVShAjk4xBqEYu+F6XElxJYj8WfsTvEM1MIh7EIT0GtgpbwbJ8UP5K7xtTHOpyUAyVDpMZhUm4NDG7dcbLxYDcrU65fiB4gQsyrlSfMN2Di+jQfkgRw/IGix/OnPDlOhYQdReP5SDXLCYy39zY9WAedpzKHMDokLT5LniFTIBlTqd/A1Si0Dtg4CJZ64K4yaEqhQAM+TgHmbQYmLisi6coUqp16N58M/frFcCnybgMTmip3+T22vi/yLekJW49ZGr/rCsgeqSCXWgcQIMr88ARTkFwbKZPPh0uBKMAQOseqys/MLPDRScy4gkereHbgLZHka8g/w+lNkDTCkFtCkPAbMPxBSD66IXU0uGaR8zCTVULfkH0CqpxHUhsn62xMjdQURDyUQP4CEBGgDSEhoA0hIaANISLgnzsfhZ8FxbBk2Mp4JxvW2q1JFzPNF+HQAhlNopcfxC42i2rNVBY4KLAIBSay+hhPo8QNStYMWRqDKf6BjgfgB7vEA8/pEMULFoB6vCpRHzOfGA5cOQPVoL39Mts7sWDnqJ4WmFnOh+VpYgy1+QKJ20MIIQJH/QMuiPuFFnUhE0K+eozj9pdEmVDVH+VoG1If/i1eoplaQD6y3PmlfU1C/7HAIAwvVEHulUPOd+ggqhgUXA16f+Z+mvjl11E4lNkDFQwC1RzJ7fd3uAru0hb1RbW/nRxgpXEkCDiYg8T+MEaGFZxI2skIbhd05Iuk60NkcHNR+bqD8FsJnvHH+yEyxr6x7j9qfaG4ZOENTDAUtD45zzD9gtBd5sJFKLCWux2m3gzqRiKBfNlnI8bv5/mp9+J8NctnBxNhgy34jpixM/JxtlROJEi8tls7UtFRKBSJmeNK4lhgoZvSFjP3VcTX6mr+ofwACKVRBl9xglPjSDOIIerWujuIClX343BnpLtjLsyvoAkeoosW+7J92diZZZ+tAHounOuq+CuyvEPuugy4Y+tCpflaIBX8tljRQm3+Av4eHDCgaIGuRIBbTECB+YJ0QLZ7Krw6rAeIHkCrwIdt493r0hZC6jkihn5zKbLg9MRIS2gASEtoAEhLaABLSBtsTi/gB9kc5cKCCQ0HFw/TBcA6ooR4ZJEEVD87DEQyJCmwaTgl4xQ8o75HhB+TdI6iKZnEpiB/gHg+o4SgAxdMK2JuAyJroR7dFqI+WkQBHMCQqsBHYGv6e8APqe2T4AWn3CG1jzw+sBX5gpTMRc1r8QDq/xLqjyqHllYThWiKzAM/BHJgsnPZvqKSdRZvYkAL60eMHZAkJhA6k9TqWl7agA6QWNsDNKDrgQLu0Q8qNRUvPzd+Slo4vX/gB3T2WxZWAgprYAukMdEC0AZkZEqn70fogFYx5wvUfKX2gYMJBzUg8tFZzMKmnhjNh0jQ72dWYsYDqMM+5Q6XLRWK3nRqdEmyFH2CHAQMcqGpGSBC7vlYg90BvYtgPlPKAZA5LinIwjFpSqOHl67qR9sRm5ZH8QloTb5KUv9tj0D0tlp2qLH6gUG4BinbQq33iAlrgQDWeUE4q9TEiwfSIRtr0wntdpwQJ1JfRFzKBgskc1v06wOUW0AAHqog9t8APSEaRtowh6F/ILmBIVJCF73top0f8QJakQEhIIGOB1CLED6wLQvxABb4QUpcZQQfvXpd7YqRuI8QP4DqAhIQ2gISENoCEhDaAhFRyT+yKH7AJ2nQmGX5AmzdAV0QGejBLNCQqABvAgjFITwg+kuIHVNqQAQf0+QcUnOKyiB/gHg844Ae0AfJFTSAf+64JOqD8PXaVNks0JCoAYyCEDbyC/THNfyDiB1TakAEH9PkHVJwS66vpw9H2QAqkvhClrd42xIfSCjEEkj/c7Qnk4fQ6AdTTkbrEqZ26EsStAQDiUcPSwEFSXR/68gna8eqiV6pA0gqAJ1TXXVWoj1K3IW4/xiw5k8ICnSRRMerKmzrt3g3TmpsAeM9xZOELueMHKjABMQWahR6oxZhQBiZT1zNETWVtjva3zT8goOD04XIazVEel9EN6IL2QApqhx+Q5V6iRDvXWVaHqH+wAkfzw5D6ejXLwqY9j0siTUhDi2A4N8ye2NyHvFvZ2XmEWiOAPdXTOdTerjTNtqlUxcJtGTDMGdXv6LqLSuEH2rUvkptjK/KdlhqK1o1xDrW3G15atuU8IZB4QkhW64AtfqASV8gVP2AuIgu210k0j2yDQBt4hUScBD+QYgIU0ABZ+xT5B4RCBPMOpIT4ge6mkscN1MQjQvwAUhW+YtuZrK89MVLXkJ8DwRA/gISENoCEhDaAhIQ2gISEe2I5foDavYX1hSwQkwXI8lHbvDoCj/iBXPhPOcAC206wyz+QTx6ggBHkOXJvEZQgA8QP5B4POD8p9o0syEf5UpVI82F03vADlL9eDrDAt9Mq/0A+eYAMRiBwFDJwyEAGyZ11ezja1lwEVvkHws5JtRfGp7EYJdUhmQXfukhm+ML9w6cnsD7AXd0iCnpWdgJzDSTWDdGXFjjyYamSr7RmJ85RzkWnmi6q3gb4/AOC00G5Ir6RBfk1myiHRDYyFKO2YBWIQqDH3BwKR8mYJoQakvIQowiGhVUeq3YS4daB9tXKjB8QLhKt51H2naMxWYCX1UU6LKg7x2ICmXa25LvmH9BybLlCNJ+QTGBRz9NH25qLoN/DxJkYhhdkgYUfYbshdpCZhKtRz2ua5ZLhJ/8AsSpNXFhuxD2xv8Fb6dRCW3kfs00sdbIaxwEm8i+9DBjcfj/rnvYaAgeYzYf1RkXn7PhCFljwSQLus7h7U2C/yRMySRT5lzcBtwQLjjtKGVbACmSA6wDr8BPWwxGdHSH63BeywDWa3yZ4mAvCLy3RnH/AIJCVWjD/gEzbquwECvyA0Ncbl4rgB3AVrR1h/oE27gc6k0EWqdpBjPiBos8zkGpDmH+gyj0xEhLaABIS2gASEtoAEtLG2BMbH/rIwuM9P2C2yj9ApaHwdvVVFeMk5o/5sc2JUBA/EAfyO+AHRBUQDbogu8aoinktAYgf4NVqfLnJh6JT/9FtxvwDlP9BiVawDOeneTmkQJ1cBOaEtEJ0rfEDYp31SQpABHZksfAAdcw/0EYEQb95LjZCBbznqnfnqjhhM79CkEK8iG17HQQ6Rfx5CCRSpxeq1/CnjJPeLgRBv0RZqoleOUkRv1ogBq5iv1GrGEmqcpiodAooM9DMmpE5Vkb8gIehS0mV0xd4s9U2IghYG0ihAsQ4JVN+Qfb5pp03Pn5uKGdWhuh7yrZWkQKBWtq9hUAOBtmK3baJFzL+SvidknKiqPXb4TYiCKR4YsqqUhYex0IFKnaExLh+d4sjYm4igZ12uRMQBga71wqU7QbABj/Ae/z6X/WICKg2h0S374kZM1BBugr46148WWb+kuXMLOGCWp6SXrUvbD8oreosi/d2wjFvEOpVb01UgfXtTUIginHNA2CoqMDO3GBaSqAbM7s6m6shfbaGpNwPcBgBA1TAcwC6ff4B64B/u4pqJLrmRLARWA4/INsgqNAFHH4gMwgEDrQI8w+sC0L8gH9fCKnbjKCDd68nXwipawnxA7gOICGhDSAhoQ0gIaENICGV2xNTt/0R1YTYl4AWsGHtMkHZJddwfkN0vhCcX1qg9/wDfOQ0UeIHJC3SYCCiE4kQP5AO/uKnRctCTYtAC7iwdtY08+PHOZxf/QRQwA9QLwK95x8A7gR2qsQPSFqkwUAkSThqQyttPnFXcfZ6Yg/x5NL6ys8lNDmGnTgtHlZELM5VtxFpdWy/U7WcBVrgByxYC4fNgw3KgbtY93mest45hbZWu18zFccWwM5TzFxC/GPIoLWsS8Iq5UPNbtC2MomYRq7tBTuBlviBrJgBP0BAYwKy+lJoCz4HvE4wK2032H59tVTTmWT292QMLnAEmo+XL8eSehZoiR+gxBI/4LhFy8vvEvxAo+0S+13GAs2PAFrlhGDZ0+acQhYbYjaeXr4hdhdoiR9gS/vBI1Gb4PakvXh2rOLcaXPfMvsqv8uApe9IC6QPpOqNLI94oZKHXpRU30YX/ADRXaTq1JpCZ6Id6PAD0j9pHqDXfhNIg+cdRapi7pPrVF2woMCSfldxT0jaUgV+wBWMsUHWAYm3S6gEMRDui1v+A3e8fQloAX+P/qAXmoEci8Nwc6Uo8SbQO35AUAonIauerEVC/gHED7Sopwuiy5HK9BDiBwr6QkjdZgR188y6fE9c4FkNUmcJ8QO4DiAhoQ0gIaENICGhDSAhldsTZ69CW0G86nf30lgUH4kJLM76t04HIB6cXUyi2CB1xmsLgTkhNvgB5T1y/ICYrkCfwgDxA9zQ5nqB2A9c8JOYwOKsf+t0APmCtKBEsUHUrvLU2E6www+o75HiB8R0BYYUBvXBD6zUJWaOmZZoNj+18AI0Dbai/hMTWByibp0OwO5cVGJbJ/b1NS0hsIR27LjJqqfCUtRm/qepb07bXjEWR5ZzbqI/CatQKk1OUHViAl8Ltb9IeeJDIDXH9HisHhHE1iz7BknXgfZbZX++E4gwrEMzINw6rZ7vPCQmoLlYGwkbKoTjWOJwNU6G7Pj+/Hi1sEY7gZJm2eEHKKiqKFaPKDK5UVKJ5fmhRgdk+jxnzk9iAiJ4usYi1jsNF2dbEGjMOuAkUOrRGdOEEJmrn6ul2CLpeoAv/6uwgTYnJrAYbtysrIyU95xS0CywqLPmOedVW0ARXUC9kN8QiA8nSOYi2SzUtGTPuBexMgFlpLyxZfbtshNYjW4c1V4FKGLdrgPsPkD/hNxHYgKLs/6FIlTxgoC2TsDQH/RjiqyXneevY0UtXo2Uyz8gU7EqO0F+1wG5R6aII8D8A+uCED/gyRdC6mIj6ODduCdGqgEhfgDXASQktAEkJLQBJCS0ASQktAEkJLQBJCS0ASQktAEkJLQBJCS0ASQktAEkJLQBJCS0ASQktAEkJLQBJCS0AaTuofsH0QaQNrYJvLk4iDaAtIFp8E2AthsBYwPTEaV/7dnG/BB97N4KjftHxwabcCEuuWNsZ1DrnqT8+OjoC42w7NZdHVbkuYnR0YkLrfbsGhsb3wONbcHFvdUIPB/wvj88Ia0xFqpq5zOj4+eiSW06V3AiuNAYHB27P9Dh/Z8O9RVQ8/6x0cEG7BzdEdyxWzo5Brcx5SfGRrdH0j49nXYcNFqdl/KfSOrE8IBdW0efiWrWCHhMNNLrTLd3eBVYDP9dfKFjNjAzE/8X06OP50o2nyUw/tjJoeNj8El4eiYoSbc0A42vRb/uvdn3w6Xzo+HXTXeandXkz6wsX538eNCWme/DGej56PCWe8swevfq8uThagQ+effqyGNh27dNhQPt4OnZu58EWJp4jC/W2DYZ/Dt+fHjosT3wscd+c/j8eHj5K48Nbj4+Ds2rwcBdfUvkHvNhyk8ubj4czlDb1lpdB6twcibuvIT/T00ubYnqxPDY/dHB5ZOfDP/eMvmdLZMj6fUZqIkJ3I4//+lgp2wgpRfGxrZDoL1gchkfGx1PZ6aHLvZBEw5dgk/BXfhieOXe1bswPhD/eufYwMDazI3w68tH93dWlfOLKwRWQrP9YG4QxufeurowDzcWRj4Cf16RwIWR1+HDYJBH5zOszL71yGKgic/eyxX7RPTvh3DpEjwBg3DwUngPwLfg8sXg292RNTgh6/yYT1b+C7B2MTwJ4gJ7GsR2GEu+Jfzvwtq1uHzGg86+vbIY9dE9OHQtsBuxjp3dC8yHRh78t7i9szaw4/zQy4d3LIazw5b3F5aPJLYZDKqL0BNYAZyEfwZ/d2xbE3qXepsfXk5//UHK4MdqcFTHQ/Bc8O+DUwNX4e7fn3g+Wva3/uSBtysTuB/6AF4aCr/+Qs+2sYlAT0/npZ15M/x3DQYGAh1+LvyIJvIH4m+9e3sbH16SsI75ZOXXwk4Ivv30EFNoFe6MTtxh+P8bOLcns4GYx2eDmv2XaJFuQM+5sJuefrs+JhDuBeYh/u/qYEdtgMKlLckonn9g+6/CvZYNDASqO/CNcK2a+/LQ40HX7Rt8aNP/GN0Z/joFAymDnmAO6vSO4DYcCZaBw3NXgppdJEcmQ6fg+vmLeyoTuAxDsOdbkSdzcerLw5MPAHx+IFfo3cFYUxFdjMdr9m1waWCCPDT6FYF3zCcrvwm+MRj0yt67nN/Uc2vz5F6G/5FTLz7as5rjMTU//I0Hwm/XTj314tyqpI51oc0dtYFgHnkkGcU7H/3nX4djraEdqO7p5V+ZCzpzYeVSMPNcX7h8541fW/5M+OsctDYByXTVSRM4cey1vxdMLGsk7vqnowlx4HLkIFVBe48fO/8WNP9JOutehFVl2bn4YzbVafrt+uLl5pXPLP+a4ras/MKZX9422wt33md/vvEnKxfjaT/h//GjL39/bSzP5U5SsweOfun7U2P1GvZ3RiFxhWD89290dj8AzSaciL7chl98nbGNJgx8fuG9tUb6N8B5MjC18nvx4vpw63bo6awyG0+ufT9c4ydC/yQePNU+Am7e7H35OsBjL4bPWOJBqJ4GekL9Hg+q1kxmjePQbEQq279p4OKK6sas/Mq7izd6+uCxpyJpPOuM/0q4H6AS81uLXadDzG6hNkYQuUKBEQx+vrP7gQHYfx5OBUOnGfjUD2fb203hk4jRxtljBMbH9gxCuLB/msCB2CQGDzSbPdMT4df7On143fjnRq6Fn3fhUrSZ3H8gaMsXxvYcgIpW/q/CfWvRg7XwyRoQOD+okRSo7Dx8M5g0ompNhzZz/v5Iu/R1mGs8pzLsVvnxsaXdU/OptIS2PR80j4Q/J/z7oGcPNIB76kngof8b2EVwrTfcDzSgbkYQ+Wnz0NZVQGYDV84uP3X2Hfjd2d1wZO5vvc90wgH4dt/Qv3ztLXil7+bIwcDV3tN7FQ4NR17u1a/f3T5ydjGeY36ns6qkF38ieuK9Go3Ed84uL59ZgM/13bx18J1qBP7jqZ9gHrH/8OxTIyfnlYXfO3nrqaA+3zmzfOtg5Je8ceap5bD8HhiBweFDituy8sM9+26/ll8uhv/g5kdPvsHwf+XMyM0zSy3XKKnZoeMxj1dOjx4/vVi7XcC70cPc3Z9vr1T7c6ebOwbshtD2D6/Xdae1Pmla84B/7wfvl+TQlha0xA8uwu+32QRczl4/9zPzVuW2DbyF47KdFEyeyil9YvCaDYOehZrYAAxuvgH1tQEkpOptoAOEMXNIG53QBpDQBpCQ0AaQkDYy4Z4YKUeF8/MVT+zXWZG4DiBtdOoXTIPJXUvcbYu7JwlX4dlQEHPAtfK6k+yj9Y3yPNJSaTpsCT8m46+En1ADGgkhmiplksT0dTL24kcshGmFrt5JAnlDNmSkCmygNBHxb7EPiZgKlAIzSrLBknwjwN6RG0tEwi8tQnM3tL4R85qavzf6kOV1F9hLPxJDZm9W1zu+Ht2MJtAxG0jTrZN0Kiatr+H0lHRq/AMz24V/0VZ5YYJLh4U45cpn2OwiP9CSsURBwY9wbAXW+apFjckNNuZeL74ow691G61rSlTa9hs7IdJgA/GQI+w0xk5slJ1rCTd3k7SziXyujGudTdJEOfjZYSJM3oRxvER++YFPRW+M9fdoZlTqKlGV2+K0QpJkWQNdvRmD6cwysDH2xAoboHZqYedIsQ5EXMGJbDiohjxhHGyiaSTR8ONGfYtLyjnnorWaI2sLd5VyC5OfkUZUPROusLS+i8V69YXSbSDrftstQtTLisWvKSXSpxN+y8AvR8RtmpFxyhuHp/k3GvUtgcQ0CyBVuR8g5nWROCyfVLkPJrYj0bgE0nJW48rC2yMbVijhvCS7XQlSdc+FNI9I5d5q6y/pwwyaXxAsns3I50rF6CPWjCSufSE/2M/8LNa7009ESdtv7LDIfsWinKzEzJqffE0WbN4Z4H14YaBl9+gmtkxAMgx4GekIMXsh0rpl/LILYKpTxkn5lFLFnv+Q+1b63UfCs1PmoHhno13QiPPDgiIPGAoI1DamUKyE40Trs086xs+LeNo9b71o620Iv0czDbMCLSyoFQeB+sY4x0rQgDphAp0mH655F2mmSIxAbWtoKOr8nph4KNFm188PP+JJZHfYQYFpud1NsxdIwK8NICGpBlp71wJvAtEGkMpO6DQJ26r7SoU2gFTV4Or2/R/iB5B8rR7dKrCH5JlK4+gd41aEV/xUeNLNxtCBOpJe8ky3TCA/Bh649CE4vh+wLOlpO+0i0OH9AFW9vXV/mE6JziZA+F34URaUz/IqFsiPRoBk4wtRSlsfNImho+llmsJL4l8h90tyL88r+IX9MeVLlaYnDUYqN3px7CPZ74m5iZO0QCsMYgD413MiyCDHi3Aog+j/RAzgVISspRgCadSyc6QcIrOQLGzAMHnygUCEDy0u9NJCFilNcxgC3o1pBfI7bVJwLUCytYFkcrXfqVD1bp2at/JUbmm8ZbiEaisND9cAJEsbyIYdtQ6mZ30f5WglFpbk/HoGff02UJRcwflgXMVRuqoTdosJKdykGYMvZPsEhVCSn8ypdp4XHzNRIlqI9YTtLW4KSU8z60aISL2ycR1FhiYfrTFNuIBR9i/mO8kFlXI3ZYxjvvFDoigSlUqrQIXKaOI3VffwH2gK5SbP6SQJWiu7ffoHsPnup7McUMm19N9pEP8qKETGOhbMfOXuYT+Y6/2SaZWIf5D8j1whwn0l7O6YsLvl3D2aXW1eqo1PpbrHy6NVpNR/SH0I9nv8J3Ml+atVqvV//oLULbIVomQNM8xvqo+Z7EL3xUqUCuTHZaDMApA4KzPTkrE7I/tg3ZsZs8/jJoRjPcOUUFQlXxQM+4FaG0GH7sX9QD4XbL7MtGSATSv/KC3EhTV763TuJowbRXL0hbRjOD9383fM+BTClTPcxN7KFJ1R7YmRkDQjNJpQZ2RT8LR8Vp4WPqb9CMmxntatQCCZ/9OvuA4gOXhE05FDwXoWzCXGTZmZztz66PJ0UjZ22Lm/igrJs56ZFvnkubBFw31xdAFzcCBV4zN1Tx3QF0La6ITrANJGJ1wHkNAGkJDQBpCQ0AaQkNAGkJDQBpCQ0AaQkNAGkJA2Hv1/LbgEYxBZtO8AAAAASUVORK5CYII=</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-11-23 11:14:48 +0100" MODIFIED_BY="Laura Amato" NO="7" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 ACAM versus NTX, outcome: 2.1 Return to any drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-11-23 11:19:21 +0100" MODIFIED_BY="Laura Amato" NO="8" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Acamprosate versus naltrexone, outcome: 2.2 Cumulative abstinence duration .</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-11-23 11:14:56 +0100" MODIFIED_BY="Laura Amato" NO="9" REF_ID="CMP-003.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 ACAM + NTX versus PBO, outcome: 3.1 Return to any drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-11-23 11:21:11 +0100" MODIFIED_BY="Laura Amato" NO="10" REF_ID="CMP-003.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 ACAM + NTX versus PBO, outcome: 3.2 CAD.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-11-23 11:15:04 +0100" MODIFIED_BY="Laura Amato" NO="11" REF_ID="CMP-004.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 ACAM + NTX versus ACAM, outcome: 4.1 Return to any drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2010-11-23 11:21:37 +0100" MODIFIED_BY="Laura Amato" NO="12" REF_ID="CMP-004.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 ACAM + NTX versus ACAM, outcome: 4.2 CAD.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2010-11-23 11:15:09 +0100" MODIFIED_BY="Laura Amato" NO="13" REF_ID="CMP-005.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Sensitivity analysis of risk of bias, outcome: 5.2 Funding source.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-10-28 09:53:54 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2010-07-10 15:19:12 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-07-10 15:19:12 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-11-05 10:40:53 +0100" MODIFIED_BY="[Empty name]">Abbreviations</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-29 11:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Term (abbreviation)</B>
</P>
<P>Acamprosate (ACAM)</P>
<P>Acceptable Quality Level (AQL)</P>
<P>Alcoholics Anonymous (AA)</P>
<P>Carbohydrate-deficient transferrin (CDT)</P>
<P>Case report form (CRF)</P>
<P>Cognitive Behavioral Intervention (CBI)</P>
<P>Clinical Trials Registry Platform Search Portal (ClinicalTrials.gov)</P>
<P>Cochrane Drugs and Alcohol Group (CDAG)</P>
<P>Confidence interval (CI)</P>
<P>Cumulative abstinence duration (CAD)</P>
<P>Diagnostic and Statistical Manual of Mental Disorders (DSM)</P>
<P>Food and Drug Administration (FDA)</P>
<P>Gamma-glutamyltransferase (GGT)</P>
<P>Good Clinical Practice (GCP)</P>
<P>Individual patient database (IPD)</P>
<P>Intention-to-treat (ITT)</P>
<P>International Statistical Classification of Diseases (ICD)</P>
<P>International Unit (IU)</P>
<P>Mean corpuscular volume (MCV)</P>
<P>Mean difference (MD)</P>
<P>Meta-analysis based on literature (MAL)</P>
<P>
<I>Meta</I>Register of Controlled Trials (<I>m</I>RCT)</P>
<P>Motivational Enhancement (ME)</P>
<P>Naltrexone (NTX)</P>
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
<P>N-methyl-D-aspartic acid (NMDA)</P>
<P>Number needed to treat for an additional beneficial outcome (NNTB)</P>
<P>Number needed to treat for an additional harmful outcome (NNTH)</P>
<P>Placebo (PBO)</P>
<P>Randomized controlled trial (RCT)</P>
<P>Risk benefit (RB)</P>
<P>Risk difference (RD)</P>
<P>Risk ratio (RR)</P>
<P>Systematic Assessment for Treatment Emergent Effects (SAFTEE)</P>
<P>Standard deviation (SD)</P>
<P>Standard error (SE)</P>
<P>Standard drink unit (SDU)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-07-10 15:19:12 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-05-15 11:13:44 +0200" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-08 15:45:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Search strategy for CENTRAL </B>
</P>
<OL>
<LI>Alcohol-Related Disorders[mesh]</LI>
<LI>((alcohol) NEAR/2 (dependen* or disorder* or drink* or misuse or abuse* or consumption))</LI>
<LI>alcoholism [mesh]</LI>
<LI>alcohol*</LI>
<LI>exp drinking behaviour [mesh]</LI>
<LI>1 or 2 or 3 or 4 or 5</LI>
<LI>acamprosate or  Campral</LI>
<LI>alcohol deterrents [mesh]</LI>
<LI>7 or 8</LI>
<LI>6 AND 9</LI>
</OL>
<P>
<B> Search strategy for PubMEd </B>
</P>
<OL>
<LI>Alcohol-Related Disorders[mesh]</LI>
<LI>((alcohol) AND (dependen* or disorder* or drink* or misuse or abuse* or consumption))</LI>
<LI>alcoholism [mesh]</LI>
<LI>alcohol*</LI>
<LI>exp drinking behaviour [mesh]</LI>
<LI>1 or 2 or 3 or 4 or 5</LI>
<LI>Acamprosate [substance name]</LI>
<LI>acamprosate [tiab]</LI>
<LI>Campral [tiab]</LI>
<LI>alcohol deterrents [mesh]</LI>
<LI>7 or 8 or 9 or 10</LI>
<LI>randomized controlled trial[pt]</LI>
<LI>controlled clinical trial[pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo[tiab]</LI>
<LI>drug therapy[mesh]</LI>
<LI>trial[tiab]</LI>
<LI>groups[tiab]</LI>
<LI>12 or 13 or 14 or 15 or 16 or 17 or 18</LI>
<LI>animals [mesh]</LI>
<LI>humans [mesh]</LI>
<LI>animals NOT (20 and 21)</LI>
<LI>19 NOT 22</LI>
<LI>6 AND 11 AND 23</LI>
</OL>
<P> </P>
<P>
<B>Search strategy for EMBASE (Host: OVID)</B>
</P>
<OL>
<LI>exp Alcohol-Related Disorders</LI>
<LI>exp drinking behaviour</LI>
<LI>((alcohol) and (abuse* OR dependen* OR disorder*or drink* or consumption))</LI>
<LI>alcoholism.ti,ab</LI>
<LI>1 or 2 or 3 or 4</LI>
<LI>exp acamprosate</LI>
<LI>acamprosate.ti,ab</LI>
<LI>campral.ti,ab</LI>
<LI>Aotal.ti,ab</LI>
<LI>N-acetylhomotaurin*.ti,ab</LI>
<LI>6 or 7 or 8 or 9 or 10</LI>
<LI>random*.ti,ab</LI>
<LI>placebo. ti,ab</LI>
<LI>(control* or prospective* or volunteer*).ti,ab</LI>
<LI>(single or double or treble or triple) and (blind* or mask*)).ti,ab</LI>
<LI>crossover*.ti,ab</LI>
<LI>exp randomized controlled trial/</LI>
<LI>clinical-trial/</LI>
<LI>exp double blind procedure/</LI>
<LI>exp single blind procedure/</LI>
<LI>exp crossover procedure/</LI>
<LI>exp Latin square design/</LI>
<LI>exp placebos/</LI>
<LI>exp multicenter study/</LI>
<LI>OR 12/24</LI>
<LI>5 AND 11 AND 25</LI>
<LI>limit 26 to human</LI>
</OL>
<P> <B>Search strategy for CINAHL (Host: EBSCO)</B>
</P>
<OL>
<LI>MESH alcohol-related disorders</LI>
<LI>TX (((alcohol) and (abuse* OR dependen* OR disorder*or drink* or consumption))</LI>
<LI>TX alcoholism    </LI>
<LI>or 2 or 3</LI>
<LI>MH Alcohol Deterrents</LI>
<LI>TX acamprosate</LI>
<LI>TX campral</LI>
<LI>5 or 6 or 7</LI>
<LI>MH Random Assignment/</LI>
<LI>MH Clinical Trials/</LI>
<LI>TW random*</LI>
<LI>TW placebo*</LI>
<LI>TW group*</LI>
<LI>TW (single or double or triple or treble) and (mask* or blind*)</LI>
<LI>MH crossover design</LI>
<LI>TW (crossover* or allocate* or assign*)</LI>
<LI>OR 9/16</LI>
<LI>4 AND 8 AND 17</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-10-28 09:53:54 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>